---
document_datetime: 2025-02-17 11:32:09
document_pages: 115
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/cellcept-h-c-82-ii-0170-g-epar-assessment-report_en.pdf
document_name: cellcept-h-c-82-ii-0170-g-epar-assessment-report_en.pdf
version: success
processing_time: 168.382444
conversion_datetime: 2025-12-27 22:00:36.266626
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

14 November 2024 EMA/554250/2024 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

CellCept

International non-proprietary name: Mycophenolate mofetil

Procedure No. EMEA/H/C/000082/II/0170/G

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure ..............................................                              | 6                                                                                                          |
|------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|
| 1.1. Type II group of variations ....................................................................................  | 6                                                                                                          |
| 1.2. Steps taken for the assessment of the product                                                                     | ........................................................ 7                                                 |
| 2. Scientific discussion ................................................................................              | 9                                                                                                          |
| 2.1. Introduction                                                                                                      | ........................................................................................................ 9 |
| 2.1.1. Problem statement                                                                                               | ............................................................................................ 9             |
| 2.1.2. About the product                                                                                               | ........................................................................................... 10             |
| 2.1.3. The development programme/compliance with CHMP guidance/scientific advice                                       | ...... 10                                                                                                  |
| 2.2. Non-clinical aspects ............................................................................................ | 10                                                                                                         |
| 2.2.1. Introduction                                                                                                    | .................................................................................................... 10    |
| 2.2.2. Ecotoxicity/environmental risk assessment .........................................................             | 11                                                                                                         |
| 2.2.3. Discussion on non-clinical aspects .....................................................................        | 16                                                                                                         |
| 2.2.4. Conclusion on the non-clinical aspects                                                                          | ............................................................... 17                                         |
| 2.3. Clinical aspects                                                                                                  | .................................................................................................. 17      |
| 2.3.1. Introduction                                                                                                    | .................................................................................................... 17    |
| 2.3.2. Pharmacokinetics                                                                                                | ............................................................................................ 23            |
| 2.3.3. Pharmacodynamics ..........................................................................................     | 40                                                                                                         |
| 2.3.4. Discussion on clinical pharmacology                                                                             | ................................................................... 42                                     |
| 2.3.5. Conclusions on clinical pharmacology                                                                            | ................................................................. 44                                       |
| 2.4. Clinical efficacy                                                                                                 | .................................................................................................. 44      |
| 2.4.1. Dose response studies                                                                                           | ..................................................................................... 44                   |
| 2.4.2. Main studies                                                                                                    | ................................................................................................... 45     |
| 2.4.3. Discussion on clinical efficacy ............................................................................    | 71                                                                                                         |
| 2.4.4. Conclusions on the clinical efficacy ....................................................................       | 72                                                                                                         |
| 2.5. Clinical safety                                                                                                   | .................................................................................................... 73    |
| 2.5.1. Discussion on clinical safety ..............................................................................    | 97                                                                                                         |
| 2.5.2. Conclusions on clinical safety ............................................................................     | 99                                                                                                         |
| 2.5.3. PSUR cycle                                                                                                      | ..................................................................................................... 99   |
| 2.6. Risk management plan                                                                                              | ....................................................................................... 99                 |
| • Section 4.3 of the EU SmPC Contraindications ....................................                                    | 100                                                                                                        |
| 2.7. Update of the Product information ......................................................................          | 100                                                                                                        |
| 2.7.1. User consultation ..........................................................................................    | 101                                                                                                        |
| ...........................................................................                                            | 101                                                                                                        |
| 3. Benefit-Risk Balance                                                                                                |                                                                                                            |
| 3.1. Therapeutic Context .........................................................................................     | 101                                                                                                        |
| 3.1.1. Disease or condition                                                                                            | ...................................................................................... 101                 |
| 3.1.2. Available therapies and unmet medical need                                                                      | ..................................................... 101                                                  |
| 3.1.3. Main clinical studies                                                                                           | ....................................................................................... 102                |
| 3.2. Favourable effects ............................................................................................   | 102                                                                                                        |
| 3.3. Uncertainties and limitations about favourable effects                                                            | ........................................... 102                                                            |
| 3.4. Unfavourable effects                                                                                              | ......................................................................................... 103              |
| 3.5. Uncertainties and limitations about unfavourable effects                                                          | ....................................... 103                                                                |
| 3.6. Benefit-risk assessment and discussion ...............................................................            | 104                                                                                                        |

<div style=\"page-break-after: always\"></div>

| 3.6.1. Importance of favourable and unfavourable effects ............................................                  | 104   |
|------------------------------------------------------------------------------------------------------------------------|-------|
| 3.6.2. Balance of benefits and risks ..........................................................................        | 104   |
| 3.7. Conclusions ..................................................................................................... | 104   |
| 4. Recommendations ...............................................................................                     | 104   |
| 5. EPAR changes .................................................. Error! Bookmark not defined.                        |       |
| 6. References ..........................................................................................               | 108   |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

- ABOi blood group incompatible
- AcMPAG acylglucuronide of MPA
- ADR adverse drug reaction
- AE adverse event
- AUC   area under the plasma concentration-time curve
- AUC0-12h area under the plasma concentration-time curve from time 0 h to time 12 h
- AZA Azathioprine
- BCRP Breast cancer resistance protein
- b.i.d. twice a day (bis in die)
- BSA body surface area
- CAV cardiac allograft vasculopathy
- CHD   congenital heart disease
- Cmax maximal plasma concentration
- Ctrough concentration at the end of a dosing interval, prior to a next dose
- CMV cytomegalovirus
- CNI calcineurin inhibitor
- CsA ciclosporin A
- CSR Clinical Study Report
- EBV Epstein-Barr virus
- EC50 half maximal effective concentration
- ELTR European Liver Transplant Registry
- EHC enterohepatic recirculation
- EMA European Medicines Agency
- EMB endomyocardial biopsy
- EMIT enzyme multiplied immunoassay technique
- ERA Environmental risk assessment
- EU European Union
- Eve everolimus
- FDA US Food and Drug Administration
- GCP Good Clinical Practice
- GFR glomerular filtration rate
- HLA human leukocyte antigen
- HSCT haematopoietic stem cell transplantation
- HTx heart transplant(ation)
- IBD International Birth Date
- ICSR Individual Case Safety Report
- IH isohemaglutin

<div style=\"page-break-after: always\"></div>

- IMPDH inosine monophosphate dehydrogenase
- ILTS International Liver Transplantation Society
- ISHLT International Society for Heart and Lung Transplantation
- IV intravenous
- LTx liver transplant(ation)
- MAH Marketing Authorisation Holder
- MDR1 multidrug resistance protein 1
- MMF mycophenolate mofetil
- MPA mycophenolic acid
- MPAG phenolic 7-O-glucuronide of MPA
- MRP2 multidrug resistance-associated protein 2
- OATP organic anion transporting polypeptide
- OPTN Organ Procurement and Transplantation Network
- PD pharmacodynamic(s)
- PBMC peripheral blood mononuclear cell
- PELD paediatric end-stage liver disease
- PK pharmacokinetic(s)
- PTLD post-transplant lymphoproliferative disorder
- popPK population pharmacokinetics
- RTx renal transplant(ation)
- SAE serious adverse event
- SmPC Summary of Product Characteristics
- SOC System Organ Class
- SPLIT Society of Pediatric Liver Transplantation
- SRTR Scientific Registry of Transplant Recipients
- TAC tacrolimus
- Tmax time to maximum concentration
- UGT uridine diphosphate glucuronosyltransferase
- UK United Kingdom
- US United States

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II group of variations

Pursuant to Article 7.2 of Commission Regulation (EC) No 1234/2008, Roche Registration GmbH submitted to the European Medicines Agency on 31 May 2023 an application for a group of variations.

The following variations were requested in the group:

| Variations requested   | Variations requested                                                                                                           | Type    | Annexes affected   |
|------------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.z                  | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                 | Type IB | I, II and IIIB     |
| C.I.6.a                | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

C.I.6.a: Extension of indication to include paediatric patients (3 months to 18 years of age) for hepatic and cardiac transplants and to extend the indication for renal transplants for paediatric patients starting from 3 months, based on pharmacokinetic data, published literature and the Roche Global Safety Database. As a consequence, sections 4.1, 4.2, 4.8 and 5.2 of the SmPC are updated. The Package Leaflet is updated accordingly.

Type IB (C.I.z): Update of the precautions to be taken before handling or administering the medicinal product in section 4.2 of the SmPC for the CellCept 500 mg tablets formulation in order to be in line with the other CellCept formulations. The Package Leaflet is updated to cross reference section 2 in section 6 for sodium content, in line with the QRD guidance.

In addition, the MAH took the opportunity to introduce minor editorial changes to the PI and bring the PI in line with the latest QRD template version 10.3.

The group of variations requested amendments to the Summary of Product Characteristics, Annex II and Package Leaflet.

## Information on paediatric requirements

Not applicable

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the MAH did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## Scientific advice

The MAH did not seek Scientific Advice at the CHMP.

<div style=\"page-break-after: always\"></div>

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Thalia Marie Estrup Blicher

Co-Rapporteur:

N/A

| Timetable                                            | Actual dates      |
|------------------------------------------------------|-------------------|
| Submission date                                      | 31 May 2023       |
| Start of procedure:                                  | 17 June 2023      |
| CHMP Rapporteur Assessment Report                    | 18 August 2023    |
| CHMP members comments                                | n/a               |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report | 7 September 2023  |
| Request for supplementary information (RSI)          | 14 September 2023 |
| CHMP Rapporteur Assessment Report                    | 21 February 2024  |
| PRAC Rapporteur Assessment Report                    | 21 February 2024  |
| PRAC Outcome                                         | 7 March 2024      |
| CHMP members comments                                | n/a               |
| Updated CHMP Rapporteur Assessment Report            | 15 March 2024     |
| 2 nd Request for supplementary information (RSI)     | 21 March 2024     |
| CHMP Rapporteur Assessment Report                    | 22 June 2024      |
| PRAC Rapporteur Assessment Report                    | 22 June 2024      |
| PRAC members comments                                | 04 July 2024      |
| Updated PRAC Rapporteur Assessment Report            | 08 July 2024      |
| PRAC Outcome                                         | 11 July 2024      |
| CHMP members comments                                | 11 July 2024      |
| Updated CHMP Rapporteur Assessment Report            | 19 July 2024      |
| 3 rd Request for supplementary information (RSI)     | 25 July 2024      |
| CHMP Rapporteur Assessment Report                    | 17 September 2024 |
| PRAC Rapporteur Assessment Report                    | 17 September 2024 |
| PRAC members comments                                | n/a               |
| Updated PRAC Rapporteur Assessment Report            | 27 September 2024 |
| PRAC Outcome                                         | 03 October 2024   |
| CHMP members comments                                | n/a               |
| Updated CHMP Rapporteur Assessment Report            | n/a               |
| 4 th Request for supplementary information (RSI)     | 17 October 2024   |
| CHMP Rapporteur Assessment Report                    | 30 October 2024   |
| PRAC Rapporteur Assessment Report                    | 30 October 2024   |
| PRAC members comments                                | n/a               |

<div style=\"page-break-after: always\"></div>

| Timetable                                 | Actual dates     |
|-------------------------------------------|------------------|
| CHMP members comments                     | n/a              |
| Updated PRAC Rapporteur Assessment Report | 07 November 2024 |
| Updated CHMP Rapporteur Assessment Report | 07 November 2024 |
| CHMP Opinion                              | 14 November 2024 |

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Introduction

## 2.1.1. Problem statement

## Disease or condition

## Heart transplantation (HTx)

Congenital heart disease (CHD, also referred to as congenital cardiomyopathy) is the most common underlying diagnosis in infants younger than 1 year of age, representing a diverse group of diseases that can lead to transplantation. Among older patients, cardiomyopathy remains the predominant cause for HTx. Paediatric HTx accounts for approximately 14% of the total HTx worldwide (Dipchand et al. 2013) The number of paediatric HTx reported to the International Society for Heart and Lung Transplantation (ISHLT) registry has increased over time to 442 in 2004, 586 in 2014, and 684 in 2015 (Rossano et al. 2016). In 2019, there were 507 paediatric HTx performed in the US (14%), in patients up to 17 years of age (OPTN 2020).

## Liver transplantation (LTx)

The number of LTx in Europe recorded in the European Liver Transplant Registry in 2019 was 4,719 and paediatric LTx (less than 18 years) in Europe account for approximately 10% of the LTx annually (around 500 paediatric LTx in 2019). Over the past decade, recipient age, sex, and racial distributions have changed little. As in previous years, cholestatic biliary atresia remained the leading cause of liver failure. Children are typically undergoing transplant at higher acuity than in the past and this is likely due to the lack of suitable donor organs. Blood group incompatible (ABOi) LTx occurred in 5.4% of recipients in 2017-2019, an increase from 3.5% in the previous era (Kwong et al. 2021).

## State the claimed therapeutic indication

New text (in bold and underlined):

CellCept is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in adult and paediatric (3 months to 18 years of age) patients receiving allogeneic renal, cardiac, or hepatic transplants.

## Management

Immunosuppression therapy is used to prevent rejection of the donor organ thereby enabling organ and patient survival. It is commonly separated into induction therapy (given at time of transplant), maintenance therapy (chronic medications), and acute rejection therapy (for the treatment of acute complications).

The model of alloimmune response, involving both naïve and memory lymphocytes, in the rejection of transplanted organs has been described in detail in the literature (Halloran et al. 2004). Rejection episodes are not an organ-specific complication and can occur for any transplanted organ. Additionally, there is little evidence to suggest that the mechanism of rejection is different in adults compared with children.

<div style=\"page-break-after: always\"></div>

CellCept, in combination with ciclosporin and corticosteroids, is currently indicated in the EU for the prophylaxis of acute transplant rejection in patients receiving allogeneic renal, cardiac, or hepatic transplants, including children from 2 years of age with renal transplants. No dosing recommendation is available in paediatric population for use in cardiac or hepatic transplant. However, CellCept is used offlabel in the paediatric population with liver and heart transplants and in renal transplant patients below 2 years of age and most maintenance immunosuppressive protocols in children are similar to the protocols used in adults and employ a three-drug regimen consisting of a calcineurin inhibitor (CNI) (such as Cyclosporin A (CsA) or tacrolimus (TAC)), an antimetabolite agent (mycophenolate mofetil (MMF) or less commonly azathioprine (AZA)), and tapering doses of glucocorticoids over the first year post transplantation (Kobashigawa et al. 2006; Costanzo et al. 2010). Hence, there is an unmet need for approved medicinal product for prophylaxis of transplant rejection in paediatric patients.

## 2.1.2. About the product

Mycophenolate mofetil is the 2-morpholinoethyl ester of mycophenolic acid (MPA). MPA is a selective, uncompetitive and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), and therefore inhibits the de novo pathway of guanosine nucleotide synthesis without incorporation into DNA. Because T- and B-lymphocytes are critically dependent for their proliferation on de novo synthesis of purines whereas other cell types can utilise salvage pathways, MPA has more potent cytostatic effects on lymphocytes than on other cells.

In addition to its inhibition of IMPDH and the resulting deprivation of lymphocytes, MPA also influences cellular checkpoints responsible for metabolic programming of lymphocytes. It has been shown, using human CD4+ T-cells, that MPA shifts transcriptional activities in lymphocytes from a proliferative state to catabolic processes relevant to metabolism and survival leading to an anergic state of T-cells, whereby the cells become unresponsive to their specific antigen.

Mycophenolate mofetil (MMF, CellCept) has been available to prescribers in the EU for more than 20 years and has remained an established component of immunosuppression protocols over this time.

CellCept was first granted marketing approval in the United States (US) on 3 May 1995 for the prophylaxis of RTx rejection in adults receiving allogeneic RTx. On 14 February 1996, the initial Marketing Authorisation in the EU was granted for the prophylaxis of RTx rejection in adults. On 17 August 1998, Cellcept was approved for cardiac transplant (EMEA/H/C/00082/II/0010), and on 09 November 2000 for liver transplant (EMEA/H/C/00082/II/0024) in the EU. The product was subsequently approved in 119 countries worldwide. On 16 July 2001, the European Medicines Agency (EMA) approved the prevention of acute rejection for the paediatric RTx population aged 2 to 18 years (procedure EMEA/H/C/00082/II/0027).

## 2.1.3. The development programme/compliance with CHMP guidance/scientific advice

No scientific advice was given.

## 2.2. Non-clinical aspects

## 2.2.1. Introduction

Mycophenolate mofetil (MMF) is a prodrug, that hydrolysed to 2-morpholinoethyl ester of Mycophenolic acid (MPA) is an immunosuppressive agent. MMF has 1.3 to 2.36 times higher oral bioavailability than

<div style=\"page-break-after: always\"></div>

MPA and is rapidly and fully hydrolysed to MPA in the liver and intestine. Thus, pharmacologically active MPA levels are reached subsequent to MMF dosage of three -quarters to less than one -half of the corresponding amount of MPA.

At the time of MA approval, no Environmental Risk Assessment (ERA) was required. Moreover, CellCept has not been re-registered in Europe since such requirements came into force (2006). In order to fulfil the requirements of an extension to a paediatric indication a full ERA with the existing data, partially assessed in compliance with GLP, was submitted. Since MMF is rapidly and fully hydrolysed to MPA in the liver and intestine, the ERA has been performed for the pharmacologically active substance mycophenolic acid (MPA). Further to the CHMP request, the ERA has been performed according to the revised EMA Guideline on ERA for Human Non-GMO Medicines (EMEA/CHMP/SWP/4447/00 Rev.1) of 15 February 2024.

No new data was provided on the pharmacology, pharmacokinetics or toxicology of MMF.

## 2.2.2. Ecotoxicity/environmental risk assessment

## Phase I: Initial screening and exposure estimation

A PBT screening was carried out. The method used to determine the logDow values was non-GLP, nonOECD. However, the method followed the principles of the shake-flask method according to OECD 107. The logDow values are below the Phase I trigger value of 4.5 according to the EMA guideline and no further PBT assessment is thus warranted.

In a risk assessment of surface water, the potential environmental risks of MPA were evaluated using the default factors as stated in EMA guidance on ERA. The predicted environmental concentration for the surface water PECSW while using the default FPEN of 0.01 was calculated as 11 μg/L, which exceeds the phase I trigger value of 0.01 μg/L.

## Trigger values for soil

For triggering a risk assessment for the soil compartment the PECSW was used in combination with the organic carbon normalised adsorption partition coefficient (KOC). Because the highest KOC,SLUDGE for MPA is 37 L/kg (i.e. &lt;1,000 L/kg), no soil risk assessment is required.

## Trigger values for groundwater

A risk assessment for groundwater via bank filtration was triggered for MPA since the KOC,SLUDGE is 37 L/kg (i.e. ≤10,000 L/kg), and MPA is not readily biodegradable. Because a soil assessment is not triggered, no risk assessment for groundwater via pore water is required.

## Trigger values for secondary poisoning

With measured n-octanol/water distribution coefficient (logDOW) values of 2.28 at pH 5, 0.48 at pH 7 and -1.69 at pH 9 (i.e. &lt;3) a risk assessment for secondary poisoning is not required.

## Phase II: Environmental fate and effects analysis

## Tier A: Initial environmental fate and effects analysis

In order to evaluate the potential risks to the environment from the use of the MPA, phase II Tier A ERA studies reported in Table 1 have been conducted with MPA. PNEC values were derived accordingly based on the identified NOEC/EC10 values.

<div style=\"page-break-after: always\"></div>

Table 1: List of OECD / ISO studies with MPA.

| Study                                                            | Protocol        |
|------------------------------------------------------------------|-----------------|
| Algae and Cyanobacteria growth inhibition study                  | OECD 201        |
| Daphnid sp . Reproduction study                                  | OECD 211        |
| Shortened life-cycle study with zebrafish                        | OECD 229/210    |
| Adsorption-Desorption test using batch equilibrium method        | OECD 106        |
| Biodegradation in activated sludge                               | OECD 314B       |
| Inbibition of nitrification of activated sludge micro- organisms | ISO 9509 (1989) |
| Respiration inhibition study with activated sludge               | OECD 209        |
| Biodegradation study                                             | OECD 301 F      |

The MAH submitted a non-GLP study conducted according to ISO 9509 (1989) to investigate the inbibition of nitrification of activated sludge micro-organisms by chemicals and waste waters, used to derive the PNEC for micro-organisms in STP. The NOEC for inhibition of nitrification was determined to be 27.8 mg/L.

In addition, in a GLP study according to OECD 209 conducted in 1999, the 3h effect values EC10 = 69 mg/L, EC20 = 164 mg/L and EC50 = 2213 mg/L were derived.

Two water/sediment fate studies according to FDA 3.11 from 1994 and 1995 were provided. These studies were performed at very high dosages, 1 and 5 mg MMF/L, respectively. These dosages are about a factor 2,200 (for 1 mg/L dosage) and a factor 11,000 (for 5 mg/L dosage) higher than the calculated PECSW. At the lower dose of 1 mg/L only 5.5% of the applied radioactivity was bound to sediment, whereas the values was slightly above 10% (11.2%) at the high dosage of 5 mg/L. Especially in the study with the carboxyl-14C labelled MMF a high mineralisation of about 60% was observed. It was assumed that the metabolite (presumably 14C-MPA) was easily biodegradable. This is in conformance with the high mineralisation observed with carboxyl- 14 C labelled MPA in the biodegradation in activated sludge study. In view of the high mineralisation rate in sediment/water studies and the low DT50 values in the activated sludge study (1.7 days for primary and 2.9 d for ultimate degradation) a sediment toxicity test was considered not be required.

Biodegradability. A non-GLP study on ready biodegradability was performed on Mycophenolate mofetil (MMF, prodrug) according to OECD 301 F (BMG study no. 337/a-05), demonstrating that the substance is not readily biodegradable (4.3% biodegradation after 28 days).

KOC - soil fate and effects assessment. Adsorption constants to the organic carbon fraction in three soils and two activated sewage sludges were determined following OECD guideline 106 using 14C-labelled MPA. The average KOC (range in brackets) was 348 (168-557) L/kg in all three soils and 33.5 (30-37) L/kg in both sludges, respectively. The experimental data show that MPA will not adsorb to organic substrates. Based on the single and average adsorption constants for various soils and sewage sludges, MPA can be classified as low to medium mobile in soils and having a very high mobility in sewage sludges

<div style=\"page-break-after: always\"></div>

according to the McCall classification scheme. Hence, no consideration of the soil compartment  through landspreading of sewage sludge is necessary for MPA.

Algae growth inhibition study. An OECD 201 test (conducted in 1999) over 96 hours was performed in compliance with GLP with the green algae Raphidocelis subcapitata . The 96 h EC10 value was 12 µg/L GMC based on growth rate.

Cyanobacteria growth inhibition study. A cyanobacteria study according to OECD 201 and over 72 hours was performed with MPA in compliance with GLP with the cyanobacteria Anabaena flos-aquae . The 72 h EC10 value based on growth rate was 155 µg/L GMC.

Daphnid reprotoxicity study. An OECD 211 test in compliance with GLP was performed with MPA with Daphnia magna under semi-static media exchange conditions over 21 days. The lowest NOEC for Daphnia magna for reproduction/fecundity is 0.929 mg/L (i.e. 929 µg/L) MMC.

Fish, short-term reproduction assay. This GLP test was based on a detailed review paper of the OECD about fish life-cycle tests taking into account relevant aspects of the OECD guidelines 229 and 210. The aim of the study was to determine lethal and sub-lethal effects of MPA on the reproduction of mature Danio rerio (zebrafish) and on survival and growth of the early-life stages of this species. To achieve this, a series of concentrations of the test item in aqueous solution was prepared. The test organisms were exposed to these concentrations as well as to controls without the test item. During the test period the test solutions were renewed in a flow-through system. The NOEC was 10.9 µg/L based on mortality (posthatch survival) and on numbers of healthy fish of the F1 generation while the EC10 was established at 5.8 µg/L.

## Tier A Risk assessment

## Surface water:

As the phase I surface water assessment was above the trigger value of 0.01 µg/L, the MAH calculated a refined PECSW using consumption data in a phase II A assessment. The MAH provided consumption data from France, Germany, Italy, Spain and UK from IQVIA in the years 2018-2022. Consumption was largest in the UK in 2021 (331.5 mg/inhabitant/year), and this value was used to refine the PECSW. Using the equation Specific consumption / (365 d x default wastewater per inhabitant x default dilution) a refined PECSW was determined as 0.454 µg/L.

```
PECsW-REFINED Specific consumption 1÷ (365 d x default wastewater per inhabitant x default dilution) 331,500 μg/y ÷ (365 × 200 1/d × 10) 一 0.454 μg/l
```

For MPA a study for biodegradation in surface water according to OECD 314B was performed. Using the assessed DegT50, primary value of 1.7 days, a biodegradation rate k of 0.017 h -1  was calculated. Using this value in SimpleTreat 4.0, this results in a removal rate of MPA in sewage treatment of 0.118 (i.e. 11.8%).

Applying the removal rate to the value of 0.454 μg/L resulted in a PECSW-REFINED with removal in sewage treatment of 0.401 μg/L.

The surface water predicted no-effect concentration PNECSW was calculated as the lowest of the chronic surface water ecotoxicity EC10/LC10 values of 5.8 µg/L for fish divided by an assessment factor of 10. This results in an PNECSW of 0.58 µg/L.

<!-- formula-not-decoded -->

<div style=\"page-break-after: always\"></div>

The surface water PEC÷PNEC risk characterisation ratio (RCRSW) using the PECSW based on consumption data and elimination in sewage treatment of 0.401 μg/L and the PNECSW of 0.58 µg/L as derived above was:

<!-- formula-not-decoded -->

The resulting value of a RCRSW of 0.69 did not exceed the trigger (i.e. &lt;1) and therefore a risk caused by MPA to surface waters was not to be expected.

## Risk assessment for sediment:

The PECSED was derived using Eq. 14-17 as well as default values of the revised EMA Guidance Document. The PECSED is based on adsorption to suspended solids. In view of many default values, the PECSED ultimately depends on the (KOC) and on the surface water PEC (PECSW). The PECSED for the risk assessment is derived for the maximum KOC in soil (i.e. 575 L/kg) as a worst case.

<!-- formula-not-decoded -->

The sediment PNEC will be derived from a chronic sediment ecotoxicity test with larvae of the midge Chironomus riparius, following OECD guideline 218 and performed in compliance with GLP. A study according to OECD 218 with the sediment dweller Chironomus riparius will be performed as a postmarketing commitment.

## Risk assessment for sewage treatment plant:

The sewage treatment PEC (PECSTP) was approximated as the surface water PEC multiplied by 10 (the default surface water dilution factor used in the PECSW calculation):

<!-- formula-not-decoded -->

The bacterial PNEC for sewage treatment (PNECSTP) was calculated as the respiration inhibition EC10 of 69 mg/l divided by an assessment factor of 10:

<!-- formula-not-decoded -->

Hence, the sewage treatment PEC÷PNEC risk characterisation ratio (RQSTP) is calculated as:

<!-- formula-not-decoded -->

In conclusion the PEC÷PNEC risk characterisation ratio of 0.0006 does not indicate a risk caused by MPA to sewage treatment.

## Risk assessment for groundwater (via bank filtration):

The groundwater PEC (PECGW) is approximated in a Tier A assessment as the PECSW divided by 4. The groundwater PNEC (PNECGW) was derived from the PNECSW of 0.58 µg/L divided by an additional assessment factor of 10.

The groundwater PEC÷PNEC risk characterisation ratio (RCRGW) was calculated as follows:

<!-- formula-not-decoded -->

<!-- formula-not-decoded -->

The MAH concluded that in view of an RCRGW of 1.73 a potential risk caused by MPA to groundwater cannot be excluded. A Tier B assessment for the groundwater was triggered.

<div style=\"page-break-after: always\"></div>

If the RQGW is ≥1, further evaluation is needed in Tier B. Because the PECSW was already refined, a further refinement of the PECGW was performed by a groundwater modelling for a realistic worst-case scenario according to SiMBaFi - a bank filtration simulation model.

The refined groundwater PEC÷PNEC risk characterisation ratio (RCRGW-REFINED) was calculated:

RCRGW-REFINED = PECGW-REFINED ÷ PNECGW

RCRGW = PECGW-REFINED ÷ (PNECSW ÷ 10)

RCRGW = 0.115 µg/L ÷ (0.58 µg/L ÷ 10) = 1.99

As result for the Tier B groundwater risk assessment, a potential risk caused by MPA to groundwater cannot be excluded.

## Summary of main study results

| Substance (INN/Invented Name): Mycophenolic acid (MPA)                          | Substance (INN/Invented Name): Mycophenolic acid (MPA)   | Substance (INN/Invented Name): Mycophenolic acid (MPA)                                                        | Substance (INN/Invented Name): Mycophenolic acid (MPA)   |
|---------------------------------------------------------------------------------|----------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|----------------------------------------------------------|
| CAS-number (if available): 24280-93-1                                           | CAS-number (if available): 24280-93-1                    | CAS-number (if available): 24280-93-1                                                                         | CAS-number (if available): 24280-93-1                    |
| PBT screening                                                                   |                                                          | Result                                                                                                        | Conclusion                                               |
| Bioaccumulation potential- log D ow                                             | Shake-flask method (non-GLP)                             | logD ow at pH 5 = 2.28 logD ow at pH 7 = 0.48 logD ow at pH 9 = -1.69 pKa1 = 4.58 (COOH) pKa2 = 8.04 (phenol) | Not PBT (logD ow < 4.5)                                  |
| PBT-assessment                                                                  | PBT-assessment                                           | PBT-assessment                                                                                                | PBT-assessment                                           |
| Parameter                                                                       | Result relevant for conclusion                           |                                                                                                               | Conclusion                                               |
| Bioaccumulation                                                                 | log D ow                                                 | logD ow at pH 5 = 2.28 logD ow at pH 7 = 0.48 logD ow at pH 9 = -1.69                                         | Not Bio- accumulative (B) (logD ow < 3)                  |
|                                                                                 | BCF                                                      | Not determined                                                                                                | -                                                        |
| Persistence                                                                     | OECD 301F                                                | Not readily biodegradable                                                                                     | P                                                        |
| Toxicity                                                                        | NOEC (fish) CMR substance (MPA)                          | 0.00132 mg/L                                                                                                  | T                                                        |
| PBT-statement :                                                                 | The compound is not considered a PBT substance           | The compound is not considered a PBT substance                                                                | The compound is not considered a PBT substance           |
| Phase I                                                                         | Phase I                                                  | Phase I                                                                                                       | Phase I                                                  |
| Calculation                                                                     | Value                                                    | Unit                                                                                                          | Conclusion                                               |
| PEC SW , default                                                                | 11                                                       |  g/L                                                                                                         | > 0.01 threshold                                         |
| Phase II Physical-chemical properties and fate                                  | Phase II Physical-chemical properties and fate           | Phase II Physical-chemical properties and fate                                                                | Phase II Physical-chemical properties and fate           |
| Study type                                                                      | Test protocol                                            | Results                                                                                                       | Remarks                                                  |
| Adsorption-Desorption                                                           | OECD 106                                                 | K OC ads for soil: 348 (168- 557) L/kg K OC ads for sludge: 33.5 (30- 37) L/kg                                | KOC < 10,000 L/kg                                        |
| Ready Biodegradability Test                                                     | OECD 301 F                                               | Not readily biodegradable                                                                                     | -                                                        |
| Aerobic and Anaerobic Transformation in Aquatic Sediment systems (MP-SW system) | OECD 308                                                 | Not performed                                                                                                 | -                                                        |
| Phase IIa Effect studies                                                        | Phase IIa Effect studies                                 | Phase IIa Effect studies                                                                                      | Phase IIa Effect studies                                 |

<div style=\"page-break-after: always\"></div>

| Study type                                                              | Test protocol     | Endpoint            | value      | Unit   | Remarks                                |
|-------------------------------------------------------------------------|-------------------|---------------------|------------|--------|----------------------------------------|
| Algae, Growth Inhibition Test/Green algae ( Raphidocelis subcapitata)   | OECD 201          | ErC 10 NOErC EyC 10 | 12.0 9.0 8 | µg/L   | (Growth Rate) (Biomass) not acceptable |
| Algae, Growth Inhibition Test/Blue-green algae ( Anabaena flos-aquae )  | OECD 201          | EC 10 NOEC          | 155 83.9   | µg/L   | Growth Rate                            |
| Daphnia sp . Reproduction Test                                          | OECD 211          | EC 10 NOEC          | 929 630    | µg/L   |                                        |
| Fish, short-term reproduction assay (extended)/ Danio rerio (zebrafish) | Extended OECD 229 | NOEC EC 10          | 1.32 5.8   | µg/L   | Growth F1 Mortality F1                 |
| Activated Sludge, Respiration Inhibition                                | OECD 209          | EC 10               | 69         | mg/L   | Total respiration                      |
| Sediment dwelling organisms                                             | OECD 218          | NOEC                |            | mg/kg  | Pending                                |

## 2.2.3. Discussion on non-clinical aspects

Only data regarding the environmental risk assessment (ERA) have been submitted in this application, which was considered acceptable by the CHMP. Several GLP-compliant OECD as well as non-GLP, nonOECD studies were submitted to support the environmental risk assessment of MMF/MPA.

Some studies required according to the EMA guideline on ERA were not submitted and others were deemed not acceptable due to the design of the studies. An updated ERA should be provided taking the new studies into account. Also, the risk assessment for the aquatic compartment is not accepted as the most sensitive NOEC should be used, which results in a risk for this compartment. This should also be included in an updated ERA.

Hence, at the CHMP request, the MAH submitted an updated ERA in compliance with the guideline on the Environmental Risk Assessment of Medicinal Products for Human Use (EMEA/CHMP/SWP/4447/00 Rev. 1) published on 15 February 2024. In the study on biodegradation in water (#41485) more than 10% of applied radioactivity was bound to the sediment at test end. This sorption behaviour was confirmed in the study on biodegradation in activated sludge (OECD 314 B) where again more than 10% AR was bound to the sludge as NER on day 14. Hence, a study on toxicity to sediment swelling organisms (e.g. OECD 218) was deemed necessary. The MAH provided a letter of agreement to provide a study on toxicity to sediment dwelling organisms according to OECD 218 by Q1 2026, as requested, which is considered acceptable by the CHMP.

As result of the risk assessment, a potential risk caused by MPA to groundwater cannot be excluded. Therefore, precautionary and safety measures are included in sections 5.3 and 6.6 of the summary of product characteristics (SmPC).

The MAH calculated a refined PEC surface water value based on consumption data from 2018-2022 in the (EU) country with the highest consumption. The method is considered acceptable according to ECHA guidelines, and a refined PECSW was established at 0.454 µg/L. However, the risk assessment for the aquatic compartment should be updated and re-submitted using the most sensitive effect value NOEC = 1.32 µg/L. Using the most sensitive NOEC value from the extended OECD 229 study, a risk for the aquatic compartment is identified. The MAH acknowledges that there is also a risk to surface water for fish using the NOEC of 1.32 µg/L. The ERA report and SmPC will be amended by Q1 2026.

<div style=\"page-break-after: always\"></div>

## 2.2.4. Conclusion on the non-clinical aspects

The updated data submitted in this application lead to a significant increase in environmental exposure further to the use of MMF/MPA.

- Considering the above data, MMF/MPA should be used according to the precautions stated in the SmPC in order to minimize any potential risks to the environment.

In the context of the obligation of the MAH to take due account of technical and scientific progress, the CHMP recommends the following points are recommended for further investigation:

The MAH should provide a study on toxicity to sediment dwelling organisms according to OECD 218 by Q1 2026. In addition, the MAH should update and re-submit the risk assessment for the aquatic compartment using the most sensitive effect value by Q1 2026

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of the MAH sponsored paediatric clinical pharmacology studies, paediatric clinical studies and retrospective studies reported in the scientific literature

Paediatric kidney transplantation:

<div style=\"page-break-after: always\"></div>

| Study! Reference'                          | Study Design                                                                                                                                                                                                                                                                                          | Formulation/ Dosing                                                                                                                                                                                | Demographics (number of patients;gender; age;other details)                                                                                                                                                                | Demographics (number of patients;gender; age;other details)                                                                                                                                                                | Demographics (number of patients;gender; age;other details)                                                                                                                                                                | Demographics (number of patients;gender; age;other details)                                                                                                                                                                | Key Findings                                                                                                                                                                                                                        |
|--------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| StudyMYC2190 (Roche Study Report P-180191) | Non-randomised multi-centre, open-label dose-rangingPK Safety and Tolerance study in prevention ofrejection in paediatric renal allograft recipients (3age groups, (dnof abeJad sdnab esop Intended duration:3years; early termination. PKevaluated foreach paent during the first year of the study. | IV:vials with 500mgMMF equiv.[Iv administration abandoneddue to unavailability of formulation] Oral:capsules: 50mg.250mg (for batchID seeRoche Report) MMFdose groups:15,23 30 mg/kg bid. CellCept | 40 (27 males,13 females) first or secondrenalallograftrecipients enrolled into one of three defined age groups; Age:3mo-18yrs; 8patients-6 yrs. 15patients6-<12yrs, 17patients 12-18yrs. Evaluable subjectsforkey PK data: | 40 (27 males,13 females) first or secondrenalallograftrecipients enrolled into one of three defined age groups; Age:3mo-18yrs; 8patients-6 yrs. 15patients6-<12yrs, 17patients 12-18yrs. Evaluable subjectsforkey PK data: | 40 (27 males,13 females) first or secondrenalallograftrecipients enrolled into one of three defined age groups; Age:3mo-18yrs; 8patients-6 yrs. 15patients6-<12yrs, 17patients 12-18yrs. Evaluable subjectsforkey PK data: | 40 (27 males,13 females) first or secondrenalallograftrecipients enrolled into one of three defined age groups; Age:3mo-18yrs; 8patients-6 yrs. 15patients6-<12yrs, 17patients 12-18yrs. Evaluable subjectsforkey PK data: | 1. Thedosepredicted toprovideaMPAAUC closest to the target exposure of 27.2 hμg/ml was 600 mg/m² 2 DosescalculatedbasedonestimatedBSA reduced theCVby about 10%-hence dosing based on BSA preferred over dosing basedonbody weight. |
| StudyMYC2190 (Roche Study Report P-180191) | Non-randomised multi-centre, open-label dose-rangingPK Safety and Tolerance study in prevention ofrejection in paediatric renal allograft recipients (3age groups, (dnof abeJad sdnab esop Intended duration:3years; early termination. PKevaluated foreach paent during the first year of the study. | IV:vials with 500mgMMF equiv.[Iv administration abandoneddue to unavailability of formulation] Oral:capsules: 50mg.250mg (for batchID seeRoche Report) MMFdose groups:15,23 30 mg/kg bid. CellCept | Age (yrs)                                                                                                                                                                                                                  | Dose (mg/kg)                                                                                                                                                                                                               | Day n 14                                                                                                                                                                                                                   | Day n 21                                                                                                                                                                                                                   | 1. Thedosepredicted toprovideaMPAAUC closest to the target exposure of 27.2 hμg/ml was 600 mg/m² 2 DosescalculatedbasedonestimatedBSA reduced theCVby about 10%-hence dosing based on BSA preferred over dosing basedonbody weight. |
| StudyMYC2190 (Roche Study Report P-180191) | Non-randomised multi-centre, open-label dose-rangingPK Safety and Tolerance study in prevention ofrejection in paediatric renal allograft recipients (3age groups, (dnof abeJad sdnab esop Intended duration:3years; early termination. PKevaluated foreach paent during the first year of the study. | IV:vials with 500mgMMF equiv.[Iv administration abandoneddue to unavailability of formulation] Oral:capsules: 50mg.250mg (for batchID seeRoche Report) MMFdose groups:15,23 30 mg/kg bid. CellCept | 6 6-<12 12-18                                                                                                                                                                                                              | 15 23 OC 15 233 1523 30                                                                                                                                                                                                    | 1 4 4 4 7 6/5 3                                                                                                                                                                                                            | 6 1 5 55 7 3                                                                                                                                                                                                               | 1. Thedosepredicted toprovideaMPAAUC closest to the target exposure of 27.2 hμg/ml was 600 mg/m² 2 DosescalculatedbasedonestimatedBSA reduced theCVby about 10%-hence dosing based on BSA preferred over dosing basedonbody weight. |

| Study/Reference                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Study Design                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Formulation/ Dosing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Demographics (number of patients; gender age:other details)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Key Findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study MYCS2675 (Roche Report P-180263)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Non-randomised multi-centre,open label,singleamstudy ofMMForal suspension in paediatricrecipierts of renalallogralts.Patientsfolowed for 3yrspost-Tx.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Patients received MMF oral suspension (for batch ID see Roche Report)600 mg/m² b.i.d,upto1gbi.d After study Month9 pafients were ailowed foswichtoMMF 250mg capsules formulation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 100 first or second renal allograft recipients enrolledinto one of three defined age groups: 33paients aged 3months to6 yrs, 34 paents aged6 to <12yrs,and 33paents aged 12-18yrs. A total of 17,17,and 21patents from these respective age groups participated in the PK portion of the study.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 1.Confirmation of paediatrlc dosingrecommendation 2.No cinically sigificant differences in MPA and MPAG PK parameters among the three defned age groups. 3.A dosing regmen ofMMF 600 mg/m²bid.achived the targeled early Tx(Day 7) MPA AUC1n(27.2 hmg/L) 4.A 1.9-fold highermen dos- adustedMPA AUCs observed in the later post-Tx period(Day7vs.Month 3 posl- Tx for all patients)                                                                                                                                                                                                                                                                                                                                                                                                                |
| Assessment of Relevance The eotrapolation from adult heart and liver transplant patients to paediatric heart and liver transplant patients heavilyrelies on the comparison of adult and paediatickidney transplant patients and the derivedsmilaritiesbetween thesepopulationsin the phamacokineticsandpharmacodynamics ofMMF andits metabolites.ThepaediatricMAH-sponsored kidney transplantationprogram consisted of twopaediatric studies,aninitial dose-rangng pilot study (StudyMYC2190）anda singlepivotal study（StudyMYCS2675）enrolinga total of140paedatcrenal transplantptents3months and18yearsofage）;ll patentsinthesetwo studiesreceivedMMF.StudyMYCS2675providedthebasisforthe labelled doserecomendatonof600mg/²bi.dfortheprophylaxisof rejectioninpaediatricrenalallograft patients. | Assessment of Relevance The eotrapolation from adult heart and liver transplant patients to paediatric heart and liver transplant patients heavilyrelies on the comparison of adult and paediatickidney transplant patients and the derivedsmilaritiesbetween thesepopulationsin the phamacokineticsandpharmacodynamics ofMMF andits metabolites.ThepaediatricMAH-sponsored kidney transplantationprogram consisted of twopaediatric studies,aninitial dose-rangng pilot study (StudyMYC2190）anda singlepivotal study（StudyMYCS2675）enrolinga total of140paedatcrenal transplantptents3months and18yearsofage）;ll patentsinthesetwo studiesreceivedMMF.StudyMYCS2675providedthebasisforthe labelled doserecomendatonof600mg/²bi.dfortheprophylaxisof rejectioninpaediatricrenalallograft patients. | Assessment of Relevance The eotrapolation from adult heart and liver transplant patients to paediatric heart and liver transplant patients heavilyrelies on the comparison of adult and paediatickidney transplant patients and the derivedsmilaritiesbetween thesepopulationsin the phamacokineticsandpharmacodynamics ofMMF andits metabolites.ThepaediatricMAH-sponsored kidney transplantationprogram consisted of twopaediatric studies,aninitial dose-rangng pilot study (StudyMYC2190）anda singlepivotal study（StudyMYCS2675）enrolinga total of140paedatcrenal transplantptents3months and18yearsofage）;ll patentsinthesetwo studiesreceivedMMF.StudyMYCS2675providedthebasisforthe labelled doserecomendatonof600mg/²bi.dfortheprophylaxisof rejectioninpaediatricrenalallograft patients. | Assessment of Relevance The eotrapolation from adult heart and liver transplant patients to paediatric heart and liver transplant patients heavilyrelies on the comparison of adult and paediatickidney transplant patients and the derivedsmilaritiesbetween thesepopulationsin the phamacokineticsandpharmacodynamics ofMMF andits metabolites.ThepaediatricMAH-sponsored kidney transplantationprogram consisted of twopaediatric studies,aninitial dose-rangng pilot study (StudyMYC2190）anda singlepivotal study（StudyMYCS2675）enrolinga total of140paedatcrenal transplantptents3months and18yearsofage）;ll patentsinthesetwo studiesreceivedMMF.StudyMYCS2675providedthebasisforthe labelled doserecomendatonof600mg/²bi.dfortheprophylaxisof rejectioninpaediatricrenalallograft patients. | Assessment of Relevance The eotrapolation from adult heart and liver transplant patients to paediatric heart and liver transplant patients heavilyrelies on the comparison of adult and paediatickidney transplant patients and the derivedsmilaritiesbetween thesepopulationsin the phamacokineticsandpharmacodynamics ofMMF andits metabolites.ThepaediatricMAH-sponsored kidney transplantationprogram consisted of twopaediatric studies,aninitial dose-rangng pilot study (StudyMYC2190）anda singlepivotal study（StudyMYCS2675）enrolinga total of140paedatcrenal transplantptents3months and18yearsofage）;ll patentsinthesetwo studiesreceivedMMF.StudyMYCS2675providedthebasisforthe labelled doserecomendatonof600mg/²bi.dfortheprophylaxisof rejectioninpaediatricrenalallograft patients. |

Table 2 Comparative Data: Paediatric Kidney Transplantation (Roche Study reports)

<!-- image -->

Table 3 Comparative Data: Paediatric Kidney Transplantation (Literature References)

<!-- image -->

| Key Evidence          | Key Evidence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Key Evidence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Key Evidence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Key Evidence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Literature Reference' | Study Design                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Formulation/ Desing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Demographics (mumber of patients; gender;ageother details)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Key Findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Filer eal.2000        | AUCand trough level MPA josdnoufoougisuouaunsco paediatric renal Tx recipwnts without CNI, with CsA,with TAC (al besides steroids) to elucidate The influence of the concomitant CNIl on the PK of MMF                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Dose guided by target pre-dose trough concentration to be achieved(2-5mg/L) dnoub u esop fugnsai with no CNI (n=13). 866±401 mg/m/day, ingroup co-treated withTAC（n=14）:555± epw68 group with CsA (n=15j 1158±301mg/m/day.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 42 patents: mean±SDage: atTx11.7±34yrs, at invesbigation 14.4±4.0 yrs                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 1.PhamacokineticsofMMFare infuenced bytype of concomitant immunosuppression 2.The mean dose in order to achieve the same AUC of60 hmg/Lwithout CNl co-teatment 500mgm b.id;with TAC co-treatment dose had to be significantlyreduced to300 mg/m².b.id;with CsA co-treatment dose inoreased to 600 mg/m²bi.d 3.MeasurementofMPAconcentrationsisstrongly advised to optimise MMF therapy.                                                                                                                                                                                                                                                                                                                                                        |
|                       | Rationale for Strength of Evidence In thisrerospective study.Filler etal (2000;Charte Berfin}comparedinpaediatic kidney ransplan paents theinuence of the type of CNIgivenin combination with MMFon the resuling exposure to MPA. The MPAAUCachievedwith MMF dosing didnot differbetween TACand CsAco-treated patents,but the dose requined to achieve therapeutic eposure was signifcantly lowerinpatentsreceiving concomitant TACcompared with CsAThe reason for the difference remained unknown at the time.However,as could be shown later, the difference is due to an interaction of CsA with MPA's enterohepabicrecirculation and has been corfimed inlater studies in paediatric as wellas aduit patients across all transplant types. | Rationale for Strength of Evidence In thisrerospective study.Filler etal (2000;Charte Berfin}comparedinpaediatic kidney ransplan paents theinuence of the type of CNIgivenin combination with MMFon the resuling exposure to MPA. The MPAAUCachievedwith MMF dosing didnot differbetween TACand CsAco-treated patents,but the dose requined to achieve therapeutic eposure was signifcantly lowerinpatentsreceiving concomitant TACcompared with CsAThe reason for the difference remained unknown at the time.However,as could be shown later, the difference is due to an interaction of CsA with MPA's enterohepabicrecirculation and has been corfimed inlater studies in paediatric as wellas aduit patients across all transplant types. | Rationale for Strength of Evidence In thisrerospective study.Filler etal (2000;Charte Berfin}comparedinpaediatic kidney ransplan paents theinuence of the type of CNIgivenin combination with MMFon the resuling exposure to MPA. The MPAAUCachievedwith MMF dosing didnot differbetween TACand CsAco-treated patents,but the dose requined to achieve therapeutic eposure was signifcantly lowerinpatentsreceiving concomitant TACcompared with CsAThe reason for the difference remained unknown at the time.However,as could be shown later, the difference is due to an interaction of CsA with MPA's enterohepabicrecirculation and has been corfimed inlater studies in paediatric as wellas aduit patients across all transplant types. | Rationale for Strength of Evidence In thisrerospective study.Filler etal (2000;Charte Berfin}comparedinpaediatic kidney ransplan paents theinuence of the type of CNIgivenin combination with MMFon the resuling exposure to MPA. The MPAAUCachievedwith MMF dosing didnot differbetween TACand CsAco-treated patents,but the dose requined to achieve therapeutic eposure was signifcantly lowerinpatentsreceiving concomitant TACcompared with CsAThe reason for the difference remained unknown at the time.However,as could be shown later, the difference is due to an interaction of CsA with MPA's enterohepabicrecirculation and has been corfimed inlater studies in paediatric as wellas aduit patients across all transplant types. |

<div style=\"page-break-after: always\"></div>

| Key Evidence          | Key Evidence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Key Evidence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Key Evidence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Key Evidence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Literature Relerence' | Study Design                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Fomulationl Dosing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Demographics (number of patients: gender: ago; other detalls)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Key Findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Hoecker e al 2011     | Subgroup analysis olFDcC tral, a 12-month, prospeclivo, randomisod study. comparing fixed- dose (FD) wih concentralion- contolled (CC) MMF dosing n paediatric and adut renal Tx recpents. Paediatric and adult palients trealed on basis of the same immunosuppressive prolocol Concomitant thenpy CsA or TAC,sleroids. MPA wposuro estimaled by abbreviated samplng n Weck 4,6.12 post-Tx                                                                                                                                                                                                             | Fomulation: n.a. MMF dose (first 30 days post-Tx) FD group: 600 mgimP bid. in 1gbid. in adults CC group. Inital dose as FD group, then adjusted to nchieve larget MPAAUC 30 60 h-mg/L                                                                                                                                                                                                                                                                                                                                                                                                                   | N= 62 paediatric (males/lemles = 32/30) and N  839 adut (males/lemales = 523/316) renal Tx palients Age (mean ± SD) Paediatic 11.4±4.5 yrs Adut48.0 ± 13.3 yrs                                                                                                                                                                                                                                                                                                                                                                                                                                          | 1. MPA exposure significanlly lower in CsA-trealed paediatric and sdult patients than in TAC-treated patients 2. Overall MMF efflcacy and tolerabllty in paediatric patients under an equivalent MMF dosage and inmunosuppressive proloeol compurable with that in adults.                                                                                                                                                                                                                                                                                                                              |
|                       | Rationale for Strength of Evidence Cp uo (ttocl p pe oopeoh Aq peesad euo en bupnpu 'ses/eue dnoubqns oy pemoge ubisep si oueq sgnedeneu jewydo oy sjebirg eunsodxe ydw efficacy, safety and MPA plasma lovels in pacdiatric (≥ 2 years) vs. adult kidney transplnt patients. As the same immunosuppressive study prolocol following Good Cinieal Practice guideline3 was used across all age groups, the analeis in 62 paediatric and 839 adult de novo palients allows lor a robusl comparison ol efficacy, safety and phammacokineties in the two age groups (see also Key Findings provided above). | Rationale for Strength of Evidence Cp uo (ttocl p pe oopeoh Aq peesad euo en bupnpu 'ses/eue dnoubqns oy pemoge ubisep si oueq sgnedeneu jewydo oy sjebirg eunsodxe ydw efficacy, safety and MPA plasma lovels in pacdiatric (≥ 2 years) vs. adult kidney transplnt patients. As the same immunosuppressive study prolocol following Good Cinieal Practice guideline3 was used across all age groups, the analeis in 62 paediatric and 839 adult de novo palients allows lor a robusl comparison ol efficacy, safety and phammacokineties in the two age groups (see also Key Findings provided above). | Rationale for Strength of Evidence Cp uo (ttocl p pe oopeoh Aq peesad euo en bupnpu 'ses/eue dnoubqns oy pemoge ubisep si oueq sgnedeneu jewydo oy sjebirg eunsodxe ydw efficacy, safety and MPA plasma lovels in pacdiatric (≥ 2 years) vs. adult kidney transplnt patients. As the same immunosuppressive study prolocol following Good Cinieal Practice guideline3 was used across all age groups, the analeis in 62 paediatric and 839 adult de novo palients allows lor a robusl comparison ol efficacy, safety and phammacokineties in the two age groups (see also Key Findings provided above). | Rationale for Strength of Evidence Cp uo (ttocl p pe oopeoh Aq peesad euo en bupnpu 'ses/eue dnoubqns oy pemoge ubisep si oueq sgnedeneu jewydo oy sjebirg eunsodxe ydw efficacy, safety and MPA plasma lovels in pacdiatric (≥ 2 years) vs. adult kidney transplnt patients. As the same immunosuppressive study prolocol following Good Cinieal Practice guideline3 was used across all age groups, the analeis in 62 paediatric and 839 adult de novo palients allows lor a robusl comparison ol efficacy, safety and phammacokineties in the two age groups (see also Key Findings provided above). |

| Key Evidence                                                                              | Key Evidence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Key Evidence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Key Evidence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Key Evidence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|-------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Literature Reference                                                                      | Study Design                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Formulation/ bupsog                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Demographies (mmber of patients; gender; age:other detais]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Key Findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Weberetal 1998                                                                            | Open-label evalation of ePKofMPAin uuedcopeed toaduneal Tx recipintseary after x Concomitant adninistration of CsA steroids MPA observahons (hee. total) 1and3weeks post-Tx                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Fermulation: capsules 600mg/m² bid (up to 2g/day)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | N-18（maes/females-108) first or second cadavenic or Iiving-related donor. Age10.7±0.72 Weight:29.3±2.49 (5.9-15.3）yrs, (16.0-50.3）kg BSA:1.02±0.06 (0.68-1.50）m                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 1.Concentraftion-timeprofilesofpoediatricrenal txrecipients adminiaered 6oomg/m? MMF bi.d.comparable to those inadults on1g MMF bidaer 3weeks of surgery 2.Free MPA fraction median 1.65% (range 0.40%-13.8%) 3.Renal impairment and decreased serun albumin levels led to an increase in free MPA eposure.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Weber et al. 1999 (long-lem lollow- up d prevcusly reporled study.3 and 6 monthspost- Tx} | Same as above                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Sameas above                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Same as axove                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 1.Doubing of exposue rom3-week to3-month observation time pon(nonstationrity in total MPAj, burt not in free MPA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Weberet al 2002                                                                           | Open-label longitudinal study of PKPD (free, lotal MPA) in54 renal transplanted chidren concomitantly admiristered MMF,CsA. steroids. MPA observations (tull) Months3 and6post proles）onDays7,21 transplart.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Formulation: CelCept capsules 600mg/m bidupto2 gday                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | N=54(males/females=33/21); Age medan {range) 11.7 (range 22-17.8）yrs                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 1.Association between the risk of acute rejection episodes and MPA exposure(AUCe predose levels) 2By eceer oprng chacrsc analyi.anAUC of338 hmg/L n t inital phase y%joodsguppue%joAquuouepepeedsueod discrmination of pafients with acule rejectiors. The relative nisk f cue jction was41%with totl MPA-AUCvalsbelw33.8 h-mg/Lcompared with 14% with total MPA-AUCenvalues above 33.8hmgL 3.The respectfive discrimination threshold for the MPA pre-dose concentration was 1.2 mg/L with a sensitivity of 83% and a specificity of 64%. MMF-related side effects leukopenia andor infections. Most of these adverse events were associatedwith free MPA-AUCs levels>0 4 hmg/L                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|                                                                                           | Rationale forStrengthof Evidence Bycomparinginthe same sudy,thephamacokieticsf MPAandofMPAGinpaedaticandadurenal ansplantecipientsa equivalent doses basedonBSA Weberetal19981999）provdediaprspecvestudydefnievidenceofcomparableaborpnand dispositonf teMMF-drivedproducts nchdnandadts pqwsgeppqo AUC30 hmgL)appeared also to beappropriate for chidren Measurement ofnot only otalbut alsofreeconcentrationsinthe wopopulationsover the frst hreeweeksafter transplantationWeberetal1998）and then alsoduing 3-and 6-monthfollow-up(Weberetal1999).allowed toprovide a mechanisticeaplanation for tepreviously empinically observed non-stationantyin thepharmacokinetcsot concentrabons ondegree of renal funcbon and on albumin concentrafions could be established. The studies by Weber et al are unique in that they allow fo compare the phamacokinetics of MPA between the eary and the late (more stable) phase after transplantation. ThePK/PD relatonship published by Weber eal.(2o02）emergesfoma coniuaion of thepnevioushy published prospective phamacokinetic studiesinrenal transplant wwudd ddueugdpedduleeog ep contextwith free and total MPAconcentrafions allowed to establish diagnosticexposure thresholdsidentityingpatients atincreasedriskofacute rejection orof toxicity in the | Rationale forStrengthof Evidence Bycomparinginthe same sudy,thephamacokieticsf MPAandofMPAGinpaedaticandadurenal ansplantecipientsa equivalent doses basedonBSA Weberetal19981999）provdediaprspecvestudydefnievidenceofcomparableaborpnand dispositonf teMMF-drivedproducts nchdnandadts pqwsgeppqo AUC30 hmgL)appeared also to beappropriate for chidren Measurement ofnot only otalbut alsofreeconcentrationsinthe wopopulationsover the frst hreeweeksafter transplantationWeberetal1998）and then alsoduing 3-and 6-monthfollow-up(Weberetal1999).allowed toprovide a mechanisticeaplanation for tepreviously empinically observed non-stationantyin thepharmacokinetcsot concentrabons ondegree of renal funcbon and on albumin concentrafions could be established. The studies by Weber et al are unique in that they allow fo compare the phamacokinetics of MPA between the eary and the late (more stable) phase after transplantation. ThePK/PD relatonship published by Weber eal.(2o02）emergesfoma coniuaion of thepnevioushy published prospective phamacokinetic studiesinrenal transplant wwudd ddueugdpedduleeog ep contextwith free and total MPAconcentrafions allowed to establish diagnosticexposure thresholdsidentityingpatients atincreasedriskofacute rejection orof toxicity in the | Rationale forStrengthof Evidence Bycomparinginthe same sudy,thephamacokieticsf MPAandofMPAGinpaedaticandadurenal ansplantecipientsa equivalent doses basedonBSA Weberetal19981999）provdediaprspecvestudydefnievidenceofcomparableaborpnand dispositonf teMMF-drivedproducts nchdnandadts pqwsgeppqo AUC30 hmgL)appeared also to beappropriate for chidren Measurement ofnot only otalbut alsofreeconcentrationsinthe wopopulationsover the frst hreeweeksafter transplantationWeberetal1998）and then alsoduing 3-and 6-monthfollow-up(Weberetal1999).allowed toprovide a mechanisticeaplanation for tepreviously empinically observed non-stationantyin thepharmacokinetcsot concentrabons ondegree of renal funcbon and on albumin concentrafions could be established. The studies by Weber et al are unique in that they allow fo compare the phamacokinetics of MPA between the eary and the late (more stable) phase after transplantation. ThePK/PD relatonship published by Weber eal.(2o02）emergesfoma coniuaion of thepnevioushy published prospective phamacokinetic studiesinrenal transplant wwudd ddueugdpedduleeog ep contextwith free and total MPAconcentrafions allowed to establish diagnosticexposure thresholdsidentityingpatients atincreasedriskofacute rejection orof toxicity in the | Rationale forStrengthof Evidence Bycomparinginthe same sudy,thephamacokieticsf MPAandofMPAGinpaedaticandadurenal ansplantecipientsa equivalent doses basedonBSA Weberetal19981999）provdediaprspecvestudydefnievidenceofcomparableaborpnand dispositonf teMMF-drivedproducts nchdnandadts pqwsgeppqo AUC30 hmgL)appeared also to beappropriate for chidren Measurement ofnot only otalbut alsofreeconcentrationsinthe wopopulationsover the frst hreeweeksafter transplantationWeberetal1998）and then alsoduing 3-and 6-monthfollow-up(Weberetal1999).allowed toprovide a mechanisticeaplanation for tepreviously empinically observed non-stationantyin thepharmacokinetcsot concentrabons ondegree of renal funcbon and on albumin concentrafions could be established. The studies by Weber et al are unique in that they allow fo compare the phamacokinetics of MPA between the eary and the late (more stable) phase after transplantation. ThePK/PD relatonship published by Weber eal.(2o02）emergesfoma coniuaion of thepnevioushy published prospective phamacokinetic studiesinrenal transplant wwudd ddueugdpedduleeog ep contextwith free and total MPAconcentrafions allowed to establish diagnosticexposure thresholdsidentityingpatients atincreasedriskofacute rejection orof toxicity in the |

<div style=\"page-break-after: always\"></div>

## Paediatric heart transplantation:

## Table 4 Comparative Data: Paediatric Heart Transplantation (Literature References)

| Key Evidence          | Key Evidence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Key Evidence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Key Evidence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Key Evidence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Literature Reference  | Study Design                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Formulation/ Dosing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Demographics (number of patients; gender;age;other details)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | KeyFindings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Dipchand et al. 2001a | Reviewof paediatricheart Tx database (Nov 1997-Oct 1988) Review relationshipof serum trough MPA levels and dose,target trough level >3μg/L（sic)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | CellCeptcrushed tablets                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | N-44 (males/females=27/17): Medianage atTx2.7yrs (7 days-18.4yrs).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 1.HigherMMFdosesmayberequired bychildrenat 2.Dosing by body surface area may be advantageous. 3.Therapeutic drug monitoring of MPA.may berequired for optimal dosing.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|                       | Rationale forStrengthofEvidence Dipchand et al.(200ia)present the cross-sectional resultsfrom areview of data in thepaediatric heart transplant databaseat the Chidrens Hospital inDenver Colorado(observation period approximately oneyear).The analysis was based on a sizeablenumber of patients(n=44). but limited number of troughMPAlevels（n=128).From the majorityofpatientsmore than one samplecouldbe obtained.Given thepaucity ofinformation frompaediatnicheart transplantpatients,the results from thisanalysis are veryvaluable andimportant conclusionscouldbe drawn,notonlyonpharmacokinetics,but also ontherelationshipofMPA concentrationsandrejection episodes.Withamedian ageat transplantof 27yrs,many veryyoungpatients wereapparentlyincludedinthestudy.ThisstudywasthefirstintheliteraturetoreportMMF | Rationale forStrengthofEvidence Dipchand et al.(200ia)present the cross-sectional resultsfrom areview of data in thepaediatric heart transplant databaseat the Chidrens Hospital inDenver Colorado(observation period approximately oneyear).The analysis was based on a sizeablenumber of patients(n=44). but limited number of troughMPAlevels（n=128).From the majorityofpatientsmore than one samplecouldbe obtained.Given thepaucity ofinformation frompaediatnicheart transplantpatients,the results from thisanalysis are veryvaluable andimportant conclusionscouldbe drawn,notonlyonpharmacokinetics,but also ontherelationshipofMPA concentrationsandrejection episodes.Withamedian ageat transplantof 27yrs,many veryyoungpatients wereapparentlyincludedinthestudy.ThisstudywasthefirstintheliteraturetoreportMMF | Rationale forStrengthofEvidence Dipchand et al.(200ia)present the cross-sectional resultsfrom areview of data in thepaediatric heart transplant databaseat the Chidrens Hospital inDenver Colorado(observation period approximately oneyear).The analysis was based on a sizeablenumber of patients(n=44). but limited number of troughMPAlevels（n=128).From the majorityofpatientsmore than one samplecouldbe obtained.Given thepaucity ofinformation frompaediatnicheart transplantpatients,the results from thisanalysis are veryvaluable andimportant conclusionscouldbe drawn,notonlyonpharmacokinetics,but also ontherelationshipofMPA concentrationsandrejection episodes.Withamedian ageat transplantof 27yrs,many veryyoungpatients wereapparentlyincludedinthestudy.ThisstudywasthefirstintheliteraturetoreportMMF | Rationale forStrengthofEvidence Dipchand et al.(200ia)present the cross-sectional resultsfrom areview of data in thepaediatric heart transplant databaseat the Chidrens Hospital inDenver Colorado(observation period approximately oneyear).The analysis was based on a sizeablenumber of patients(n=44). but limited number of troughMPAlevels（n=128).From the majorityofpatientsmore than one samplecouldbe obtained.Given thepaucity ofinformation frompaediatnicheart transplantpatients,the results from thisanalysis are veryvaluable andimportant conclusionscouldbe drawn,notonlyonpharmacokinetics,but also ontherelationshipofMPA concentrationsandrejection episodes.Withamedian ageat transplantof 27yrs,many veryyoungpatients wereapparentlyincludedinthestudy.ThisstudywasthefirstintheliteraturetoreportMMF |

| Key Evidence         | Key Evidence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Key Evidence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Key Evidence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Key Evidence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Literature Reference | Study Design                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Formulation/ Dosing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Demographics (number of patients; gender;age;other details)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Key Findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Gajarski et al. 2004 | Retrospective josisAjeue medicalrecords of paediatric and young adult cardiac Tx patents trealed withMMF in combination with aCNI(TAC, CsA)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Formulationc n.a. Paediatric dosing: 1200mg/m²（≤3g) perday                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | n-16 chldren,n-10 adults Age15.4±9.5yrs(1month-                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 1.Nocorrelationof MMFdosewithMPA/MPAGlevels; standard MMF dosing fails to consistently achieve therapeutic\"MPAconcentrations. 2.Concentration-ratherthandose-drivenmanagementis more prudent strategywhen usingMMF 3.Plasmalevels≥2.5mg/Lare associated with lower biopsy grades.                                                                                                                                                                                                                                                                                                                                                                                                        |
| Gajarski et al. 2004 | Rationale forStrengthof Evidence Ina retrospective review of patient records,Gajarskiet al.(2004) addressed the frequency with which standard dosing could achieve therapeuticplasma concentraionsinpaediatricandadulthearttransplantpatients,withaviewof determining athresholdMPA were wellawareof imitations andbias,whichcould beintroduced by their analysis.To mitigate these,theyusedvarious modalities for analyzing their database.Hence,the conclusions onno statistical difference in MPA exposure at therapeutic levels between paediatnc and young adult groups,ona trend to underdosing withrecommended dosing regimens,andontheproposed threshold trough level of 2.5mg/L | Rationale forStrengthof Evidence Ina retrospective review of patient records,Gajarskiet al.(2004) addressed the frequency with which standard dosing could achieve therapeuticplasma concentraionsinpaediatricandadulthearttransplantpatients,withaviewof determining athresholdMPA were wellawareof imitations andbias,whichcould beintroduced by their analysis.To mitigate these,theyusedvarious modalities for analyzing their database.Hence,the conclusions onno statistical difference in MPA exposure at therapeutic levels between paediatnc and young adult groups,ona trend to underdosing withrecommended dosing regimens,andontheproposed threshold trough level of 2.5mg/L | Rationale forStrengthof Evidence Ina retrospective review of patient records,Gajarskiet al.(2004) addressed the frequency with which standard dosing could achieve therapeuticplasma concentraionsinpaediatricandadulthearttransplantpatients,withaviewof determining athresholdMPA were wellawareof imitations andbias,whichcould beintroduced by their analysis.To mitigate these,theyusedvarious modalities for analyzing their database.Hence,the conclusions onno statistical difference in MPA exposure at therapeutic levels between paediatnc and young adult groups,ona trend to underdosing withrecommended dosing regimens,andontheproposed threshold trough level of 2.5mg/L | Rationale forStrengthof Evidence Ina retrospective review of patient records,Gajarskiet al.(2004) addressed the frequency with which standard dosing could achieve therapeuticplasma concentraionsinpaediatricandadulthearttransplantpatients,withaviewof determining athresholdMPA were wellawareof imitations andbias,whichcould beintroduced by their analysis.To mitigate these,theyusedvarious modalities for analyzing their database.Hence,the conclusions onno statistical difference in MPA exposure at therapeutic levels between paediatnc and young adult groups,ona trend to underdosing withrecommended dosing regimens,andontheproposed threshold trough level of 2.5mg/L |

CNl-calcineurininhbitor,CsA-ciclosporin A:MMF-mycophenolate mofetil,MPA=mycophenolic acid;MPAG=mycophenolic acid phenolic glucuronide;n.anot available;TAC=tacrolimus;Tx= transplantation]. yrs=years.

## Paediatric liver transplantation:

## Table 5 Comparative Data: Paediatric Liver Transplantation (Roche Study Report)

| Study/ Reference'                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Study Design                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Formuiationl Dosing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Demographics (number ofpatients: gender;age;other                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | KeyFindings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Lobritto et al. 2007 Study PA16497 (Roche Report No.1019844)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Open-label study in paediatric patients with liver Tx26month'sprior tostudy entry.AlI patients on stable CsA≥2daysprior toplasma sampling.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Formulaton n.a. MMF dose medan125mg (meantSD 138±522mg corresponding to 270mg/m² (285±81,1mg/m²) 12.6mg/kg （12.9±3.32mg/kg）                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | N=8patients (males/femalesm3/5). median age 16(range 9-60)months;median body weight 10.5kg (mean±SD10.6±2.1 kgmedian BSA 0.465m (0.476±0.064 m²) Time since Tx. 26months.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 1.Rationale for dose recommendation inpaediatric liver Tx patientswith concomitant CsAtreatment. 2. In combinationwithCsA,MMFdosing of740 mg/m²twice daily achieves MPAexposures inpaediatricliver Txpatients sinilar to those observedinadult iverTxrecipients,58h-mg/Lduring the laepost-Txperiod (>6months)and29 hmg/Lin the immediate post-Tx period.                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Assessment of Relevance Asingle open-label,multi-centre uncontrolledstudy inpaediatnicliver allograftrecipients(StudyPA16497)wasconductedinRoche'spaediatncliver transplantation program.The study was to estimate theMMF doserequired in thispopulationinpresence of CsAand corticosteroidsforprophylaxis ofacute organ rejection.An exposurewas targetedin the study that would provide an MPAexposureinpaediatricpatients thatwas comparable to that achievedin adult Iiver transplant patients receiving the approved dose of MMF in Study MYCS2646(58h μg/mL in the late,29 h μg/mL in theimmediate post-transplant period. Thefirstpartof the study was designed to estimatea dose thatwouldprovidethe targetMPA exposure in the latepost-ransplantperiod;thesecond confrmatory | Assessment of Relevance Asingle open-label,multi-centre uncontrolledstudy inpaediatnicliver allograftrecipients(StudyPA16497)wasconductedinRoche'spaediatncliver transplantation program.The study was to estimate theMMF doserequired in thispopulationinpresence of CsAand corticosteroidsforprophylaxis ofacute organ rejection.An exposurewas targetedin the study that would provide an MPAexposureinpaediatricpatients thatwas comparable to that achievedin adult Iiver transplant patients receiving the approved dose of MMF in Study MYCS2646(58h μg/mL in the late,29 h μg/mL in theimmediate post-transplant period. Thefirstpartof the study was designed to estimatea dose thatwouldprovidethe targetMPA exposure in the latepost-ransplantperiod;thesecond confrmatory | Assessment of Relevance Asingle open-label,multi-centre uncontrolledstudy inpaediatnicliver allograftrecipients(StudyPA16497)wasconductedinRoche'spaediatncliver transplantation program.The study was to estimate theMMF doserequired in thispopulationinpresence of CsAand corticosteroidsforprophylaxis ofacute organ rejection.An exposurewas targetedin the study that would provide an MPAexposureinpaediatricpatients thatwas comparable to that achievedin adult Iiver transplant patients receiving the approved dose of MMF in Study MYCS2646(58h μg/mL in the late,29 h μg/mL in theimmediate post-transplant period. Thefirstpartof the study was designed to estimatea dose thatwouldprovidethe targetMPA exposure in the latepost-ransplantperiod;thesecond confrmatory | Assessment of Relevance Asingle open-label,multi-centre uncontrolledstudy inpaediatnicliver allograftrecipients(StudyPA16497)wasconductedinRoche'spaediatncliver transplantation program.The study was to estimate theMMF doserequired in thispopulationinpresence of CsAand corticosteroidsforprophylaxis ofacute organ rejection.An exposurewas targetedin the study that would provide an MPAexposureinpaediatricpatients thatwas comparable to that achievedin adult Iiver transplant patients receiving the approved dose of MMF in Study MYCS2646(58h μg/mL in the late,29 h μg/mL in theimmediate post-transplant period. Thefirstpartof the study was designed to estimatea dose thatwouldprovidethe targetMPA exposure in the latepost-ransplantperiod;thesecond confrmatory | Assessment of Relevance Asingle open-label,multi-centre uncontrolledstudy inpaediatnicliver allograftrecipients(StudyPA16497)wasconductedinRoche'spaediatncliver transplantation program.The study was to estimate theMMF doserequired in thispopulationinpresence of CsAand corticosteroidsforprophylaxis ofacute organ rejection.An exposurewas targetedin the study that would provide an MPAexposureinpaediatricpatients thatwas comparable to that achievedin adult Iiver transplant patients receiving the approved dose of MMF in Study MYCS2646(58h μg/mL in the late,29 h μg/mL in theimmediate post-transplant period. Thefirstpartof the study was designed to estimatea dose thatwouldprovidethe targetMPA exposure in the latepost-ransplantperiod;thesecond confrmatory |

BSA-body surface area;CsA=ciclosporin A:MMFnycophenolate mofetil;MPAntycophenolicacid;Txmtransplant(ation):yrs=years.

<div style=\"page-break-after: always\"></div>

## Table 6 Comparative Data: Paediatric Liver Transplantation (Literature References)

| Key Evidence          | Key Evidence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Key Evidence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Key Evidence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Key Evidence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Literature Reference\" | Study Design                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Formulation/ Dosing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Demographics (number of patients: gender; age;other details)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Key Findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Browm et al. 2002     | 21 stable paedatric liver Txpatients (9 females, 12males)on oral MMF therapy combined with either low-doseTAC(n=11) orlow-dose CsA (n-10)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | n.a.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Age median(range)9.5 (2.1-15,5yrs）weight 9.4-80kg Median（range） time since Tx 4.7(1.3-11.4)yrs.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Co-medicationwithCsAdemandedhigherMMF doses to achieve equivalent trough levels than with TAC. 2 Trough levels were closely coelated withAUC. 3 Wide inler-individualvariabilty inMPA phamacokinetics showed need for therapeutic drug monitoning.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Browm et al. 2002     | Rationale forStrength of Evidence The pubication by Brown et al.(2002)was the first to reporton the absorpion and disposition charactensticsofMPA/MPAGinpaediatricIiver transplant patients （stable phase after transplantation）.To find the nght dose,initially low doses of MFwereincreasedif welltolerated (up to1gtwice daily）or reduced if side effects emerged.Concomitantly administeredimmunosuppressants were a CNl (CsA or TAC)and stercids.The analysis of this prospective studyis based on7-h concentration-timeprofiles andis ofhighqualty.MPAandMPAGconcentrationswere detemned byaspecifc HPLCmethod.Findings from Brown etal (2002) served as reference for laterstudies in the same paediatric populaton as they clarified the key aspects of MPApharmacokinetics in iver transplanted children;they also addressed the effects ofcovariateson MPAand MPAGpharmacokinetics and the influence of the type of co-administered CNl onMPA dispositonThe number of chldren in the studymay seem limited,but was adequate to define fhe | Rationale forStrength of Evidence The pubication by Brown et al.(2002)was the first to reporton the absorpion and disposition charactensticsofMPA/MPAGinpaediatricIiver transplant patients （stable phase after transplantation）.To find the nght dose,initially low doses of MFwereincreasedif welltolerated (up to1gtwice daily）or reduced if side effects emerged.Concomitantly administeredimmunosuppressants were a CNl (CsA or TAC)and stercids.The analysis of this prospective studyis based on7-h concentration-timeprofiles andis ofhighqualty.MPAandMPAGconcentrationswere detemned byaspecifc HPLCmethod.Findings from Brown etal (2002) served as reference for laterstudies in the same paediatric populaton as they clarified the key aspects of MPApharmacokinetics in iver transplanted children;they also addressed the effects ofcovariateson MPAand MPAGpharmacokinetics and the influence of the type of co-administered CNl onMPA dispositonThe number of chldren in the studymay seem limited,but was adequate to define fhe | Rationale forStrength of Evidence The pubication by Brown et al.(2002)was the first to reporton the absorpion and disposition charactensticsofMPA/MPAGinpaediatricIiver transplant patients （stable phase after transplantation）.To find the nght dose,initially low doses of MFwereincreasedif welltolerated (up to1gtwice daily）or reduced if side effects emerged.Concomitantly administeredimmunosuppressants were a CNl (CsA or TAC)and stercids.The analysis of this prospective studyis based on7-h concentration-timeprofiles andis ofhighqualty.MPAandMPAGconcentrationswere detemned byaspecifc HPLCmethod.Findings from Brown etal (2002) served as reference for laterstudies in the same paediatric populaton as they clarified the key aspects of MPApharmacokinetics in iver transplanted children;they also addressed the effects ofcovariateson MPAand MPAGpharmacokinetics and the influence of the type of co-administered CNl onMPA dispositonThe number of chldren in the studymay seem limited,but was adequate to define fhe | Rationale forStrength of Evidence The pubication by Brown et al.(2002)was the first to reporton the absorpion and disposition charactensticsofMPA/MPAGinpaediatricIiver transplant patients （stable phase after transplantation）.To find the nght dose,initially low doses of MFwereincreasedif welltolerated (up to1gtwice daily）or reduced if side effects emerged.Concomitantly administeredimmunosuppressants were a CNl (CsA or TAC)and stercids.The analysis of this prospective studyis based on7-h concentration-timeprofiles andis ofhighqualty.MPAandMPAGconcentrationswere detemned byaspecifc HPLCmethod.Findings from Brown etal (2002) served as reference for laterstudies in the same paediatric populaton as they clarified the key aspects of MPApharmacokinetics in iver transplanted children;they also addressed the effects ofcovariateson MPAand MPAGpharmacokinetics and the influence of the type of co-administered CNl onMPA dispositonThe number of chldren in the studymay seem limited,but was adequate to define fhe |

| Key Evidence                       | Key Evidence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Key Evidence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Key Evidence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Key Evidence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Literature Reference'              | Study Design                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Formulation/ Dosing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Demographics (number of patients;gender; age:other details)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Key Findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Barau et al. 2012 (Barau et  2011) | Paediatric Iiver Tx patients recerved oral MMF therapy combinedwith either Intensive sampling to TAC(n=23）or CsA (9=u) determine populabon parameters,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Formulation:n.a. (partly oral suspension) MMF starting dose median380mg/m² adjustment to achieve MPA-guided dose (13.0 mg/kg）.range 186-594mg/m²-b.i.d MPAAUCsn beween 30-60hmg/L                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | N=28patents (males/females=14r14) Age range 1.1-18 (median 8.65) yrs: BSA 0.44-1.69m² Time since Tx median (range) Weight 9.3-63.2kg 17.2(0.2-188.5)months.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | From Barau et al. 2012 (full dataset) 1. Time after Tx（Svs.>6 months）and age affect MPA PKinpaediaticliver Txpatients 2. MPA exposure helps tooptimise paediatic pafient care From Barau etal.2011 (smaller,overlapping dataset) procedure. and can be determned by a simple sampling 1. MMF dosage had to be increased in all but 1 patient to reach at least30 h-mg/Lexposure Aninitial MMFdoseof 600mg/m²bid.isrequiredfor paediatric liver txrecipients whenMMFsadministered together with TACto achieve the target MPA AUCsan of 30hmg/L 2. For 2 patients with co-administered rifampicin in addition to MMF,MPA AUCoremained low despite 2-fold increase in the MMF dose. |
| Barau et al. 2012 (Barau et  2011) | Rationale for Strength of Evidence TheprospectivestudiesbyBarauetal.pubishedfirstwithareducedand laerwithanenlargeddatasetaddressseveral therapy-relevant phamacokinetic aspects of MMF dosing in paediatric liver transplant patients,Notonly were total and also free(protein-unbound)concentrations from dode contributing to the overall high variability seeninMPAconcentrations. Quantificationof MPAand MPAGlevels and protein binding deteminations were based on state-of-the-artmethods(validated HPLCmethods,unbound an extemal validation data set. Both,early and late（stable）transplant penodswere coveredby theirpaediatricpopulation and allowed to elucidate | Rationale for Strength of Evidence TheprospectivestudiesbyBarauetal.pubishedfirstwithareducedand laerwithanenlargeddatasetaddressseveral therapy-relevant phamacokinetic aspects of MMF dosing in paediatric liver transplant patients,Notonly were total and also free(protein-unbound)concentrations from dode contributing to the overall high variability seeninMPAconcentrations. Quantificationof MPAand MPAGlevels and protein binding deteminations were based on state-of-the-artmethods(validated HPLCmethods,unbound an extemal validation data set. Both,early and late（stable）transplant penodswere coveredby theirpaediatricpopulation and allowed to elucidate | Rationale for Strength of Evidence TheprospectivestudiesbyBarauetal.pubishedfirstwithareducedand laerwithanenlargeddatasetaddressseveral therapy-relevant phamacokinetic aspects of MMF dosing in paediatric liver transplant patients,Notonly were total and also free(protein-unbound)concentrations from dode contributing to the overall high variability seeninMPAconcentrations. Quantificationof MPAand MPAGlevels and protein binding deteminations were based on state-of-the-artmethods(validated HPLCmethods,unbound an extemal validation data set. Both,early and late（stable）transplant penodswere coveredby theirpaediatricpopulation and allowed to elucidate | Rationale for Strength of Evidence TheprospectivestudiesbyBarauetal.pubishedfirstwithareducedand laerwithanenlargeddatasetaddressseveral therapy-relevant phamacokinetic aspects of MMF dosing in paediatric liver transplant patients,Notonly were total and also free(protein-unbound)concentrations from dode contributing to the overall high variability seeninMPAconcentrations. Quantificationof MPAand MPAGlevels and protein binding deteminations were based on state-of-the-artmethods(validated HPLCmethods,unbound an extemal validation data set. Both,early and late（stable）transplant penodswere coveredby theirpaediatricpopulation and allowed to elucidate    |

| Key Evidence          | Key Evidence                                                                                                                                                                                                                                                                                                                                           | Key Evidence                                                                                                                                                                                                                                                                                                                                           | Key Evidence                                                                                                                                                                                                                                                                                                                                           | Key Evidence                                                                                                                                                                                                                                                                                                                                           |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Literature Reference' | Study Design                                                                                                                                                                                                                                                                                                                                           | Formulationl Dosing                                                                                                                                                                                                                                                                                                                                    | Demographics (number of patients; gender; age;other detalls)                                                                                                                                                                                                                                                                                           | Key Findings                                                                                                                                                                                                                                                                                                                                           |
| Ueno etal.2020        | 5paediatricIiver Tx patients on oral MMFtherapy combined with TAC and steroids.MMF dose adjustment to reach target trough MPA2mg/L Duration of observation: 17 (6- 30)months                                                                                                                                                                           | Formulation:n.a. Mean (range)initial MMF dose.32 (23-53）mg/kg.770 (570-960)mg/m²/day                                                                                                                                                                                                                                                                   | Mean (range) Age at Tx8(3-10）months Weight 7.6(4.7-10.7 kg) BSA 0.35 (0.260.39) m                                                                                                                                                                                                                                                                      | Meanfinal MMFdosefor2mg/Ltarget trough concentrationwas1200mg/m/day or50mg/kg/day                                                                                                                                                                                                                                                                      |
|                       | Rationale forStrength of Evidence focus,butbecausea veryyoungpatientpopulaion(5infantsaferliving-donorliver transplantatonageat transplant310months)wasstudied. Thisstudy allowed toventfy(andconfirm)observationsbyseveralauthors thatdoserequirements arehigherin theveryyoungpopulation thanin ozounonueqbyujoopjeguueuubugnpeseumepsunpusuedupedpo | Rationale forStrength of Evidence focus,butbecausea veryyoungpatientpopulaion(5infantsaferliving-donorliver transplantatonageat transplant310months)wasstudied. Thisstudy allowed toventfy(andconfirm)observationsbyseveralauthors thatdoserequirements arehigherin theveryyoungpopulation thanin ozounonueqbyujoopjeguueuubugnpeseumepsunpusuedupedpo | Rationale forStrength of Evidence focus,butbecausea veryyoungpatientpopulaion(5infantsaferliving-donorliver transplantatonageat transplant310months)wasstudied. Thisstudy allowed toventfy(andconfirm)observationsbyseveralauthors thatdoserequirements arehigherin theveryyoungpopulation thanin ozounonueqbyujoopjeguueuubugnpeseumepsunpusuedupedpo | Rationale forStrength of Evidence focus,butbecausea veryyoungpatientpopulaion(5infantsaferliving-donorliver transplantatonageat transplant310months)wasstudied. Thisstudy allowed toventfy(andconfirm)observationsbyseveralauthors thatdoserequirements arehigherin theveryyoungpopulation thanin ozounonueqbyujoopjeguueuubugnpeseumepsunpusuedupedpo |

<div style=\"page-break-after: always\"></div>

| Supportive Evidence   | Supportive Evidence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Supportive Evidence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Supportive Evidence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Supportive Evidence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|-----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Literature Reference' | Study Design                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Formulationl Dosing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Demographics (number ofpatients;gender: age;other details)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Key Findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Parant et al.2009     | Prospective open-label study in paediatnc patients withliver Tx ≥3months prior to study enrolment; TAC co-administration                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Formulation CellCept MMF dosemedian431 (range 189-833) mg/n²/day                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | N-20patents (males/females=11/9); Median (range) Age 12（1-18）yrs; Weight 31.4(8.2-61) kg: Paediatric/adu donors:12/8; Time sinceTx.≥3months Analytics:EMIT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 1. Donor characteristics had an influence on MPA exposure in the youngest chidren. 2. Toachievea target MPA-AUCof 45hmg/L,MMF dosesrequiredwere400-800mg/m2ldaywhen combinedwithTAC;young children receiving livers frompaediatric donorsrequired dosesof600-1000 mg/m²/day                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|                       | RationaleforStrengthofEvidence Theprospective study byParant et al.(2009)in stablepaediatric liver transplant chidren had an interesting focus,namelyreasons forthe highvariability in MPA'spharmacokineticswith a view of factorsrelating torecipienf ageand donor characteristics（paediatricvs.adult）.The study uncovered that there Inthe study repeat profilesfrom children（up to4repeats/individual）were available.Unfortunately,no evaluation orinformationinthe study descnption isgiven on theresultsfrom theserepeatedmeasurements-amissedopportunity The presentedstudy has several limitations andresuiltsrequire confirmationina largercohortThe low starting dose of 20 mg/kg led to underexposure inamajority ofpatients andhad beenfoundparticularypronouncedintheyoungerpatients.Thiswasobviouslyasurprise to the authors,butbasedon andolderpaedatcpaents,witha boundaryvalueof10years,isartificialandconclusions fortheyoungcategorymaynotapplytoallagesbelow 10years.Forquantficaton of MPAin the study,the non-specificEMIT assay was appliedFurthernore,theAUCeposure measure in the study was estimated based onan abbreviatedprofile(4 datapoints determined up to 6 h post administration). Theuse of this reducedAUCto explore single time pointmeasures,which could equally wellpredict thefullAuCisnot appropriateand conclusionsby thestudy authorsrelating to thisneed clearty | RationaleforStrengthofEvidence Theprospective study byParant et al.(2009)in stablepaediatric liver transplant chidren had an interesting focus,namelyreasons forthe highvariability in MPA'spharmacokineticswith a view of factorsrelating torecipienf ageand donor characteristics（paediatricvs.adult）.The study uncovered that there Inthe study repeat profilesfrom children（up to4repeats/individual）were available.Unfortunately,no evaluation orinformationinthe study descnption isgiven on theresultsfrom theserepeatedmeasurements-amissedopportunity The presentedstudy has several limitations andresuiltsrequire confirmationina largercohortThe low starting dose of 20 mg/kg led to underexposure inamajority ofpatients andhad beenfoundparticularypronouncedintheyoungerpatients.Thiswasobviouslyasurprise to the authors,butbasedon andolderpaedatcpaents,witha boundaryvalueof10years,isartificialandconclusions fortheyoungcategorymaynotapplytoallagesbelow 10years.Forquantficaton of MPAin the study,the non-specificEMIT assay was appliedFurthernore,theAUCeposure measure in the study was estimated based onan abbreviatedprofile(4 datapoints determined up to 6 h post administration). Theuse of this reducedAUCto explore single time pointmeasures,which could equally wellpredict thefullAuCisnot appropriateand conclusionsby thestudy authorsrelating to thisneed clearty | RationaleforStrengthofEvidence Theprospective study byParant et al.(2009)in stablepaediatric liver transplant chidren had an interesting focus,namelyreasons forthe highvariability in MPA'spharmacokineticswith a view of factorsrelating torecipienf ageand donor characteristics（paediatricvs.adult）.The study uncovered that there Inthe study repeat profilesfrom children（up to4repeats/individual）were available.Unfortunately,no evaluation orinformationinthe study descnption isgiven on theresultsfrom theserepeatedmeasurements-amissedopportunity The presentedstudy has several limitations andresuiltsrequire confirmationina largercohortThe low starting dose of 20 mg/kg led to underexposure inamajority ofpatients andhad beenfoundparticularypronouncedintheyoungerpatients.Thiswasobviouslyasurprise to the authors,butbasedon andolderpaedatcpaents,witha boundaryvalueof10years,isartificialandconclusions fortheyoungcategorymaynotapplytoallagesbelow 10years.Forquantficaton of MPAin the study,the non-specificEMIT assay was appliedFurthernore,theAUCeposure measure in the study was estimated based onan abbreviatedprofile(4 datapoints determined up to 6 h post administration). Theuse of this reducedAUCto explore single time pointmeasures,which could equally wellpredict thefullAuCisnot appropriateand conclusionsby thestudy authorsrelating to thisneed clearty | RationaleforStrengthofEvidence Theprospective study byParant et al.(2009)in stablepaediatric liver transplant chidren had an interesting focus,namelyreasons forthe highvariability in MPA'spharmacokineticswith a view of factorsrelating torecipienf ageand donor characteristics（paediatricvs.adult）.The study uncovered that there Inthe study repeat profilesfrom children（up to4repeats/individual）were available.Unfortunately,no evaluation orinformationinthe study descnption isgiven on theresultsfrom theserepeatedmeasurements-amissedopportunity The presentedstudy has several limitations andresuiltsrequire confirmationina largercohortThe low starting dose of 20 mg/kg led to underexposure inamajority ofpatients andhad beenfoundparticularypronouncedintheyoungerpatients.Thiswasobviouslyasurprise to the authors,butbasedon andolderpaedatcpaents,witha boundaryvalueof10years,isartificialandconclusions fortheyoungcategorymaynotapplytoallagesbelow 10years.Forquantficaton of MPAin the study,the non-specificEMIT assay was appliedFurthernore,theAUCeposure measure in the study was estimated based onan abbreviatedprofile(4 datapoints determined up to 6 h post administration). Theuse of this reducedAUCto explore single time pointmeasures,which could equally wellpredict thefullAuCisnot appropriateand conclusionsby thestudy authorsrelating to thisneed clearty |

| Supportive Evidence   | Supportive Evidence                                                                                                                                                                                                                                                                                                                                                                                                        | Supportive Evidence                                                                                                                                                                                                                                                                                                                                                                                                        | Supportive Evidence                                                                                                                                                                                                                                                                                                                                                                                                        | Supportive Evidence                                                                                                                                                                                                                                                                                                                                                                                                        |
|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Literature Reference' | Study Design                                                                                                                                                                                                                                                                                                                                                                                                               | Formulation/ Dosing                                                                                                                                                                                                                                                                                                                                                                                                        | Demographics (number ofpatients;gender;age;other details)                                                                                                                                                                                                                                                                                                                                                                  | Key Findings                                                                                                                                                                                                                                                                                                                                                                                                               |
| Tannurietal 2007      | MMF,initiation in 11paediatrieliver Tx patients after renal impaiment induced by CNI; reduction of CNI doseto50%                                                                                                                                                                                                                                                                                                           | Fornulation:na. MMF dose initally 20 mg/kg/day. increased o 40 mg/kg/day within 2woek intorval                                                                                                                                                                                                                                                                                                                             | N-11chidren(males/females=5/6)withliver Tx and renal dysfuncbon,time post-Tx1.3-12.5yrs Age range:3-15yrs Weight range:14-55kg                                                                                                                                                                                                                                                                                             | 1, 40mg/kg/day MMFpromotedprolonged improvementinrenal function without changingliver function. 2 Eartyintroduction ofMMF benefits patients with mininal renal dysfuncbion andprevents irreversiblerenal damage                                                                                                                                                                                                            |
|                       | Rationale forStrengthof Evidence Tannurietal.(2007）ivesigatedretrospecivelyaspecial siuatonnamelyinitiationofMMF therapyandreductionof CNIdosesinpaediaticliver transplant patents withrenalimpaiment（secondary to prolongeduse ofCsAorTAC).At the time ofintroduction of MMF,the 11 transplantrecipients were importantlytoan assessment ofthebeneficial kidney-sparingeflectsof MMFinpaediatricIiver transplanl patients | Rationale forStrengthof Evidence Tannurietal.(2007）ivesigatedretrospecivelyaspecial siuatonnamelyinitiationofMMF therapyandreductionof CNIdosesinpaediaticliver transplant patents withrenalimpaiment（secondary to prolongeduse ofCsAorTAC).At the time ofintroduction of MMF,the 11 transplantrecipients were importantlytoan assessment ofthebeneficial kidney-sparingeflectsof MMFinpaediatricIiver transplanl patients | Rationale forStrengthof Evidence Tannurietal.(2007）ivesigatedretrospecivelyaspecial siuatonnamelyinitiationofMMF therapyandreductionof CNIdosesinpaediaticliver transplant patents withrenalimpaiment（secondary to prolongeduse ofCsAorTAC).At the time ofintroduction of MMF,the 11 transplantrecipients were importantlytoan assessment ofthebeneficial kidney-sparingeflectsof MMFinpaediatricIiver transplanl patients | Rationale forStrengthof Evidence Tannurietal.(2007）ivesigatedretrospecivelyaspecial siuatonnamelyinitiationofMMF therapyandreductionof CNIdosesinpaediaticliver transplant patents withrenalimpaiment（secondary to prolongeduse ofCsAorTAC).At the time ofintroduction of MMF,the 11 transplantrecipients were importantlytoan assessment ofthebeneficial kidney-sparingeflectsof MMFinpaediatricIiver transplanl patients |

| Supportive Evidence   | Supportive Evidence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Supportive Evidence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Supportive Evidence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Supportive Evidence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Literature Reference' | Study Design                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Formulation/ Dosing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Demographics (number of patients;gender;age; other details)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Key Findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Attard et al. 2008    | Validation of imited sampling strategyin paediatic iver Tx recipients by measurenent of serial 0- 8h MPA plasma open-label multi-centre concentrations from an study.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Formulation:n.a. MMF (mean [SEM] Center Balimore. TACco-md:219(40) mg/day Center London: TACco-med285(45) mg/day CsAco-med:548(71) AepEcu                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | N=41 chldnen from two centres;mean (SEM), Center Balfimore males/feales =8/12,median Age4.0 (0.5-17.2)yrs Weight26.7 (4.3）kg BSA:0.9(0.1）m² MPA analytics: HPLC Center London: males/females-10/11,medianAge6.2 (1.2-16.5)yrs Weight 33.6(4.2)kg Height 128(5.5)cm BSA:1.1(0.1)m MPA analytics:EMIT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 1.HigherrequiredMMF doses whencombinedwith TAC thanwith CsA 2.The very young patients (age<1 yr)achieved lower overal plasma MPA AUC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|                       | Rationale forStrength of Evidence Two different daasetswere available toAttard etal.(2008）foranevaluonof the vale of alimted sampling strategy.alowing toesmate,inpadiatic Iivertransplant patents treatedwithMMF,MPAexposure usingrelevant and feasiblemetnics.Two transplant centres contbuted concentration-time profles covering 8 h (of the 12-h dosing interval?).As one of the centres included patients co-treated with TAC or CsA,observed differences in MPA exposure botween groups with a different CNl could refiably be assessed. There were inportant imitations in the study to judge the observed phamacokinetic characteristics of MPA.Time of sanple collection affer transplantaion senusoppunountgedfupnpuepqpsepddeBgpypdsou) Mean doses administered are given in mgday and it is not clear to what dose relatve to BSA they relate to.Furthermore,there were diffrences betwegn the centresin dosesadministered (despite no apparenit differencesin height,weight,BSA between patients),andin the analtical methods employed for | Rationale forStrength of Evidence Two different daasetswere available toAttard etal.(2008）foranevaluonof the vale of alimted sampling strategy.alowing toesmate,inpadiatic Iivertransplant patents treatedwithMMF,MPAexposure usingrelevant and feasiblemetnics.Two transplant centres contbuted concentration-time profles covering 8 h (of the 12-h dosing interval?).As one of the centres included patients co-treated with TAC or CsA,observed differences in MPA exposure botween groups with a different CNl could refiably be assessed. There were inportant imitations in the study to judge the observed phamacokinetic characteristics of MPA.Time of sanple collection affer transplantaion senusoppunountgedfupnpuepqpsepddeBgpypdsou) Mean doses administered are given in mgday and it is not clear to what dose relatve to BSA they relate to.Furthermore,there were diffrences betwegn the centresin dosesadministered (despite no apparenit differencesin height,weight,BSA between patients),andin the analtical methods employed for | Rationale forStrength of Evidence Two different daasetswere available toAttard etal.(2008）foranevaluonof the vale of alimted sampling strategy.alowing toesmate,inpadiatic Iivertransplant patents treatedwithMMF,MPAexposure usingrelevant and feasiblemetnics.Two transplant centres contbuted concentration-time profles covering 8 h (of the 12-h dosing interval?).As one of the centres included patients co-treated with TAC or CsA,observed differences in MPA exposure botween groups with a different CNl could refiably be assessed. There were inportant imitations in the study to judge the observed phamacokinetic characteristics of MPA.Time of sanple collection affer transplantaion senusoppunountgedfupnpuepqpsepddeBgpypdsou) Mean doses administered are given in mgday and it is not clear to what dose relatve to BSA they relate to.Furthermore,there were diffrences betwegn the centresin dosesadministered (despite no apparenit differencesin height,weight,BSA between patients),andin the analtical methods employed for | Rationale forStrength of Evidence Two different daasetswere available toAttard etal.(2008）foranevaluonof the vale of alimted sampling strategy.alowing toesmate,inpadiatic Iivertransplant patents treatedwithMMF,MPAexposure usingrelevant and feasiblemetnics.Two transplant centres contbuted concentration-time profles covering 8 h (of the 12-h dosing interval?).As one of the centres included patients co-treated with TAC or CsA,observed differences in MPA exposure botween groups with a different CNl could refiably be assessed. There were inportant imitations in the study to judge the observed phamacokinetic characteristics of MPA.Time of sanple collection affer transplantaion senusoppunountgedfupnpuepqpsepddeBgpypdsou) Mean doses administered are given in mgday and it is not clear to what dose relatve to BSA they relate to.Furthermore,there were diffrences betwegn the centresin dosesadministered (despite no apparenit differencesin height,weight,BSA between patients),andin the analtical methods employed for |

AUC=areaunder the concentration-time curve;AUC=area under the concentration-time curve from time 0 h to 12 h;BSA=body surface area; CNlcalcineurin inhibitor.

CsAciclosporinA:EMIT=enzyme multiplied immunoassay technique;HPLCHigh Performance LiquidChromatography:MMF=mycophenolate mofetl;MPAmycophenolic acid;

n.anot available; SEM=standard error of mean; SD=standard deviation TAC=tacrolimurs;Txransplanation;vsversus;yrs=years.

The paediatric extrapolation approach used is based primarily on PK-comparison with the adult reference population,  under  the  assumption  that  a  similar  exposure  produces  a  similar  efficacy.  This  follows  the recommendation in the guideline on the role of pharmacokinetics in the development of medicinal products

<div style=\"page-break-after: always\"></div>

in the paediatric population (EMEA/CHMP/EWP/147013/2004). The approach is supported by one paediatric clinical study in liver transplant patients, study PA16497, previously submitted paediatric clinical studies in renal transplant patients and by published studies in the literature. All submitted clinical studies of MAH, except for the study PA16497 in paediatric liver transplant recipients, have previously been assessed.

## 2.3.2. Pharmacokinetics

## ADME

## Similarity in MPA absorption and disposition between paediatric and adult transplant Recipients

The key characteristics of MPA absorption and disposition observed in adult transplant recipients are also seen in paediatric patients (Filler et al. 2008; Barau et al. 2012). Concentration-time profiles of paediatric renal transplant recipients receiving MMF at a dose of 600 mg/m2 twice daily in combination with CsA were comparable to those in adults on 1 g MMF twice daily (again with concomitant CsA) in the first 3 weeks after transplantation (Weber et al. 1998; Filler et al. 2004b). Similar to adults, children rapidly absorb MMF and form the active compound, MPA, which peaks at 45 minutes after oral intake. MPA is highly bound to albumin. Albumin binds many drugs, preferentially drugs with acidic functionalities such as MPA. Its reference values change with age. Recently Sethi et al. (2016) characterized the ontogeny of albumin by determining albumin concentration in age cohorts with sufficient data points and in relevant age categories. Levels of albumin progressively increase in the plasma during maturation. Increases from one age group to the next were modest, such that no one group was significantly different from the next. However, values from infants up to 3 years were significantly lower than for adults. Free fractions of MPA in plasma were no different in paediatric (1.7%) than in adult (1.9%) transplant patients when serum albumin concentrations were in the physiological range (Weber et al. 1998). These binding values in transplanted children were confirmed by studies in paediatric patients after haematopoietic stem cell transplantation (HSCT), where a difference between boys (1.7%) and girls (2.6%) was found according to Zhang et al. (2016).

Similar to adults, there is a second peak in concentrations because of enterohepatic recirculation (EHC) of the main metabolite MPAG. Similar to adults, when combining immunosuppressant drugs in a therapeutic strategy, CsA interferes with MPA disposition (EHC) and decreases MPA plasma levels (Filler et al. 2000; Dhawan 2011). Absence of such an interaction with TAC has equally been found in children and adults (Filler et al. 2004b). Similar to adults there is a non-stationarity seen in the exposure to MPA when comparing values in the immediate post-transplantation phase (  6 months) with values in the stable post-transplantation period (  6 months) (Weber et al. 1999).

Drug distribution depends to a great extent on body composition. The body composition of neonates and young infants differs from that of adults: they have more extracellular and total body water, which may lead to lower plasma levels of drugs when they are administered on a weight basis (Siber et al. 1975).

MPA concentrations critically depend on the liver's capacity for glucuronidation and for EHC. Weightcorrected doses for drugs eliminated by glucuronidation generally are similar in children compared to those in adults (Anderson 2010) because enzymatic activity of uridine diphosphate glucuronosyltransferase (UGT) differs significantly less between children and adults than what is observed for key cytochrome-P450 isozymes (Anderson 2010).

However, this may not apply to very young children. UGT activity in neonates is deficient at birth and increases significantly during the first years of life to reach adult levels by 2 -4 years of age (Miyagi and Collier 2007; Anderson 2010). In early neonatal life, glucuronidation is substantially lower (50% -70% of

<div style=\"page-break-after: always\"></div>

adult values) (Loebstein and Koren 1998). The pharmacological consequences of reduced glucuronide formation in neonates has been shown with acetaminophen, a drug also extensively conjugated by phenolic glucuronidation in adults. In case of acetaminophen, increased sulfation in neonates could make up for the reduced glucuronidation pathway (Levy et al. 1975; Miller et al. 1976). Older children appear to have slightly increased UGT activity compared with adult levels.

UGT1A9 is amongst the most abundantly expressed UGTs in neonatal liver. Its activity develops in an age-dependent manner (Miyagi et al. 2012) with zero activity at birth and increasing to its maximum by 4 months of age. Activity does not differ between genders. Enzyme activity is correlated with expression. Expression of UGT1A9 correlated strongly with age, but only in children younger than 1 year. Adult expression was reached by 3.8 months; maximum expression was reached by 12 months of age. After 1 year of age, intrinsic clearance of a UGT1A9 model substrate (4-methylumbelliferone) slowly decreases to reach adult levels at approximately 20 years of age

The foetal liver is capable of enterohepatically recycling glucuronides. The activity of β-glucuronidase in the liver is highest in the neonatal liver and decreases to steady-state adult levels by 4 months of age (Miyagi and Collier 2007). Hence, the balance of glucuronide metabolism and disposition shifts very early in the neonate from cleavage and recirculation to conjugation and clearance.

## PK in adult reference population and in paediatric renal transplant population

## Exposure target in adult reference population - kidney transplantation (Study MYC058)

A relationship between exposure to MPA and prevention of rejection was established in adult kidney transplant patients to determine the appropriate dosing of MMF (Study MYC058). In this concentrationcontrolled study, 150 patients were dosed with MMF to achieve three different target exposure levels; patients were randomly assigned 1:1:1 to either a low (16.1 h  mg/L), intermediate (32.2 h  mg/L) or high (60.6 h  mg/L) exposure. Multiple MPA and 7-O-MPA glucuronide (MPAG) concentration profiles were determined early and late after transplantation. Patient MMF dosage was individualised based on the observed MPA area under the plasma concentration-time curve from time 0 h to time 12 h (AUC0-12h) to achieve these target levels. The primary efficacy comparison (biopsy-proven rejection vs. successful completion of study with no biopsy-proven rejection) was analysed using logistic regression for the variable median ln(MPA AUC0-12h). This analysis led to the conclusion that an MPA AUC0-12h of 27.2 h  mg/L as the target value in the early post-transplant period provided an optimal benefit in the prevention of rejection with an acceptable safety profile.

The target exposure (AUC0-12h) of 27.2 h·  g/mL established in Study MYC058 was used to select the appropriate dose in Roche's renal transplant program and also guided dosing in paediatric liver transplant patients.

## Comparison of pharmacokinetics across transplant indications in adults

A comparison of PK parameters of MPA in adult renal, cardiac, and hepatic transplant patients at various times after transplantation as derived from studies conducted by Roche is shown in Table 7 below. Whereas Tmax and Cmax reflect MMF to MPA conversion and absorption characteristics, the inter-dosing interval AUC0-12h is influenced by  besides the extent of absorption, the MPA disposition and EHC. The comparison shows a high degree of similarity in absorption and disposition behaviour of MPA during early and late phases after transplantation in the three groups of patients. In the early post-transplant period (  40 days post transplant) renal, cardiac and hepatic transplant patients all had mean AUCs approximately 20% -40% lower and mean Cmax values approximately 32% -44% lower compared to the late transplant period (3 to 6 months post-transplant).

<div style=\"page-break-after: always\"></div>

Table 7 Comparative Pharmacokinetic Parameters of Mycophenolic Acid in Adult Renal, Cardiac, and Hepatic Transplant Patients

| Time after transplantation                  | Dose/Route                                  | Tmax (h)                                    | Cmax (mg/L)                                 | Interdosing Interval AUCo-12h (h·mg/L)      |
|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|
| Renal Transplant Patients (b.i.d. dosing)   | Renal Transplant Patients (b.i.d. dosing)   | Renal Transplant Patients (b.i.d. dosing)   | Renal Transplant Patients (b.i.d. dosing)   | Renal Transplant Patients (b.i.d. dosing)   |
| 5 days                                      | 1.0 g b.i.d. / IV                           | 1.58 (±0.46) (n=31)                         | 12.0 (±3.82) (n=31)                         | 40.8 (±11.4) (n=31)                         |
| 6 days                                      | 1.0 g b.i.d. / oral                         | 1.33 (±1.05) (n=31)                         | 10.7 (±4.83) (n=31)                         | 32.9 (±15.0) (n=31)                         |
| Early (<40 days)                            | 1.0 g b.i.d. / oral                         | 1.31 (±0.76) (n=25)                         | 8.16 (±4.50) (n=25)                         | 27.3 (±10.9) (n=25)                         |
| Early (<40 days)                            | 1.5 g b.i.d. / oral                         | 1.21 (±0.81) (n=27)                         | 13.5 (±8.18) (n=27)                         | 38.4 (±15.4) (n=27)                         |
| Late (>3 months)                            | 1.5 g b.i.d. / oral                         | 0.90 (±0.24) (n=23)                         | 24.1 (±12.1) (n=23)                         | 65.3 (±35.4) (n=23)                         |
| Cardiac Transplant Patients (b.i.d. dosing) | Cardiac Transplant Patients (b.i.d. dosing) | Cardiac Transplant Patients (b.i.d. dosing) | Cardiac Transplant Patients (b.i.d. dosing) | Cardiac Transplant Patients (b.i.d. dosing) |
| Early (Day before discharge)                | 1.5 g b.i.d. / oral                         | 1.8 (±1.3) (n=11)                           | 11.5 (±6.8) (n=11)                          | 43.3 (±20.8) (n=11)                         |
| Late (>6 months)                            | 1.5 g b.i.d. / oral                         | 1.1 (±0.7) (n=52)                           | 20.0 (±9.4) (n=52)                          | 54.1a (±20.4) (n=49)                        |
| Hepatic Transplant Patients (b.i.d. dosing) | Hepatic Transplant Patients (b.i.d. dosing) | Hepatic Transplant Patients (b.i.d. dosing) | Hepatic Transplant Patients (b.i.d. dosing) | Hepatic Transplant Patients (b.i.d. dosing) |
| 4 to 9 days                                 | 1 b.i.d. / IV                               | 1.50 (±0.517) (n=22)                        | 17.0 (±12.7) (n=22)                         | 34.0 (±17.4) (n=22)                         |
| Early (5 to 8 days)                         | 1.5 b.i.d. / oral                           | 1.15 (±0.432) (n=20)                        | 13.1 (±6.76) (n=20                          | 29.2 (±11.9) (n=20)                         |
| Late (>6 months)                            | 1.5 b.i.d. / oral                           | 1.54 (±0.51) (n=6)                          | 19.3 (±11.7) (n=6)                          | 49.3 (±14.8) (g=u)                          |

## Paediatric kidney transplantation

The paediatric program consisted of two paediatric studies, an initial dose-ranging pilot study (MYC2190) and a single pivotal study (MYCS2675), enrolling a total of 140 paediatric renal transplant patients (defined as an individual between 3 months and 18 years of age, inclusive); all patients in these two studies received MMF. Study MYCS2675 provided the basis for the labelled dose recommendation of 600 mg/m2 for the prophylaxis of rejection in paediatric renal allograft patients. The development of MMF for paediatric use was based extensively on the balanced risk-benefit profile previously established in adults.

<div style=\"page-break-after: always\"></div>

## Dose-ranging Study MYC2190

The pilot paediatric study (Study MYC2190) using CellCept capsules was conducted to determine the PK of MPA and MPAG in patients aged 3 months through 18 years of age and to determine the dose which would deliver in this paediatric patient population a target MPA exposure of AUC0-12h of 27.2  g·h/mL. This target exposure had previously been derived from the PK/PD Study MYC058 in adult kidney transplant patients. In that PK/PD study this exposure of 27.2  g·h/mL had been computed to be associated, on average, with a 1 g twice daily (b.i.d) dose for adults in the early post-transplant period ⎯ a dose which had been established as safe and efficacious in the primary adult renal transplant trials.

The dose selected after evaluating the results from Study MYC2190 was then subsequently tested in the paediatric pivotal Study MYCS2675.

## Study Summary

The patients received 15, 23, or 30 mg/kg CellCept b.i.d. for the prevention of renal allograft rejection. In this study, 23 mg/kg b.i.d. most closely achieved the adult target MPA AUC0-12h of 27.2  g·h/mL. The study was originally intended to last for 3 years. However, the study was terminated early by the Sponsor, because, based on PK data collected in this paediatric population, it was possible to make more specific dosing recommendations, which were then implemented in a follow-on study (2190v2). At study closure, most patients had received MMF for 1-2 years. Most patients then enrolled into Study 2190v2 in which they could continue on MMF at a dosage of 23 mg/kg b.i.d. until they had completed 3 years on MMF.

## Pharmacokinetic results

For the 11 patients who received 23 mg/kg, the mean MPA AUC0-12h was 28.1  11.9  g·h/mL and maximum concentration (Cmax; n = 12) was 8.57  4.62  g/mL on Day 14. Because of the substantial intersubject variability, additional analyses were performed which indicated that calculating doses based on estimated body surface area (BSA) (mg/m2) reduced the coefficient of variation by about 10% (Study MYC2190). Table 8 was then constructed from linear regression of MPA AUC0-12h versus dose from MYC2190 data and adult data. The dose which was predicted to provide a MPA AUC0-12h closest to the desired 27.2  g·h/mL was 600 mg/m2.

Table 8 Projected MPA AUC to CellCept Dose from Adult and Paediatric Data

|   CellCeptdose (mg/m²) |   Projected MPA AUCo-12h(μug*h/mL) a |
|------------------------|--------------------------------------|
|                    450 |                                 20.7 |
|                    500 |                                 23.2 |
|                    550 |                                 25.7 |
|                    600 |                                 28.2 |
|                    650 |                                 30.8 |
|                    700 |                                 33.3 |

AUC=area under the plasma concentration-time curve; AUCo-12h=area under the plasma concentration-timecurvefromtime0htotime12h;MPA=mycophenolicacid.

a from adult data (Studies MYC024/GER, ICM 1753, MYC1866 and NSK024) and paediatric data (Study MYC2190,Day 21)

## Pivotal Study MYCS2675

Study MYCS2675 is the pivotal study of the renal paediatric program as it provides the majority of the safety, PK, and efficacy data.

<div style=\"page-break-after: always\"></div>

## Study Summary

Study MYCS2675 was a single-arm, open-label, safety, and PK study in 100 paediatric patients receiving a first or second renal allograft. Pharmacokinetic sampling was performed in a subset of 55 of the 100 paediatric patients (age range 1-18 years; the age distribution is shown in Figure 1 . Results from three age groups were compared (3 months to  6 years, 6 to  12 years, and 12 to 18 years). Each patient received MMF suspension dosed at 600 mg/m2 b.i.d. (body surface area (BSA)) up to a maximum of 1 g b.i.d., with ciclosporin and corticosteroids administered as per local centre practice. After nine months in the study, patients with a BSA of at least 1.25 m2 who were able to swallow capsules and preferred the convenience of capsules to that of suspension, could elect to receive the capsule formulation of MMF.

Figure 1 Distribution of Age of the Number of Paediatric Patients in Study MYCS2675 for which Full Pharmacokinetic Profiles Were Determined

<!-- image -->

Blood sampling to determine full PK profiles of MPA and MPAG were collected at Day 7, Month 3, and Month 9 in a subset of 55 of the 100 paediatric patients in Study MYCS2675. The PK-subset was generally representative of the larger sample. Allograft biopsies and treatment of acute rejection were monitored to allow determination of rejection-related endpoints through six months post-transplant. Safety parameters included deaths, malignancies, opportunistic infections, and other adverse events (AEs).

## Pharmacokinetic results

Pharmacokinetic parameters for MPA and 7-O-mycophenolic acid glucuronide (MPAG) stratified by age and time after transplantation in the pharmacokinetically characterized patients are given in Table 9 and Table 10 , respectively.

A 1.9-fold increase in mean dose-adjusted MPA AUC0-12h was observed in the later post-transplant period (Day 7 vs. Month 3 post transplant) for all patients. The increase was 1.11-fold between Months 3 and 9.

MMF suspension given to patients 1 to 18 years of age produced no statistically significant differences (p  0.05) in mean MPA plasma concentrations or in mean computed parameters (e.g., AUC0-12h) between the three age groups, with one exception. The dose-adjusted maximum concentration (Cmax) at Month 9 in the oldest group (12-18 years) was lower than in children of younger age. This observation is considered to be of minor relevance as the therapeutic effect is associated with the average exposure during a dosing interval (area under the plasma concentration-time curve from time 0 h to time 12 h [AUC0-12h]) rather than with maximum concentrations. Importantly, the mean dose-adjusted MPA AUC0-12h for all patients was similar to the desired target MPA AUC0-12h (27.2 hmg/L). There was a statistically

<div style=\"page-break-after: always\"></div>

significant difference in mean dose-adjusted MPAG AUC0-12h across the age groups at all time points, with values increasing from the youngest to the oldest group, see Table 10 .

Six of the patients in Study MYCS2675 studied for PK parameters were between the age of 1-2 years. A listing of their individual demographic details is given in Table 11 along with calculated PK parameters. Although few in number, the values for mean calculated MPA PK parameters in the &lt;2-year age group were similar to those of the other age groups ( Table 10 ). The mean MPA AUC0-12h was numerically lower (22.5 h mg/L) than the target mean MPA AUC0-12h, with a wide degree of variability (95% CI: 17.2-27.8 h mg/L), due to the small sample size. Figure 2 shows that dose-adjusted MPA AUC0-12h was not affected by age in the range of 1 18 years. Patients in the &lt;2-year subgroup had the lowest mean dose-adjusted MPAG AUC0-12h at the earlier time points, but by Month 9 the value was similar to that observed for the &lt;6-year group.

A retrospective demographic analysis of patients &lt;2 years old across the paediatric studies performed in renal transplant patients revealed one additional patient in this low age group who had been included in Study MYC2190. His data are included in Table 11 . The BSA of this child aged 1 year, 8 months at enrolment was much lower than the one in the patients of even younger age from Study MYCS2675. Likewise, his dose-adjusted AUC0-12h was substantially lower than what had been found in the six subjects in Study MYCS2675.

Table 9 Mean Computed MPA PK Parameters by Age and Time After Transplantation

| Age Group (n)   | Tmax hr       | Adjusted Cmax μg/ml^   | Adjusted AUCo.12 μgoh/ml (C1^   |
|-----------------|---------------|------------------------|---------------------------------|
| Day 7           |               |                        |                                 |
| <6y (17)        | 1.63 ± 2.85   | 13.2± 7.16             | 27.4± 9.54 (22.8-31.9)          |
| 6-<12y (16)     | 0.940 ± 0.546 | 13.1± 6.30             | 33.2 ± 12.1(27.3 -39.2)         |
| 12-18y (21)     | 1.16± 0.830   | 11.7± 10.7             | 26.3 ± 9.14 (22.3 -30.3)        |
| p-value B       |               |                        |                                 |
| (6)             | 3.03 ± 4.70   | 10.3 ± 5.80            | 22.5± 6.68(17.2-27.8)           |
| Month 3         |               |                        |                                 |
| <6y (15)        | 0.989±0.511   | 22.7± 10.1             | 49.7± 18.2                      |
| 6-<12y (14)E    | 1.21± 0.532   | 27.8± 14.3             | 61.9± 19.6                      |
| 12-18y (17)     | 0.978 ± 0.484 | 17.9± 9.57             | 53.6± 20.2F                     |
| p-value B       |               |                        |                                 |
| (4)             | 0.725 ± 0.276 | 23.8± 13.4             | 47.4± 14.7                      |
| Month 9         |               |                        |                                 |
| <6y (12)        | 0.869 ± 0.479 | 30.4± 9.16             | 60.9 ± 10.7                     |
| 6-<12y (11)     | 1.12± 0.462   | 29.2± 12.6             | 66.8 ± 21.2                     |
| 12-18y (14) B   | 1.069 ± 0.518 | 18.1± 7.29             | 56.7 ±14.0                      |
| p-value         |               | 0.004                  |                                 |
| (4)             | 0.604 ± 0.208 | 25.6± 4.25             | 55.8± 11.6                      |

<div style=\"page-break-after: always\"></div>

Table 10 Mean Computed MPAG PK Parameters by Age and Time After Transplantation

| Saimpling Time (n)   | Saimpling Time (n)   | Tmax hr     | Adjusted Cmax μg/m1A   | Adjusted AUCo-12 μgoh/mlA   |
|----------------------|----------------------|-------------|------------------------|-----------------------------|
| Day 7                |                      |             |                        |                             |
| <6y                  | (17)                 | 2.41 ± 2.70 | 60.8± 30.5             | 378±205                     |
| 6-<12y               | (16)                 | 2.69± 1.21  | 73.2± 16.4             | 537± 166                    |
| 12-18y p-value B     | (21)                 | 2.61± 1.32  | 76.6± 37.9             | 685 ± 417D 0.011            |
| <2y                  | (6)                  | 3.60 ± 4.41 | 46.8± 19.8             | 260 ± 85.9                  |
| Month 3              |                      |             |                        |                             |
| <6y                  | (15)                 | 2.96± 1.76  | 65.2± 21.5             | 475± 178                    |
| 6-<12y               | (15)                 | 2.36± 1.07  | 75.1± 20.4             | 529± 169                    |
| 12-18y p-value  B    | (17)                 | 2.93± 1.68  | 86.5± 36.9             | 790± 402E                   |
|                      |                      |             |                        | 0.006                       |
| <2yC                 | (4)                  | 3.48±3.04   | 55.0± 24.3             | 412±151                     |
| Month 9              |                      |             |                        |                             |
| <6y                  | (12)                 | 2.75 ±1.85  | 64.8 ±17.6             | 453 ±132                    |
| 6-<12y               | (11)                 | 2.20±0.918  | 76.2±22.4              | 546±181                     |
| 12-18y               | (14)                 | 2.85 ±1.12  | 84.2±24.2              | 680±212                     |
| p-value B            |                      |             |                        | 0.011                       |
| <2yC                 | (4)                  | 3.48 ±3.00  | 61.1 ±23.8             | 445 ±94.5                   |

Table 11 Listing of Patients Less Than Two Years Old: Pooled Data from Studies MYCS2190V1 and MYCS2675

MPA

| Dose Adj. Subject AUC -12 Number (μg*h/ml)   | AUC 0-12 (μug*h/ml)   | Dose Adj. Cmax (μg/ml)   | Cmax (μg/ml)   | Tmax (h)   | AUC12   | Dose Adj. AUC 0-12 (μg*h/ml) (μg*h/ml)   | Dose Adj. Cmax (μg/ml)   | Cmax (μg/ml)   | Tmax (h)   | Dose (mg/m²)   | AGE (yr)      | RACE             | SEX            | HEIGHT WEIGHT (cm)   | (by)   |
|----------------------------------------------|-----------------------|--------------------------|----------------|------------|---------|------------------------------------------|--------------------------|----------------|------------|----------------|---------------|------------------|----------------|----------------------|--------|
|                                              | 23.3 23.1             | 11.5                     | 11.4           |            | 1.03    | 323.                                     | 321.                     | 55.9           | 55.5       | 2.02 596.      | 1yr 6 mo      | CAUCASIAN FEMALE |                | 78.3                 | 10.3   |
|                                              | 28.8                  | 28.0                     | 17.9           | 17.4       | 0.500   | 278.                                     | 270.                     | 59.2           | 57.5       | 1.50 583.      | 1yr 3mo       |                  | CAUCASIAN MALE | 72.5                 | 11.3   |
|                                              | 17.4                  | 16.9                     | 1.79           | 1.74       | 12.6    | 158.                                     | 153. 18.6                | 18.1           | 12.6       | 583.           | 1yr 4 mo      | CAUCASIAN FEMALE |                | 76.5                 | 10.7   |
|                                              | 16.8                  | 15.2                     | 11.9           | 10.7       | 1.05    | 178.                                     | 161.                     | 32.4           | 29.3       | 1.50 542.      | 1yr10mo       | CAUCASIAN FEMALE |                | 74.0                 | 11.2   |
|                                              | 32.0                  | 32.5                     | 13.6           | 13.8       | 1.50    | 382.                                     | 388.                     | 73.2           | 74.2       | 2.00 609.      | 1yr9mo        | CAUCASIAN MALE   |                | 77.3                 | 10.0   |
|                                              | 16.8                  | 17.1                     | 5.46           | 5.57       | 1.50    | 239.                                     | 244.                     | 41.4           | 42.2       | 2.00 612.      | 1yr 11mo      | CAUCASIAN FEMALE |                | 74.0                 | 11.5   |
|                                              | 9.67                  | 6.94                     | 4.67           | 3.35       | 0.500   | 103.                                     | 73.8                     | 21.1           | 15.1       | 2.00 431.      | 1yr8mo        | HISPANIC         | MALE           | 45.0                 | 9.70   |
| Mean                                         | 20.7                  | 20.0                     | 9.54           | 9.14       | 2.67    | 237.                                     | 230.                     | 43.1           | 41.7       | 3.37 565.      | 1yr 7mo       |                  |                | 71.1                 | 10.7   |
| Std.Dev.                                     | 7.80                  | 8.59                     | 5.71           | 5.75       | 4.39    | 98.3                                     | 108.                     | 20.5           | 22.1       | 4.07           | 63.7 3m0      |                  |                | 11.7                 | 0.695  |
| %CV                                          | 37.7                  | 43.0                     | 59.9           | 63.0       | 165.    | 41.4                                     | 47.0                     | 47.6           | 52.9       | 121.           | 11.3 15.8     |                  |                | 16.4                 | 6.51   |
| Min                                          | 9.67                  | 6.94                     | 1.79           | 1.74       | 0.500   | 103.                                     | 73.8                     | 18.6           | 15.1       | 1.50 431.      | 1yr 3mo       |                  |                | 45.0                 | 9.70   |
| Max                                          | 32.0                  | 32.5                     | 17.9           | 17.4       | 12.6    | 382.                                     | 388.                     | 73.2           | 74.2       | 12.6           | 612. 1yr 11mo |                  |                | 78.3                 | 11.5   |
| N                                            | 7                     | 7                        | 7              | 7          |         | 7                                        | 7                        | 7              | 7          | 7              | 7             | 7                |                | 7                    | 7      |
| 95%CI[14.9,26.5]                             | [13.6, 26.3]          |                          |                |            |         |                                          |                          |                |            |                |               |                  |                |                      |        |

<div style=\"page-break-after: always\"></div>

Figure 2 Dose Adjusted MPA AUC on Day 7 Versus Age (Study MYCS2675)

<!-- image -->

Source: PDBS GAN - AUC\\_CMAX\\_AGE.XLS.AUC-D7 (12/14/99 5:21 PM) -- Page 1 of 1

In summary, data generated in Roche-sponsored studies and available in the literature show that there is no difference in the mean PK characteristics of MMF/MPA in paediatric transplant patients across the age group of 1-18 years. At the recommended dosage, the same therapeutic target exposure is reached independent of patient age.

## Comparison of MPA exposure in paediatric RTx and adult RTx, LTx and HTx studies

Data collected earlier by the MAH to support the paediatric renal transplantation indication allowed to compare paediatric renal transplant MPA AUC0-12h ( Figure 3 ) and Cmax ( Figure 4 ) from Study MYCS2675 to adult transplant data, including cardiac and hepatic transplant data in addition to transport. The adult cardiac and hepatic transplant data in this comparison are derived from patients who received a CellCept dose of 1.5 g b.i.d. In such cardiac transplant patients, the MPA AUC0-12h is expected to be ~33% higher than in renal patients receiving 1 g b.i.d. and this is indeed observed in the cardiac data. However, in hepatic transplant patients given CellCept 1.5 g b.i.d., the non-dose-adjusted MPA exposure was similar to renal transplant patients adjusted to a CellCept dose of 1 g b.i.d., in the early post-transplant period. As shown in Figure 3 and Figure 4 the MPA exposure in paediatric renal transplant patients from Study MYCS2675 is superimposable on data from adult renal transplant patient as well as adult patients with cardiac or hepatic transplants receiving CellCept doses up to 1.5 g b.i.d. over time. From these comparisons it was concluded that the MPA AUC0-12h resulting from a paediatric dose of 600 mg/m2 overlays almost completely that for 1 g b.i.d. in adult renal patients as well as 1 -1.5 g b.i.d. in adults with renal, cardiac, and hepatic transplants in both the early and late post-transplant periods.

<div style=\"page-break-after: always\"></div>

Figure 3 Comparison of Mycophenolic Acid AUC0-12h from Paediatric Renal and Adult Renal, Cardiac, and Hepatic Transplant Studies

<!-- image -->

AUCo-12h=area under the concentration-time curve from time 0 h to 12 h; b.i.d.=twice a day.

<div style=\"page-break-after: always\"></div>

Figure 4 Comparison of Mycophenolic Acid Cmax from Paediatric Renal and Adult Renal, Cardiac and Hepatic Transplant Studies

<!-- image -->

b.i.d.=twice a day;Cmax=maximum concentration.

## Paediatric liver transplantation

Clinical pharmacology experience in paediatric liver transplantation comes mainly from open-label, mostly retrospective studies published in the literature. A single PK study in liver transplant children for dose finding was conducted by Roche (Study PA16497); its results are consistent with the literature reports. The collective PK experience with MPA in liver transplanted children can be compared with findings from similar studies in paediatric kidney transplant patients as previously conducted by Roche (Study MYC2190 and Study MYCS2675) or as reported in the literature.

## Clinical study PA16497 in paediatric liver transplants patients

This was an open label, multi-centre, non-controlled study in paediatric liver transplant patients. A total of 9 patients were enrolled in the study (5 females, 4 males), see Table 12 below. One patient was prematurely withdrawn. Six out of 8 patients were less than 24 months old and the youngest child was 9 months old. Patients had to have received stable MMF dosing (&gt; 6 months of MMF dosing) for at least seven days in order to get a steady-state concentration-time profile. A single 12-hour plasma profile of MPA was then obtained, and MPA AUC0-12h was calculated.

<div style=\"page-break-after: always\"></div>

Table 12 Listing of patient demographic data by trial treatment and CRTN/Patient Number

<!-- image -->

In this study, paediatric liver transplant patients received MMF doses of 200-424 mg/m2. These doses were all lower than the approved dose for paediatric renal transplantation (600 mg/m2). MMF doses in the study were reduced over time from initial post transplantation doses, in line with standard practice at the participating centres, and the PK study was performed at a point when patients were on stable doses. No patient had the MMF dose reduced because of AEs.

The administered doses generated AUCs (dose-normalized) of MPA of less than value of 58  g·h/mL (late posttransplant target) in 7 out of 8 cases when one patient excluded as outlier, see Table 13 below. The only patient who achieved an AUC greater than 58  g·h/mL was considered an outlier because his AUC of 195  g·h/mL was more than 2-fold higher than that of all the other patients.

<div style=\"page-break-after: always\"></div>

Table 13 Individual Raw and Dose-Normalised MPA PK Parameters (Excluding Outlier)

<!-- image -->

|         |                 |          |              |                    | Normalised to600mg/m2   | Normalised to600mg/m2   |
|---------|-----------------|----------|--------------|--------------------|-------------------------|-------------------------|
| Patient | DoseMMF (mg/m²) | Tmax (h) | Cmax (μg/mL) | AUCo-12h (μg-h/mL) | Cmax (μg/mL)            | AUC0-12h (μg-h/mL)      |
|         | 304             | 2.03     | 10.0         | 30.9               | 19.7                    | 60.9                    |
|         | 424             | 0.50     | 12.1         | 37.2               | 17.1                    | 52.7                    |
|         | 370             | 1.95     | 9.28         | 25.2               | 15.1                    | 40.9                    |
|         | 236             | 0.52     | 5.96         | 11.0*              | 15.2                    | 28.1*                   |
|         | 313             | 0.63     | 4.61         | 14.0               | 8.85                    | 26.8                    |
|         | 200             | 2.00     | 5.61         | 29.1               | 16.8                    | 87.2                    |
|         | 213             | 0.75     | 3.07         | 11.5               | 8.66                    | 32.5                    |
| Mean    |                 | 1.20     | 7.23         | 22.7               | 14.5                    | 47.0                    |
| SD      |                 | 0.75     | 3.27         | 10.5               | 4.21                    | 21.8                    |
| CV%     |                 | 62.6     | 45.2         | 46.3               | 29.1                    | 46.4                    |
| Median  |                 | 0.75     | 5.96         | 25.2               | 15.2                    | 40.9                    |
| Min     |                 | 0.50     | 3.07         | 11.0               | 8.66                    | 26.8                    |
| Max     |                 | 2.03     | 12.1         | 37.2               | 19.7                    | 87.2                    |
| GeoMean | GeoMean         | 1.00     | 6.58         | 20.4               | 13.9                    | 43.2                    |

AUCo-12h=area under the plasma concentration-time curve from time 0 h to time 12 h; Cmax=maximum concentration; CV=coefficient of variation; MMF=mycophenolate mofetil; MPA=mycophenolic acid; PK=pharmacokinetic; SD=standard deviation.

Note: * = had a BLQ at 12 h which was assigned as Missing. The AUCo-12h (AUC.) value calculated for this patient was 11.4 μg-h/mL and the AUCiast value was 11.0 μg-h/mL Because there was less than 5% difference between these two values the AUCiast value was substituted for AUCo-izh (AUC.) so that an estimate of AUC for this patient was reported rather than recording it as not calculable due to no measurable MPA plasma concentration result beyond8h.

The adjusted AUC for a dose of 600 mg/m 2  (excluding the youngest patient) was 47.0  g·h/mL (based on the arithmetic mean) and 43.2  g·h/mL (based on the geometric mean). To achieve the target AUC of 58 µg·h/mL, a dose in the range of: [(58  g·h/mL / [47.0 or 43.2  g·h/mL]) * 600 mg/m 2 ] = 740-806 mg/m 2  would therefore be required.

In this study, paediatric patients appeared to be relatively under-dosed at 6 months post-transplant compared to the adult population. The dose of CellCept administered to patients was determined by their BSA at transplant and was not adjusted to increasing BSA over time. However, as the majority of patients in this study were between 1 and 2 years of age at the time of transplant, it is expected that their body weight would increase significantly in the 6-month period between transplant and enrolment in this study. Therefore, it is likely that patients were under-dosed as no dose adjustment was made for this increase in body weight.

<div style=\"page-break-after: always\"></div>

## Literature references of MMF in paediatric liver transplantation

The results of the literature search of paediatric liver transplantation studies are summarised in introduction 2.3.1 of this report.

## Publication of Barau et al. 2011

In an attempt to optimise the dosing regimen of MMF in paediatric liver transplant recipients, Barau et al. (2011) determined the MMF dosage required to achieve an AUC0-12h of  30 h·mg/L. A PK study of 15 children (median age 8.3 years, range 1.1 -15.2 years) was performed at a median of 11.0 months (range 0.5 -88.0 months) after liver transplantation, see Table 14 below. The authors concluded from their study that an initial MMF dose of 600 mg/m2 twice a day led to MPA AUC0-12h values greater than the minimum targeted threshold of 30 h·mg/L. Considering the inter-individual variability of MPA PK, therapeutic drug monitoring was recommended to optimise the daily MMF dosage.

Table 14 MPA AUC0-12h Values and MMF Doses Before and After Dose Adjustments in Patients Receiving Tacrolimus, cyclosporine, and Rifampin

|                                                          | BeforetheDoseAdjustment     | BeforetheDoseAdjustment      | BeforetheDoseAdjustment   | AftertheDoseAdjustment      | AftertheDoseAdjustment       | AftertheDoseAdjustment   |
|----------------------------------------------------------|-----------------------------|------------------------------|---------------------------|-----------------------------|------------------------------|--------------------------|
|                                                          | MMFDose (mg/m² Twice a Day) | MMF Dose (mg/kg Twice a Day) | MPA AUC (mg-hour/L)       | MMFDose (mg/m² Twice a Day) | MMF Dose (mg/kg Twice a Day) | MPA AUC (mg-hour/L)      |
| Patients receiving tacrolimus                            |                             |                              |                           |                             |                              |                          |
| 2                                                        | 351                         | 10.6                         | 7.3                       | 755                         | 23.8                         | 39.4                     |
| 3                                                        | 302                         | 13.7                         | 11.3                      | 596                         | 26.8                         | 45.0                     |
| 4                                                        | 300                         | 10.2                         | 12.0                      | 682                         | 24.4                         | 31.8                     |
| 5                                                        | 235                         | 10.3                         | 12.9                      | 557                         | 24.2                         | 28.5                     |
| 6                                                        | 205                         | 9.7                          | 15.4                      | 511                         | 24.3                         | 37.9                     |
| 7                                                        | 265                         | 9.1                          | 19.9                      | 442                         | 15.2                         | 34.0                     |
| 8                                                        | 455                         | 15.6                         | 6.8                       | 909                         | 31.3                         | 65.6                     |
| 6                                                        | 186                         | 8.3                          | 5.8                       | 371                         | 16.7                         | 39.3                     |
| 10                                                       | 421                         | 24.0                         | 35.0                      | 617                         | 24                           | 41.1                     |
| 11                                                       | 205                         | 6.1                          | 6.9                       | 1014                        | 30.2                         | 68.7                     |
| 14                                                       | 554                         | 20.8                         | 41.6                      | 571                         | 21.7                         | 39.5                     |
| Median (range)                                           | 300                         | 10.3                         | 12.0                      | 596                         | 24.2                         | 39.4                     |
|                                                          | (186-554)                   | (6.1-20.8)                   | (5.8-41.6)                | (371-1014)                  | (15.2-31.3)                  | (28.5-68.7)              |
| Patients receiving cyclosporine                          |                             |                              |                           |                             |                              |                          |
| 1                                                        | 426                         | 40.0                         | 10.2                      | 851                         | 40                           | 91.8                     |
| 12                                                       | 435                         | 14.7                         | 11.7                      | 652                         | 22.1                         | 39.5                     |
| Patients receiving rifampin along with immunosuppressive |                             |                              |                           |                             |                              |                          |
| therapy                                                  |                             |                              |                           |                             |                              |                          |
| 13                                                       | 391                         | 16.7                         | 14.6                      | 782                         | 33.4                         | 13.0                     |
| 15                                                       | 295                         | 10.0                         | 9.2                       | 615                         | 20.9                         | 14.8                     |

## Publication by Ueno et al. 2020

In a recent study, Ueno et al. (2020) investigated dosing needs, efficacy and safety of MMF in five infants younger than 1 year (mean 8 [range 3 -10] months) of age at transplantation, who received living-donor liver transplants. The initial dose was 40-50 mg/kg/day, which was increased to a target MPA trough level of 2 mg/L. The patients also received TAC and, after at least 4 months post transplantation, steroids. The mean final daily MMF dose was 66 (range 47 -106) mg/kg or 1430 (range 1280 -1920) mg/m 2 . According to linear regression analyses, the target Ctrough level of 2 mg/L was reached at a daily MMF dose of approximately 1200 mg/m 2  or 50 mg/kg. In the children younger than 1 year of age a higher dose than in older children was needed to achieve the same exposure target. A dose of 1200 mg/m 2 /day was minimally needed to maintain efficacious concentrations.

<div style=\"page-break-after: always\"></div>

## Literature references of paediatric heart transplantation

There are no Roche-sponsored studies available on the pharmacokinetics and/or pharmacodynamics of CellCept in paediatric HTx patients. However, studies published in the public domain support the conclusions that the pharmacokinetic and metabolic processes underlying MPA absorption and disposition as described for adult HTx patient are equally applicable to paediatric patients.

The literature studies available for evaluation of the PK in HTx children are all based on retrospective analyses and on measurements of trough (pre-dose) levels, and not full pharmacokinetic profiles (Dipchand et al. 2001; Gajarski et al. 2004,). Their focus was on the dose-concentration relationship to determine whether the recommended dose for paediatric RTx children, 600 mg/m2 b.i.d., was sufficient to achieve therapeutic exposures also in HTx children. The concomitant CNI administered in these studies overall was more often CsA than TAC; nevertheless, inclusion of patients on both types of CNI allowed for a comparison of MPA levels achieved and confirmation that indeed MPA levels in presence of TAC were higher than in presence of CsA in paediatric HTx patients.

## Publication by Dipchand et al. (2001)

The study by Dipchand et al. (2001) is based on a review of 128 trough levels collected from 44 paediatric HTx recipients (age at transplant 7 days to 18.4 years). It evaluated MPA doses which were required to achieve a target trough concentration of  3 mg/L, a level which had previously been found adequate by Meiser et al. (1997, 1999) to prevent acute rejection episodes in adult heart allograft recipients co-treated with TAC and corticosteroids. Dipchand et al. (2001) showed that daily doses of MMF required in children of 5 years to over 16 years were close to 1800 mg/m2, corresponding to a 3 g/day dose in an adult patient. Younger children required somewhat higher doses, depending on the age range considered, see Table 15 and Table 16 below, from the publication of Dipchand et al.

Table 15 Dose of MPA required to achieve therapeutic level* by age

|                                      | Age range   | Age range   | Age range   | Age range    | Age range   |
|--------------------------------------|-------------|-------------|-------------|--------------|-------------|
|                                      | 0 to 1 year | 1 to5years  | 5to10years  | 10 to16years | >16 years   |
| # ofpatientst                        | 11          | 10          | 9           | 8            | 6           |
| # of patients with therapeutic level | 3           | 4           | 7           | 5            | 5           |
| # of therapeutic levels*             | 4           | 4           | 10          | 14           | 7           |
| Dosetoachieve therapeuticlevel mg/kg | 125± 29     | 101 ± 51    | 67 ± 31     | 47 ± 24      | 49 ± 17     |
| mg/m                                 | 2,189 ± 696 | 2,254 ± 887 | 1,833 ± 931 | 1,573±833    | 1,792± 579  |

<div style=\"page-break-after: always\"></div>

Table 16 MPA levels in patients on cyclosporine versus tacrolimus by age group

|                 | MMF dose (mg/kg)   | MMF dose (mg/kg)   | MMF dose (mg/kg)   | MMF dose (mg/m²)   | MMF dose (mg/m²)   | MMF dose (mg/m²)   |
|-----------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|
|                 | 5 to 10 year's     | 10 to 16 years     | >16 years          | 5 to10 years       | 10 to 16 years     | >16 years          |
| Cyclosporine    |                    |                    |                    |                    |                    |                    |
| MMF (mean ± SD) | 71 ± 24            | 54 ± 14            | 44 ± 14            | 1,956 ± 663        | 1651 ± 498         | 1,576 ± 476        |
| MMFmedian       | 68                 | 57                 | 41                 | 1,832              | 1,693              | 1,497              |
| MMF range       | 35to115            | 26 to 81           | 30 to 68           | 957 to 3132        | 803 to 2730        | 1.085 to 2411      |
| Tacrolimus      |                    |                    |                    |                    |                    |                    |
| MMF (mean ± SD) | 41 ± 10            | 46 ± 11            | 41 ± 21            | 1,000 ± 329        | 1,498 ± 373        | 1484 ± 700         |
| MMF median      | 42                 | 49                 | 42                 | 974                | 1,627              | 1,620              |
| MMF range       | 27 to52            | 22 to 58           | 13 to 67           | 627 to 1429        | 717 to 1820        | 534 to 2366        |

MMF, mycophenolate mofetil.

The age-dependency of MMF dosing could later also be demonstrated by Filler's group (Yoo et al. 2016) analysing 2639 MPA trough levels collected from 37 paediatric RTx recipients co-treated with TAC over 6.6-14 years post-transplantation. Patients at younger age were at greater risk for underimmunosuppression than older children. Therefore, higher starting doses of 1800 mg/m2 (900 mg/m2 b.i.d) of MMF or even more in combination with TAC in children &lt;6 years of age were recommended by Filler's group.

## Publication by Gajarski et al. (2004)

In the study by Gajarski et al. (2004) a total of 120 trough levels from 10 children and 10 adults (from one months to 33 years) were available. In this study paediatric doses were at 1200 mg/day (600 mg b.i.d); target MPA concentrations in the study were set at 1.0-3.5 mg/L. As expected, TAC co-administration led to higher MPA levels than CsA (3.0  2.2 mg/L vs. 1.6  1.5 mg/L). Levels of &gt;2.5 mg/L in the study were found to be associated with lower biopsy grades. However, the 1200 mg/m2 dosing failed to achieve levels &gt;1 mg/L in 50% of the patients.

## MPA target exposure measures, MPA Ctrough and the standard AUC0-12hr

It is generally agreed that the inter-dosing interval MPA AUC0-12h is the most reliable index of risk for acute rejection and that the correlation between trough (pre-dose) MPA values and the full AUC (Shaw et al. 2001; Shaw et al. 2003; Filler and Mai 2000) or between trough levels and rejection (Oellerich et al. 2000) are inferior. As it is impractical to collect a full set of timed plasma samples over a 12-h dosing interval, limited sampling strategies have been proposed to estimate the full AUC0-12h from only a few well-timed collected samples. Also, the clinical utility of MPA trough values have been evaluated; Shaw et al. (2003) applied a target range of 1-3.5 mg/L for adult patients with concomitant CsA, and 1.7-4.0 mg/L with tacrolimus (TAC).

Similar exposure ranges (AUC0-12h 30-60 h · mg/L; trough concentration [Ctrough] 1.5-3 mg/L) as established in adults have been confirmed in paediatric renal (Oellerich et al. 2000; Weber et al. 1998, Weber et al. 2002; Filler et al. 2008), heart (Dipchand et al. 2001; Gajarski et al. 2004; Rauschenfels et al. 2009), and liver (Aw et al. 2003; Ueno et al. 2020) transplant patients. In some of these studies, a correlation of trough concentration with a measure of AUC was found.

The most comprehensive studies on MPA's PK/PD relationship were conducted by Weber et al. (2002) in paediatric renal transplant patients aged 2.2-17.8 years on an immunosuppressive regimen with CsA, MMF, and corticosteroids. This study established the therapeutic ranges for both, MPA-AUC0-12h values

<div style=\"page-break-after: always\"></div>

and trough MPA levels in this patient population. MMF was administered orally at a dose of 600 mg/m2 BSA twice a day up to a maximum of 2 g/day. The analyses of the collected information on total and unbound drug showed that both MPA-AUC0-12h and trough MPA levels are statistically significantly associated with the risk of acute rejection in this patient population. According to the study results, for minimizing the risk of rejection after transplantation, total MPA-AUC values in the early stages posttransplant should be maintained within the therapeutic window of 30-60 h · mg/L, or the trough concentration in the range of 1-3.5 mg/L.

Similar to paediatric renal transplant patients, Aw et al. (2003) established a good correlation between an (abbreviated) 7-hour AUC and trough levels in 21 paediatric stable liver transplant patients aged 2-16 years (r = 0.84, p &lt;0.001). From the data shown, it appears that a trough concentration range of 1.5-3 mg/L corresponds to an AUC0-7 range of 30-60 h · mg/L.

When Filler (2006) analyzed pre-dose trough levels and full AUCs from 161 patients with variable pathologies (paediatric heart, liver, and kidney transplant recipients as well as patients with autoimmune diseases), there was a weak, but significant correlation between the pre-dose morning trough level and the AUC.

In conclusion, from these studies across transplant indications, it appears that target exposures of AUC012h 30-60 h · mg/L and Ctrough 1.5-3 mg/L are associated with prevention of acute rejection not only in adult, but also in paediatric patients.

## Dose recommendation and rationale in paediatric heart and liver transplant patients

The collective experience from Roche-sponsored studies and studies from the literature outlined here supports the following dosing recommendation for paediatric heart and liver transplant patients:

The recommended starting dose for cardiac and hepatic paediatric patients is 600 mg/m2 (of body surface area) of MMF powder for oral suspension, administered twice daily (maximum total daily dose of 2 g or 10 ml).

The dose and product form should be individualised based on clinical assessment. Oral solid product forms (capsules and tablets) should not be used by patients unable to swallow them and/or with a body surface area lower than 1.25 m2 due to the increased risk of choking in this age group. Patients with a body surface area of 1.25 to 1.5 m2 may be prescribed MMF capsules at a dose of 750 mg twice daily (1.5 g daily dose). Patients with a body surface area greater than 1.5 m2 may be prescribed MMF capsules or tablets at a dose of 1 g twice daily (2 g daily dose).

For paediatric cardiac and hepatic transplant patients, if the recommended starting dose is well tolerated, the maintenance dose can be increased to 900 mg/m2 body surface area twice daily (maximum total daily dose of 3 g or 15 ml). The dose should be individualised based on clinical assessment.

These dosing recommendations are based on the relationship between exposure to MPA and prevention of rejection as established in adult kidney transplant patients to determine the appropriate dosing of MMF (Study MYC058), see Exposure target in adult reference population.

The target exposure (AUC0-12h) of 27.2 h·mg/L established in Study MYC058 was used to select not only the appropriate dose in Roche's renal transplant program, but also guided dosing in paediatric liver transplant patients.

An exposure-response relationship for desired (prevention of rejection) or undesired (AEs) effects as established in adult renal transplant patients, was not found in Roche-sponsored studies in adult heart or liver transplant patients, most likely due to an insufficient number of study participants and/or high

<div style=\"page-break-after: always\"></div>

intersubject variability. Based on the assumption of independence of the mechanism of action of transplanted organ, dosing in these populations was therefore guided to achieve the same exposure range (30-60 h·mg/L) as in renal adult transplant patients. Roche-sponsored clinical studies and clinical studies from the literature have shown that not only the pharmacodynamics, but also the pharmacokinetics of MPA in adults is comparable across transplant indications.

The same guiding principle, namely to determine the doses required to achieve the same target exposure in paediatric as in adult patients and to determine the doses required to achieve that target was applied to treatment of paediatric heart and liver transplant recipients. The underlying assumption, that the same exposure in children as in adults will lead to the same therapeutic effect, was rationalised by the results from studies performed by Roche in support of the registration of CellCept in both adult kidney transplantation and paediatric kidney transplantation. These studies revealed a good scalability of dosing across age groups when comparing adult renal with paediatric renal patients. This scalability is further corroborated by published literature reports. It is rooted in the comparable absorption and disposition behaviour of MPA in adult and paediatric patients and on an age-independent receptor responsiveness.

## Off-label use of MMF in 1-2-year-old transplant patients

Transplantation in 1- to 2-year-old patients is always a singular event and pharmacotherapy will have to take into account all patient and treatment factors that determine outcome of the intervention.

The dosing scheme of 600 mg/m2 b.i.d. for paediatric renal transplant patients (corresponding to the 1 g b.i.d. dose in an adult with BSA of 1.73 m2) has been used successfully over the last 20 years in several countries and thus has been validated over a long period of time. However, individually applied dosing schemes vary widely.

Nine reports for 1-2-year-old renal transplant patients were received between 1 January 2000 and 30 September 2023. Sufficient daily dosage information was provided for 7 patients; doses were in the range 600-2041 mg/m2 (average 1119 mg/m2 per day), including multiple dosing regimens for two patients. Hence, these infants received on average the recommended daily dose of 1200 mg/m2; the distribution of individual doses showed that most of the infants received a lower dose than recommended. No events of transplant rejection were reported; one patient on MMF 140 mg b.i.d. (daily dose based on the average BSA for a 1-year-old patient: 571 mg/m2), experienced 'slightly elevated creatinine' (unspecified, Preferred Term [PT] Blood creatinine increased).

Ten reports for 1-2-year-old liver transplant patients were received between 1 January 2000 and 30 September 2023. Sufficient daily dosage information was provided for 7 patients; doses were in the range of 208-1224 mg/m2 (average 700 mg/m2 per day). One patient on MMF 250 mg daily (510 mg/m2 daily based on age-adjusted average BSA), experienced liver transplant rejection.

While acknowledging the limitations associated with the small number of reports, these data suggest a high variability in the dosage being used in the off-label population of 1-2 years old paediatric patients with renal and liver transplant, and a tendency to underdose these vulnerable patients with obvious consequences in terms of risk of graft rejection and patient's survival.

## Drug-drug interactions

The published literature on paediatric transplant patients does not give information on concomitantly administered (non-immunosuppressive) drugs. Hence, no information on possible drug-drug interactions can be derived from them. However, potential drug interactions applicable to the administration of MMF to paediatric transplant recipients are expected to be the same as those described for the adult transplant population. In general, PK interactions relevant to the use of MMF involve drugs that (1) interfere with

<div style=\"page-break-after: always\"></div>

EHC of MPAG/MPA (such as bile-acid sequestrants or antibiotics) or (2) compete with renal tubular secretion of MPAG (such as acyclovir).

## 2.3.3. Pharmacodynamics

## Mechanism of action

Mycophenolic acid (MPA) is a potent, selective, uncompetitive and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH) and inhibits the de novo pathway of guanosine nucleotide synthesis without incorporation into DNA.

Two IMPDH isoforms have been identified, isoform type I, which is present in most known cells (including resting human lymphocytes) and isoform type II, which is strongly and predominantly expressed in activated human B- and T-lymphocytes. The type II isoform is nearly five times more sensitive to inhibition by MPA than is the type I isoform.

Because T- and B-lymphocytes are critically dependent for their proliferation on de novo synthesis of purines whereas other cell types can utilise salvage pathways, MPA has more potent cytostatic effects on lymphocytes than on other cells.

In addition to its inhibition of IMPDH and the resulting deprivation of lymphocytes, MPA also influences cellular checkpoints responsible for metabolic programming of lymphocytes. It has been shown, using human CD4+ T-cells, that MPA shifts transcriptional activities in lymphocytes from a proliferative state to catabolic processes relevant to metabolism and survival leading to an anergic state of T-cells, whereby the cells become unresponsive to their specific antigen (Guentert et al. 2021).

MMF does not act on the transplanted organ itself. The immunological mechanisms underlying MPA's mechanism of preventing organ rejecting are independent on organ type and are the same in HTx and LTx as in RTx recipients.

## Primary and secondary pharmacology

MPA inhibits the activity of inosine monophosphate dehydrogenase (IMPDH) and with this the proliferation of host B and T lymphocytes. The half maximal effective concentration (EC50) values for IMPDH inhibition by MPA in both children and adults ( Table 17 ) are in line with the proposed target MPA exposures (Tang et al. 2017). A 40%-60% inhibition of IMPDH may be sufficient for effective immunosuppression (Langman et al. 1996; Fukuda et al. 2011).

<div style=\"page-break-after: always\"></div>

Table 17 Comparative EC50 Values for Inosine Monophosphate Dehydrogenase Inhibition by Mycophenolic Acid in Renal Transplant Patients

| Reference                           | Age Group'(years)   | Age Group'(years)   | N   | EC5o (mg/L)                    |
|-------------------------------------|---------------------|---------------------|-----|--------------------------------|
|                                     | Range               | Mean±SD             |     |                                |
| Fukuda etal.2011                    | 2.1 -20.2           | 12.5 ±5.3           | 28  | Mean: 0.97 (95% Cl: 0.55-1.41) |
| Tang et al.2017                     | 19.2-58.4           | 43.7 ± 11.0         | 54  | Median 3.17 (Range 0.84-7.81)  |
| Tang et al.2017                     | 60.1-76.2           | 65.8±4.9            | 26  | Median 1.54 (Range 0.92-4.50)  |
| Langmanetal.1995 Langman et al.1996 | Adult               | NA                  | 5   | Range:2-5                      |
| Budde etal.2007                     | NA                  | 42± 13              | 21  | Mean: 2.96 (95% CI: 2.96-6.15) |

ECso=half maximal effective concentration; NA=not available; SD=standard deviation.

1 renal transplant patients; for ECso determined in vitro using isolated IMPDH see Nowak and Shaw (1997).

## Ontogeny

IMPDH does not undergo ontogenic changes in children above 2 years of age. A German study group analysed IMPDH activity in peripheral blood mononuclear cells (PBMCs) in 80 healthy children between the ages of 2.0 and 17.9 years (Rother et al. 2012). No developmental regulation of IMPDH activity in PBMCs in children older than 2 years was observed. Furthermore, pre-transplant IMPDH activity was comparable in children (median [range], 83.8 [39.6-163.0] µmol s-1 mol-1 adenosine monophosphate; n=31) and adults with end-stage renal disease (92.0 [16.7-213], N=81). IMPDH activity in both children and adults was inversely correlated with MPA plasma concentration indicating that MPA inhibits IMPDH activity in children and adults to a comparable extent. IMPDH activity displayed high interindividual variability (coefficient of variation, 41%) during childhood. Others have reported similarly large interpatient variability in IMPDH activity (Langman et al. 1996; Fukuda et al. 2011).

<div style=\"page-break-after: always\"></div>

Table 18 Supportive Data from Ontogeny of Inosine Monophosphate Dehydrogenase Activity (Literature References)

<!-- image -->

| Key Evidence                            | Key Evidence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Key Evidence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Key Evidence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Key Evidence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|-----------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Literature Reference                    | Study Design                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Formulation/ Dosing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Demographics (number of patients; gender;age:other details)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Key Findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Rother et al.2012                       | Measurement of IMPDH activity in peripheral blood mononuclear cells (PBMC)from healthy children, healthy adult, children and adolescents after MMF dosing.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | n.a.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 17children/adolescents withrenal Tx: n-8 patents (males/femalles=7/1) 2.0-11.9yrs;time post-Tx 16±4 days:BSA 0.68 (0.58-1.25)m² n=9（males/femalesm4/5) 12.0-18.9 yrs;time post- Tx17±4days;BSA 1.27 (1.17-1.82)m²                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 1.Thereisnopronounceddevelopmental regulation of IMPDH activity in thepaediatricpopulation. 2.IMPDH activity didnot differ significantly between different age groups from 2yrsof age toadults Comparable inhibition of IMPDHactivity by MPA in children and adolescents afterrenal Tx-in accordance with that observedin adult renal transplantrecipients. 4.IMPDH inhibition afterMMFdosing israthera function of free MPA than of total MPA.                                                                                                                                                                                                                                           |
| Rother et al.2012                       | Rationale for Strength of Evidence The prospective comparison of IMPDH activityin renally transplanted children andinhealthy control subjects（paediatric,adult)alongwith the determination of thePK/PDprofie ofMPAin the transplanted childrengivesvery valuableinsightinto the ontogeny of the target enzyme for MPA'simmunosuppressive activity.The study allowed to determine andcompare IC50 valuesbetween paediaticages and between early andlate post-transplant periods.Noteworthy.animprovedassay forIMPDHactivityinpenpheral bloodmononuclear cells providesa mechanisticbasis forthe empinicalobservation of comparable effectivenessof MPAatthe same exposure acrosspaediatric | Rationale for Strength of Evidence The prospective comparison of IMPDH activityin renally transplanted children andinhealthy control subjects（paediatric,adult)alongwith the determination of thePK/PDprofie ofMPAin the transplanted childrengivesvery valuableinsightinto the ontogeny of the target enzyme for MPA'simmunosuppressive activity.The study allowed to determine andcompare IC50 valuesbetween paediaticages and between early andlate post-transplant periods.Noteworthy.animprovedassay forIMPDHactivityinpenpheral bloodmononuclear cells providesa mechanisticbasis forthe empinicalobservation of comparable effectivenessof MPAatthe same exposure acrosspaediatric | Rationale for Strength of Evidence The prospective comparison of IMPDH activityin renally transplanted children andinhealthy control subjects（paediatric,adult)alongwith the determination of thePK/PDprofie ofMPAin the transplanted childrengivesvery valuableinsightinto the ontogeny of the target enzyme for MPA'simmunosuppressive activity.The study allowed to determine andcompare IC50 valuesbetween paediaticages and between early andlate post-transplant periods.Noteworthy.animprovedassay forIMPDHactivityinpenpheral bloodmononuclear cells providesa mechanisticbasis forthe empinicalobservation of comparable effectivenessof MPAatthe same exposure acrosspaediatric | Rationale for Strength of Evidence The prospective comparison of IMPDH activityin renally transplanted children andinhealthy control subjects（paediatric,adult)alongwith the determination of thePK/PDprofie ofMPAin the transplanted childrengivesvery valuableinsightinto the ontogeny of the target enzyme for MPA'simmunosuppressive activity.The study allowed to determine andcompare IC50 valuesbetween paediaticages and between early andlate post-transplant periods.Noteworthy.animprovedassay forIMPDHactivityinpenpheral bloodmononuclear cells providesa mechanisticbasis forthe empinicalobservation of comparable effectivenessof MPAatthe same exposure acrosspaediatric |
| andadult agegroups. Supportive Evidence | andadult agegroups. Supportive Evidence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | andadult agegroups. Supportive Evidence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | andadult agegroups. Supportive Evidence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | andadult agegroups. Supportive Evidence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Tonsholf et al2011                      | Review artcle                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | n.a.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | n.a.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 1.Ontogenyof IMPDH:Thereisno change in IMPDHactivity with developmentalregulationinchildrenolderthan2yrs                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Tonsholf et al2011                      | Rationale forStrength of Evidence The reviewarticle byTonshoff et al.(2011) brings togethermanyof theaspectsrelevant forimmunosuppressive therapy inapaediatric transplant population.Thescope of the aricleis toreview the specificpaediatic aspectsof concentration-controlledMPA dosing in solid organ transplantation (including ontogeny).lt stresses the need for therapeutic drugmonitoring particularly in patientsat high immunological risk(e.g,initial post-transplantperiod,withdrawallowdose CNl treatment strategies,steroidavoidance,drug adherence) However,nonewdata are presented in this aricle.                                                                       | Rationale forStrength of Evidence The reviewarticle byTonshoff et al.(2011) brings togethermanyof theaspectsrelevant forimmunosuppressive therapy inapaediatric transplant population.Thescope of the aricleis toreview the specificpaediatic aspectsof concentration-controlledMPA dosing in solid organ transplantation (including ontogeny).lt stresses the need for therapeutic drugmonitoring particularly in patientsat high immunological risk(e.g,initial post-transplantperiod,withdrawallowdose CNl treatment strategies,steroidavoidance,drug adherence) However,nonewdata are presented in this aricle.                                                                       | Rationale forStrength of Evidence The reviewarticle byTonshoff et al.(2011) brings togethermanyof theaspectsrelevant forimmunosuppressive therapy inapaediatric transplant population.Thescope of the aricleis toreview the specificpaediatic aspectsof concentration-controlledMPA dosing in solid organ transplantation (including ontogeny).lt stresses the need for therapeutic drugmonitoring particularly in patientsat high immunological risk(e.g,initial post-transplantperiod,withdrawallowdose CNl treatment strategies,steroidavoidance,drug adherence) However,nonewdata are presented in this aricle.                                                                       | Rationale forStrength of Evidence The reviewarticle byTonshoff et al.(2011) brings togethermanyof theaspectsrelevant forimmunosuppressive therapy inapaediatric transplant population.Thescope of the aricleis toreview the specificpaediatic aspectsof concentration-controlledMPA dosing in solid organ transplantation (including ontogeny).lt stresses the need for therapeutic drugmonitoring particularly in patientsat high immunological risk(e.g,initial post-transplantperiod,withdrawallowdose CNl treatment strategies,steroidavoidance,drug adherence) However,nonewdata are presented in this aricle.                                                                       |

BSA=body surface area;IMPDH-inosine monophosphate dehydrogenase;MMF=mycophenolate mofetil;MPA=mycophenolic acid;PBMC=peripheral blood mononuculearcells;n.a.-not available;Tx=transplant(ation):yrs-years.

Two supporting literature references were provided but none included patients below the age of 2.

## 2.3.4. Discussion on clinical pharmacology

In this application, the MAH initially applied for an extension of the current paediatric indication of MMF in RTx approved from 2 years of age to include children as of 3 months of age undergoing RTx, HTx and LTx. However, only limited data were available for infants (3 months to 1 year) and there was not enough data to support the justification for the PK comparability of MMF/MPA in infants and the proposed dosing regimen in this population. Therefore, the MAH proposed to revise the indication for an use in paediatric patients from 1 year of age. This was considered acceptable by the CHMP.

For use in children undergoing HTx and LTx, an initial dose of 600 mg/m2 of BSA is proposed and if immunosuppression is insufficient, the dose can be increased to 900 mg/m2. The paediatric extrapolation is primarily based on PK-comparison with the adult reference population and is supported by one paediatric clinical study in liver transplant patients (PA16497), previously submitted paediatric clinical studies in renal transplant patients (MYC2190 and MYCS2675) and by several paediatric studies in the literature in RTx, LTx and HTx.

Based on literature references, the MAH argued that the key ADME processes/parameters of MMF/MMP in paediatric patient above 1 year are comparable to adult patients. Comparability is reasonably justified for children above 1 year, in particular with regards to similarity in metabolic activity of the key enzyme UGT1A9, involved in the clearance of MPA and comparability with regards to plasma protein binding of MPA. Furthermore, key PK characteristics of MPA in adult patients as CsA DDI and non-stationarity were also observed in children. Hence, the PK comparability of MMF/MPA between paediatric and adult population is agreed by the CHMP.

<div style=\"page-break-after: always\"></div>

In adult RTx, a reference exposure target value, AUC0-12h, for the active drug MPA in early post-transplant period was established by PK/PD analysis and applied for the renal paediatric PK extrapolation approach and PK-driven extrapolation to adult LTx and HTx. This target exposure value has been shown to provide an optimal benefit in the prevention of organ rejection in combination with an acceptable safety profile. The pharmacokinetics of MMF/MPA in adult RTx was reasonably comparable with HTx and LTx patients, supporting the previous approval for use in these types of transplantation. The recommended dosing in adults is though different: 1.5 g b.i.d. (3 g daily dose) MMF in HTx and LTx compared to 1 g b.i.d. (2 g daily dose) MMF in RTx. A comparable translation from paediatric RTx to paediatric LTx and HTx should therefore also be valid.

In kidney paediatric transplant studies, supporting previous approval for use in 2-18 years old renal transplant patients in combination with ciclosporin and corticosteroid, a paediatric dose of 600 mg/m2 (maximum daily dose of 2 g) was established using the adult reference exposure target value. Body surface area (BSA) based scaling paediatric dosing was demonstrated to be superior to weight-based dosing and it was shown that a BSA based dosing results in reasonably comparable target exposure in RTx paediatric patients from 1 to 18 years. In addition, MPA AUC values across paediatric age groups were similar in the early and late post-transplant period. This information and a summary of the mean PK parameters by age and post-transplant have been included in section 5.2 of the SmPC. In conclusion, the data on MMF/MPA exposure in 1-2 year renal transplantation patients support an extension of the paediatric population to also include children down to 1 year, with the same dose of 600 mg/m2 (maximum daily dose of 2 g) as for RTx paediatric patients above 2 year.

In the clinical study PA16497, conducted in 8 paediatric LTx patients (6 patients &lt; 2 years), it was demonstrated that a slightly higher dose of 740 mg/m2 dose was necessary to reach the late posttransplant target exposure reference value of 58  g·h/mL A summary of these results has been added in section 5.2 of the SmPC. Overall, the paediatric studies reported in the literature were supportive of the PA16497 study and use of MMF in paediatric LTx patients in combination with ciclosporin and corticosteroid at the initial dose of 600 mg/m2 b.i.d.

Sponsored clinically studies are not available of MMF in paediatric heart transplant patients. The use of MMF in paediatric HTx patients is supported by two literature references (Dipchand et al. (2001) and Gajarski et al. (2004)), which both applied MPA Ctrough target values in their analysis. MMF dosing and MPA Ctrough values in the two publication appear to be in the range with other RTx and LTx paediatric studies. The mean Ctrough level was lower in the group of infants whose exact age is not available, compared to older children. According to the MAH, an early MPA Ctrough value of 1.5-3 mg/L appears as the optimal range. Overall, the paediatric studies reported in the literature were supportive for the use of MMF in paediatric HTx patients in combination with ciclosporin and corticosteroid at the initial dose of 600 mg/m2 b.i.d.

In conclusion, the starting dose of 600 mg/m2 MMF was shown to be adequate in children above 1 years. Data from the study conducted by the MAH and literature reports provides some support for using a higher MMF dose than 600 mg/m2 MMF children with insufficient immunosuppression due to inadequate MPA exposure. The MAH argued for not increasing the initial dose in younger children as the dose of MMF should be adjusted in LTx and HTx patients according to the need of the individual patient. If immunosuppression is assessed as insufficient, a dose increase to 900 mg/m2 twice a day (maximum daily dose of 3 g) is recommended. This recommendation to increase the dose to individual needs is consistent with the recommended adult dose for HTx and LTx, 1.5 g b.i.d. (3 g daily dose). This dosing regimen in LTx and HTx has been adequately justified and is accepted by the CHMP.

Overall, sufficient evidence have been provided to support the use of MMF in paediatric LTx and HTx patients, 1-18 year, and expanding the use in RTx in children down to 1 year. The recommended

<div style=\"page-break-after: always\"></div>

paediatric dosing regimen has been reasonably justified by the MAH and is consistent with the adult MMF dosing regimen and the already approved paediatric dosing scheme.

The mechanism of action of MPA is a potent, selective, uncompetitive and reversible inhibition of inosine monophosphate dehydrogenase (IMPDH) and the de novo pathway of guanosine nucleotide synthesis without incorporation into DNA. This is independent of transplant type and can be transferred from HTx and LTx and RTx to one another.

The pharmacodynamics relevant for both PD relationship with efficacy as well as safety is as described the IMPDH inhibition typically measured in EC50 levels. Ontogeny has been addressed and thus the claim that the PD is independent of age is accepted by the CHMP.

## 2.3.5. Conclusions on clinical pharmacology

PK comparability of MMF/MPA in children from 1 to 18 years has been demonstrated for RTx, LTX and HTx. In conclusion, the pharmacokinetic data are sufficient to support the following posology (section 4.2 of the SmPC) of MMF in children from 1 year to 18 year for all 3 types of transplantation:

- The recommended mycophenolate mofetil initial dose for paediatric renal, cardiac and hepatic transplant patients is 600 mg/m2 (of body surface area (BSA)), administered orally, twice daily (initial total daily dose not to exceed 2 g, or 10 ml of the oral suspension).
- The dose and product form should be individualised based on clinical assessment. If the recommended initial dose is well tolerated but does not achieve clinically adequate immunosuppression in paediatric cardiac and hepatic transplant patients, the dose can be increased to 900 mg/m2 BSA twice daily (maximum total daily dose of 3 g, or 15 ml of the oral suspension). The recommended maintenance dose for paediatric renal transplant patients remains at 600 mg/m2 twice daily (maximum total daily dose of 2 g or 10 ml of the oral suspension).

## 2.4. Clinical efficacy

No new study has been presented for this type II variation. A review of relevant clinical data literature is presented below supporting the application for extension of indication.

According to the MAH, the clinical efficacy data supporting the application originate from available publications of studies conducted in the paediatric population, including 14 studies relevant to paediatric heart transplant (HTx) and 15 studies relevant to paediatric liver transplant (LTx) patients.

In addition, clinical efficacy data from the Roche-sponsored pivotal trials conducted in the adult population, and data extracted from the Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR) Registries for HTx and LTx in the United States (US) are also included to provide the context for interpretation of the available literature data.

The MAH also resubmitted the clinical studies conducted in paediatric renal transplant.

## 2.4.1. Dose response studies

No new dose-response studies were conducted for this variation application. For background on dosing recommendations please see the PK-section above.

<div style=\"page-break-after: always\"></div>

## 2.4.2. Main studies

## Renal Transplantation in Adult Recipients

The pivotal clinical trials with MMF, which formed the basis for approval for use in prevention of organ rejection in adult RTx patients, were three randomised, double-blind, multi-centre trials assessing the safety and efficacy of MMF in combination with corticosteroids and ciclosporin A (CsA): Studies ICM1866, MYC0221, and MYC023.

The pivotal studies compared two dose levels of oral MMF (1 g twice a day [b.i.d.] and 1.5 g b.i.d.) with either azathioprine (AZA; 2 studies) or placebo (1 study) when administered in combination with CsA and corticosteroids to prevent acute rejection episodes.

The primary efficacy endpoint was the proportion of patients in each treatment group that experienced treatment failure within the first 6 months after transplantation.

Treatment failure was defined as:

- Biopsy-proven acute rejection upon treatment, or the occurrence of death or graft loss; or
- Early termination from the study for any reason without prior biopsy-proven rejection. MMF was studied in the following three therapeutic regimens:
- a) Anti-thymocyte globulin induction/MMF or AZA/CsA/corticosteroids;
- b) MMF or AZA/CsA/corticosteroids;
- c) MMF or placebo/CsA/corticosteroids.

The following tables ( Table 19 , Table 20 , and

Table 21 ) summarise the results of these studies.

MMF in combination with corticosteroids and CsA significantly reduced the incidence of treatment failure within the first 6 months following transplantation (p  0.05).

More patients receiving MMF discontinued therapy (without prior biopsy-proven rejection, death, or graft loss) than in control groups, with the highest rate in the MMF 3 g/day group. Patients who prematurely discontinued treatment were not followed for the occurrence of acute rejection after termination. Therefore, the acute rejection rates may be underestimated, particularly in the MMF 3 g/day group.

Table 19 Renal Transplant Study ICM1866 (Syntex Report CL 6813): Incidence of Treatment Failure at 6 Months Post-Transplant

| US/Canada Study* ICM1866 (N=499)               | Mycophenolate mofetil 2 g/day (n= 167)   | Mycophenolate mofetil 3 g/day (n=166)   | Azathioprine 1-2mg/kg/day (n=166)   |
|------------------------------------------------|------------------------------------------|-----------------------------------------|-------------------------------------|
| All treatmentfailures                          | 31.1%                                    | 31.3%                                   | 47.6%                               |
| Earlyterminationwithoutprior acute rejeclion** | 9.6%                                     | 12.7%                                   | 6.0%                                |
| BPAR episode on treatment                      | 19.8%                                    | 17.5%                                   | 38.0%                               |

<div style=\"page-break-after: always\"></div>

Table 20 Renal Transplant Study MYC023 (Syntex Report CL6821): Incidence of Treatment Failure at 6 Months Post-Transplant

| Europe/Canada/Australia Study*MYC023 (N=503)   | Mycophenolate mofetill 2 g/day (n=173)   | Mycophenolate mofetil 3 g/day (n=164)   | Azathioprine 100150mg/day (n=166)   |
|------------------------------------------------|------------------------------------------|-----------------------------------------|-------------------------------------|
| Alltreatmentfallures                           | 38.2%                                    | 34.8%                                   | 50.0%                               |
| Earlyterminationwithoutprior acuterejection**  | 13.9%                                    | 15.2%                                   | 10.2%                               |
| BPARepisode on treatment                       | 19.7%                                    | 15.9%                                   | 35.5%                               |

Table 21 Renal Transplant Study MYC022 (Syntex Report CL6819): Incidence of Treatment Failure at 6 Months Post-Transplant

| EuropeStudy*MYC022 (N=491)                    | Mycophenolate mofetill 2 g/day (n=165)   | Mycophenolate mofetil3 g/day (n=160)   | Placebo (n=166)   |
|-----------------------------------------------|------------------------------------------|----------------------------------------|-------------------|
| Alltreatmentfailures                          | 30.3%                                    | 38.8%                                  | 56.0%             |
| Earlyterminationwithoutprlor acuterejection** | 11.5%                                    | 22.5%                                  | 7.2%              |
| BPAR eplsode on treatment                     | 17.0%                                    | 13.8%                                  | 46.4%             |

Cumulative incidence of 12-month graft loss and patient death are presented in Table 22 . Numerically, patients receiving MMF 2 g/day and 3 g/day experienced a better outcome than controls in all three studies. Patients receiving MMF 2 g/day experienced a better outcome than MMF 3 g/day in two of the three studies. Patients in all treatment groups who terminated treatment early were found to have a higher incidence of graft loss and death at 12 months post transplantation.

Table 22 Cumulative Incidence of Combined Graft Loss and Patient Death at 12 Months PostTransplant

| Study                         | Mycophenolate mofetil 2g/day   | Mycophenolate mofetil 3g/day   | Control (AZAor placebo)   |
|-------------------------------|--------------------------------|--------------------------------|---------------------------|
| USICM1866                     | 8.5%                           | 11.5%                          | 12.2%                     |
| Europe/Canada/AustrallaMYC023 | 11.7%                          | 11.0%                          | 13.6%                     |
| Europe MYC022                 | 8.5%                           | 10.0%                          | 11.5%                     |

<div style=\"page-break-after: always\"></div>

Long-term (1-3 year) efficacy results for Studies MYC023 and MYC022 are summarised in Table 23 .

Table 23 Long-Term Efficacy Results of Studies MYC023 and MYC022

| Study   | Treatment group             | Graft rejection   | Treatment failure   | Graft loss   | Death   |
|---------|-----------------------------|-------------------|---------------------|--------------|---------|
| MYC023  | Mycophenolate mofetil 2 g/d | 34.5%             | 24%*                | 15.1%        | 4.7%    |
|         | Mycophenolate mofetil 3 g/d | 29.3%             | 30%*                | 8.7%         | 9.2%    |
|         | Azathioprine 100-150 mg/d   | 50.0%             | N/A                 | 15.7%        | 8.8%    |
|         | Mycophenolate mofetil 2 g/d | 17.0%**           | 30.3%**             | 8.5%         | 7.3%    |
| MYC022  | Mycophenolate mofetil 3 g/d | 13.8%             | 38.8%               | 12.5%        | 8.1%    |
|         | Placebo                     | 46.4%             | 56.0%               | 15.7%        | 10.8%   |

## Renal Transplantation in Paediatric Recipients

Approval in paediatric patients was based on one open-label, PK, safety and efficacy study in 100 paediatric RTx recipients aged 3 months to 18 years (Study MYCS2675). MMF powder for oral suspension was dosed at 600 mg/m2 b.i.d. (up to 1 g b.i.d.) in all age groups and was combined with CsA and maintenance corticosteroids. The patients were followed for up to 3 years post-transplant. The efficacy data are summarised in Table 24 .

Table 24 Efficacy Results of Paediatric Renal Transplant Study MYCS2675

|                          | 6month post-transplant   | 12months post-transplant   | 3years post-transplant   |
|--------------------------|--------------------------|----------------------------|--------------------------|
| Biopsy-proven rejection* | 24%                      | 25%                        | 30%                      |
| Graftandpalienl survival | 93%                      | 93%                        | 93%                      |

The study concluded that a 600 mg/m2 MMF dosing regimen provides a predictable PK profile in paediatric RTx patients. The results indicated that MMF treatment in paediatric patients is associated with patient and graft survival rates comparable to those in adult populations.

## Evidence of Efficacy in Cardiac Transplantation in Adult Recipients

Approval in adult cardiac transplant patients was based on one randomised, double-blind, multi-centre trial MYCS1864 (Niranjan et al. 2008).

Study MYCS1864 compared the efficacy of MMF and AZA in 578 cardiac transplant recipients. Patients received MMF 1.5 g b.i.d (n = 289) or AZA 1.5 -3 mg/kg/day (n = 289), in combination with CsA and corticosteroids, as maintenance immunosuppressive therapy. No difference was established between MMF (32%) and AZA (35%) with respect to biopsy-proven rejection with hemodynamic compromise (p = 0.338). At 3 years, the incidence of death or re-transplantation was 18.3% in AZA-treated patients and 11.8% in MMF-treated patients (difference 6.5%, 95% confidence interval [CI]: 1.1 to 12.0%). The authors

<div style=\"page-break-after: always\"></div>

suggested that MMF might provide some benefit in survival compared to AZA in patients who are able to take oral medication in the immediate post-transplant period. Efficacy results are summarised in Table 25 .

Table 25 Summary of Efficacy Results from Roche Study MYCS1864

| Treatmentgroup              | Follow-up period   | Graftrejection   | Deathor re-transplantation   |
|-----------------------------|--------------------|------------------|------------------------------|
| Mycophenolate mofetil 3 g/d | years              | 14.5%            | 11.8%                        |
| Azathioprine 1.5-3 mg/kg/d  | years              | 24.2%            | 18.3%                        |

## Evidence of Efficacy in Hepatic Transplantation in Adult Recipients

Approval in adult hepatic transplant patients was based on one randomised, double-blind, multi-centre trial MYCS2646.

Study MYCS2646 was a randomised, double-blind, parallel-group, multi-centre, comparative study in 564 primary hepatic transplant recipients that was performed at 16 centres in the US, 2 in Canada, 4 in Europe, and 1 in Australia. Patients either received MMF 1 g b.i.d intravenously for up to 14 days followed by MMF 1.5 g b.i.d. orally, or AZA 1 -2 mg/kg/day intravenously followed by AZA 1 -2 mg/kg/day orally, in combination with CsA and corticosteroids, as maintenance immunosuppressive therapy. Efficacy results are summarised in Table 26 .

Table 26 Efficacy Results of Study MYCS2646

|                                                                               | Azathloprine (n=287)   | Azathloprine (n=287)   | Azathloprine (n=287)   | Mycophenolate mofetil (n=278)   | Mycophenolate mofetil (n=278)   | Mycophenolate mofetil (n=278)   |
|-------------------------------------------------------------------------------|------------------------|------------------------|------------------------|---------------------------------|---------------------------------|---------------------------------|
|                                                                               | 6months                | 12months               | 3 years                | 6months                         | 12months                        | 3 years                         |
| Blopsy-proven and treated rejection or graft loss (death/re- (ransplantation) | 47.7%                  | 50.2%                  | 54.7%                  | 38.1%                           | 42.4%                           | 48.9%                           |
| Death or re- transplantation                                                  | 14.6%                  | 14.6%                  | 19.9%                  | 14.0%                           | 14.7%                           | 21.6%                           |

n=number.

## Real World Data from Registries

The off-label use of MMF-containing regimens in paediatric heart and liver transplant recipients has increased over time. In paediatric HTx approximately 93% of children received MMF and for paediatric LTx, 49% of children received MMF as part of an immunosuppressive regiment in 2019. From the literature, use of immunosuppressants (including MMF) in paediatric liver and heart transplant patients is consistent between countries.

## Methods

A systematic literature search was conducted in the electronic databases BIOSIS Previews, Derwent Drug File, Embase, Medline, Cochrane Library and NICE website. The literature search was cumulative until end of 2022. The search terms were keywords from MeSH and Emtree thesaurus for clinical studies, clinical trials, meta-analysis, efficacy, effectiveness, treatment outcome, disease progression, evidence-based medicine, guidelines and related concepts, combined with the drug terms 'mycophenolate mofetil', 'cellcept' or 'mmf' in paediatric population with liver and heart transplant(s). A free text search in title and abstract with those terms was also performed. Exclusion criteria were case reports, letters, editorials, notes, preclinical studies and non-English publications. From the 105 publications identified, randomised clinical trials, observational studies, meta-analyses, and guidelines concerning the approved indications

<div style=\"page-break-after: always\"></div>

were considered. Reference lists from the identified publications were also examined to identify any relevant information that may have been missed in the systematic search.

## Paediatric Heart transplant

A summary of the available publications of studies showing a potential benefit related to the efficacy of MMF when used in paediatric HTx recipients is included in

<div style=\"page-break-after: always\"></div>

Table 27 , below. The publications are grouped by the potential benefit and provide supportive evidence. This includes 12 retrospective studies and 2 prospective observational studies.

<div style=\"page-break-after: always\"></div>

## Table 27 Summary of Paediatric Heart Transplant Studies Contributing to Efficacy Evaluation (Supportive Evidence)

| Studyl Reference Ranking   | Study Design                                                                                                                                                                                                                                           | Dosing,Formulation,Duration                                                                                                                                                                                                                                                                                             | Demographics                                                                                                                                                                                                                 | Key Findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | KeyBenefit                                                                                                                                                                                                                   |
|----------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Rejection                  |                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                              |
| Dipchand et al. 2001       | Single center, retrospective chart reviewofpatients switchedfrom AZA to MMF forrejection, dosereduction or facilitationofsteroid cessationor tolerability issues with existing regimen.                                                                | TheaverageMMFdosewas 40±14 mg/kg. MMFwasstartedinpatients takingsteroid andAZA;20/21 patientsalsoreceivedTAC (median dose 0.18 mg/kg, range received CsA(10 mg/kg).AZA wasdiscontinuedwhenMMF 0.03-0.64 mg/kg)and 1/21 initiated. Formulation not specified. Follow-up:median1.3years afterHTx(range72daysto5.4 years). | N=21 Median age at review:12.3years (range:11 months to 16.9 years). Median age at HTx:10.7years 16.7 years.). MMF (range:55days to startedata medianof 4.3months after HTx (range: 1 day to 4.5 years). Males:females=12 :9 | MMFappearstobeeffectivefortreatmentof rejectioninthepaediatricheartTxpopulationand has an acceptable side-effectprofile.Inaddition,it mayhavearoleinprimaryrejectionprophylaxis andmayfacilitatereducedsteroiddosageor steroid-freeimmunosuppression.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Rejectiontreatmentand prophylaxis. Steroid sparinq. Switching formAZAto MMF appears to be effectiveforthetreatment and prevention of organ rejection in HTx. MMFfacilitatesreduced steroid andsteroidfree immunosuppression. |
|                            | RationaleforClassificationofEvidence: This studyis asmall,single-centre,retrospective chartreview.                                                                                                                                                     | RationaleforClassificationofEvidence: This studyis asmall,single-centre,retrospective chartreview.                                                                                                                                                                                                                      |                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                              |
| Groetzneret. al.2005       | Single center, retrospective study of clinical outcomes.                                                                                                                                                                                               | Pre-1994:CsA,corticosteroids and AZA. Post-1994:TAC or CsA, corticosteroids andAZA. Post-1995:TACorCsA, corticosteroidsandMMF. Target troughlevelsfor1st year: TAC 11-15 ng/mL,CsA                                                                                                                                      | N=47 (30 with dilated cardiomyopathy. 17 with congenital heart disease). Mean age:9.4±6.9 years (range: 4 days to 17.9 years).                                                                                               | Freedomfromacuterejectionafter5yearswas 40%with CsA-based immunosuppression, and 56%withTAC-basedimmunosuppression.Since theintroductionof MMF,freedomfromacute rejectionincreased to62%. Actuarial1,5, and10-year survival was86%,80%， and80%,respectively.Actuarialsurvivalimproved significantly since 1995:1year:92%vs.78%; p=0.09;5 years:92%vs.68%;p=0.04                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Rejectionprophylaxis Sincetheintroductionof MMFfreedomfrom rejection improved significantly.                                                                                                                                 |
| Studyl Reference Ranking   | Study Design                                                                                                                                                                                                                                           | Dosing，Formulation，Duration                                                                                                                                                                                                                                                                                             | Demographics                                                                                                                                                                                                                 | Key Findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | KeyBenefit                                                                                                                                                                                                                   |
|                            |                                                                                                                                                                                                                                                        | 250-350ng/mL,mycophenolic acid 2-4 mg/L Formulation:250mg/dayIV post-operatively,thenorallyafter extubation(oralformulationnot specified) Follow-up:mean5.25±3.6years                                                                                                                                                   | Males:females=29 :18                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                              |
|                            | RationaleforClassificationofEvidence: Thisstudyis asmall,single-centreretrospectivereview.                                                                                                                                                             | RationaleforClassificationofEvidence: Thisstudyis asmall,single-centreretrospectivereview.                                                                                                                                                                                                                              |                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                              |
| Lammerset al.2010          | Retrospective study of acuterejectionto identify predisposing factors, including population risk factors (gender, ethnicity, number of HLA regime,as well as mismatch) and immunosuppression mismatchesandABO factors such asCMV status(and mismatch). | Triple therapy: TAC (or sirolimus, if severe renal dysfunction). Steroid(withdrawn if possible after2nnegative endomyocardial biopsy). Dose: not specified. Formulation:not specified. AZA(pre-April2005)orMMF (post-April 2005). Follow-up:mean2.6±1.6years (range: 0-5.5)                                             | N=105(66dilated cardiomyopathy, 12restrictive cardiomyopathy, 27 congenital heart disease). 8.3±5.8years. Age at Tx: Males:females=50 :55                                                                                    | 7patientsdied(6.7%),5duringadmissionTxfrom acute graft failure/pulmonary hypertension (4.8%). These5patientswerecensoredfromfurther analysis. 50/100childrenwhosurvivedandweredischarged fromhospitalaftertheirTx,receivedTACand There were 23episodes(21.9%)of significant wereonadditionalsteroid). MMF.6childrenreceivedsirolimusandMMF（5 withadditionalsteroid).31receivedTACandAZA, 13receivedTACwithoutacellcycleinhibitor(six rejection in 271.9patient-years in 21patients (20%). Sirolimus therapy without a CNI, CMV (IgG) positivestatusbeforeTxandnon-Caucasian ethnicitywasassociatedwithhemodynamically compromisingrejectiononunivariateanalysis. None of the patients presenting with hemodynamic collapse was on MMF. Sirolimuswas alsoassociatedwithahigher incidence of symptomaticrejection(p<0.0001) whereasTACwasassociatedwithalowerrisk (p<0.0001). Theauthorsfound thelowestincidence ofrejection withimmunosuppressiveregimesincludingTAC andMMF.However,thedifferencebetweenTAC andMMFvs.TACandAZAwasnotstatistically different.AuthorsconcludedthatTAC+MMFthe wasregimenof choiceandMMFmight be protectiveagainstrejectionresulting in hemodynamiccollapse,asnone of thepatients | Rejectionprophylaxis Lowerincidenceof rejection withTAC and MMFthanwithTACand AZA or TAC alone. MMFmightbeprotective in hemodynamic collapse. againstrejectionresulting                                                      |

<div style=\"page-break-after: always\"></div>

## Table 27 continuation

| Studyl Reference Ranking   | Study Design                                                                                                                                                                    | Dosing,Formulation，Duration                                                                                                                                                                                                                                                                                                  | Demographics                                                                                                                                                                    | Key Findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | KeyBenefit                                                                                                                                                                                                                         |
|----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                            |                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                 | requiringECMOasrescuetherapyforrejection episodesreceivedMMFandnocasesofsevere hemodynamiccompromisewere seenTAC+MMF- treatedpatients.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                    |
|                            | RationaleforClassificationofEvidence: This study is a single-centre,retrospectivereview.                                                                                        | RationaleforClassificationofEvidence: This study is a single-centre,retrospectivereview.                                                                                                                                                                                                                                     | RationaleforClassificationofEvidence: This study is a single-centre,retrospectivereview.                                                                                        | RationaleforClassificationofEvidence: This study is a single-centre,retrospectivereview.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | RationaleforClassificationofEvidence: This study is a single-centre,retrospectivereview.                                                                                                                                           |
| Marshallet al. 2013        | Retrospective, historical-control, observational study to compareoutcomesfor CsA-AZA-steroid and TAC-MMF.                                                                       | Pre-April 2008(control group): CsA-AZA-prednisone without induction group): TAC-MMF and no steroid globulin induction with high-dose steroid for 5 days) Post-April2008(newprotocol maintenance(antithymocyte Dose: not specified. Formulation:not specified. Follow-up: control group 6.3±1 years,newprotocol3.6±0.6 years. | N=103(64 control, 39 new protocol). Aqe at Tx: years. 7.8±6.7 years. Control 9.7±6.1 New protocol Gendernotstated.                                                              | In the controlgroup,37/64 subjects(58%)had≥1 episodeofrejectioninthefirstyear afterTx, compared with14/39 subjects(36%)in the new protocol group (OR=0.41,95% Cl:0.18 to 0.92, p=0.42). experiencedarejectionepisodeduringthesecond Among subjects whowerefollowedfor≥2years, 2/37subjects(5%)receivingthenewprotocol year.In the control group,2/56 subjects (4%) experienced arejectionepisodeduring the second year(p=0.67).In the control group,37/64 subjects (58%)had>1episodeof rejection in the first year afterTx,comparedwith14/39subjects(36%)in the new protocol group(OR=0.41,95% Cl:0.18 to 0.92,p=0.042).Death within the first year after Tx occurredin8/64patients(13%)inthecontrol group,comparedwith only1/39patients(3%)in the newprotocolgroup,but thedifferencewasnot statistically significant(OR=0.18,95% Cl:0.022 to 1.53,p=0.15) Overallgraftsurvivalwasnotdifferentbetweenthe two groups (p=0.68) but the TAC-MMF regimen wasassociatedwithimprovedfreedomfrom rejection. | Rejectionprophylaxis Switching from anAZA containing without regimen toa MMF containing one with inductiontreatment inductiontreatmentshows significantly less episodes of acuterejection.This benefitextendedto1year aftertheHTx. |
| Marshallet al. 2013        | RationaleforClassificationofEvidence: Thisis aretrospectiveobservational,singlecentrestudy using a historicalcontrol whichcomparedoutcomesof twodifferentcombinationtreatments. | RationaleforClassificationofEvidence: Thisis aretrospectiveobservational,singlecentrestudy using a historicalcontrol whichcomparedoutcomesof twodifferentcombinationtreatments.                                                                                                                                              | RationaleforClassificationofEvidence: Thisis aretrospectiveobservational,singlecentrestudy using a historicalcontrol whichcomparedoutcomesof twodifferentcombinationtreatments. | RationaleforClassificationofEvidence: Thisis aretrospectiveobservational,singlecentrestudy using a historicalcontrol whichcomparedoutcomesof twodifferentcombinationtreatments.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | RationaleforClassificationofEvidence: Thisis aretrospectiveobservational,singlecentrestudy using a historicalcontrol whichcomparedoutcomesof twodifferentcombinationtreatments.                                                    |

| Studyl Reference Ranking       | StudyDesign                                                                                                                                                                                         | Dosing，Formulation,Duration                                                                                                                                                                                                                                                                                                                                                | Demographics                                                                                                                                                                                    | Key Findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | KeyBenefit                                                                                                                                                                                                                                                                           |
|--------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Lamouret al. 2019              | Prospective,multi- institutional observational cohort study of children Tx. withoutDSAsat timeof                                                                                                    | Steroidavoidanceregimenthat included noroutineuseof corticosteroidsbeyond thefirst weekafterTx. thymoglobulin induction therapy (total cumulative dose 7.5mg/kg) Allpatientsreceived andmaintenance immunosuppression with TAC and MMF Dose:datanot collected. Formulation:not specified/ Follow-up:minimum of 1year                                                       | N=186 Median age 6 years (range: 1-14) Males:females=90 :96                                                                                                                                     | 182subjectssurvived tohospital discharge,181 weredischargedonTAC.MMFwasthesole adjunct immunosuppression in 155 subjects at1 year was 94.5%(95%Cl:1to 97).In the first yearpost Tx,58subjects(31.2%)had an acute AZAinthefirstyear.Probabilityofpatientsurvival rejection event, and 21 subjects(11.3%)had recurrentrejection(>2episodes).Freedomfrom acute cellular rejection was78.6%,AMR94.4% andrejectionwithhemodynamiccompromise identifiedriskfactorsforacutecellularrejectionthat 97.1%.Multivariablelogisticregressionmodel includedolderage(p=0.0055)and non-blackrace (p=0.059),whereasaseparatemultivariable logisticmodelidentifiedriskfactorsforany rejection that included olderage (p=0.0117),non- blackrace(p=0.0043),and presence of non-DSA antibodiesbeforeTx(p=0.0527).Newonset diabetes was observed in3 subjects(1.6%). | Rejectionprophylaxis Steroid sparinq HTxrecipients without DSAsattransplant,and managedwitha steroid avoidanceregimen,have excellentshort-term survivalandlowriskof first-year diabetes mellitus andPTLDwhentreated with MMF as part of their maintenance immunosuppressive regimen. |
|                                | RationaleforClassificationofEvidence: This is a prospective, multi-centre observational study,provides supportive evidence and was not designed to assess the efficacy or effectiveness of MMF.     | RationaleforClassificationofEvidence: This is a prospective, multi-centre observational study,provides supportive evidence and was not designed to assess the efficacy or effectiveness of MMF.                                                                                                                                                                            | RationaleforClassificationofEvidence: This is a prospective, multi-centre observational study,provides supportive evidence and was not designed to assess the efficacy or effectiveness of MMF. | RationaleforClassificationofEvidence: This is a prospective, multi-centre observational study,provides supportive evidence and was not designed to assess the efficacy or effectiveness of MMF.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | RationaleforClassificationofEvidence: This is a prospective, multi-centre observational study,provides supportive evidence and was not designed to assess the efficacy or effectiveness of MMF.                                                                                      |
| Cardiac Allograft Vasculopathy | Cardiac Allograft Vasculopathy                                                                                                                                                                      | Cardiac Allograft Vasculopathy                                                                                                                                                                                                                                                                                                                                             | Cardiac Allograft Vasculopathy                                                                                                                                                                  | Cardiac Allograft Vasculopathy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Cardiac Allograft Vasculopathy                                                                                                                                                                                                                                                       |
| Moffett et al. 2014            | Singlecenter retrospective analysis of patients whose HTx wasperformed between1996and 2012, with the aim to identifytheeffectof the different immunosuppressive regimens on the development of CAV. | Patientswhoreceiveddifferent medicationregimenswere followedto1of3endpoints:date of firstCAVdiagnosis,reTxr death.CAVwasdetermined by angiography/imaging or pathology. Medicationregimensincluded: CsA,TAC,MMF,sirolimus, prednisone,statin,beta-blockers and ACE inhibitors. Medicationregimen inthosethat developedCAVwascompared topatients that hadnot developed CAV. | N=148. Age<19years Males:females=57 %:43%                                                                                                                                                       | Graftlossoccurredin27%patientsandCAVwas present in24%patients.Median time toPatients wereexcludedifdeathoccurredpriortofirstclinic visit,nottransplantedatinstitutionhadmulti-organ Tx,orreTx.Statisticalanalysisincludedunivariate andmultivariatehazardmodels. Mediantime toCAVwas5.52years(range: 1.0-12.3).Nodifferencewas seen inpatients who developed CAVto thosewhohadnot withrespect toageatHTx,sex,orCMVstatus.Ofthosewho developedCAV,97%wereonsteroids compared to78%without CAV;26%patients who developed CAVwere onMMF compared to 60%without CAV. MultivariateHRshowedthatstatinsandMMFwere protectivefrom thedevelopment of CAV(HR=0.39 andHR=0.45,respectively)                                                                                                                                                               | CAV prophylaxis The useof MMFhas a protectiveeffectagainst thedevelopmentof CAV inpaediatricrecipientsof HTx.                                                                                                                                                                        |
|                                | RationaleforClassificationofEvidence: RetrospectiveanalysisevaluatingtheeffectofdifferentregimensonthedevelopmentofCAv.                                                                             | RationaleforClassificationofEvidence: RetrospectiveanalysisevaluatingtheeffectofdifferentregimensonthedevelopmentofCAv.                                                                                                                                                                                                                                                    | RationaleforClassificationofEvidence: RetrospectiveanalysisevaluatingtheeffectofdifferentregimensonthedevelopmentofCAv.                                                                         | RationaleforClassificationofEvidence: RetrospectiveanalysisevaluatingtheeffectofdifferentregimensonthedevelopmentofCAv.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | RationaleforClassificationofEvidence: RetrospectiveanalysisevaluatingtheeffectofdifferentregimensonthedevelopmentofCAv.                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

## Table 27 continuation

| Study/ Reference Ranking   | StudyDesign                                                                                                                                                                                        | Dosing,Formulation，Duration                                                                                                                                                                                                                                | Demographics                                                                                                          | Key Findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | KeyBenefit                                                                                                                                    |
|----------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|
| Renal Sparing              | Renal Sparing                                                                                                                                                                                      | Renal Sparing                                                                                                                                                                                                                                              | Renal Sparing                                                                                                         | Renal Sparing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Renal Sparing                                                                                                                                 |
| Boyer et al. 2005          | Prospective study in paediatric patients receiving CNI and AZA whodeveloped a renal function>2 years progressive decline in aftercardiacTx.                                                        | CNIdosereducedby50%and AZA replaced by MMF. MMF300mg/m²b.i.d,increased after1weekto600mg/m²b.i.d. Follow-up: mean 26.3 months Formulation:not specified. (range: 15-36).                                                                                   | 14/52 paediatric cardiacTx recipients received MMF duetorenal decline (age at Tx: 0.5-204 months). Males:females=6: 8 | Inulinclearanceinthe14childrenreceivingMMF decreased from84.2mL/min/1.73m²at1yearpost- Txto46.5±9.6mL/min/1.73m²atthetimeof changeinimmunosuppressivetherapy.Significant renallesionswereobservedinrenalbiopsies performedpriortothechange.At1year,inulin hadaseconddetermination2yearsafterthe clearancehad increased by67%.In6patients who switch，inulinclearancewasnotsignificantly differentfromthevalueat1year.Therewerethree reversibleacuterejectionepisodesinthree patients.The incidence of rejectionepisodes was not different from a control group of patients whose treatment was not changed. The reduction of CNI dosageandreplacementofAZAbyMMFisasafe waytoimproverenalfunctioninchildrenwithheart Tx and CNI-induced nephrotoxicity.   | Renal sparing CNIreductionand replacementofAZAwith MMFimprovedrenal function.                                                                 |
|                            | RationaleforClassificationofEvidence:                                                                                                                                                              | RationaleforClassificationofEvidence:                                                                                                                                                                                                                      | RationaleforClassificationofEvidence:                                                                                 | RationaleforClassificationofEvidence:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | RationaleforClassificationofEvidence:                                                                                                         |
| Rosenthalet al. 2021       | A single-center retrospective analysis to assess the safety of long-term CNl-free immunosuppression withregardtosurvival, graft failure,and the impactonrenal function in paediatric HTx patients. | PatientsthatdiscontinuedCNI were maintained on MMF and everolimuswithouttheuseof corticosteroids. The medianfollow-up time after switchof immunosuppression regiment was6years(range: 0-11). median time of 9years (range: CNIwasdiscontinuedaftera 3-14). | N=15                                                                                                                  | Rejectionsurveillancewasperformedwithannual catheterizationforevaluationofhemodynamics andendomyocardialbiopsy.Serumcreatinine levelsandestimatedglomerularfiltrationrates wereanalyzedtoassessrenalfunction. Mediansurvivaltimeaftertransplantationwas 15years(range:5-23).Onepatientdiedofacute humoralrejection15years afterTx,theother14 patients were alive with good graft function. No increasedrejectionratecouldbeobservedafter discontinuationofCNl.Serumcreatininelevels significantlydecreased andestimatedglomerular filtrationsignificantlyincreased. CNI discontinued maintenance therapy appears to be safeinpaediatric HTxrecipients withno increasedriskofrejectionordeathandleadsto significant recovery of impaired renal function. | Renal sparing DiscontinuationofCNIs undera MMF and TAC immunosuppressive regimenissafe andleads to significant improvement of renal function. |
|                            | RationaleforClassificationofEvidence:                                                                                                                                                              | RationaleforClassificationofEvidence:                                                                                                                                                                                                                      | RationaleforClassificationofEvidence:                                                                                 | RationaleforClassificationofEvidence:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | RationaleforClassificationofEvidence:                                                                                                         |

| Study/ Reference Ranking   | StudyDesign                                                                          | Dosing，Formulation，Duration                                                                                                                                                                                                                                                                                                         | Demographics                                                                  | Key Findings                                                                                                                                                                                                                                                                                                                                                                                                            | KeyBenefit                                                                                                                                                                                    |
|----------------------------|--------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Steroid Sparing            | Steroid Sparing                                                                      | Steroid Sparing                                                                                                                                                                                                                                                                                                                     | Steroid Sparing                                                               | Steroid Sparing                                                                                                                                                                                                                                                                                                                                                                                                         | Steroid Sparing                                                                                                                                                                               |
| Singhet al. 2010           | Retrospective study evaluatingearly outcomes of steroid avoidance immunosuppression. | Allpatientsreceived induction with thymoglobulin 1.5mg/kg/dose and treatment with IV steroid. Dose:Patientsweretreatedwith oral TAC based on age and MMF 1,200 mg/m² per day dividedin2or3doses.MMF dosewas adjustedto achieve a target trough level of 2-4mg/dL Formulation:not specified Follow up: median 19 months (range:2-46) | N=55 Median age: 7.1 years (range: 2 weeks to 22 years). Males:females=27 :28 | 50patients survived todischarge afterTx.Of these,2patients(4%)weredischargedonsteroids, and8patients(16%)startedmaintenancesteroids atfollow-up.Rejectionwasdiagnosedin8patients (cellularrejection in3patients andAMR in5). Freedomfromrejectionwas92%at6months(95% Cl:80to97)and87%at1yr(95%Cl73-94).Post Tx survival was 91%at6months and88%at 12 and 24months(95%Cl:75to95).Therewas 1 deathduetoAMR8monthsafterTx. | Steroid sparing A steroid avoidance immunosuppression protocol containing MMF wasassociatedwithlow incidence of rejection during thefirst year after transplant in paediatric HTx recipients. |
| Singhet al. 2010           | RationaleforClassificationofEvidence:                                                | RationaleforClassificationofEvidence:                                                                                                                                                                                                                                                                                               | RationaleforClassificationofEvidence:                                         | RationaleforClassificationofEvidence:                                                                                                                                                                                                                                                                                                                                                                                   | RationaleforClassificationofEvidence:                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

## Table 27 continuation

| Study/ Reference Ranking   | Study Design                                                                 | Dosing，Formulation，Duration                                                                                                                                                                                                                                                                            | Demographics                                                      | Key Findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | KeyBenefit                                                                                                  |
|----------------------------|------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|
| ABO IncompatibleTransplant | ABO IncompatibleTransplant                                                   | ABO IncompatibleTransplant                                                                                                                                                                                                                                                                             | ABO IncompatibleTransplant                                        | ABO IncompatibleTransplant                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | ABO IncompatibleTransplant                                                                                  |
| Urschel et. al. 2013       | Multi-center, retrospective survey (Canada, UK, Germany and US) of ABOi HTx. | Inductionimmunosuppression includedanti-thymocyteglobulin (61%),basiliximab(32%)or none (7%).All patientsreceived CNIs (90%TAC,10%CsA),62% with MMF,10%with AZA, 2% witheverolimus and24%with steroids. Dose: not specified. Formulation:not specified. Follow-up: median 37.7months (range: 0.46-117) | N=58 Age at Tx: 6.8 months (range: 0.03-90). Males/Females=3 0:28 | Graft survivalwas100%/96%/69%at1/5/10years, respectively. Two patients died in the follow-up period. One due toacutemulti-organfailurewithsystemicinfection whilelistedforre-Txforseveregraftvasculopathy at5.5yearspost-Tx.Theotherpatient died dueto combinedcellularrejectionandAMRassociated withdonor-specificHLA antibodiesandpositive lymphocytecrossmatchbutminimalserum antibodies to thedonorBG(highest anti-Btiters pre-and post-Tx:1:2),85 days post-Tx.Two patientsunderwentreTx.Onegraft(A intoO recipient),reTxafter5.7years,haddeveloped refractory hypertrophicobstructive cardiomyopathy andmitralregurgitationwithunsuccessfulsurgical repair.TheotherreTxwasperformedafter 6.5years(anABdonorintoanArecipient)dueto chronicgraftfailure.Childrenwholosttheirgrafts didnotshowaspecificpatternwithregard to demographicdata,pre-Txhistoryandinductionor maintenanceimmunosuppression.All were<1year oldatthetimeofTxandnonehadreportedtitersof circulating antibodiestodonorBGof>1:4post-Tx. Noneof these4graft losseswasattributedtoABOi by theclinical team.Authorsconcludedthat successfulABOiHTxcanbeperformedatanolder ageandwithhigherisohemagglutinintitersthan initiallyassumedand usingsimilar immunosuppressive regimens as for ABO- compatibleTx.Rejection and graft vasculopathy arerare. | ABOi transplant ABOiHTxwith immunosuppressive regimenscontainingMMF is feasible in children under8yearsold. |
|                            | RationaleforClassificationofEvidence:                                        | RationaleforClassificationofEvidence:                                                                                                                                                                                                                                                                  | RationaleforClassificationofEvidence:                             | RationaleforClassificationofEvidence:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | RationaleforClassificationofEvidence:                                                                       |

| Study/ Reference Ranking    | Study Design                                                                                                                                           | Dosing,Formulation，Duration                                                                                                                                                                                                                                                                            | Demographics                                                                                                                                           | Key Findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | KeyBenefit                                                                                                                                             |
|-----------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|
| Other MMFBenefits           | Other MMFBenefits                                                                                                                                      | Other MMFBenefits                                                                                                                                                                                                                                                                                      | Other MMFBenefits                                                                                                                                      | Other MMFBenefits                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Other MMFBenefits                                                                                                                                      |
| Nunodaet al.2013 (Abstract) | Single center retrospective review.                                                                                                                    | Patientsreceivedstandardtriple therapy including CsA or TAC, MMF,and a corticosteroid. Fiveof26patientsreceived proliferationsignalinhibitors(one withsirolimusandfourwith everolimus)duringthelatepost- transplant period. Dose: not specified. Formulation:not specified. Follow up: 9.24±5.54years. | N=26 Age at Tx: 7.6±4.2 years. Males:females=16 :10                                                                                                    | Patient survival at1,5,10,and 20years post-Tx was 96.2%, 91.3%,85.3%, and 85.3%, respectively.During the follow-upperiod,one patientdiedofCAVat4.8years,andone dueto PTLDat7.3years,onesufferedprimarygraft failureandreceivedreTxtwodayslater.Pediatric survivalrateswerebetterthanthoseobservedin thecentersfortheadultcohort:survivalrateswere 94.7%,94.7%,81.2%,and 72.2% at 1,5,10, and 15yearspost-Tx).Growthinpatientsreturned to normal afterTx.25of 26patients(96%)required noactivitylimitationafterTxandreturnedto school,onepatientrequiredtotalassistancedueto a post-Tx stroke. | Lonq-term follow-up                                                                                                                                    |
|                             | RationaleforClassificationofEvidence: Thisis asingle-centreretrospectivereviewprovidinglongtermfollowupdataonpatientswhoreceivedMMFcontainingregimens. | RationaleforClassificationofEvidence: Thisis asingle-centreretrospectivereviewprovidinglongtermfollowupdataonpatientswhoreceivedMMFcontainingregimens.                                                                                                                                                 | RationaleforClassificationofEvidence: Thisis asingle-centreretrospectivereviewprovidinglongtermfollowupdataonpatientswhoreceivedMMFcontainingregimens. | RationaleforClassificationofEvidence: Thisis asingle-centreretrospectivereviewprovidinglongtermfollowupdataonpatientswhoreceivedMMFcontainingregimens.                                                                                                                                                                                                                                                                                                                                                                                                                                        | RationaleforClassificationofEvidence: Thisis asingle-centreretrospectivereviewprovidinglongtermfollowupdataonpatientswhoreceivedMMFcontainingregimens. |
| Lietal.2015                 | Single center retrospective chart review.                                                                                                              | Maintenanceimmunotherapy comprisedCsA,MMF and steroidbefore2011andTAC, MMFandsteroidfrom2011. Dose: not specified. Formulation:not specified. Follow-up 1-70 months.                                                                                                                                   | N=19 Age at Tx:mean 12.6 years, median 15 years (range: 3 months to 18 years). Males:females=10 :9                                                     | TheoverallsurvivalafterTxforthepediatric population is approximately90% at 1year.The survivalrateduringhospitalizationwas100%at thiscenter.Allpatientswerefollowed after discharge.Thefollow-uptimerangedfrom1month to70 months.Onlyonepatient suddenly died of primary graft failure.Therewas no graft vascular diseaseorlymphoproliferativediseaseduring follow-up.                                                                                                                                                                                                                         | Benefits in Chinese population MMFusedaspart the immunosuppression regimen of Chinese HTx patients.                                                    |
|                             | RationaleforClassificationofEvidence: Thisisasingle-centreretrospectivechartreviewofpatientswhoreceivedMMFcontainingregimens.                          | RationaleforClassificationofEvidence: Thisisasingle-centreretrospectivechartreviewofpatientswhoreceivedMMFcontainingregimens.                                                                                                                                                                          | RationaleforClassificationofEvidence: Thisisasingle-centreretrospectivechartreviewofpatientswhoreceivedMMFcontainingregimens.                          | RationaleforClassificationofEvidence: Thisisasingle-centreretrospectivechartreviewofpatientswhoreceivedMMFcontainingregimens.                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | RationaleforClassificationofEvidence: Thisisasingle-centreretrospectivechartreviewofpatientswhoreceivedMMFcontainingregimens.                          |

<div style=\"page-break-after: always\"></div>

## Table 27 continuation

| Study/ Reference Ranking   | StudyDesign                                                                                                | Dosing，Formulation，Duration                                                                                | Demographics                                                                                               | KeyFindings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | KeyBenefit                                                                                                                                                                                                                             |
|----------------------------|------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Castleberry etal.2017      | Surveybased assessmentofclinical practicepatterns betweenpediatricTx centers.                              | Dose:datanotcollected. Formulation:datanotcollected. Follow-up:datanotcollected.                           | Datanotcollected.                                                                                          | Theresponseratewas77%(40responsesfrom52 contactedcenters,37withcompleteresponses). ThemajorityofrespondentswerefromTxcenters locatedintheUS(36/40,90%)otherparticipants were from theUK(2/40,5%),Canada(1/40,2.5%) and Brazil(1/40, 2.5%). Most centersreportedTAC(36/38,95%)andMMF (36/38,95%)asmaintenanceimmunosuppression. ThemediannumberofheartTxperformed annuallywas8(IQRof3-19),andmedianvolume overthepast3yearswas25(IQRof7-57). Cliniciansat58%ofcenters(23/40)werewillingto acceptapositivecross-matchdonorforsensitized patients,and87%centers(33/38)wouldperform ABOiTxsininfants. Thesurveyfoundthattherewasahighlevelof uniformityandagreementonmaintenance immunosuppressionandtreatmentofrejection. | Otherbenefits Amajorityofclinical protocols atpediatric centersacrosstheUS andotherinternational centersreportedutilizing TACandMMF(36/38 95%forboth)for most patientsaspartof their long-termmaintenance immunosuppression treatment. |
|                            | RationaleforClassificationofEvidence: Thisisaretrospectivesurveyassessmentacrosscentresof theregimensused. | RationaleforClassificationofEvidence: Thisisaretrospectivesurveyassessmentacrosscentresof theregimensused. | RationaleforClassificationofEvidence: Thisisaretrospectivesurveyassessmentacrosscentresof theregimensused. | RationaleforClassificationofEvidence: Thisisaretrospectivesurveyassessmentacrosscentresof theregimensused.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | RationaleforClassificationofEvidence: Thisisaretrospectivesurveyassessmentacrosscentresof theregimensused.                                                                                                                             |

## Table 27 continuation

| Study/ Reference Ranking      | StudyDesign                                                                                                                                                        | Dosing,Formulation，Duration                                                                                                                                                                                                                                                                                                                      | Demographics                                                                                                               | KeyFindings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | KeyBenefit                                                                                                                                                                           |
|-------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Haregu et al. 2021 (abstract) | One center, retrospectivereviewof 12 highly sensitized HTxcandidateswho underwent desensitizationtherapy at theUniversityof Virginia Hospital between2014and 2020. | Themajorityofpatientsreceived anoralimmunosuppressive regimen ofprednisone (0.3mg/kg/daytomaxdoseof 12.5mg)andanantimetabolite (CellCept60mg/kg/doseQ12up to1,000mgQ12orImuran1- 2 mg/kg/day) followed by a singleinfusionofrituximab (37mg/m²)andmonthlyIVIG (2 g/kg) infusions; plasmapheresiswasusedinone patientandbortezomibwasused in two. | N=12                                                                                                                       | Calculatedpanelreactiveantibodiesdecreasedby anaverageofnearly20%afteranaverageof 17.5weeks.HLAIantibodiesweremore susceptibletodesensitizationthanHLAII antibodies(60%vs36%averageantibody reduction,respectively). Immunosuppressionmedicationswerewell toleratedwithonlyonepatientrequiringrituximab discontinuationduetohypotension,tachycardia andrespiratorydistress.Therewerenocasesof AMRinthosepatientswhounderwentTx. Inthiscohort,B-cel/antibodytargetedtherapies were safe and effective in improving allosensitizationandallowingforsuccessfulTx, thoughHLAIlantibodiesweremoreresistantto therapy. | Desensitizationtherapy Desensitizationtherapyin paediatricHTxcandidates isfeasibleusingB-cell/ antibodytargeted therapiesand an immunosuppressive regimen containing steroidsandMMF. |
|                               | RationaleforClassificationofEvidence: Thisisasingle-centreretrospectivereviewofMMFcontainingregimensusedindesensitisation.                                         | RationaleforClassificationofEvidence: Thisisasingle-centreretrospectivereviewofMMFcontainingregimensusedindesensitisation.                                                                                                                                                                                                                       | RationaleforClassificationofEvidence: Thisisasingle-centreretrospectivereviewofMMFcontainingregimensusedindesensitisation. | RationaleforClassificationofEvidence: Thisisasingle-centreretrospectivereviewofMMFcontainingregimensusedindesensitisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | RationaleforClassificationofEvidence: Thisisasingle-centreretrospectivereviewofMMFcontainingregimensusedindesensitisation.                                                           |

AMR=antibodymediatedrejection;AZA=azathioprine;b.i.d.=twicea day;Cl=confidenceinterval;CNl=calcineurininhibitor;CMV=cytomegalovirus;CsA=ciclosporinA; DSA=donor-specific antibodies;ECMO=extracorporeal membrane oxygenation;HLA=humanleucocyte antigen;HR=hazardratio;HTx=heart transplant(ation); lymphoproliferativedisorder;reTx=retransplantation;TAC=tacrolimus;Tx=transplant(ation);US=UnitedStates.

## Paediatric Liver Transplantation

A summary of the available publications of studies showing a potential benefit related to the efficacy of MMF when used in paediatric LTx recipients is included in Table 28 , below. The publications are grouped by the potential benefit and provide supportive evidence. This includes 8 retrospective studies and 7 prospective (mainly observational or single arm) studies.

<div style=\"page-break-after: always\"></div>

## Table 28 Summary of Paediatric Liver Transplant Studies Contributing to Efficacy Evaluation (Supportive Evidence)

| Study/ Reference   | Study Design                                                                                                                                                                  | Dosing, Formulation, Duration                                                                                                                                                 | Demographics                                                                                                                                                                  | Key Findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | KeyBenefit                                                                                                                                                                    |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Rejection          | Rejection                                                                                                                                                                     | Rejection                                                                                                                                                                     | Rejection                                                                                                                                                                     | Rejection                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Rejection                                                                                                                                                                     |
| Chardotet al. 2001 | Retrospective analysis.                                                                                                                                                       | Medianinitialoral dose of MMF: 23 mg/kg/day (range: 12-43). Formulation:not specified Follow-up: median follow-up after initiation of MMF 642 days (range: 229-1606).         | N=19 Median age at Tx: 30 months (range: 7-149) Males:females=8:11.                                                                                                           | MMFwasindicatedforrejectionorinsufficient immunosuppressionin16cases,withnormalizationof both liverfunctiontests and liver histology in10 cases(62%). MMF was successfully used in one patient with post-Tx immunehepatitisandonepatientwithsteroiddependence. In threepatientswithrenalfunctionimpairment,MMF allowedreductionofCsAorTACdosewithoutsubsequent rejection.                                                                                                                                                                                                                                                                                                                                                           | Rescuefor alloqraft rejection MMFiseffectivefor paediatric LTx recipients with rejection or insufficient immunosuppression.                                                   |
| Chardotet al. 2001 | RationaleforClassificationofEvidence: Thisis a single-centreretrospective analysison theuseof MMFasrescueinchildrenwith insufficient immunosuppression orallograft rejection. | RationaleforClassificationofEvidence: Thisis a single-centreretrospective analysison theuseof MMFasrescueinchildrenwith insufficient immunosuppression orallograft rejection. | RationaleforClassificationofEvidence: Thisis a single-centreretrospective analysison theuseof MMFasrescueinchildrenwith insufficient immunosuppression orallograft rejection. | RationaleforClassificationofEvidence: Thisis a single-centreretrospective analysison theuseof MMFasrescueinchildrenwith insufficient immunosuppression orallograft rejection.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | RationaleforClassificationofEvidence: Thisis a single-centreretrospective analysison theuseof MMFasrescueinchildrenwith insufficient immunosuppression orallograft rejection. |
| Awetal. 2008       | Retrospectivesingle arm study on long-term outcome of theuseof MMF torescue liver allografts with steroid resistant biopsy-proven cellularrejection.                          | MMFwas addedat adoseof 10 mg/kg/day in divided doses, and the dosewas increasedtoa maximum of 40 mg/kg/day over 2 weeks. Follow-up: median 8.8 years (range: 7.7-11.5).       | N=26 children(28Txs) Age at Tx:1.7years (range: 0.4-13.6) Males:females=10:16                                                                                                 | PrimaryimmunosuppressionwasCsA-basedtripletherapy in 22children andTAC-based dual therapy in6children.25 childrenhadbeenconvertedtoTACpriortotheadditionof MMF.The median time toMMFrescue was1.8months (range:0.4-35.8),with patientshaving received a median of 2coursesofhigh-dosesteroid.21outofthe28episodesof steroidresistantrejectionshowedaninitialpositiveresponse toMMF.Themedianfollow-upwas8.8years(range: 7.7-11.5).Inresponders,there Was1death fromPTLD,no grafts werelost tochronicrejection.In the7non-responders, 3graftswerelostduetochronicrejection,and2resultedin death.Survivingchildrenwere clinicallywell,withgoodliver function,and17remainedonMMF.Threechildrenhad glomerularfiltration<80mL/min/1.73m² | Rescuefor alloqraft rejection MMFiseffective in treating steroid resistant acute allograft rejection in paediatric LTx recipients.                                            |
| Awetal. 2008       | RationaleforClassificationofEvidence: Thisisaretrospectivesingle-armstudyevaluatingtheuseofMMFinrescueofsteroidresistantrejection.                                            | RationaleforClassificationofEvidence: Thisisaretrospectivesingle-armstudyevaluatingtheuseofMMFinrescueofsteroidresistantrejection.                                            | RationaleforClassificationofEvidence: Thisisaretrospectivesingle-armstudyevaluatingtheuseofMMFinrescueofsteroidresistantrejection.                                            | RationaleforClassificationofEvidence: Thisisaretrospectivesingle-armstudyevaluatingtheuseofMMFinrescueofsteroidresistantrejection.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | RationaleforClassificationofEvidence: Thisisaretrospectivesingle-armstudyevaluatingtheuseofMMFinrescueofsteroidresistantrejection.                                            |

| Studyl Reference   | Study Design                                                                                                                                                                                                                                                                                                             | Dosing, Formulation, Duration                                                                                                                                                                                                     | Demographics                                                                                                                                       | Key Findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Key Benefit                                                                                                                                                                                                   |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Renal Sparing      | Renal Sparing                                                                                                                                                                                                                                                                                                            | Renal Sparing                                                                                                                                                                                                                     | Renal Sparing                                                                                                                                      | Renal Sparing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Renal Sparing                                                                                                                                                                                                 |
| Aw et al. 2001     | Prospective study of the efficacy of MMFenabling CNI reductioninpediatric LTx recipients with CNI-related nephrotoxicity without an increasedrejectionrate.                                                                                                                                                              | MMF 20 mg/kg/day in two divided dosesfor1week Increased to 40 mg/kg/day in two divideddosesafter 1week.CsA/TAC dosesreduced Formulation: not specified Study period:12 months Median follow up: 24monthsafter introduction of MMF | N=14 Median age at Tx:4.2 years(range:0.9-13.8) Gendernotspecified                                                                                 | The median(range) GFR inml/min/1.73 m²increased from a baseline of 52(31-71),to 69(38-111)at6 months and 73 (35-98) at12 months (p=0.00014).At the time of study converted toTAC.Tenof these children were stillonCsAat entry,13childrenwerestillonCsAandonehadbeen the end of the studyperiod. Sideeffectsof MMFincludeleucopenia intwoandbackache inone,two of whom discontinued MMF.Acute allograft rejectionoccurred in threechildren.All 14 were well with a medianfollow-upof24months(range:14-38)fromMMF introduction. Paediatric LTxrecipientswithstablegraft functionandCNI- related nephrotoxicity may benefit from the addition of MMF totheirimmunosuppressiveregimen,withconsequent reductionoftheCNldose.Ideallythistreatmentmodification shouldbeattemptedbeforeGFRdeterioratesto <50 ml/min/1.73m² | Renal sparing TheadditionofMMFto the immunosuppressive regimen of children with CNI-related nephrotoxicity allows reduction of CNI dose andrecoveryofrenal functionwitha21% incidence of allograft rejection. |
| Aw et al. 2001     | RationaleforClassificationofEvidence: Thisisasingle-armprospectivestudyevaluatingthepotentialforMMFtoenableCNlreductionandrecoveryofrenalfunction.                                                                                                                                                                       | RationaleforClassificationofEvidence: Thisisasingle-armprospectivestudyevaluatingthepotentialforMMFtoenableCNlreductionandrecoveryofrenalfunction.                                                                                | RationaleforClassificationofEvidence: Thisisasingle-armprospectivestudyevaluatingthepotentialforMMFtoenableCNlreductionandrecoveryofrenalfunction. | RationaleforClassificationofEvidence: Thisisasingle-armprospectivestudyevaluatingthepotentialforMMFtoenableCNlreductionandrecoveryofrenalfunction.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | RationaleforClassificationofEvidence: Thisisasingle-armprospectivestudyevaluatingthepotentialforMMFtoenableCNlreductionandrecoveryofrenalfunction.                                                            |
| Nobiliet al.2003   | Theconsequencesof introducing MMF and reduction of CNI in LTx children was analysed. CNIreduced andMMF added inpatients transplanted≥5years ago with stable graft functionandrenal dysfunction.Serum creatinine,uric acid concentration,azotemia andcreatinineclearance before and6months afterstudy entrywere measured. | Dose:initial dose of MMF 20 mg/kg/day in two divided doses increased to 40 mg/kg/day during first month Formulation:not specified Follow-up: 6 months                                                                             | N=8 Mean age: 13 years. (range: 10-15) Males:females=4:4                                                                                           | Sixmonthsafterstudyentry，serumcreatinineuricacid concentration,azotemiaandcreatinineclearanceimproved inallthepatients.Aspartateaminotransferaseandalanine studyperiod andserumbilirubindid notincrease.The aminotransferaseconcentrationswerestableduringthe results indicate thatrenal dysfunctionsignificantlyimproved whenMMFtherapyisstartedandCNIreduced.                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Renal sparing TheadditionofMMFto the immunosuppressive regimenof childrenwith CNIrelated nephrotoxicity allows reduction of CNIdose andrecoveryofrenal function                                               |
| Nobiliet al.2003   | RationaleforClassificationofEvidence: Thisisasingle-armprospectivestudyevaluatingthepotentialforMMFtoenableCNlreductionandrecoveryofrenalfunction.                                                                                                                                                                       | RationaleforClassificationofEvidence: Thisisasingle-armprospectivestudyevaluatingthepotentialforMMFtoenableCNlreductionandrecoveryofrenalfunction.                                                                                | RationaleforClassificationofEvidence: Thisisasingle-armprospectivestudyevaluatingthepotentialforMMFtoenableCNlreductionandrecoveryofrenalfunction. | RationaleforClassificationofEvidence: Thisisasingle-armprospectivestudyevaluatingthepotentialforMMFtoenableCNlreductionandrecoveryofrenalfunction.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | RationaleforClassificationofEvidence: Thisisasingle-armprospectivestudyevaluatingthepotentialforMMFtoenableCNlreductionandrecoveryofrenalfunction.                                                            |

<div style=\"page-break-after: always\"></div>

## Table 28 continuation

| Study/ Reference   | StudyDesign                                                                                                                                                                             | Dosing, Formulation, Duration                                                                                                                                              | Demographics                                                                                                                                                               | Key Findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | KeyBenefit                                                                                                                                                                                               |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Ferrariset al.2004 | Prospectiveevaluationof theincidenceofchronic renal dysfunction in patients>5yearsold. decreased CsA dose+ AfterLTxandbenefitof introduction of MMF on immuneresponse. renalfunctionand | MMFdose: 600 mg/m² b.i.d specified. Formulation: not Follow-up: 1 year after CsA dose reduction and introduction of MMF.                                                   | Txrecipients: N=60 Survival >5 years: N=50 renal dysfunction:N=14 Patients included in Patientswithchronic study: N=11 Meanage at study: (Males:females=5:6) 12.5±2 years. | 14patientsdevelopedchronicrenaldysfunctionsecondary toCsAtoxicityasevaluatedbyrenalbiopsy.In11/14,CsA MMF added toregimen. 0.8±0.03 ng/dL, p<0.007), creatinine clearance increased dosewasdecreasedto40-90mg/mLtargetlevels,and Plasmacreatininedecreased(from1.0±0.03to (from66.8±3.0 to99.2±6.3mL/min/1.73m²,p<0.002),and microalbuminuriadecreased(from21.0±8.6to 3.6±1.1mg/24h,p<0.05)after12monthsofCsAcombined withMMFtherapy.During combined therapy,the proliferative,cytolyticresponseandcytotoxicantibodies showednosignificantchanges,whereasCD4/CD8ratio increased(from1.2±0.2to1.4±0.1,p<0.05).Tumor necrosis factor-alpha secretionincreased(p<0.005)duringMMF therapy.Therelease of interleukin-10wasstrikingly augmentedunderbothimmunosuppressiveregimens,but thereleaseof transforminggrowthfactor-betaand interferon-gamma did not change.Authorsconcluded that initiationofMMFcombinedwithreduceddosesofCsA allowed therecoveryofrenalfunctionwithminorchangesin theimmuneresponse. | Renal sparing For children withCsA inducedrenal dysfunction the addition doseof CsAtobe ofMMFallowed the reduced with an function and no improvement in renal apparentincrease in the risk of rejection. |
|                    | RationaleforClassificationofEvidence: Thisisasingle-centreprospectivestudyevaluating thepotentialforMMFtoenableCNlreductionandrecoveryofrenalfunction.                                  | RationaleforClassificationofEvidence: Thisisasingle-centreprospectivestudyevaluating thepotentialforMMFtoenableCNlreductionandrecoveryofrenalfunction.                     | RationaleforClassificationofEvidence: Thisisasingle-centreprospectivestudyevaluating thepotentialforMMFtoenableCNlreductionandrecoveryofrenalfunction.                     | RationaleforClassificationofEvidence: Thisisasingle-centreprospectivestudyevaluating thepotentialforMMFtoenableCNlreductionandrecoveryofrenalfunction.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | RationaleforClassificationofEvidence: Thisisasingle-centreprospectivestudyevaluating thepotentialforMMFtoenableCNlreductionandrecoveryofrenalfunction.                                                   |
| Evanset al.2005    | Retrospective analysis of theeffectof MMF on renal dysfunction after LTx.                                                                                                               | MMF monotherapy (n=36) MMFwith steroids (n=4) MMFwithlowdose CsA or TAC (n=8) Dose:up to 40 mg/kg per day in 2 divided doses. Formulation:not specified. Follow-up:1 year. | N=48 Age: median 11.1 years (range: 0.9-18.1) Males:females=23:25                                                                                                          | In92%childrenwithrenaldysfunctionafterpaediatricLTx, MMFtreatmentprovidedsafeandeffective immunosuppression and allowedCsAorTACtobe function.Theimprovement wasgreatest inyoungerchildren discontinuedorreduced,leadingtoimprovementofrenal and thosewhobeganMMFearlypost-LTx.Sideeffects wereuncommon.Authorconcludedthatadditionalsteroid coverduringthetransfertoMMFshouldbeconsideredto prevent liver-allograft rejection.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Renal sparing TheadditionofMMFto theimmunosuppressive regimen of children with CNIrelated nephrotoxicity allows reduction of CNI dose andrecoveryofrenal function.                                       |
|                    | RationaleforClassificationofEvidence: Thisisasingle-centreretrospective analysisevaluatingthepotentialforMMFtoenableCNlreductionandrecoveryofrenalfunction.                             | RationaleforClassificationofEvidence: Thisisasingle-centreretrospective analysisevaluatingthepotentialforMMFtoenableCNlreductionandrecoveryofrenalfunction.                | RationaleforClassificationofEvidence: Thisisasingle-centreretrospective analysisevaluatingthepotentialforMMFtoenableCNlreductionandrecoveryofrenalfunction.                | RationaleforClassificationofEvidence: Thisisasingle-centreretrospective analysisevaluatingthepotentialforMMFtoenableCNlreductionandrecoveryofrenalfunction.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | RationaleforClassificationofEvidence: Thisisasingle-centreretrospective analysisevaluatingthepotentialforMMFtoenableCNlreductionandrecoveryofrenalfunction.                                              |

| Study/ Reference   | StudyDesign                                                                                                                                                 | Dosing, Formulation, Duration                                                                                                                                                                                                                                                                                    | Demographics                                                                                                                                                | Key Findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | KeyBenefit                                                                                                                                                              |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Tannuriet al.2007  | Retrospectiveanalysison the use of MMF in children with LTx and impairedrenalfunction due to CNI.                                                           | Dose: The usual immunosuppression glucocorticoid was CsA)with In 2001,protocol was changed to TAC with glucocorticoid. MMF was added at 10 mg/kg b.i.d, and increasedto 40 mg/kg/day over 2weeks. CNI dosage was reduced to50% of baseline dosage over 1 month. Formulation:not specified. Follow-up: 24 months. | N=11 Age range: 3 -15 years. Males:females=5:6                                                                                                              | ThetimeintervalbetweenLTxandtheintroductionofMMF variedfromoneyearandfourmonthsto12yearsandsix months.Ninepatients(82%)showedimprovementofall reductionofCNI dosages,incomparisonwith thepre- renalfunctionparametersafterintroductionofMMFand treatment values.The twopatients that didnot show any improvement inrenalfunctionparametershadthelongest intervalof timebetweenTxandtheintroductionof MMF(11 unchanged.No episodes of acute or chronic rejection during and12years).Allparametersof liverfunctionremained theperiodwere detected. | Renal sparing The addition of MMF to the immunosuppressive regimen of children with CNIrelated nephrotoxicity allows reduction of CNI dose andrecoveryofrenal function. |
|                    | RationaleforClassificationofEvidence: Thisisasingle-centreretrospective analysisevaluatingthepotentialforMMFtoenableCNlreductionandrecoveryofrenalfunction. | RationaleforClassificationofEvidence: Thisisasingle-centreretrospective analysisevaluatingthepotentialforMMFtoenableCNlreductionandrecoveryofrenalfunction.                                                                                                                                                      | RationaleforClassificationofEvidence: Thisisasingle-centreretrospective analysisevaluatingthepotentialforMMFtoenableCNlreductionandrecoveryofrenalfunction. | RationaleforClassificationofEvidence: Thisisasingle-centreretrospective analysisevaluatingthepotentialforMMFtoenableCNlreductionandrecoveryofrenalfunction.                                                                                                                                                                                                                                                                                                                                                                                      | RationaleforClassificationofEvidence: Thisisasingle-centreretrospective analysisevaluatingthepotentialforMMFtoenableCNlreductionandrecoveryofrenalfunction.             |

<div style=\"page-break-after: always\"></div>

## Table 28 continuation

| Studyl Reference               | StudyDesign                                                                                                                                            | Dosing, Formulation, Duration                                                                                                                                                                                                         | Demographics                                                                                                                                                                                                                                                                                              | KeyFindings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | KeyBenefit                                                                                                                             |
|--------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|
| Leiskau et al. 2018            | Single center matched cohort study (2 age and diagnosis matched patients foreach study patient,oneof them treatedwithTACandone with CsA and steroids). | Dose:MMFstarted 7 days post-Tx at a doseof 10mg/kg in 2dosesfor2weeks gradually increased tomaxdoseof 20 mg/kg (max 2x750mg) in 2 doses. Formulation:not specified. Follow-up: 1 year after Tx.                                       | MMF+TAC:N=19 Ageat Tx:6years and 9 months (range: 3 monthsto16years 6 months). Males:females=10:9 TAC: N=19 Ageat Tx:5years and 7 months (range: 7 months to 16 years and 11 months). Males:females=7:12 CsA+steroids:N=19 Age:5years,5months (range:5months to 15years and 9 months). Males:females-9:10 | Allpatientssurvivedforthe1styear.Allpatientssurvivedfor thefirstyearafterLTx.Graftsurvivalwas89.5%MMF+TAC; 94.8% CSA and TAC groups,respectively (p=0.55). Inboth the MMF+TACand theTACgroup,BPAR(RAIscore ≥3)in31.5%of cases during thefirst year after LTx.In the CSA group,42.1%of thepatients suffered fromBPAR (OR=1.50;95% Cl:0.42 to 5.44;p-0.52).No cases of chronicrejectionwereobserved. Allgroupsshowedasignificant deteriorationinrenal function post-Txwiththenadirat3months,andstabilization achievedby12-months.Nosignificantdifferencesin creatinineGFRorestimatedGFRbetweenthe3groups wereseenatanytimeduringtheobservationperiod.Results differfromobservations of Tannuriand Evans,who sawan improvement of renal function shortly following the commencementof MMF treatment post-Tx.Notably,most of thesepatientsreceivedMMFmonotherapy.Otherstudies documentingbetterrenalfunctionobservedanimprovement onlyafterseveralyears.ThereductionofTACmightnotbe sufficienttonoticearenalbenefit.Theauthorsnotethatin previouspaediatricstudiesMMFwasintroducedinpatients withCNl-inducedrenal dysfunction,whereasinthisstudy， patientsreceived denovoMMF therapy. | Renal sparing Benefit of usingTAC and MMF de novo in paediatric LTx recipients was not supported.                                      |
|                                | RationaleforClassificationofEvidence:                                                                                                                  | RationaleforClassificationofEvidence:                                                                                                                                                                                                 | RationaleforClassificationofEvidence:                                                                                                                                                                                                                                                                     | RationaleforClassificationofEvidence:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | RationaleforClassificationofEvidence:                                                                                                  |
| Steroid Sparing                | Steroid Sparing                                                                                                                                        | Steroid Sparing                                                                                                                                                                                                                       | Steroid Sparing                                                                                                                                                                                                                                                                                           | Steroid Sparing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Steroid Sparing                                                                                                                        |
| Teisseyre etal.2011 (Abstract) | Prospective study to compareTACplusMMF (Group A) to TAC plus steroids(GroupB)in children afterLTx.                                                     | Group A: MMF from Day0toDay90, thenreducedand discontinued4 months afterTx. GroupB:steroids according to alow- dosescheme,after 7months steroid withdrawalinitiated. Dose:not specified. Formulation:not specified. Follow-up:3years. | GroupA:22patients aged0.2-18years. GroupB:22patients aged 0.12-18.1 years. Gendernotstated.                                                                                                                                                                                                               | Liverandrenalfunction,bloodglucoseandincidenceof CMVinfectionswere similarinbothgroups at1,2and3 years afterTx. GroupAvsGroupB:showedareducedneedfor antihypertensive treatment(p<0.05)earlyandat1and2 yearspost-Tx.Lowerincidenceof EBVinfectionin1,2and 3yearsafterTx(p<0.05).Acuterejectionepisodesmore frequent insecondyearspost-Tx(p<0.05).Morepatients showed normal liver histology oneyearpost-Tx however this difference wasnot significant. Steroidresistant acuterejectionwasnotseenineither group.ImmunosuppressionusingaregimenwithTACand MMFbutwithoutsteroidsisfeasibleandsafeinchildren after LTx.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Steroid sparing Immunosuppression without steroidsis feasible post LTx.                                                                |
|                                | RationaleforClassificationofEvidence: This is a single-centre prospective study evaluating the use of MMF in enabling steroid sparing.                 | RationaleforClassificationofEvidence: This is a single-centre prospective study evaluating the use of MMF in enabling steroid sparing.                                                                                                | RationaleforClassificationofEvidence: This is a single-centre prospective study evaluating the use of MMF in enabling steroid sparing.                                                                                                                                                                    | RationaleforClassificationofEvidence: This is a single-centre prospective study evaluating the use of MMF in enabling steroid sparing.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | RationaleforClassificationofEvidence: This is a single-centre prospective study evaluating the use of MMF in enabling steroid sparing. |

| Studyl Reference          | Study Design                                                                                                                                                   | Dosing, Formulation, Duration                                                                                                                                                                                                                                                                                   | Demographics                                                                                                                                                   | Key Findings                                                                                                                                                                                                                                                                                                                    | Key Benefit                                                                                                                                                    |
|---------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ABOIncompatibleTransplant | ABOIncompatibleTransplant                                                                                                                                      | ABOIncompatibleTransplant                                                                                                                                                                                                                                                                                       | ABOIncompatibleTransplant                                                                                                                                      | ABOIncompatibleTransplant                                                                                                                                                                                                                                                                                                       | ABOIncompatibleTransplant                                                                                                                                      |
| Schukfeh etal.2015        | Single center, prospective study comparing patients receivingABOiLTxto patients receiving ABO- compatible Tx in the same period.                               | Dose: Immunosuppressive regimen for all patients consisted of IV or oral steroid (initially 15 mg/m2 days 1-10 postoperatively), TAC(from2x0.05 to 0.1 mg/kg) orally, and MMF (2x10 mg/m² orally since Day 3) Formulation:oral-- precise formulation not specified. Follow-up: median 2.6 years (range: 1-4.5). | ABOi N=6 Age: median 13 months (range: 6-30). Males:females-4:2 ABOcompatibleN=6 matched patients                                                              | ABOi group:patientandgraftsurvival83%. Onefemalepatient diedwithin24hoursduetofulminant gram-negative sepsis.Another patient developed acute responded to steroid treatment.No further complications occurred. ABO-compatible qroup: patient survival 100%, graft survival 83%. Onepatientreceivedre-transplantationafter4days. | ABOi transplant ABOi living related LTx using TAC and MMF immunosuppression is based feasible inchildren under 3 years of age.                                 |
|                           | RationaleforClassificationofEvidence: This is a single-centre prospective study evaluating the use of MMF containing regimens in facilitating ABOi transplant. | RationaleforClassificationofEvidence: This is a single-centre prospective study evaluating the use of MMF containing regimens in facilitating ABOi transplant.                                                                                                                                                  | RationaleforClassificationofEvidence: This is a single-centre prospective study evaluating the use of MMF containing regimens in facilitating ABOi transplant. | RationaleforClassificationofEvidence: This is a single-centre prospective study evaluating the use of MMF containing regimens in facilitating ABOi transplant.                                                                                                                                                                  | RationaleforClassificationofEvidence: This is a single-centre prospective study evaluating the use of MMF containing regimens in facilitating ABOi transplant. |

<div style=\"page-break-after: always\"></div>

## Table 28 continuation

| Study/ Reference   | Study Design                                                                                                                                     | Dosing, Formulation, Duration                                                                                                                                                                                                                                                                                          | Demographics                                                                                                                                                          | KeyFindings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | KeyBenefit                                                                                                                                       |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|
| Mysoreet al.2018   | Single center retrospectivecomparison of Tx outcomes in ABO- compatible and ABOiLTx patients.                                                    | For ABOipatients immunosuppressive regimendetermined by IH titers. Dose: Patients with hich immunosuppressive regimen including IH titer (≥1:32): enhanced plasmapheresis, rituximab,IVIG,and MMF (15 mg/kg b.i.d). PatientswithlowIH titers (<1:16): steroids and TAC. Formulation:not specified. Follow-up: 3 years. | ABO-compatiblecontrol qroup N=19 Median age: 13.5 months (range: 8.2-20.6) ABOi qroup N=10 months (range: 5.1 Median age: 8.9 months to 9.3 years). Males:females=5:5 | Ratesofcomplications(rejection,infections,biliary,and vascular)atboth1yearandupto3yearspost-Txwere comparablebetweenthegroups.PatientswithABOiLTx hadgood graft function,with100%survivalata median follow-up of 3.3years. Thestudywasnotdesignedtocompareefficacyof immunosuppressive regimens,but demonstrated that in high intensive immunosuppressiveregimens includingMMF riskABOipatients,aregimenbasedonIH titers(with beingadministeredincaseofhighIHtiters)resulted in complicationratescomparabletothoseseeninlowerrisk ABOcompatiblecontrols. | ABOi transplant ABOi transplant using immunosuppressive protocolstailored toIH titresisfeasible.                                                 |
| Mysoreet al.2018   | RationaleforClassificationofEvidence: Thisisasingle-centreretrospectivestudyevaluatingtheuseofMMFcontainingregimensinfacilitatingABOitransplant. | RationaleforClassificationofEvidence: Thisisasingle-centreretrospectivestudyevaluatingtheuseofMMFcontainingregimensinfacilitatingABOitransplant.                                                                                                                                                                       | RationaleforClassificationofEvidence: Thisisasingle-centreretrospectivestudyevaluatingtheuseofMMFcontainingregimensinfacilitatingABOitransplant.                      | RationaleforClassificationofEvidence: Thisisasingle-centreretrospectivestudyevaluatingtheuseofMMFcontainingregimensinfacilitatingABOitransplant.                                                                                                                                                                                                                                                                                                                                                                                                         | RationaleforClassificationofEvidence: Thisisasingle-centreretrospectivestudyevaluatingtheuseofMMFcontainingregimensinfacilitatingABOitransplant. |

| Studyl Reference   | Study Design                                                                                                                                     | Dosing, Formulation, Duration                                                                                                                                                                         | Demographics                                                                                                                                     | Key Findings                                                                                                                                                                                                                                                                                                                                                                                  | KeyBenefit                                                                                                                                       |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|
| Dhungelet al.2019  | Single center retrospective study of childrenreceivingABOi LTx.                                                                                  | Dose:MMFnot specified, started 1 week before Tx. MMF,TAC and CS usedpost operatively. Formulation:not specified. Protocol consisted of rituximab2 weeks prior(>3 years) and plasmapheresis beforeLTx. | N=8 Median age: 31 months (range: 7-91) Gender:not specified.                                                                                    | Patientandgraftsurvivalwas100%inrecipientsatamean follow-up of 33months(range:2-80).                                                                                                                                                                                                                                                                                                          | ABOitransplant ABOi transplant using immunosuppressive protocols containing MMFarefeasible.                                                      |
|                    | RationaleforClassificationofEvidence: Thisisasingle-centreretrospectivestudyevaluatingtheuseofMMFcontainingregimensinfacilitatingABOitransplant. | RationaleforClassificationofEvidence: Thisisasingle-centreretrospectivestudyevaluatingtheuseofMMFcontainingregimensinfacilitatingABOitransplant.                                                      | RationaleforClassificationofEvidence: Thisisasingle-centreretrospectivestudyevaluatingtheuseofMMFcontainingregimensinfacilitatingABOitransplant. | RationaleforClassificationofEvidence: Thisisasingle-centreretrospectivestudyevaluatingtheuseofMMFcontainingregimensinfacilitatingABOitransplant.                                                                                                                                                                                                                                              | RationaleforClassificationofEvidence: Thisisasingle-centreretrospectivestudyevaluatingtheuseofMMFcontainingregimensinfacilitatingABOitransplant. |
| OtherMMFBenefits   | OtherMMFBenefits                                                                                                                                 | OtherMMFBenefits                                                                                                                                                                                      | OtherMMFBenefits                                                                                                                                 | OtherMMFBenefits                                                                                                                                                                                                                                                                                                                                                                              | OtherMMFBenefits                                                                                                                                 |
| Shen et al. 2008   | Single center retrospectiveanalysisof indications, surgical techniques and post- operativemanagement.                                            | Dose:MMF not specified. Formulation:not specified. Follow-up: mean 21.8 months                                                                                                                        | N=31 Age atTx:12.4years (range: 5 months to 18 years).                                                                                           | 30/31patientsreceivedTAC+MMF+steroids.1/31 patientsreceivedCsA-basedregimen. 5/31patientsdiedduringperioperativeperiod(mortalityrate 16.1%).Postoperativecomplicationsin10patientsincluded biliaryleakage,acuterejection,abdominalinfection,hepatitis BvirusorhepatitisCvirusinfection,andpulmonary infection.Cumulativesurvivalrateat1-,3-,and5-yearswas 78.1%,62.6%,and 62.6%,respectively. | Useina Chinese paediatricpopulation                                                                                                              |
|                    | RationaleforClassificationofEvidence:                                                                                                            | RationaleforClassificationofEvidence:                                                                                                                                                                 | RationaleforClassificationofEvidence:                                                                                                            | RationaleforClassificationofEvidence:                                                                                                                                                                                                                                                                                                                                                         | RationaleforClassificationofEvidence:                                                                                                            |

<div style=\"page-break-after: always\"></div>

Table 28 continuation

| Study/ Reference   | Study Design                                                                                                                                                                  | Dosing, Formulation, Duration                                                                                                                                                                                     | Demographics                                                                                                                                                                  | KeyFindings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | KeyBenefit                                                                                                                                                                    |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Xiniaset al.2010   | Singlecenter retrospectivecasereview                                                                                                                                          | Dose: CsA (2-6 mg/kg/day -target level 200- 400 ng/mL) or TAC (0.3 mg/kg/day - target level5- 15 ng/mL)+MMF (100 mg/m2 b.i.d) and steroid. Formulation:not specified. Follow-up: median 35 months (range: 23-180) | N=16 (19 Txs conducted, but 3patients died immediately after procedure). Mean age 4.7±2.3 years. Males:females=8:8                                                            | 13patientswere alive(follow-upperiod:23-180months).4 patientshadatleast1episodeofchronicgraftrejection. Twoweremanagedwithcortisonepulsesandtworequired anti-thymocyteglobulin.Theonlyalterationsin immunosuppressionrequiredwereswitchesfromCsAto authors comment that newer immunosuppressant agents TACin3cases,andfromTAC toCsAinonecase.The suchasMMFdonotadverselyaffectrenalfunction,and thereforeit ispossibletoachieveimmunosuppressionusing CNlsatdosesthatavoidsideeffects.                                                                                                                                                                                                                                                                                        | MMFmaintenance regimen used in 13 living patients.                                                                                                                            |
| Xiniaset al.2010   | RationaleforClassificationof Evidence: Thisisasingle-centreretrospectivecasereviewincludingMMFinmaintenance.                                                                  | RationaleforClassificationof Evidence: Thisisasingle-centreretrospectivecasereviewincludingMMFinmaintenance.                                                                                                      | RationaleforClassificationof Evidence: Thisisasingle-centreretrospectivecasereviewincludingMMFinmaintenance.                                                                  | RationaleforClassificationof Evidence: Thisisasingle-centreretrospectivecasereviewincludingMMFinmaintenance.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | RationaleforClassificationof Evidence: Thisisasingle-centreretrospectivecasereviewincludingMMFinmaintenance.                                                                  |
| Martinet al.2011   | Observationalstudywith long-term follow-up to compare outcomes to overall pediatric LTx population (non-AIH) following liver Tx for AIH                                       | Dose: not specified. Formulation:not specified. Follow-up: 5-years.                                                                                                                                               | AIH N=113 Age: 12.9±0.4 years (mean 14.2) Males:females=35%: 65% Non-AIH N=1.411 Age:6.7±0.1 years. (mean 4.8) Males:females=49%: 51%                                         | Initial immunosuppression inAIHvs.non-AIHpatients(TAC based:72.6%vs.62.6%,p=0.045;MMFuse:31.0%vs. 21.6 %,p=0.02) and immunosuppression at 2yearspost-Tx in a greater proportion of AlH patients than non-AlH from the timeofTx;overtime,similarbutsmallreductionsintheuse (monotherapy:51.9%vs.17.3%,p<0.0001).MMFwasused of MMFwasreported inbothgroups.Late(>3months),but notsteroid-resistantorchronicrejection,wasmorecommon in AIH (log-rank p=0.0015). 5-year post-Tx survival for AIH was 86%(95%Cl:73to 93). Studydid notaimtocompareimmune-suppression regimens,butdiddemonstratethatstandardregimenswere effective following Tx in patients with AlH, although these patientsrequiredahigherdegreeof immunosuppression thanpatientstransplantedforotherindications. | Auto immunehepatitis Immunosuppressive regimens including LTx as a result of AIH. MMFareeffectivein childrenwhoreceive                                                        |
| Martinet al.2011   | RationaleforClassificationofEvidence: Thisisamulti-centreobservationalstudycomparingoutcomesinchildrenwithanunderlyingdiagnosisofAIHwithnonAlHbothofwhomreceivedMMFcontaining | RationaleforClassificationofEvidence: Thisisamulti-centreobservationalstudycomparingoutcomesinchildrenwithanunderlyingdiagnosisofAIHwithnonAlHbothofwhomreceivedMMFcontaining                                     | RationaleforClassificationofEvidence: Thisisamulti-centreobservationalstudycomparingoutcomesinchildrenwithanunderlyingdiagnosisofAIHwithnonAlHbothofwhomreceivedMMFcontaining | RationaleforClassificationofEvidence: Thisisamulti-centreobservationalstudycomparingoutcomesinchildrenwithanunderlyingdiagnosisofAIHwithnonAlHbothofwhomreceivedMMFcontaining                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | RationaleforClassificationofEvidence: Thisisamulti-centreobservationalstudycomparingoutcomesinchildrenwithanunderlyingdiagnosisofAIHwithnonAlHbothofwhomreceivedMMFcontaining |

ABOi= blood group incompatible; AlH=autoimmune hepatitis; b.i.d.=twice a day; BPAR =biopsy-proven acute rejection; CI=confidence interval; CMV =cytomegalovirus; CNI=calcineurin inhibitor;CsA=ciclosporin A;EBV=Epstein-Barr virus;GFR=glomerularfiltration rate;IH=isohemagglutinin;IVIG=intravenous immunoglobulin;LTx=liver transplant(ation);MMF=mycophenolatemofetil;OR=oddsratio;PTLD=post-transplant lymphoproliferative disorder;TAC=tacrolimus;Tx=transplant(ation).

## Comparison and analyses of results across studies Study populations

## Paediatric Heart Transplant - Real World Data from Registries

The demographic characteristics of children receiving HTx in the US between 2007-2009 and 2017-2019 are provided from the OPTN/SRTR registry data and shown in Table 29 . Across the two periods, the demographic baseline of HTx recipients has remained stable.

<div style=\"page-break-after: always\"></div>

Table 29 Demographic Characteristics of Paediatric Heart Transplant Recipients, 2007-2009 and 2017-2019

| Characteristics   | N (%)          | N (%)          |
|-------------------|----------------|----------------|
|                   | 2007-2009      | 2017-2019      |
| All recipients    | 1064 (100.00%) | 1414 (100.00%) |
| Age               |                |                |
| <1 year           | 304 (28.6%)    | 364 (25.7%)    |
| 1-5 years         | 263 (24.7%)    | 336 (23.8%)    |
| 6-10 years        | 153 (14.4%)    | 195 (13.8%)    |
| 11-17years        | 344 (32.3%)    | 519 (36.7%)    |
| Sex               |                |                |
| Female            | 484 (45.4%)    | 625 (44.2%)    |
| Male              | 580 (54.5%)    | 789 (55.8%)    |
| Race/ethnicity    |                |                |
| White             | 567 (53.3%)    | 738 (52.2%)    |
| Black             | 212 (19.9%)    | 280 (19.85%)   |
| Hispanic          | 197 (18.5%)    | 284 (20.1%)    |
| Asian             | 65 (6.1%)      | 69 (4.9%)      |
| Other/unknown     | 23 (2.2%)      | 43 (3.0%)      |
| Insurance         |                |                |
| Private           | 513 (48.2%)    | 548 (38.8%)    |
| Medicaid          | 426 (40.0%)    | 733 (51.8%)    |
| Other government  | 86 (8.1%)      | 96 (6.8%)      |
| Unknown           | 39 (3.7%)      | 37 (2.6%)      |
| Geography         |                |                |
| Metropolitan      | 897 (84.3%)    | 1142 (80.8%)   |
| Non-metropolitan  | 167 (15.7%)    | 272 (19.2%)    |

Source: Colvin et al. 2021.

## Published Literature

Most of the retrieved publications presented studies comparing the calcineurin inhibitor-azathioprine (CNI-AZA) containing immunosuppressive regimes to regimens containing MMF and evaluating the effect that switching AZA for MMF would have on the renal function, episodes of rejection, use of corticosteroids and overall survival post-transplant. Some studies have looked at the effects that ciclosporin A (CsA)containing regimens have on the kidney function in paediatric HTx patients. When exposed to CsA posttransplant as part of the maintenance immunosuppressive regimen, some children develop nephrotoxicity and reduced renal function.

Boyer et al. (2005) showed an improvement in both glomerular and tubular renal functions in 14 children under the age of 17 treated with MMF. According to the MAH, reducing or discontinuing CsA dosage with

<div style=\"page-break-after: always\"></div>

concomitant replacement of AZA by MMF is a safe way to improve renal function in children with HTx and CNI-induced nephrotoxicity (Boyer et al. 2005, Rosenthal et al. 2021).

Several studies have also looked into the effects of MMF on organ rejection in children under 17 years old with a HTx. Most of them seem to agree that switching from AZA to MMF as part of their maintenance immunosuppressive treatment has a significant and positive impact on the rejection episodes of these patients (Groetzner et al. 2005, Lammers et al. 2010, Lamour et al. 2019, Marshall et al. 2013), with one study indicating that MMF can even have a positive effect in the treatment of these events (Dipchand et al. 2001).

Chronic steroid usage can lead to complications such as stunted growth, hypertension, glucose intolerance/diabetes, hyperlipidemia, weight gain and osteoporosis. All these effects may affect long-term outcomes and quality of life of children. Steroid sparing is of particular interest in paediatric patients who will need immunosuppression for the rest of their lives, and also are undergoing growth.

Dipchand et al. (2001) showed that switching from AZA to MMF also facilitates steroid dose reduction, and the implementation of a steroid-free regimen in children under 17 years old. Other studies have shown that patients receiving MMF as part of their treatment can be managed safely with steroid avoidance immunosuppression regimens, with low rejection rates and good survival outcome (Lamour et al. 2019, Singh et al. 2010).

Cardiac allograft vasculopathy (CAV) is an important cause of graft failure in HTx recipients. One study looked at the effects of different immunosuppressive regimens in children under the age of 19 years old on the development of CAV. The use of MMF appeared to have a protective effect against the development of CAV in these patients (Moffett et al. 2014)

## Paediatric Liver Transplant - Real World Data from the Registries

The demographic characteristics of children receiving LTx in the US between 2007-2009 and 2017-2019 are provided from the OPTN/SRTR registry data (see Table 30 ). Across the two periods, the demographic baseline of LTx recipients has remained stable.

<div style=\"page-break-after: always\"></div>

Table 30 Demographic Characteristics of Paediatric Liver Transplant Recipients, 2007-2009 and 2017-2019

| Characteristics   | N (%)          | N (%)          |
|-------------------|----------------|----------------|
|                   | 2007-2009      | 2017-2019      |
| All recipients    | 1790 (100.00%) | 1713 (100.00%) |
| Age               |                |                |
| <1year            | 542 (30.3%)    | 442 (25.8%)    |
| 1-5 years         | 692 (38.7%)    | 668 (39.0%)    |
| 6-10 years        | 232 (13.0%)    | 248 (14.5%)    |
| 11-17 years       | 324 (18.1%)    | 355 (20.7%)    |
| Sex               |                |                |
| Female            | 892 (49.8%)    | 825 (48.2%)    |
| Male              | 898 (50.2%)    | 888 (51.8%)    |
| Race/ethnicity    |                |                |
| White             | 925 (51.7%)    | 861 (50.3%)    |
| Black             | 321 (17.9%)    | 280 (16.3%)    |
| Hispanic          | 387 (21.6%)    | 397 (23.2%)    |
| Asian             | 118 (6.6%)     | 125 (7.3%)     |
| Other/unknown     | 39 (2.2%)      | 50 (2.9%)      |
| Insurance         |                |                |
| Private           | 797 (44.5%)    | 626 (36.5%)    |
| Medicaid          | 15 (0.8%)      | 19 (1.1%)      |
| Other government  | 120 (6.7%)     | 134 (7.8%)     |
| Unknown           | 64 (3.6%)      | 84 (4.9%)      |
| Geography         |                |                |
| Metropolitan      | 1439 (80.4%)   | 1403 (81.9%)   |
| Non-metropolitan  | 351 (19.6%)    | 310 (18.1%)    |

Source: Kwong et al. 2021.

## Published Literature

The majority of the retrieved publications presented studies that included children who had been exposed to CNI-based immunosuppressant regimens in the post-transplant period and subsequently developed nephrotoxicity and reduced renal function. Within this group of children, the studies evaluated the benefit of adding MMF to the regimen to enable CNI dose reduction or cessation, in order to preserve renal function. The endpoint is typically an improvement in renal function as measured by glomerular filtration rate (GFR), and balanced with the risk of rejection (Aw et al. 2001, Nobili et al. 2003, Ferraris et al. 2004, Evans et al. 2005, Tannuri et al. 2007). One study (Leiskau et al. 2018) evaluated the benefit of using a combination of TAC and MMF without the development of renal impairment or renal toxicity.

Three other studies provided information on the use of MMF containing regimens in children who received ABOi LTx. The children included in these studies were typically below 3 years of age and received MMF within an individualised and intensive immunosuppressive regimen typically incorporating plasmapheresis, immunoglobulin and B cell depleting agents in addition to agents such as CNI, antimetabolites and steroids. Graft and patient survival were used as evidence of benefit of the regimen,

<div style=\"page-break-after: always\"></div>

and to show that this type of transplant is feasible (Schukfeh et al. 2015, Mysore et al. 2018, Dhungel et al. 2019).

The use of MMF in rescue for children with allograft rejection was evaluated in two retrospective studies (Chardot et al. 2001, Aw et al. 2008). The studies included children with steroid resistant rejection, or those who had received insufficient immunosuppression.

Steroid sparing is also particularly important for children who will need immunosuppression for the rest of their lives while undergoing growth. One study evaluated use of MMF in children under 18 years old with a LTx and initiating immunosuppression (Teisseyre et al. 2011).

Other studies presented evidence of the benefits of MMF when used in Chinese children receiving LTx (Shen et al. 2008), in children with an underlying diagnosis of autoimmune hepatitis (Martin et al. 2011), and in children who have received LTx and where MMF has been used as a maintenance treatment (Xinias et al. 2010).

## Comparison of efficacy results of all studies

## Paediatric Heart Transplant

Despite significant improvements in paediatric HTx outcomes, significant morbidity and mortality are still associated with it in the form of graft rejection, graft failure, infection, long-term corticosteroid use and other complications related to either under-immunosuppression or over-immunosuppression.

During the period of 1994-1999, the majority of paediatric HTx recipients were maintained on a triple therapy regimen with CsA, AZA, and prednisone. In contrast, during the period of 2001-2010, the most common regimen consisted of dual therapy with TAC and MMF, with most patients weaned off steroids (Marshall et al. 2013).

Currently, MMF has replaced the use of AZA in most centres (Singh et al. 2016), and is widely used as part of regular immunosuppressive regimens in clinical practice. One survey of several transplant centres in the United Kingdom (UK), Brazil, the US and Canada conducted by Castleberry et al. (2017) showed that a majority of the clinical protocols in those centres included MMF as long-term maintenance immunosuppression drug in paediatric HTx patients. MMF is also widely used in transplant centres in China as a routine component of the immunosuppressive treatment for paediatric HTx (Li et al. 2015).

Changes in immunosuppression regimens and the adoption of MMF have shown to be associated with improved 1-year, 5-years and 10-years survival in a 23-year retrospective, single-institution analysis of 180 paediatric and congenital patients by Tuite et al. (2021). These findings support the concept that advances in immunosuppressive strategies are associated with improved survival after HTx for paediatric and congenital cardiac disease, especially in high-risk cases (Tuite et al. 2021). These results are in line with the trends observed in the OPTN/SRTR registries.

## Rejection

Despite improved immunosuppression, rejection accounts for significant morbidity and mortality in children after HTx.

Groetzner et al. (2005) reported that since the introduction of MMF to the immunosuppression protocols used in their centre in paediatric HTx patients, freedom from acute rejection after 5 years increased to 62%, compared to 40% with primary CsA immunosuppression regimen and 56% with TAC. It is also shown in this study that MMF in combination with CNI (started in 1995, n = 27) led to a significantly higher freedom from acute rejection in the first year, compared to CNI combined with AZA or steroids (n = 23; p = 0.0013 from Kaplan-Meier analysis).

<div style=\"page-break-after: always\"></div>

Lammers et al. (2010) reports the incidence and outcome of rejection of 105 children following HTx performed between January 2002 and August 2007. In this cohort, combination of MMF and TAC appeared to provide the best protective profile as the maintenance combination immunosuppressive therapy of choice, to prevent (hemodynamically relevant) rejection following orthotopic HTx in children. Of note, among the patients whose immunosuppression regimen contained MMF (n = 50), none presented with a rejection resulting in hemodynamic collapse. The observed trend of a lower incidence of rejection with TAC and MMF than with TAC and AZA or TAC alone is in line with emerging data on MMF therapy in adults, and preliminary experience in children, as reported by other centres.

Marshall et al. (2013) performed a retrospective, historical-control, observational study comparing shortterm outcomes in patients who received a classic CsA-AZA-steroid-based treatment regimen without induction, and those who were transplanted using a TAC-MMF-based steroid-sparing protocol with the use of cytolytic induction therapy. A total of 103 paediatric HTx patients who underwent primary HTx at the Morgan Stanley Children's Hospital of New York between 1 January 2005 and 31 May 2010 were included in the study. 64 patients were from the control group (undergoing transplant between January 2005 and Apr 2008), and 39 from the new protocol group (undergoing transplant between May 2008 and May 2010). The results showed that in the first year after transplantation, the proportion of patients with at least one episode of acute rejection was lower in the new protocol group compared to the control group (38% vs. 58%; odds ratio [OR] 0.41; 95% CI: 0.18 to 0.92, p = 0.042). Also, patients that received treatment with the new protocol had a greater freedom from rejection time during the first year after the HTx than those in the control group (p = 0.044). During the second year, the proportion of patients experiencing one episode of rejection was comparable in the two groups, 5% in the new protocol group vs. 4% in the control group.

## Cardiac Allograft Vasculopathy (CAV)

CAV is an important cause of graft failure in HTx recipients. Moffett et al. (2014) performed a single centre, retrospective analysis on 148 patients aged under 19 years old who underwent HTx between 1996 and 2012, with the aim to identify the effect of the different immunosuppressive regimens on the development of CAV. Patients' medication regimens were followed for 1 of 3 endpoints: date of first CAV diagnosis, re-transplantation, or death. CAV was determined by angiography/imaging or pathology. The multivariate hazard model analyzing the time to CAV suggested that the use of MMF resulted in a decreased risk of developing CAV in paediatric HTx patients (hazard ratio [HR] = 0.45, CI: 0.2, 0.98, p = 0.04).

## Renal Sparing

Safely improving renal function in HTx paediatric patients has become a major objective while handling immunosuppressive regimens in paediatric HTx patients.

Boyer et al. (2005) showed an improvement in both glomerular and tubular renal functions in 14 children with MMF following a dosage reduction of CNI (e.g., CsA). Both insulin and creatinine clearance increased significantly following the switch and this effect appears to be of rapid onset and long lasting. They concluded that reducing CsA dosage with concomitant replacement of AZA by MMF appears to be a safe way to improve renal function in children with HTx and CNI-induced nephrotoxicity.

CsA-discontinued immunosuppressive therapy can be safe in HTx patients with no increase in organ rejection or death, and leads to a significant recovery of kidney function (Rosenthal et al. 2021).

## Steroid Sparing

Another goal of utilising MMF in paediatric HTx patients is to minimise corticosteroid exposure. As survival after HTx continues to improve in the paediatric population, the morbidity complications associated with long-term corticosteroid therapy such as stunted growth, hypertension, glucose intolerance/diabetes,

<div style=\"page-break-after: always\"></div>

hyperlipidemia, weight gain and osteoporosis may affect long-term outcomes and quality of life in children. These metabolic side effects may be minimised by a 'steroid-avoidance' approach to immunosuppression in paediatric HTx recipients.

Published literature on both heart and renal transplant show evidence that MMF may allow for lower doses or even elimination of corticosteroids from the immunosuppression regimens.

Dipchand et al. (2001) reported that it is possible to successfully reduce and/or discontinue corticosteroids in HTx paediatric patients, with successful discontinuation in 28% of patients on MMF, and ongoing dosage reduction in 20% of patients enrolled in their study (n = 21).

Lamour et al. (2019) have shown that paediatric HTx recipients without donor specific antibodies at transplant and treated with a MMF containing regimen can safely avoid steroid treatment and have excellent short-term survival and low risk of first-year diabetes mellitus and post-transplant lymphoproliferative disorder (PTLD).

Singh et al. (2010) performed a single centre, retrospective analysis of 55 HTx patients that had entered a steroid-avoidance immunosuppression protocol consisting of thymoglobin induction, followed by a TACMMF, corticosteroid-free regimen. The primary outcome variable was freedom from moderate rejection (International Society for Heart and Lung Transplantation grade 2R/3A or antibody-mediated rejection). Median age was 7.2 years. Results showed that freedom from rejection was 92% at 6 months, and 87% at 1 year. Post-transplant survival was 91% at 6 months and 88% at 12 and 24 months. This demonstrates that an immunosuppression protocol consisting of induction treatment and followed by corticosteroid avoidance, and a TAC-MMF based regimen appears to achieve acceptable rejection rates during the first year post transplant in paediatric HTx recipients.

## ABO-Incompatible Transplant

In a retrospective, multicentre analysis of 55 ABOi paediatric patients that underwent HTx, Urschel et al. (2013) concluded that successful ABOi HTx can be performed at an older age and with higher isohemagglutinin titers than initially assumed and using similar immunosuppressive regimens as for ABOcompatible transplants. Rejection and graft vasculopathy are rare. Sixty-two percent of the patients included in this study received MMF as part of their immunosuppression regime, along with CNI and low dose steroids. Furthermore, the authors concluded that given the lack of effective suppression of B-cell immunity by CNI, one could postulate that an anti-proliferative drug such as MMF should be a mandatory part of the regimen in ABOi HTx.

## Paediatric Liver Transplant

Paediatric LTx is performed to treat acute and chronic liver failure due to any cause, in appropriately selected patients and without contraindications (e.g., only a few cases related to malignancy, terminal conditions, poor expected quality of outcome). In children, cholestatic biliary atresia is the most frequent cause of liver failure. Over the last decade, graft survival has improved. Acute cellular rejection is encountered in up to 60% of recipients within the first few years after liver transplantation and chronic rejection can be seen in as many as 10% of paediatric transplantation patients in some series (Yazigi 2013). Long-term use of corticosteroids and CNIs in paediatric LTx patients can lead to growth failure, renal impairment, dyslipidemia, hypertension, diabetes mellitus, and PTLD. Therefore, it could be beneficial to opt for short-term utilisation of these drugs in paediatric patients or use alternative immunosuppressant regimens containing, for example, MMF (Ruth et al. 2014).

<div style=\"page-break-after: always\"></div>

## Rejection

Chardot et al. (2001) published a preliminary, retrospective experience on the use of MMF as a rescue therapy in 19 children that underwent LTx. The median initial oral dose of MMF was 23 mg/kg/day (range: 12-43). In the earlier experience, the initial dose of MMF was extrapolated from the adult dose (2-3 g/day) to 40 mg/kg/day. With increasing experience, this initial dose was reduced to 20 mg/kg/day. No MMF assay was available during the period of the study, and MMF therapy was adapted according to clinical and biological tolerance. Median follow-up after initiation of MMF therapy was 642 days (range: 229-1606 days). MMF was indicated for rejection or insufficient immunosuppression in 16 cases, with normalisation of both liver function tests and liver histology in 10 cases (62%). MMF was successfully used in one patient with post-LTx immune hepatitis and one patient with corticosteroid dependence. In three patients with renal function impairment, MMF allowed reduction of CsA or TAC blood levels, without subsequent rejection.

Aw et al. (2008) evaluated the long-term outcomes of 26 children who received rescue therapy with MMF for steroid resistant rejection. The median age at transplant was 1.7 years (range: 0.4-13.6). Primary immunosuppression was CsA-based in 22 patients, and TAC-based in 6. All patients except one had been converted to TAC prior to MMF, having already received a median of 2 (1 to 5) courses of high-dose intravenous methylprednisolone. The median time to MMF rescue therapy was 1.8 months (range: 0.435.8). In 21 of the 28 episodes of steroid resistant rejections, patients responded to MMF therapy. MMF was added at a dose of 10 mg/kg/day in divided doses, and the dose was increased to a maximum of 40 mg/kg/day over 2 weeks (mycophenolic acid [MPA] assay tests were not available at the time). The median follow-up was 8.8 years (range: 7.7-11.5). In responders, there was 1 death from PTLD, and no grafts were lost due to chronic rejection. In the 7 non-responders, 3 grafts were lost due to chronic rejection, and 2 resulted in death. Surviving children were clinically well, with good liver function, and 17 remained on MMF.

## Renal Sparing

LTx allows survival of children with end-stage liver disease; however, the need for immunosuppression is typically prolonged or life-long. Immunosuppressive regimens based on CNIs have had a positive impact on reducing rejection episodes. However, concerns exist related to the long-term impact on renal function by use of CNIs, as well as the risks of hypertension, neurological toxicity, cardiovascular risk, metabolic and cosmetic side effects. MMF has a different mechanism of action than CNIs and regimens using MMF alone or in combination have been studied in children with liver transplants. Based on the available evidence, MMF is frequently used as a part of renal sparing immunosuppression in the protocols of many transplant centres. The benefit of renal sparing is carefully balanced with the increased risk of opportunistic infection and neutropenia associated with MMF treatment.

Aw et al (2001) studied the use of MMF as a renal rescue to reduce the CNI exposure in 14 paediatric LTx recipients with CNI related nephrotoxicity. Patients had stable liver graft function and a glomerular filtration rate (GFR)  80 mL/min/1.73 m2. MMF was introduced at 20 mg/kg/day and increased to 40 mg/kg/day after one week. CNI dose was then reduced to achieve blood levels 25% of baseline. GFR was reassessed after 6 and 12 months. The median GFR increased from a baseline of 52 to 69 at 6 months and 73 mL/min/1.73m2 at 12 months, respectively (p  0.001). Side effects of MMF included decreased white cell count in two patients and backache in one. Two patients discontinued MMF. Acute allograft rejection occurred in three patients. All 14 patients were well at a median follow-up of 24 months from MMF introduction.

Nobili et al. (2003) reported on eight children that underwent paediatric LTx at least 5 years previously and had stable graft function with probable CNI induced renal dysfunction. CNI therapy was replaced by MMF in all patients. MMF was introduced at a dose of 20 mg/kg/day in two divided doses and increased to 40 mg/kg/day during the first month. TAC or CsA, at the same time, was reduced by 25% and

<div style=\"page-break-after: always\"></div>

subsequently gradually reduced every 2 weeks to achieve blood levels 25% of baseline over a period of 2 months. Serum creatinine, uric acid concentration, azotemia and creatinine clearance before and 6 months after study entry were measured. The patients were monitored closely for adverse events of MMF as well as graft function. The mean serum creatinine values were 1.18 mg/dL at 6 months before MMF introduction, and 0.83 mg/dL at 6 months after MMF introduction (p = 0.01). The mean uric acid concentration were 7.72 mg/dL at 6 months prior to MMF, and 5.66 mg/dL at the last follow-up (p = 0.001). The mean BUN varied from 25.4 mg/dL at 6 months before MMF introduction to 18.80 mg/dL after 6 months of MMF treatment (p = 0.005). Additionally, creatinine clearance had improved in all patients at the last follow-up. The mean values were 71.20 mL/min at 6 months before MMF introduction, and 88.40 mL/min at 6 months after MMF. The difference in creatinine clearance was not statistically significant. The AST and ALT concentrations were stable during the study period and no increase in serum bilirubin was observed. Only one patient reported temporary pruritus and nausea.

Ferraris et al. (2004) characterised the incidence of chronic renal dysfunction (n = 52), and the effect of combining MMF and a reduced CsA dose on renal function (n = 14) and immune response was evaluated five years after LTx. Fourteen patients developed chronic renal dysfunction (creatinine clearance  75 ml/min/1.73 m2 ) secondary to CsA toxicity as evaluated by renal biopsy. In 11 patients CsA dose was decreased to target levels 40 -90 mg/mL with MMF 600 mg/m2 b.i.d. Plasma creatinine levels decreased (from 1.0  0.03 to 0.8  0.03 ng/dL, p  0.007), creatinine clearance increased (from 66.8  3.0 to 99.2  6.3 mL/min/1.73 m2 , p  0.002), and microalbuminuria decreased (from 21.0  8.6 to 3.6  1.1 mg/24 h, p  0.05) after 12 months of MMF therapy combined with reduced CsA. MMF allowed the reduction of CsA, with an improvement in renal function, no risk of rejection, and minor changes in the immune response.

In a retrospective analysis, Evans et al. (2005) evaluated the long-term use of MMF in children who received the drug as a result of renal dysfunction (calculated glomerular filtration rate [cGFR]  65 mL/min/1.73 m2) after orthotopic LTx. Forty-eight children began MMF at a median age of 11.1 years (range: 0.9 -18.1) and at a median of 4.0 years (range: 0.3 -12.4) post-LTx. Median baseline cGFR was 54 mL/min/1.73 m2 (range: 29-65). Immunosuppression after transfer was MMF monotherapy in 36 children, MMF with steroids, in 4 children and MMF with low-dose CsA or TAC in 8 children. Twenty-three children were transferred to MMF monotherapy by introducing MMF at 20 mg/kg per day in two divided doses and at the same time, halving the CsA dose. After 2 weeks, CsA was discontinued as long as liver biochemistry and a full blood count were normal. The remaining 13 children were transferred to MMF in the same way, but prednisone at a dose of 5 mg/day was added to their therapy temporarily for 3 months to prevent liver-allograft rejection. This was then reduced and discontinued, leaving the patients on MMF monotherapy. For those receiving CsA or TAC with prednisone, MMF was simply added to the regime at a dose of 20 mg/kg per day in two divided doses and after 2 weeks, if liver biochemistry was stable, the CsA or TAC dose was reduced to give low levels of 40 -60  g/L or 3 -5 ng/mL, respectively. The same approach was used for those receiving CsA in combination with AZA, except that AZA was discontinued when MMF was introduced. In all cases, MMF was increased to a maximum of 40 mg/kg per day in two divided doses if renal dysfunction had not improved by 3 months after transfer to MMF. In 44 patients (92%) there was a statistically significant increase to a median cGFR of 69 mL/min/1.73 m2 (range: 28-114) by 1 month and a further increase to a median cGFR of 77 mL/min/1.73 m2 (range: 24 -105) by 2 months of MMF treatment, after which cGFR levels were maintained. Children aged less than 3 years at LTx or who were less than 5 years post-LTx, when MMF was introduced, demonstrated greater increases in cGFR. Four children with a median baseline cGFR of 34 mL/min/1.73 m2 (range: 31 -49) did not respond and progressed to end stage renal failure. Liver function abnormalities occurred in seven children (15%): transient transaminitis in three, acute rejection in two, and chronic rejection in two of whom one required re-transplantation.

Tannuri et al. (2021) retrospectively evaluated the efficacy and safety of the long-term use of MMF with reduced doses of CNIs. Out of 191 paediatric LTx recipients, 11 children developed renal dysfunction

<div style=\"page-break-after: always\"></div>

secondary to prolonged use of CsA or TAC, 1-12 years post-LTx. MMF was introduced at an initial twicedaily dose of 10 mg/kg and increased gradually to 40 mg/kg/day within a two-week interval. After introduction of MMF, the CNI dosage was reduced gradually to 50% of baseline dosage over a period of one month, without concern for drug levels. Renal function improved in 9 of 11 patients (82%). There were no episodes of acute or chronic rejection or increased infection rates during the 24-month study period. Two patients developed transitory diarrhea and leukopenia that recovered with reduction of MMF dosage to 30 mg/kg/day.

A single study was identified where the effectiveness and safety of de novo MMF and TAC-based regimens (n = 19) were compared to retrospectively age and diagnosis matched cohorts treated with TAC monotherapy (n = 19) or CsA and prednisolone (n = 19; Leiskau et al. 2018). TAC reduction in combination therapy (0.7  g/L over the year) was lower than targeted (2  g/L). Biopsy proven acute rejection occurred equally in MMF/TAC and TAC groups (31.6% each), being slightly higher in CsA group (42.1%; OR = 1.5; 95% CI: 0.42 to 5.44; p = 0.5). GFR deteriorated comparably in all 3 groups (p  0.01 each), without significant differences between the groups.

## Steroid Sparing

An abstract of a study was identified publishing the three year follow up of a study comparing immunosuppression with TAC, with or without MMF for early steroid withdrawal in children after LTx (Teisseyre et al. 2011). Group A included 22 patients aged 0.2 -18 years treated with TAC and MMF, group B included 22 patients aged 0.12-18.1 years treated with TAC and steroids. MMF was administered from 0-90 days and then reduced and discontinued finally 4 months after LTx. In group B, steroids were administered according to a low-dose scheme and at the end of month 7 steroid withdrawal was started. The incidence of acute rejections, liver and renal function, serum glucose, blood pressure, frequency of viral infections and liver biopsy: 0-6 months, 1, 2, and 3 years after LTx were evaluated. Liver and renal function, blood glucose and incidence of cytomegalovirus infections were similar in both groups 1, 2 and 3 years after LTx. Patients in Group A showed a reduced need for antihypertensive treatment (p  0.05) in the early post-transplant period and 1 and 2 yrs post transplantation. A reduced incidence of Epstein-Barr virus infection was observed in Group A without steroids in 1, 2 and 3 years after LTx (p&lt;0.05). Acute rejection episodes were more frequently recognised in Group A in the second year post LTx (p  0.05). Steroid resistant acute rejection was not observed in either group. More patients from group A showed normal liver histology one year post LTx however this difference was not significant.

## ABO-Incompatible Transplant

ABOi transplant has been performed primarily in children and typically in urgent cases as a way to address the scarcity of donor organs. The liver is viewed as an organ with greater resistance to acute rejection than the kidney or heart and was initially the organ where ABOi transplant was more frequent (Starzl et al. 1982, Demetris et al. 1988). Early trials showed poor graft survival due to antibody mediated rejection. Subsequently many approaches have been implemented to reduce the risk with the primary goal being reduction of ABO antibodies and suppression of B cell activity. Plasmapheresis, splenectomy, intravenous immunoglobulin, intrahepatic portal and arterial infusion, anti-lymphocyte antibodies, B cell depleting agents and enhanced immunosuppression represent some of the methods used to increase the success of ABOi transplant.

Three studies were identified where ABOi liver transplants were performed and MMF was part of the immunosuppressive regimen.

Schukfeh et al. (2015) published a prospective analysis of six paediatric ABOi LTx recipients under 3 years of age, matched with six patients receiving ABO-compatible transplant comparable in the recipient's preoperative paediatric end-stage liver disease (PELD), age, gender and the technical aspects of transplant and receiving transplant in the same period. At the time, there was experience of ABOi LTx

<div style=\"page-break-after: always\"></div>

from Asian countries with good outcomes, but the procedure was rarely performed in Europe. The median follow-up was 2.6 years (range: 1-4.5). At the time of operation, the mean body weight was 7.7 kg (range: 5.7-16 kg) in ABO-compatible LTx recipients and 8.8 kg (range: 5.5 -18 kg) in ABOi LTx recipients. In each group, the median PELD score was 28 (range: 28-35). The postoperative immunosuppressive regimen consisted of intravenous or oral prednisolone (initially 15 mg/m2 body surface area [BSA] at days 1-10 postoperatively), TAC (from 2 x 0.05 to 0.1 mg/kg) orally, and MMF (2  10mg/m2 BSA). MMF was introduced orally at Day 3, and four ABOi transplanted patients received intravenous immunoglobulins at Days 1, 3, and 5 after liver transplantation. Patient and graft survival in this group was 83%. One female patient died within 24 hours due to fulminant gram-negative sepsis. Another patient developed acute cellular rejection at the Day 8 postoperative, which responded to steroid treatment. No further complications occurred. In the ABO-compatible group, patient survival was 100% and graft survival was 83%; one patient in this group received re-transplantation after 4 days. During follow-up, two patients of the ABOi group had maximum alloantibody titers of four against the donor's blood group; all other patients had titers below four.

Mysore et al. (2018) developed and implemented a novel immunosuppression protocol in their Texasbased centre specifically for children undergoing ABOi LTx and based on quantification of isohemagglutinin (IH) titres. Children with high pre-transplant IH titers (  1:32) underwent an enhanced immunosuppression protocol including plasmapheresis, rituximab, IVIG, and MMF (15 mg/kg/dose b.i.d.), while children with IH titers  1:16 received steroids and TAC. Outcomes of ABOi LTx with ABO-compatible recipients of similar age and diagnosis over a 2-year period were retrospectively compared. Ten children with median age of 8.9 months underwent ABOi LTx, 4/10 patients underwent enhanced immunosuppression due to high IH titers. Rates of complications (rejection, infections, biliary and vascular) at both 1 year and up to 3 years post-transplant were comparable between the groups. Patients with ABOi LTx had good graft function with 100% survival at a median follow up of 3.3 years.

A further abstract was identified in which 8 cases of patients receiving ABOi LTx were described where immunosuppression with MMF was started 1 week before transplant as part of the regimen and continued as part of triple therapy post operatively (no dose details given). Patient and graft survival was 100% in recipients at a mean follow-up of 33 months (range: 2-80; Dhungel et al. 2019).

## Comparison of results in subpopulations

The retrieved publications include studies that offer limited information on the comparison of outcomes in different subpopulations. The information available from OPTN/SRTR registries provides some evidence related to outcomes in different subpopulations, though this cannot be directly and/or solely attributed to a particular MMF regimen or dosage.

## Paediatric Heart Transplant

## Real World Data from the Registries

Age

Overall, the rate of acute rejection at 1 year post transplant for transplants between 2017-2018 was similar for all age groups at approximately 20%. Five-year patient survival for transplants between 20122014 was similar for all groups ranging from 81.3% for recipients aged younger than 1 year to 85.4% for ages 11 -17 years.

Sex

<div style=\"page-break-after: always\"></div>

No information is published specific to outcome and patient survival for paediatric HTx recipients by sex. However, for adults, the data for males and females overlay each other and suggest that survival is not impacted by sex.

## Paediatric Liver Transplant

## Real World Data from the OPTN/SRTR Registries

Age

Across age groups, the incidence rate ranges from 21.3% in recipients aged younger than 1 year to 29.4% in those aged 1-5 years. There was little variation by age in the 5-year graft survival rates ranging from 81.1% for recipients aged younger than 1 year to 85.5% for ages 11-17 years.

Sex

No information is published specific to outcome for paediatric or adult LTx recipients by sex. The registry data do confirm that the paediatric candidates wait-listed for LTx have consistently followed an equal distribution with respect to sex since 2008.

## Living-Donor Recipients vs Deceased-Donor Recipients

Paediatric living-donor transplant recipients show a reduced rate of graft failure compared with deceaseddonor transplants that is apparent from approximately one year after transplant and most evident at ten years post-transplant where deceased-donor recipients have a failure rate of 24.8% and living-donor recipients have a failure rate of 17.6%.

## 2.4.3. Discussion on clinical efficacy

The off-label use of MMF-containing regimens in paediatric heart and liver transplant recipients has increased over time. These regimens are broadly aligned with the use patterns in adults, although the benefit of steroid and CNI sparing may be more important for paediatric patients who are undergoing growth and who have a need to preserve renal function for a longer time compared with adults.

In graft survival for heart and liver, and patient survival for heart and liver transplant, the efficacy of MMF is comparable with that observed in adults, although paediatric patients tend to have better outcomes relative to adults, particularly at time points beyond the first year post-transplant.

The MAH proposes to extend the current indication of MMF to allow paediatric patients access to the medicine.

No new dose-response trials were conducted in paediatric patients. The mechanism of action of MMF (conversion of the mycophenolate prodrug MMF into its active moiety MPA, which then inhibits IMPDH resulting in a decreased lymphocyte proliferation) is independent of transplant type. Exposure to MPA is determined by measuring the conversion of MMF to MPA and by MPA's metabolism to its inactive 7-Oglucuronide MPAG. This is also independent of patient age.

When expanding indications for CellCept from the RTx indication in adults to other transplant types in adults (heart, liver) and to RTx in children, it was assumed that similar systemic exposure to MPA will yield comparable efficacy independent of transplanted organ and age. This has been accepted by the CHMP.

The MAH also demonstrated that the pharmacokinetics of MPA show high inter-patient variability in general, even higher in paediatric than in adult patients, in liver and heart transplant than in renal transplant patients and early after transplantation than later. It was thus supported that in order to secure adequacy of immunosuppression, individual dosing, was needed (see section 4.2 of the SmPC).

<div style=\"page-break-after: always\"></div>

The MAH also provided evidence that often higher doses than 600 mg/m2 are needed to achieve the target exposure (29 h · mg/L in the early or 58 h · mg/L in the late post-transplantation period) that has been shown to be effective in adults and more pronounced for heart and liver than for renal patients. Thus it is accepted that a higher maintenance dose than currently recommended might be needed for HTx and LTx.

The clinical efficacy data provided supporting the application originate from available publications of studies conducted in the paediatric population, including 14 studies relevant to paediatric heart transplant (HTx) and 15 studies relevant to paediatric liver transplant (LTx) patients.

In addition, clinical efficacy data from the Roche-sponsored pivotal trials conducted in the adult population, and data extracted from the Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR) Registries for HTx and LTx in the United States (US) are also included to provide the context for interpretation of the available literature data.

However, as pointed out by the MAH, the published studies are largely observational over a period of time, too small in sample size, and not designed to demonstrate the efficacy of MMF. They typically include MMF together with other therapeutic agents as a part of the immunosuppressive regimen, and it is therefore not possible to directly link or attribute any of the observed outcomes to MMF.

Furthermore, very few of the publications retrieved were prospective studies; most studies were retrospective comparisons of transplant outcomes in the years before the introduction of MMF versus outcomes in the years after the inclusion of MMF in standard of care immunosuppressive regimens. Therefore, although the studies consistently show a benefit for MMF, the impact of improved surgical and medical management is also likely to have influenced these findings.

Despite all these limitations, the results from the retrieved published studies suggest that as in adults, regimens containing MMF are effective in paediatric patients, with benefits of reducing the incidence of acute rejection and allowing calcineurin inhibitor (CNI) and steroid dose reduction. In addition, treatment with regimens containing MMF may improve the results of blood group incompatible (ABOi) transplantation.

However, all these additional data are only supportive. Since extrapolation from adults to children has been demonstrated, clinical efficacy is considered demonstrated.

## 2.4.4. Conclusions on the clinical efficacy

The available evidence suggests that regimens containing MMF are effective in paediatric patients. It is anticipated that the effect of immunosuppression with MMF is independent of type of solid organ transplantation and the efficacy is considered acceptable for paediatric RTx, HTx and LTx recipients in the following indication:

CellCept is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in adult and paediatric (1 to 18 years of age) patients receiving allogeneic renal, cardiac or hepatic transplants.

<div style=\"page-break-after: always\"></div>

## 2.5. Clinical safety

## Introduction

No company-sponsored pivotal clinical trials were conducted to support the safety of MMF in the prophylaxis of organ rejection in paediatric recipients of allogeneic heart or liver transplants.

A Phase IV study evaluating the safety, tolerability and pharmacokinetics of oral MMF in paediatric liver transplant (LTx) recipients on concomitant treatment with ciclosporin A (CsA) and corticosteroids was conducted by the MAH between 2003 and 2005 (Study PA16497).

The majority of safety data supporting this application originate from available publications of studies conducted in the paediatric population, including 17 clinical studies relevant to paediatric heart transplant (HTx) and 26 studies relevant to paediatric LTx patients.

In addition, an analysis of cumulative post-marketing safety data was also conducted to compare the proportions of adverse events (AEs) reported in paediatric HTx or LTx patients with the proportions of AEs reported in adult HTx or LTx patients, respectively. For paediatric patients, the proportions of AEs reported in patients with HTx or LTx (i.e., off-label use) were also compared with the proportion of AEs reported in patients with RTx (i.e., on-label use).

All the data presented should be interpreted with caution, bearing in mind the limitations of the underlying assumptions. In addition, post-marketing reports are voluntary and subject to under-reporting and reporting biases, which further limit the strength of the resulting evidence. Bearing in mind these caveats, the overall safety profile from these comparisons appears largely similar to the safety profile established in non-paediatric patients and paediatric RTx recipients. No new safety signal in paediatric patients with HTx or LTx emerged from this analysis. There are a few imbalances presented and discussed.

## Study PA16497

Part I of Study PA16497 was an open-label, multi-centre, non-controlled study that aimed to estimate the dose predicted to achieve an exposure of 58 μg.h/mL in stable paediatric hepatic transplant patients. The objective of part I of the study was to estimate the dose predicted to achieve an exposure of 58 μg.h/mL in stable paediatric hepatic transplant patients. The study planned to enroll 12 patients who would be dosed with MMF per center practice, not 600 mg/m2. Paediatric transplant recipients aged 9 months to 12 years of age, inclusive, who had received a first liver allograft from a cadaveric or living donor were targeted. Patients were enrolled for the time required for PK sampling and then contacted 14-16 days after sampling for adverse events.

However, the study was terminated early due to challenges with subject recruitment (e.g., only 35 patients were screened, and 9 patients were enrolled into Part I of the study between August 2002 and December 2004, infrequent use of the combination of triple therapy with MMF, CsA and steroids, etc.).

<div style=\"page-break-after: always\"></div>

Table 31 Summary of Demographic Data (All Patients)

<!-- image -->

Exposure: Nine paediatric patients were enrolled in Study PA16497. All patients received MMF twice a day (b.i.d.) at stable doses per centre practice (not 600 mg/m2) for at least 7 days prior to pharmacokinetic sampling. Mean MMF dose/m2 was 285 (81.1) mg/m2, with a range of 202 - 424 mg/m2. The mean MMF dose/kg was 12.9 (3.32) mg/kg and the range was 8.47 - 17.2 mg/kg.

<div style=\"page-break-after: always\"></div>

Table 32 Actual CellCept Dose Expressed as mg, mg/m 2  and mg/kg

| Patient        |   Age (months) |   Weight (kg) |   Height (cm) |   BSA (m²) |   Actual Dose (mg) |   Dose/m² (mg/m²) |   Dose/kg (mg/kg) |
|----------------|----------------|---------------|---------------|------------|--------------------|-------------------|-------------------|
|                |           18   |         10    |         76.2  |      0.46  |              140   |             304   |             14    |
|                |           24   |         14.5  |         85    |      0.59  |              250   |             424   |             17.2  |
|                |           17   |         10.5  |         73    |      0.46  |              170   |             370   |             16.2  |
|                |            9   |          8.1  |         71.12 |      0.4   |               90   |             225   |             11.1  |
|                |           60   |         11.6  |         86.36 |      0.53  |              125   |             236   |             10.8  |
|                |           10   |          8    |         72.39 |      0.4   |              125   |             313   |             15.6  |
|                |           14   |         11.8  |         75    |      0.5   |              100   |             200   |              8.47 |
|                |           15   |         10.5  |         76    |      0.47  |              100   |             213   |              9.52 |
| Mean           |           20.9 |         10.6  |         76.9  |      0.476 |              138   |             285   |             12.9  |
| SD             |           16.5 |          2.11 |          5.72 |      0.064 |               52.2 |              81.1 |              3.32 |
| CV%            |           79   |         19.8  |          7.4  |     13.4   |               38   |              28.4 |             25.8  |
| Median         |           16   |         10.5  |         75.5  |      0.465 |              125   |             270   |             12.6  |
| Min            |            9   |          8    |         71.1  |      0.4   |               90   |             200   |              8.47 |
| Max            |           60   |         14.5  |         86.4  |      0.59  |              250   |             424   |             17.2  |
| Geometric Mean |           17.4 |         10.4  |         76.7  |      0.473 |              130   |             276   |             12.5  |

Safety Results: One subject reported one adverse event (pyrexia) during the course of the study. This adverse event was mild in intensity and was assessed by the investigator as unrelated to trial treatment. There were no serious adverse events, no deaths or adverse events that led to the withdrawal of a patient recorded during the study.

Conclusions: Based on the assumptions that MPA exhibits linear PK, that an AUC achieved ≥ 6 months post-transplant is two-fold higher than an AUC in the immediate post-transplant period on the same dose of MMF, and an AUC of 29 μg.h/mL provides effective immunosuppression in the immediate posttransplant period, a dose of 740 - 806 mg/m2 would be required in the early post-transplant period to achieve adequate immunosuppression.

## Published Literature Studies

A search of all published scientific literature in standard databases (Medline, EmBase, BIOSIS Previews and Derwent Drug File) was conducted to include data up until 31 December 2022. All publications with a minimum of 10 paediatric patients and providing substantive safety information related to MMF therapy were presented. The majority of the retrieved articles did not provide exact details on patient age (and other demographic characteristics), number of patients exposed to MMF, or length of exposure. Safety data and AEs reported in these articles could not always be linked to specific patients or treatment regimen.

Paediatric HTx: From the systematic literature search, 366 publications of studies in paediatric HTx were retrieved and ranked according to decreasing strength of evidence. Of these 366 publications, 17 were selected based on the above-mentioned criteria and are presented (see Table 33 ):

- Prospective studies: 3 publications (at least 63 HTx patients on MMF)

- Retrospective studies: 8 publications (at least 6,559 HTx patients on MMF)

<div style=\"page-break-after: always\"></div>

- Conference abstract: 5 publications (at least 101 HTx patients on MMF)
- Consensus statement: 1 publication

Little data are available in terms of the duration of treatment, the dose and formulation of MMF. Where reported, MMF was used at a dose of 250 mg/day (Groetzner et al. 2005), 1,200 mg/m2 (Singh et al. 2010), 596 ± 99 mg/m2 (Siddiqi et al. 2015), titration to maximum 40 ± 14 mg/kg (Dipchand et al. 2001), or 600 mg/m2/dose b.i.d. to a maximum of 2,000 mg/day (Singh et al. 2016).

Paediatric LTx: From the systematic literature search, 806 publications of studies in paediatric LTx were retrieved and ranked according to decreasing strength of evidence. Of these 806 publications, 26 were selected based on the above-mentioned criteria and are presented (see Table 34 ):

- Prospective studies: 2 publications (44 LTx patients on MMF)
- Retrospective studies: 15 publications (at least 627 LTx patients on MMF)
- Conference abstracts: 9 publications (at least 459 LTx patients on MMF)

Little data are available in terms of the duration of treatment, the dose and formulation of MMF. Where reported, MMF was mostly used at a dose of 10-20 mg/kg b.i.d; Lightdale et al. 1997, Chardot et al. 2001, Evans et al. 2005, Aw et al. 2008, Leiskau et al. 2018, Ozturk et al. 2019, Renz et al. 1999, Tannuri et al. 2007, Honda et al. 2018, Nayagam et al. 2022. Ferraris et al. (2004) based their dosing regimen on body surface area (600 mg/m2 b.i.d).

Table 33 Summary of Paediatric Heart Transplant Studies Contributing to Safety Evaluation

| Study/ Reterence   | Study Design                                                                                                                                                                                                                                                                                             | Dosing.Formulation, Duration (Where Avallable)                                                                                                                      | Demographics                                                                                                                                                        | Key Findings                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Prospective        | Prospective                                                                                                                                                                                                                                                                                              | Prospective                                                                                                                                                         | Prospective                                                                                                                                                         | Prospective                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Fine ot al.2021    | Hearttransplanrecpeontsbetwoen 10 and21 years of age and =1 yeorpost- transplantatonweferecruiedat theTme of cinically ndicated invasive corotary angiogrephy or within 6months of invasive angiography to undergo real. timg myocordial contrast echocardiography (RTMCE) examination. Comparatotam:Yes | o uontiopue osog MMF not reported                                                                                                                                   | N=36:18 recelved MMF Mesn age:13.5.±4.3 yoars: Male females=21:15                                                                                                   | 318 patons oe MMF had CAV by ICA (comparod to5/36 fm thewholecohort)                                                                                                                                                                                                                                                                                                                                                                                           |
| Fine ot al.2021    | Rationale for classification of evidence: Thisis a prespectve w-centre study ina sall sample size nMF （<SD}wit apry otective  deect CAVnpedac heaansplant receients                                                                                                                                      | Rationale for classification of evidence: Thisis a prespectve w-centre study ina sall sample size nMF （<SD}wit apry otective  deect CAVnpedac heaansplant receients | Rationale for classification of evidence: Thisis a prespectve w-centre study ina sall sample size nMF （<SD}wit apry otective  deect CAVnpedac heaansplant receients | Rationale for classification of evidence: Thisis a prespectve w-centre study ina sall sample size nMF （<SD}wit apry otective  deect CAVnpedac heaansplant receients                                                                                                                                                                                                                                                                                            |
| Schubert etal.2008 | Prospective,single-centre,observatonal study monitoeng mmunosuppression and EBv load measurement using quantitative real-timePCR during Janary2001toDecember20065 years 11months). Comparator amm:Yes                                                                                                    | MMF-CSA (N17) CSA-AZA(N-11) CsA-Eve (N=9) CsAonly (N-4) Dose and formuaton of MMF not.reporied.                                                                     | N-41;17 recelved MNF years (median nge Age7.2months-19.3 8.1yoars) Malesfemales-16:25                                                                               | 1/17patients(5.8%) onMMFand CsA 2/11 pabonts （182%）onCsA-AZA and 1/9 pallents (11.1%) cn CsA-Eve developed PTLD EBvload wes significantlyincreosed in pafients with CsA-AZA in comparison topatents with CsA-MMFandCsAonly.PatientswithCsA-Eve had an eleveted EBVlood as compared with CsA-MMF,which was not statistically significart. EBVload decreasedin 6patients in whomAZA wasceasedand changed to CsA-Evea t-yeaf follow-up.withouf occumence of PTLD, |
| Schubert etal.2008 | Rationale for classification of evidence: (<50)                                                                                                                                                                                                                                                          | Rationale for classification of evidence: (<50)                                                                                                                     | Rationale for classification of evidence: (<50)                                                                                                                     | Rationale for classification of evidence: (<50)                                                                                                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

| Study/Reference      | StudyDesign                                                                                                                                                                                                                                                                                                             | Dosing,Formulation, Duration(Where                                                                                                                                                                                                                                                                                                                                                                                                                    | Demographics                                                                                                                                                                                     | KeyFindings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Jacobsen et al. 2018 | Prospectivelongitudinal cohortstudyof children undergoingHTxfor1-yearpost Tx. Comparator arm: No                                                                                                                                                                                                                        | Available) Allpatientswere inducedwithbasiliximab and IV steroids. Maintenance therapy was with TAC and MMF with oral steroids weanedby6months. Doseandformulationof MMF not reported.                                                                                                                                                                                                                                                                | N=28;all 28received MMF. Age:5 months to 16 years. Gender not specified.                                                                                                                         | 7/28patients(25%)hadCMVDNAdetection within first 12 weeks post-Tx.                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|                      | Rationaleforclassificationofevidence: This is a prospective single-centre study with a primary objective to determine specific immunity to CMV in a small sample size (<50) paediatric                                                                                                                                  | Rationaleforclassificationofevidence: This is a prospective single-centre study with a primary objective to determine specific immunity to CMV in a small sample size (<50) paediatric                                                                                                                                                                                                                                                                | Rationaleforclassificationofevidence: This is a prospective single-centre study with a primary objective to determine specific immunity to CMV in a small sample size (<50) paediatric           | Rationaleforclassificationofevidence: This is a prospective single-centre study with a primary objective to determine specific immunity to CMV in a small sample size (<50) paediatric                                                                                                                                                                                                                                                                                                                                     |
| Retrospective        | cardiactransplant recipientsonMMF                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Dipchand et al. 2001 | RetrospectivereportonMMFexperience in21pediatricheart transplantrecipients toevaluateMMFaseffectiveagentfor thetreatmentofbothestablished rejection andprimaryrejection prophylaxis in solid-organ transplantation (Tx).                                                                                                | Average MMF dose 40±14 mg/kg Formulation not provided                                                                                                                                                                                                                                                                                                                                                                                                 | N=21; all patients on MMF Age:12.3 years (range 11 months to 16.9 years). Age at Tx: 10.7 years (55 days to 16.7 years).                                                                         | AEsreported in38%of thepatients:diarrhoea, 10%; gastrointestinal discomfort,20%;leukopenia,20%. Dosereductionortemporarydiscontinuationwas required in63%of thepatients who experienced side-effects(24%of the total numberof patients). Opportunisticinfectionsdevelopedin10% (cryptococcus, CMV). MMF appears to be effectivefortreatmentofrejectioninthepediatric hearttransplantpopulationandhasanacceptable safetyprofile.Inaddition,it mayhavearole in reducedsteroiddosageorasteroid-free immunosuppressionregimen. |
|                      | Rationaleforclassificationofevidence: Thisstudy is arejection-focused,small sample(<50),single-centre,retrospectivechartreview.                                                                                                                                                                                         | Rationaleforclassificationofevidence: Thisstudy is arejection-focused,small sample(<50),single-centre,retrospectivechartreview.                                                                                                                                                                                                                                                                                                                       | Rationaleforclassificationofevidence: Thisstudy is arejection-focused,small sample(<50),single-centre,retrospectivechartreview.                                                                  | Rationaleforclassificationofevidence: Thisstudy is arejection-focused,small sample(<50),single-centre,retrospectivechartreview.                                                                                                                                                                                                                                                                                                                                                                                            |
| Dipchand et al. 2022 | Retrospective,single-centre, observationalstudymonitoringearly experiencewithlive-attenuatedvaricella vaccineinacohortof31children followingheart transplantation                                                                                                                                                       | Tacrolimus-MMF (N=13) Sirolimus-MMF (N=1)                                                                                                                                                                                                                                                                                                                                                                                                             | N=31;14received MMF Age: 2.4 weeks-5.9 years(medianage at transplant 8.64 months). Age at vaccination 3.17-17.93 (median age at vaccination 11.7 years). Males:females=13:18                     | 13/31patients(41.9%)onMMFand tacrolimus and 1/31(3.2%)on MMF and sirolimus.No major adverse events;rash was reported in 29%(of 31), spotswere few and self-resolving in1to3days. ThepatientsonMMFexperiencedminimal adverseeventsasdescribed，providingearly evidence thatchildrenonMMFcanbeeligiblefor vaccine.                                                                                                                                                                                                            |
| Study/Reference      | Study Design                                                                                                                                                                                                                                                                                                            | Dosing,Formulation, Duration (Where Available)                                                                                                                                                                                                                                                                                                                                                                                                        | Demographics                                                                                                                                                                                     | Key Findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|                      | Rationaleforclassificationofevidence: This is aretrospective,small sample(<50),single-centre,observational studyspecificallyfocused onvaricellavaccineexperience followingheart transplantation.                                                                                                                        | Rationaleforclassificationofevidence: This is aretrospective,small sample(<50),single-centre,observational studyspecificallyfocused onvaricellavaccineexperience followingheart transplantation.                                                                                                                                                                                                                                                      | Rationaleforclassificationofevidence: This is aretrospective,small sample(<50),single-centre,observational studyspecificallyfocused onvaricellavaccineexperience followingheart transplantation. | Rationaleforclassificationofevidence: This is aretrospective,small sample(<50),single-centre,observational studyspecificallyfocused onvaricellavaccineexperience followingheart transplantation.                                                                                                                                                                                                                                                                                                                           |
| Giuliano et al.2022  | TheUnitedNetworkforOrganSharing databasewasqueriedforpediatric(<18 years)hearttransplantrecipientsfrom Freedomfrommalignancy after transplantwas assessedwithKaplan- October1987throughNovember2019. Meier analysis.Coxregressionwas performedtogeneratehazardratios (HRs) and 95%Clsforrisk of malignancy development. | MMFnearlyalways used in combination with other agents. Doseand formulation of MMF not reported.                                                                                                                                                                                                                                                                                                                                                       | N=8,581,ofwhom 5.2%(n=444) were repeat transplants and multiorgan recipients. 0.7% (n=63) were On MMF >65% Average age at Tx 6.7 (SD, 6.2) years, Males:females=4,781:3 ,800                     | 3,818patientsinthecohort hadknownrecipient anddonorCytomegalovirusandEBVstatuses. Malignancy developed in 8.1%of the whole cohort was associated withreduced riskof malignancy,a findingthathasbeenreportedinadultheart (86.4%PTLD).Onmultivariableanalysis,MMF transplantpatients.MMFisnearlyalwaysused in combinationwithotheragents,but thisdoes support thesafe additionof MMF toaregimen.                                                                                                                             |
|                      | Rationaleforclassificationofevidence: This is aretrospectivelarge-sized(>1oo)studytoexamine theincidence and riskfactorsforposttransplant malignancy.                                                                                                                                                                   | Rationaleforclassificationofevidence: This is aretrospectivelarge-sized(>1oo)studytoexamine theincidence and riskfactorsforposttransplant malignancy.                                                                                                                                                                                                                                                                                                 | Rationaleforclassificationofevidence: This is aretrospectivelarge-sized(>1oo)studytoexamine theincidence and riskfactorsforposttransplant malignancy.                                            | Rationaleforclassificationofevidence: This is aretrospectivelarge-sized(>1oo)studytoexamine theincidence and riskfactorsforposttransplant malignancy.                                                                                                                                                                                                                                                                                                                                                                      |
| Groetzneret al.2005  | Retrospective analysisof clinical outcomeofpaediatricHTxpatients between 1988 and 2002(14 years). Comparator arm:No                                                                                                                                                                                                     | The majority of patients (35 of47;74%)received CsA as primary immunosuppression regimen.Overtime, afterintroduction of TAC, a growing number of patientsreceived TAC (12 of 47; 26%). Long- term immunosuppression consisted of CNI and AZA (11; 25%) or MMF (33; 75%). MMF administered intravenously (250 mg/day)on the first postoperative days and continued orallyafter extubation.Target trough levels were 2-4 mg/L for MPA in the first year. | N=47;33 received MMF. Age: 4 days to 17.9 years. Gender not specified.                                                                                                                           | MMFwasassociatedwithseveregastrointestinal side effects in 4/33 patients(12.1 %) necessitating a switch to AZA. 5years-freedomfromacuterejectionimproved significantlywhenCNI wereadministered in combination with MMFas a secondary immunosuppressant(40%withprimary ciclosporin immunosuppressionregimen,56%withTAC and 62% with MMF). Amongthe47totalpatients,threepatientsdied due toprimarygraft failureand therapydetails werenot available.                                                                         |
|                      | Rationaleforclassificationofevidence: Thisstudyisasingle-centre,retrospectivereviewprovidingfreedomofrejectiondataforasmallsampleofpatientsonMMF(<50)                                                                                                                                                                   | Rationaleforclassificationofevidence: Thisstudyisasingle-centre,retrospectivereviewprovidingfreedomofrejectiondataforasmallsampleofpatientsonMMF(<50)                                                                                                                                                                                                                                                                                                 | Rationaleforclassificationofevidence: Thisstudyisasingle-centre,retrospectivereviewprovidingfreedomofrejectiondataforasmallsampleofpatientsonMMF(<50)                                            | Rationaleforclassificationofevidence: Thisstudyisasingle-centre,retrospectivereviewprovidingfreedomofrejectiondataforasmallsampleofpatientsonMMF(<50)                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| Study/Reference     | StudyDesign                                                                                                                                                                                                                                                                                                                                 | Dosing,Formulation, Duration (Where Available)                                                                                                                                                                                                        | Demographics                                                                                                                                                                                                                                          | Key Findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Marshallet al. 2013 | Retrospective,observationalstudy comparingshort-termoutcomesin patients who received a CsA-AZA- steroid-based protocol without induction, and those who were transplanted using a TAC-MMF-based steroid-sparing protocol with the use of cytolytic induction therapybetween1January 2005and 31May 2010(5years 5 months). Comparator arm:Yes | Study group: TAC+MMF;n=39 Control Group: CsA+AZA+Steroids; n=64 Dose and formulation of MMF not reported.                                                                                                                                             | N=103;39 received MMF. Age:7.8±6.7 years. Gender not specified.                                                                                                                                                                                       | Mortalitywithinthefirstyear afterTxoccurred in 8/64patients(13%) in the control group compared with only 1/39 patients (3%) in the study group (TAC+MMF). Patientsinbothgroupsexperiencedsimilarrates of bacterial, fungal, and viral infections (EBV infection,CMVinfection)within thefirst 12months after transplant. Anaemia(51%vs14%)andneutropenia(18%vs 5%)were more commonly seen in the study group compared to control group.There was no differenceinthefrequencyof thrombocytopenia between the two groups (OR=1.1, 95% Cl: 0.3 to 4, p>0.9).                                |
| Marshallet al. 2013 | RationaleforClassification of Evidence: Thisis aretrospectiveobservational, smallsample(<50) single-centrestudy using a historicalcontrol which comparedoutcomesof two diferent                                                                                                                                                             | RationaleforClassification of Evidence: Thisis aretrospectiveobservational, smallsample(<50) single-centrestudy using a historicalcontrol which comparedoutcomesof two diferent                                                                       | RationaleforClassification of Evidence: Thisis aretrospectiveobservational, smallsample(<50) single-centrestudy using a historicalcontrol which comparedoutcomesof two diferent                                                                       | RationaleforClassification of Evidence: Thisis aretrospectiveobservational, smallsample(<50) single-centrestudy using a historicalcontrol which comparedoutcomesof two diferent                                                                                                                                                                                                                                                                                                                                                                                                         |
| Siddiqi et al. 2015 | Retrospective analysisto assessthe outcomestargetingMPA-troughlevelof 0.8-2.0 μg/mL in paediatric HTx collected 2-12 months,post-transplant. Comparator arm: No                                                                                                                                                                             | Mean MMFdosewas 596±99 mg/m².                                                                                                                                                                                                                         | N=22; all 22 received MMF. Age:4.8 months -19 years (median age: 2.5 years). Males:females=12:not reported.                                                                                                                                           | Of the22patientsexposed toMMF,adverse eventsreportedwithitsusewereleukopenia (WBC count <3000 cells/μL; n=13), gastro- intestinal events (n=3),bacterial pneumonia (n=1), and acute rejectionrequiring treatment with steroids (n=1).MMF was discontinued in two patientsforleukopenia,andonepatientwas switched from MMF to AZA for gastrointestinal complaints with subsequent resolution of gastrointestinal symptoms.                                                                                                                                                               |
| Siddiqi et al. 2015 | RationaleforClassification of Evidence: This is a small(<50),retrospectivestudyto assess effect of MMF doseand troughlevelson adverseeffects inpediatricheart transplant recipients.                                                                                                                                                        | RationaleforClassification of Evidence: This is a small(<50),retrospectivestudyto assess effect of MMF doseand troughlevelson adverseeffects inpediatricheart transplant recipients.                                                                  | RationaleforClassification of Evidence: This is a small(<50),retrospectivestudyto assess effect of MMF doseand troughlevelson adverseeffects inpediatricheart transplant recipients.                                                                  | RationaleforClassification of Evidence: This is a small(<50),retrospectivestudyto assess effect of MMF doseand troughlevelson adverseeffects inpediatricheart transplant recipients.                                                                                                                                                                                                                                                                                                                                                                                                    |
| Study/ Reference    | StudyDesign                                                                                                                                                                                                                                                                                                                                 | Dosing,Formulation, Duration (Where Available)                                                                                                                                                                                                        | Demographics                                                                                                                                                                                                                                          | Key Findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Singh et al. 2010   | Retrospective analysisofclinical outcomesinacohortofpaediatricHTx recipientsmanagedusingasteroid- avoidanceprotocol duringthestudy period (2005-2009; 4 years). Comparator arm:No                                                                                                                                                           | Rabbit anti thymocyte globulin and methylprednisolone for 5 days followed by TAC+MMF Formulation not (1,200 mg/m²). reported. MMF dosage was adjustedtoachieve a target trough level of 2-4 mg/dL                                                     | N=55;all55received MMF. Age: 2 weeks to 22 years (median age: 7.1 years). Males:females=27:28                                                                                                                                                         | Adverseeventsreportedwere:CMVantigenemia in 11patients (20%),EBVviremia in8patients (14.5%), insulin-dependent diabetes mellitus in 1 patient(1.8%) and transient glucose intolerancein 1 patient (1.8%). There were 6 deaths, 5 of which wereearlyhospital deathsinthepost-Txperiod due tomultiple-organfailure. Patientswithdiabetesmellitusandtransient glucoseintolerancehadfamilyhistoryofdiabetes.                                                                                                                                                                                |
| Singh et al. 2010   | RationaleforClassificationofEvidence:                                                                                                                                                                                                                                                                                                       | RationaleforClassificationofEvidence:                                                                                                                                                                                                                 | RationaleforClassificationofEvidence:                                                                                                                                                                                                                 | RationaleforClassificationofEvidence:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Singh et al. 2022   | Thisis a medium-sized(50-100) two-centreretrospectivestudyevaluating thepotential of MMFcontainingregimens toenablesteroidsparing. Anoverviewof theinfantrecipientand donorcharacteristicsovertimewithan analysisof>3,500infant heart trans- plants                                                                                         | Dose and formulation of MMF not reported.                                                                                                                                                                                                             | N>3,500; on MMF >1,250 (≈70% in the period 2005-2009 and 91% in the period 2009-2018) Age <1 year (Infants) Genderrationot provided                                                                                                                   | Mycophenolatemofetil was thepreferred antimetaboliteagent,usedin91%of infants transplanted during 2010-2018at discharge. FreedomfromPTLDwas98.8%at1year,95.3% at 5 years, and 88.4%at 10 years post-transplant in infant heart transplant recipients.It islikelythat someof thedecline inMMFusebetween dischargeand1yearpost-transplant isduetoits side effects(unspecified).Significant riskfactors associatedwithhigher5-yearmortality,conditional upon surviving the first post-transplant year, were femalesexand history of treatedrejectionduring the first post-transplant year. |
| Singh et al. 2022   | RationaleforClassification of Evidence: Largesample(>100),retrospectivepediatricheart transplantreportof theInternational ThoracicOrganTransplantRegistrywithafocusoninfant transplant recipients,less than oneyear of age at the time of transplant.                                                                                       | RationaleforClassification of Evidence: Largesample(>100),retrospectivepediatricheart transplantreportof theInternational ThoracicOrganTransplantRegistrywithafocusoninfant transplant recipients,less than oneyear of age at the time of transplant. | RationaleforClassification of Evidence: Largesample(>100),retrospectivepediatricheart transplantreportof theInternational ThoracicOrganTransplantRegistrywithafocusoninfant transplant recipients,less than oneyear of age at the time of transplant. | RationaleforClassification of Evidence: Largesample(>100),retrospectivepediatricheart transplantreportof theInternational ThoracicOrganTransplantRegistrywithafocusoninfant transplant recipients,less than oneyear of age at the time of transplant.                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

| Study/Reference                                 | Study Design                                                                                                                                                                                                                                                                         | Dosing,Formulation, Duration(Where Available)                                                                                                                                      | Demographics                                                                                                                                                                   | Key Findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|-------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Conferenceabstract(limited informationprovided) | Conferenceabstract(limited informationprovided)                                                                                                                                                                                                                                      | Conferenceabstract(limited informationprovided)                                                                                                                                    | Conferenceabstract(limited informationprovided)                                                                                                                                | Conferenceabstract(limited informationprovided)                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Hingler et al.2013                              | ProspectivestudytocheckEBVload in paediatricHTxpatientsinregardtotheir immunosuppressivetherapy.Patients withCsA-Eveand CsA-MMFwere compared inasubanalysis. Median time post-Tx was 7.5 years (range: 0.2-17.5). Comparator arm:Yes.                                                | CsA+MMF (not known). CsA+Eve (not known). Dosing and formulation of MMF and CsA not reported.                                                                                      | N=39;unknwon number of patients received MMF. Median age: 13.8 years (2.9-26.5). Gendernotspecified.                                                                           | PatientsonCsA+MMFshowedareducedEBV- activity compared topatients onCsA+Eve. ComparedtoCsA+Eve,CsA+MMFseemsto improve EBV-specificCD8+T-cellsresponse in paediatricHTxrecipientswithsameexposureof CsA.                                                                                                                                                                                                                                                                             |
| Hingler et al.2013                              | RationaleforClassificationofEvidence: This is a prospective small-sample(<50)studyto assess the impact of immunosuppressive therapy on anti-EBVspecificCD8+T-cells inpediatric                                                                                                       | RationaleforClassificationofEvidence: This is a prospective small-sample(<50)studyto assess the impact of immunosuppressive therapy on anti-EBVspecificCD8+T-cells inpediatric     | RationaleforClassificationofEvidence: This is a prospective small-sample(<50)studyto assess the impact of immunosuppressive therapy on anti-EBVspecificCD8+T-cells inpediatric | RationaleforClassificationofEvidence: This is a prospective small-sample(<50)studyto assess the impact of immunosuppressive therapy on anti-EBVspecificCD8+T-cells inpediatric                                                                                                                                                                                                                                                                                                     |
| Kis et al. 2016                                 | Tosummarisethecomplicationsafter paediatric HTx since 2007.Regular controlsweretimedevery2-6weeks, mean follow up was 3.4 (2.1)years. Comparator arm: No                                                                                                                             | heart transplantrecipientsprovidingcomparisonbetweenCsA+MMFandCsA+Everolimustreatmentregimen. Initial immunosuppressive therapy was TAC and MMF. Dose and formulation notreported. | N=29;number of paediatricpatientson MMF unknown. Age: 7.1 years old. Gendernotspecified.                                                                                       | Sixofthe29patientsexperiencedMMFrelated gastrointestinal problemsforwhichMMFwas withdrawnandEvewasgiven.                                                                                                                                                                                                                                                                                                                                                                           |
| Kis et al. 2016                                 | RationaleforClassificationofEvidence: transplantation.                                                                                                                                                                                                                               | RationaleforClassificationofEvidence: transplantation.                                                                                                                             | RationaleforClassificationofEvidence: transplantation.                                                                                                                         | RationaleforClassificationofEvidence: transplantation.                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Lehmkuhlet al. 2011                             | Clinicalstudytoevaluatesafetyand efficacy of Eve in comparison to MMF during follow-up of 24 months. Comparator arm:Yes                                                                                                                                                              | Group A: Eve; n=24. Group B: MMF; n=28 (dose and formulation not reported). All patients received CsA as de-novo immunosuppressive and were followed-up for 24 months.             | N=52;28received MMF. Age<18 years. Gender not specified.                                                                                                                       | 4 patients (16.1%) in Group A, and 5 patients (17.8%)inGroupBdevelopedCAVat12months. CMV infection occurred in 1 patient (4%)in Group A,and 4 patients (14.2%)in GroupB.Sixchildren died (n=1 in Group A, and n=5 in Group B). Two childrendiedduetoacutecellularrejection(Group B). Sideeffectssuchasinfections,hospitalisation rates,haemoglobinconcentration,plateletcount, thedevelopmentof lymphoproliferativedisease andcholesterolvaluesweresimilarbetweenthe groups.       |
| Lehmkuhlet al. 2011                             | RationaleforClassificationof Evidence: Thissmall-sample(<50) study evaluates efficacy,safety and survival duringfollow-upof 24monthsforEvein comparison toMMF.                                                                                                                       | RationaleforClassificationof Evidence: Thissmall-sample(<50) study evaluates efficacy,safety and survival duringfollow-upof 24monthsforEvein comparison toMMF.                     | RationaleforClassificationof Evidence: Thissmall-sample(<50) study evaluates efficacy,safety and survival duringfollow-upof 24monthsforEvein comparison toMMF.                 | RationaleforClassificationof Evidence: Thissmall-sample(<50) study evaluates efficacy,safety and survival duringfollow-upof 24monthsforEvein comparison toMMF.                                                                                                                                                                                                                                                                                                                     |
| Study/Reference                                 | StudyDesign                                                                                                                                                                                                                                                                          | Dosing,Formulation, Duration(Where Available)                                                                                                                                      | Demographics                                                                                                                                                                   | KeyFindings                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Nunoda et al.2013                               | Prospectiveobservationalstudyof HTx patientsbefore the ageof 18years. Median time post-Tx was 7.5 years (range: 0.2-17.5). Comparator arm: No                                                                                                                                        | Allpatientsreceived standard tripletherapy includingCsA or TAC, MMF (dose and formulationnot reported), and a corticosteroid.                                                      | N=26; all received MMF. Age:7.6±4.2years. Males:females=16:10                                                                                                                  | Patient survival at1,5,10, and20-yearspost-Tx was 96.2%,91.3%,85.3%,and 85.3%, respectively. survival rates that were 94.7% at1year, 94.7% at Paediatricsurvivalrateswerebetterthanadult 5years,81.2%at10 years,and72.2%at 15years.Onepatient diedofCAV at4.8years afterHTxandoneduetoPTLDat7.3yearsafter HTx Adverse events during the late post-Txperiod includedCAV(n=3),PTLD(n=4),and renal dysfunction(n=2),howevertime toonsetofthese eventsafterinitiationof MMFwasunknown. |
| Nunoda et al.2013                               | RationaleforClassificationofEvidence: Thisis asingle-centreretrospectivereviewproviding long termfollowupdataona small sampleof patientsonMMFcontainingregimens(<50).                                                                                                                | RationaleforClassificationofEvidence: Thisis asingle-centreretrospectivereviewproviding long termfollowupdataona small sampleof patientsonMMFcontainingregimens(<50).              | RationaleforClassificationofEvidence: Thisis asingle-centreretrospectivereviewproviding long termfollowupdataona small sampleof patientsonMMFcontainingregimens(<50).          | RationaleforClassificationofEvidence: Thisis asingle-centreretrospectivereviewproviding long termfollowupdataona small sampleof patientsonMMFcontainingregimens(<50).                                                                                                                                                                                                                                                                                                              |
| Reichelet al.2000                               | Retrospective comparative assessment ofpaediatricpatientsreceivingHTx during82patient-monthof immunosuppression with MMF and a historical group ofpaediatricpatients whoreceivedHTxduring 41patient- monthtreatmentwithAZA.Durationof the study was not specified. Comparatorarm:Yes | MMF (N=8). AZA (N=6). Dosing and formulation of MMF and AZA not reported.                                                                                                          | N=14;8received MMF. Agerange:6 months to 9 years (mean age:3.5 years). Gender not specified                                                                                    | Frequenciesofinfectionduring immunosuppression were0.21perpatient-month during treatment withMMF,and0.44perpatient- month during treatment withAZA,and frequencies ofsevere infectionswere 0.17perpatient-month for MMF and 0.10 perpatient-month for AZA. Frequenciesofrejectionepisodeswerezerofor MMF and 0.17per patient-month for AZA.                                                                                                                                        |
| Reichelet al.2000                               | RationaleforClassificationofEvidence: Smallsample(<50)retrospectivecomparativeassessmentofpaediatricHTxpatientsonMMFtopaediatricHTxpatientsonAZA                                                                                                                                     | RationaleforClassificationofEvidence: Smallsample(<50)retrospectivecomparativeassessmentofpaediatricHTxpatientsonMMFtopaediatricHTxpatientsonAZA                                   | RationaleforClassificationofEvidence: Smallsample(<50)retrospectivecomparativeassessmentofpaediatricHTxpatientsonMMFtopaediatricHTxpatientsonAZA                               | RationaleforClassificationofEvidence: Smallsample(<50)retrospectivecomparativeassessmentofpaediatricHTxpatientsonMMFtopaediatricHTxpatientsonAZA                                                                                                                                                                                                                                                                                                                                   |
| Study/Reference                                 | StudyDesign                                                                                                                                                                                                                                                                          | Dosing,Formulation, Duration(Where Available)                                                                                                                                      | Demographics                                                                                                                                                                   | Key Findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Consensusstatement                              | Consensusstatement                                                                                                                                                                                                                                                                   | Consensusstatement                                                                                                                                                                 | Consensusstatement                                                                                                                                                             | Consensusstatement                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Singh etal.2016                                 | Consensusstatement.                                                                                                                                                                                                                                                                  | Initial dosing for MMF is recommended at 600 mg/m2/dose b.i.d to a maximum of 2,000 mg/day. Formulation of MMF not reported.                                                       | Not specified.                                                                                                                                                                 | MMFhasreplacedAZAinmostcentresasit appears tobe more specificfor lymphocytes than AZA,andfeweradverseeventsareexhibitedwith itsuse.Adverseeventsarelargelydoserelated and include leukopenia,anaemia,nausea, vomiting,anddiarrhoea.                                                                                                                                                                                                                                                |
| Singh etal.2016                                 | RationaleforClassificationof Evidence:                                                                                                                                                                                                                                               | RationaleforClassificationof Evidence:                                                                                                                                             | RationaleforClassificationof Evidence:                                                                                                                                         | RationaleforClassificationof Evidence:                                                                                                                                                                                                                                                                                                                                                                                                                                             |

AZA=azathioprine;b.i.d.=twice a day;CAV=cardiac allograft vasculopathy;Cl=confidence interval;CMV=cytomegalovirus;CNl=calcineurin inhibitor; MMF=mycophenolatemofetil;MPA=mycophenolicacid;MPS=mycophenolate sodium;OR=oddsratio;PCR=polymerase chainreaction; PTLD=post-transplant lymphoproliferativedisorder;RTMCE=real-timemyocardial contrastechocardiography;SmPC=Summary ofproduct characteristics;Tx=transplant(ation);TAC=tacrolimus;WBC=whitebloodcell.

<div style=\"page-break-after: always\"></div>

## Table 34 Summary of Paediatric Liver Transplant Studies Contributing to Safety Evaluation

| Study Reference   | Study Design                                                                                                                                                                                                                                                                                    | Dosing.Formulation, Duration (Where Available)                                                                                                                                                                                                                                                                      | Demographics                                                                                                                                                                                  | Key Findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Prospective       | Prospective                                                                                                                                                                                                                                                                                     | Prospective                                                                                                                                                                                                                                                                                                         | Prospective                                                                                                                                                                                   | Prospective                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| aL2010            | Prospective analysis of neuromuscular complications in48 paediatric potients with LTx Mean duration of follow-up was21.6±9.4months. Comparator arm: No                                                                                                                                          | lmmunosuppressive medication consisted ofTAC （n=44)orCsA(n=4)combined withMMF (n=33).ond prednisolone (n=18) Dosoge and fonmulation of MMF not reported                                                                                                                                                             | N=4833received MMF Mean age:9.6±4.3 years Males:females=30 18.                                                                                                                                | Of the 48patientsreceivingimmunosuppression byMMF prednisone,TAC and CsA,20 developed neurologic complications of which 17wereon MMF combination therapy.The most-common neurologic complications reported in all these patients were tremor (n=8,16.7%), comvulsions (n=6,12.5%).ins0mnia (n=6,12.5%) headache(n=5.10.4%).musclecramps(n=5,10.4%). %9=s%9= authors concluded that most-common neurologic complication after LTx in children is tremor,same as in adult patients,which may be due to higher rate of use of TAC in these patients.                                                                                                                                                                                                                                                                                                                                                                                               |
| aL2010            | Rationale forclassification ofevidence:                                                                                                                                                                                                                                                         | Rationale forclassification ofevidence:                                                                                                                                                                                                                                                                             | Rationale forclassification ofevidence:                                                                                                                                                       | Rationale forclassification ofevidence:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Ferrars etal 2004 | Prospective analysis to study effect of MMF initiation and reduction in CsA dose inpoediatric LTx with chronic renal dysfunction secondary to CsA toxicity. The total duration of reduced doses of CsA combined with MMF was 24 months Comparator Arm:No                                        | Reduced dose CsA (target trough level:40-90ngml) combaned with 600 mg/m²bi.d MMF for 24months.                                                                                                                                                                                                                      | N=11;allroceived MMF. Mean age:6 2±0.4 yearsat transplantation, and 12.5±2years at start of the study Maleslemales-5:6                                                                        | Reduction of CsAdose combined with iniliation of MMF fesuitedinasignificant improvementinrenal functionand reduction of microalbuminuria inpaediatnc LTx recipients with chronic renal dysfunction secondary to CsA nephrotoxicity.According to the Authors,MMFallows the safe reduction of CsA,with animprovement in renal function,norisk ofrejection,andmnor changesin the immune response.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Ferrars etal 2004 | Rationale for Classification of Evidence: Thisisa single-centre small sample(<50)prospective study evaluating thepotential for MMF to enable CNlreduction andrecovery of renal function                                                                                                         | Rationale for Classification of Evidence: Thisisa single-centre small sample(<50)prospective study evaluating thepotential for MMF to enable CNlreduction andrecovery of renal function                                                                                                                             | Rationale for Classification of Evidence: Thisisa single-centre small sample(<50)prospective study evaluating thepotential for MMF to enable CNlreduction andrecovery of renal function       | Rationale for Classification of Evidence: Thisisa single-centre small sample(<50)prospective study evaluating thepotential for MMF to enable CNlreduction andrecovery of renal function                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Study/Reference   | Study Design                                                                                                                                                                                                                                                                                    | Dosing,Formulation, Duration(WhereAvailable)                                                                                                                                                                                                                                                                        | Demographics                                                                                                                                                                                  | Key Findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Retrospective     | Retrospective                                                                                                                                                                                                                                                                                   | Retrospective                                                                                                                                                                                                                                                                                                       | Retrospective                                                                                                                                                                                 | Retrospective                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Aw et al.2008     | Retrospective study to evaluatethelong-term outcome of MMFrescue therapyforsteroid resistant rejection in paediatric liver median time to MMFrescue allograft recipientsThe therapy was 1.8 months (range: (0.4-35.8). The median follow-up was 8.8 (range: 7.7-11.5) years. Comparator arm: No | MMF (formulation not reported)started at 10 mg/kg/day individed doses and increased to 4,010 mg/kg/day over two weeks in biopsy-proven failedtoimprovefollowing at cellularrejectionthathad least one 3-day course of IV pulse steroid. Primary immunosuppression was CsA-based in 22, and TAC-based in 6 patients. | N=26; all received MMF. Age: 4.8 months-13.6 years (median: 1.7 years) Males:females=10: 16.                                                                                                  | 12subjects developed adverseeventsrelated toMMF: diarrhoea (n=5), vomiting (n=1), abdominal pain (n=1), protein losing enteropathy (elevated stool alpha-1- antitrypsinlevels;n=1),leukopenia(n=5),EBVseropositive (n=5, of which 3 developed PTLD). One subject stopped MMFtemporarilybecause of neutropenia.Twosubjects died: one due to graft dysfunction after the third Tx, and second due toPTLD(Bcelllymphoma). Six children hadGFR<80mL/minute/1.73m²,5 of whom had previously stopped MMF because of side effects. MMF wasreintroducedincombinationwithalowerTACdosein 4 children, with subsequent improvements in GFR in 3. Nephrotoxicity is a known adverse drugreaction of TAC MMFwasstoppedin6childrenwhileit wasrestarted successfullyintheremainingchildren.                                                                                                                                                                    |
| Aw et al.2008     | RationaleforClassification of Evidence: Thisis aretrospective single-arm study evaluating theuse of MMF inrescueof steroid resistant rejection in a small group of patients (<50).                                                                                                              | RationaleforClassification of Evidence: Thisis aretrospective single-arm study evaluating theuse of MMF inrescueof steroid resistant rejection in a small group of patients (<50).                                                                                                                                  | RationaleforClassification of Evidence: Thisis aretrospective single-arm study evaluating theuse of MMF inrescueof steroid resistant rejection in a small group of patients (<50).            | RationaleforClassification of Evidence: Thisis aretrospective single-arm study evaluating theuse of MMF inrescueof steroid resistant rejection in a small group of patients (<50).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Chardotetal2001   | Retrospective studyto analyse the use of MMF as arescue therapy in paediatricpatientswithLTx and to assess its efficacy and safety. Median follow-up after initiation of MMF therapy was 642days (range: 229-1606). Comparator arm: No                                                          | Median initial dose of MMF was23mg/kg/day(range 12- 43) orally. The median time interval betweenLTandinitiationof MMF therapy was 130 days (range:13-3732 days)                                                                                                                                                     | N=19; all received MMF. Age: 30 months (range: 7-149). Males:females=8:1                                                                                                                      | Six patients (32%)experienced eight side effects, mainly gastrointestinaland haematological,whichresolved after cessationof MMFinfivecases anddosereductionin three. One case of PTLD occurred under MMF therapy (5.2%).Fourpatientshad EBVprimary infection,while under MMF therapy,without subsequent PTLD. Three patients had CMV primary infection, and five CMV reactivation, under MMF therapy. Seven remained asymptomatic,and onepresented withCMVenteritis.One patient, with cardiomyopathy prior to LTx, died 18 months afterare-Tx,duetoprogressionof theheart disease, whereas MMF therapy was stopped five months earlier. No patient died and no graft was lost, while under MMF therapy. Authors concluded that MMF is an effective and safe immunosuppressant in paediatric LTxrecipients. Its useishampered by frequent gastrointestinal and haematologicalsideeffects.MMFdoesnotseem to increase theriskofPTLDnor CMVdisease. |
| Chardotetal2001   | RationaleforClassificationofEvidence: Thisis asingle-centresmallsample(<50)retrospective analysisonthe useof MMFasrescueinchildrenwith insufficient immunosuppression or allograft rejection.                                                                                                   | RationaleforClassificationofEvidence: Thisis asingle-centresmallsample(<50)retrospective analysisonthe useof MMFasrescueinchildrenwith insufficient immunosuppression or allograft rejection.                                                                                                                       | RationaleforClassificationofEvidence: Thisis asingle-centresmallsample(<50)retrospective analysisonthe useof MMFasrescueinchildrenwith insufficient immunosuppression or allograft rejection. | RationaleforClassificationofEvidence: Thisis asingle-centresmallsample(<50)retrospective analysisonthe useof MMFasrescueinchildrenwith insufficient immunosuppression or allograft rejection.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

| Study/Reference           | Study Design                                                                                                                                                                                                                                                                                                                                                                                       | Dosing,Formulation, Duration(WhereAvailable)                                                                                                                                                                          | Demographics                                                                                                                                                                                               | Key Findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|---------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Colombaniet al 2000       | Retrospectivestudyto reviewthecomplications of LTx surgery, immunosuppression, rejection, and overall survivalrateinorthotopic LTxbetweenNovember years, 11 months). 1992 and October 1998.(5 Comparator Arm: No                                                                                                                                                                                   | Allbut 4recipientsreceived primary TAC immunosuppressiveregimens. Theother4underwent conversion from CsA. Concomitant immunosuppression included MMFdose600mg/m2/12hours steroid and MMF. (formulation not reported). | N=30; all 30 received MMF. Age:3 months to 7 years(mean age: 28 months). Gender not specified.                                                                                                             | Complicationsofimmunosuppressivetherapyincluded persistent systemic hypertension (n=6),renal tubular acidosis (n=3), short-term hyperglycemia (n=2), neurotoxicity(n=2),nephrotoxicity(n=2),food allergies (n=8),PTLD (n=4).Two patients (n=2) required re-Tx. Post-operative surgical complicationsresulted in 4 early deaths (13%): 1 from primary nonfunction, 2 from sepsis, Therewasonelatedeathfromrecurrent diseasefrom and1fromrenalfailure-arrhythmiaandcardiacarrest. hepatitis. No informationwas availableregarding the immunosuppressive drug that caused the complications of immunosuppressive therapy.                                                                                                                                                                                                                                                                                                                                        |
| Colombaniet al 2000       | RationaleforClassificationofEvidence: Thisis a small-sample(<50) retrospective chart reviewto study complications of transplant surgery, immunosuppression,rejection, and overall                                                                                                                                                                                                                  | RationaleforClassificationofEvidence: Thisis a small-sample(<50) retrospective chart reviewto study complications of transplant surgery, immunosuppression,rejection, and overall                                     | RationaleforClassificationofEvidence: Thisis a small-sample(<50) retrospective chart reviewto study complications of transplant surgery, immunosuppression,rejection, and overall                          | RationaleforClassificationofEvidence: Thisis a small-sample(<50) retrospective chart reviewto study complications of transplant surgery, immunosuppression,rejection, and overall                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Evans etal.2005           | Retrospective study to evaluateeffectofMMFinon renal function after MMF wasstarted duetorenal dysfunction in children with orthotopic LTx. Thedurationofobservation was for at least 1 year. Comparator Arm: No                                                                                                                                                                                    | MMF monotherapy=36 (dose of 20 mg/kg per day in two divided doses;formulationnot reported). MMF with low-dose CsA or TAC=8. MMF with steroids=4.                                                                      | N=48; all 48 received MMF. Age: 10.8 months-18.1 years (median: 11.1 years). Males:females=23: 25.                                                                                                         | In 44(92%)patients,there was a statistically significant increaseofcGFR,greaterinchildrenaged<3yearsatTx or who were<5 yearspost-Tx when MMFwas started. Eightoutoftotal48patientsdevelopedadverseevents: transient bone marrow suppression with decreased WBC countin3patients,nauseaandheadachein1patient, alopecia mild and transient in 2 patients, gastrointestinal bleedingrequiring discontinuationof MMFin1patient. Liverfunction abnormalities occurred in seven patients (15%): transient transaminitis in three, acute rejection in two,andchronicrejection intwo,ofwhomonerequiredre- Tx.                                                                                                                                                                                                                                                                                                                                                         |
| Evans etal.2005           | RationaleforClassificationofEvidence: Asingle-centresmallsample(<50)retrospectiveanalysisevaluatingthepotentialforMMFtoenableCNlreductionandrecoveryofrenalfunction.                                                                                                                                                                                                                               | RationaleforClassificationofEvidence: Asingle-centresmallsample(<50)retrospectiveanalysisevaluatingthepotentialforMMFtoenableCNlreductionandrecoveryofrenalfunction.                                                  | RationaleforClassificationofEvidence: Asingle-centresmallsample(<50)retrospectiveanalysisevaluatingthepotentialforMMFtoenableCNlreductionandrecoveryofrenalfunction.                                       | RationaleforClassificationofEvidence: Asingle-centresmallsample(<50)retrospectiveanalysisevaluatingthepotentialforMMFtoenableCNlreductionandrecoveryofrenalfunction.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Study/ Reference          | StudyDesign                                                                                                                                                                                                                                                                                                                                                                                        | Dosing,Formulation, Duration(WhereAvailable)                                                                                                                                                                          | Demographics                                                                                                                                                                                               | KeyFindings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Gavaldaet al. 2012        | Thisretrospectivestudy included49paediatricsolid organ transplant recipients (32 liver, 14 kidney, and 3 combined liver-kidney) paediatric patient(<18 years) who underwent liver, kidney, or liver-kidney transplantationandhad microbiologically confirmed pH1N1infectionin6months study period in a single centre. Comparator Arm: No                                                           | Triple maintenance immunosuppressiveregimens (TAC, CsA, 6- methylprednisolone, MMF and Eve). Dose, duration and formulation not reported.                                                                             | N=49; 25received MMF. Median age: 10 years (age range: 7-14 years).                                                                                                                                        | All49patientsdevelopedconfirmedpH1N1ofwhich pneumonia was diagnosed in 4 patients(8.2%), and 3 of themrequiredrespiratory support.However, the number of paediatric patients with LTx who were given MMF and furtherprogressed to these adverseeventsisunclear. Therewere norelateddeaths.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Gavaldaet al. 2012        | RationaleforClassificationofEvidence: Thisis a small samplesize(<50)retrospectivestudywith aprimary focus on H1N1/2009infection inpaediatricsolid organ transplant recipients.                                                                                                                                                                                                                     | RationaleforClassificationofEvidence: Thisis a small samplesize(<50)retrospectivestudywith aprimary focus on H1N1/2009infection inpaediatricsolid organ transplant recipients.                                        | RationaleforClassificationofEvidence: Thisis a small samplesize(<50)retrospectivestudywith aprimary focus on H1N1/2009infection inpaediatricsolid organ transplant recipients.                             | RationaleforClassificationofEvidence: Thisis a small samplesize(<50)retrospectivestudywith aprimary focus on H1N1/2009infection inpaediatricsolid organ transplant recipients.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Haflidadottir et al. 2022 | Retrospective data collectionfrom medical records, including total and specific immunoglobulin E (lgE), eosinophil cationic protein, and eosinophil count(12months after transplantationandatyearly follow-up) to identify risk factorsfor development of food allergies in liver transplant children. Trough levels of MMF, and tacrolimus 3,6, and 12 months after transplantation wererecorded. | Dose and formulation not reported.Duration of MMF therapy varied from 0.2 monthstomorethan2years. Median follow-up time was 7.6 years (2.5-13.6 years).                                                               | N=107; 85 on MMF Age at Tx= 1.9 years (8.4 months- 8.3 years) Male:female=54:53                                                                                                                            | Altogether85patientsweretreatedwithMMFafter transplantation,and7of thosepatientsreceivedMMF temporarily before MMF was part of the protocol. MMF had tobediscontinued in24outof78patients(31%)due to side effects, such as neutropenia (n=20), gastrointestinal symptoms (n=3), and herpetic stomatitis (n=1). Age at discontinuation of MMF was 1.5 (0.9-8.6) years, and the timefromtransplantationtodiscontinuationof MMFwas 0.4 (0.2-0.5) years.Only 7 out of 24 patients with food allergyhadbeentreatedwithMMF 1year after transplantation.Food allergy was less frequent in the childrenwhoreceivedMMFincombinationwithtacrolimus 1 year after transplantationcompared topatientsnot receiving MMF (12.5% vs 37.8%, P=0.003). The patients treated with MMF at 1year after transplantation alsohad lessfoodsensitisation1yearaftertransplantation(8.9%vs 17.8%,P=0.02) and at any time (26.8% vs 57.8%, P =0.002) compared to those not receiving MMF. |
| Haflidadottir et al. 2022 | RationaleforClassificationofEvidence: This is a mediumsamplesizeretrospectivedata analysisof medical recordswithaprimaryfocus onriskfactorsfor development of food allergies in liver transplant children.                                                                                                                                                                                         | RationaleforClassificationofEvidence: This is a mediumsamplesizeretrospectivedata analysisof medical recordswithaprimaryfocus onriskfactorsfor development of food allergies in liver transplant children.            | RationaleforClassificationofEvidence: This is a mediumsamplesizeretrospectivedata analysisof medical recordswithaprimaryfocus onriskfactorsfor development of food allergies in liver transplant children. | RationaleforClassificationofEvidence: This is a mediumsamplesizeretrospectivedata analysisof medical recordswithaprimaryfocus onriskfactorsfor development of food allergies in liver transplant children.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

| Study/Reference     | Study Design                                                                                                                                                                                                                                                                    | Dosing,Formulation,                                                                                                                                                                                                                                                | Demographics                                                                                                                                                                           | Key Findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Honda et al.2018    | To analyse thelong-term outcomesofpaediatric patients who underwent ABO-i living donor LTx and theimmunosuppressive toassesstheadequacyof protocol against theABO- barrierbetweenDecember 1998andMarch2016 (17 years, 3 months). Comparatorarm:Yes                              | Duration(WhereAvailable) MMF given 10 mg/kg b.i.d, orally. Group 1:ABO-in=29 TAC+Steroid+MMF In adjunction, paediatric LDLT (2≤age<18;n=10)received additionalrituximab. Group 2: Non-ABO-i n=131 TAC plus steroid.                                                | N=160; 29 received MMF. Group 1: n=29 patients (10 male, meanage:3year) Group 2: n=131 patients (58 male, mean age: 4.6 years).                                                        | For29patientsonMMFinGroup 1:10 (34.5%)developed bacterial infection,14(48.3%) developed CMV infection, 13 (44.8%) developed acute cellular rejection,3 (10.3%) developedbiliarycomplications,3developedportalvein infection,hepaticveinstenosisandhepaticarterystenosis stenosis/portal veinthrombosis(10.3%),2(6.9%) developedantibody-mediatedrejection,andfungal were reported in3 single patients(3.4%each).During the studyperiod,mortalityrate innon-rituximabtreatedABOi group was 15.8%,and inrituximab-treated ABOi group was 30.0%. The cause of death in the former group was heart failure(inrelated totheprimarydisease,glycogen storage disease type IV),pulmonary hypertension(in relatedtotheprimarydisease,mitochondrial DNA depletionsyndrome),and interstitialpneumonia.The causeofdeathin thelattergroupwasAMRin 2patients andtheotherwasmultipleorganfailurerelatedto complicationsof theprimary disease(progressivefamilial intrahepatic cholestasis type 1) including bleeding from the ileostomy, severe. |
|                     | RationaleforClassificationofEvidence: This is a small sample size retrospective data analysis of long-term outcomes of paediatric patients who underwent ABO-i living donor LTx and of                                                                                          | RationaleforClassificationofEvidence: This is a small sample size retrospective data analysis of long-term outcomes of paediatric patients who underwent ABO-i living donor LTx and of                                                                             | RationaleforClassificationofEvidence: This is a small sample size retrospective data analysis of long-term outcomes of paediatric patients who underwent ABO-i living donor LTx and of | RationaleforClassificationofEvidence: This is a small sample size retrospective data analysis of long-term outcomes of paediatric patients who underwent ABO-i living donor LTx and of                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Imaniehet al.2022   | This study aimed to determinetheprevalenceof post-transplant lymphoproliferativedisorder (PTLD)basedontheclinical andepidemiological characteristics of donors recipients aged<18 andpediatrictransplant                                                                        | MMF dosewas unclearly statedasameanvaluefrom anunspecifiednumberof patients on MMF. Theimmunosuppressivedrugs (prednisolone,tacrolimus, silorimus,CellCept)wereused for 14.79 ± 14.40 months from thetimeof transplantationuntil thedateofPTLDdiagnosis.           | N=1207 (unknown how many on MMF) Age at LTx: PTLD group: 4.93 ± 1.07 years Non-PTLD group: 7.80 ± 5.54 Female:maleratio = 51.49% in the PTLD group and 44.56% in the non- PTLD group   | Thecumulativesurvivalproportionwashigherinmalesas wellasinthepatientsagedundersixyearscomparedto females and thepatientsoversixyearsold.Of1207 patients(unknown howmany on MMF), 49 were diagnosedwithPTLD(4%prevalence).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|                     | RationaleforClassificationofEvidence: This is aretrospectivestudyfocused onpost-transplant lymphoproliferativedisorder inpaediatric LTx.                                                                                                                                        | RationaleforClassificationofEvidence: This is aretrospectivestudyfocused onpost-transplant lymphoproliferativedisorder inpaediatric LTx.                                                                                                                           | RationaleforClassificationofEvidence: This is aretrospectivestudyfocused onpost-transplant lymphoproliferativedisorder inpaediatric LTx.                                               | RationaleforClassificationofEvidence: This is aretrospectivestudyfocused onpost-transplant lymphoproliferativedisorder inpaediatric LTx.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Study/Reference     | Study Design                                                                                                                                                                                                                                                                    | Dosing,Formulation,                                                                                                                                                                                                                                                | Demographics                                                                                                                                                                           | KeyFindings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Leiskau etal.2018   | Patients after LTxreceiving immunosuppression with MMF+TACwerecompared toretrospectivelyselected age-anddiagnosis-matched patients with TAC monotherapy and CsA+steroid therapy. Effectiveness,renalfunction and side effects were analysedfor1yearafter LTx. Comparatorarm:Yes | Duration(WhereAvailable) Group 1: MMF+TAC; n=19 (MMF started 7 days post LTx; 10mg/kg in 2 dosesfor 2 weeksgraduallyincreasingto a maximumof20mg/kg/day (max.2x750 mg) in 2 doses); formulationnotreported. Group 2:TAC monotherapy; n=19. Group3:CsA+steroid;n=19 | N=57;19received MMF. Age<18 years. Gender not specified.                                                                                                                               | Twopatientsingroup1discontinuedMMFtreatmentfor2 and3weeks,respectively,duetogastrointestinal adverse eventsbutcouldrestartwithareduceddoseof10 mg/kg/day.Leukopeniaoccurredin3patientsduring comedicationwithganciclovir,butimprovedafter discontinuation of ganciclovir.Thepatients in MMF+TAC showedasignificantlyhigherriskofsepticaemicbacterial or mycotic infections(68.4%)howeverexact numberof patientswhoexperienced theseadverseeventsis unknown) compared to TAC (31.6%),but not the CsA group(57.6%).EBVreactivationoccurredmorefrequently in CsA patients(84.2%) than in MMF/TAC(47.4) and TAC patients(52.6%)thesamewastrueforotherviral infections:47.4% (CsA) vs.15.8% (TAC).                                                                                                                                                                                                                                                                                                                                     |
|                     | RationaleforClassificationof Evidence:                                                                                                                                                                                                                                          | RationaleforClassificationof Evidence:                                                                                                                                                                                                                             | RationaleforClassificationof Evidence:                                                                                                                                                 | RationaleforClassificationof Evidence:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Nayagam et al. 2022 | Single-centre,retrospective, observational studyto evaluateEBVstatusand EBV-relatedcomplications inpaediatric autoimmune liver disease (AILD)                                                                                                                                   | In LTxpatientsMMF(median duration) was 6years [IQR,4.0-12.9], dose 24.3 mg/kg/day [IQR,16.4-33.1]).                                                                                                                                                                | N=245 (AILD) of whom 150 (61.2%) werefemales and 69 were on MMF. Median age at MMF start = 13.7 years LTxn=39;19 of them on MMF. Male:female=14:25 ,MMF use status unknown             | Thisisasmallsamplesingle-centrecomparisonofMMFcontainingregimenwithahistoricCNlcomparatorarm. Post-LTxEBVviraemiadeveloped in14of 19 LTx recipients on MMF (73.7%), median time to viraemia was 53days(IQR,20-53).Therewasnoassociationbetween pre-transplant MMF(P>0.99)on developmentof EBV viraemiapost-LTxorcharacteristicsofpost-LTxviraemia. NoPTLD was identified in the MMF group, compared to twoPTLDpatients onAZA.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|                     | RationaleforClassificationof Evidence: Asingle-centreobservational studyfocusedonEBVstatus andcomplicationsinpaediatricAILDpatientswithasmallsubpopulationofAILDliver                                                                                                           | RationaleforClassificationof Evidence: Asingle-centreobservational studyfocusedonEBVstatus andcomplicationsinpaediatricAILDpatientswithasmallsubpopulationofAILDliver                                                                                              | RationaleforClassificationof Evidence: Asingle-centreobservational studyfocusedonEBVstatus andcomplicationsinpaediatricAILDpatientswithasmallsubpopulationofAILDliver                  | RationaleforClassificationof Evidence: Asingle-centreobservational studyfocusedonEBVstatus andcomplicationsinpaediatricAILDpatientswithasmallsubpopulationofAILDliver                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Ozturk et al.2019   | transplantrecipientsonMMF Retrospective study to determinepotentialadverse effectsof immunosuppressive protocols after LTx in childrenbetweenFebruary 2006andJanuary2018(11 years, 11 months). ComparatorArm:No                                                                 | Corticosteroid,TAC,and MMF were theprimary immunosuppressive agents. MMF was started preoperatively at 20 mg/kg/day; formulation not reported andwas continued for 1 year                                                                                          | N=60;allreceived MMF. Age: 6.1 years (range: 3 months to 17 years) Males:females=34: 26.                                                                                               | Diarrhoeawastheadverseeventreportedasassociated withMMF(numberof casesunknown).Inaddition,9out of60patientshadunusual adverseevents,including3 patientswith haemolysiswhile on MMF and TAC.A positive dechallenge reported with TAC only with corrective treatment.Twopatientshadeosinophilic gastroenteritis, one of which treated with TAC alone, and theotherwithTACandMMF;theeventresolvedinboth cases aftercorrective treatmentanddrugwithdrawalof TAC.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| Study/Reference                                                                                                                                                                                  | Study Design                                                                                                                                                                                                                                                                                                                                                                   | Dosing, Formulation, Duration(Where Available)                                                                                                                                                                                                                                                            | Demographics                                                                                                                                                                                                            | Key Findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                  | RationaleforClassificationofEvidence: Medium-size (50-100) retrospective study to determine potential adverse effects of immunosuppressive protocols after LTx in children.                                                                                                                                                                                                    | RationaleforClassificationofEvidence: Medium-size (50-100) retrospective study to determine potential adverse effects of immunosuppressive protocols after LTx in children.                                                                                                                               | RationaleforClassificationofEvidence: Medium-size (50-100) retrospective study to determine potential adverse effects of immunosuppressive protocols after LTx in children.                                             | RationaleforClassificationofEvidence: Medium-size (50-100) retrospective study to determine potential adverse effects of immunosuppressive protocols after LTx in children.                                                                                                                                                                                                                                                                                                                                                                                                        |
| Renzetal.1999                                                                                                                                                                                    | Retrospective study to compare post-Tx renal function, incidence of leukopenia, and drug microemulsion-CsA, and tolerance in MMF, steroid group (CNp group), encapsulated CsA, and with AZA, oil-based gel- steroid with anti-T cell antibody induction therapy group (ACp group). Follow-up median (range, months)are CNp: 21 (12- 28) and ACp: 41(29-50). Comparator arm:Yes | CNp group: n=26. ACp group: n=19. MMF dose: initially at 10 to 12.5 mg/kg/dose (orally b.i.d.), gastrointestinal symptoms and leukopenia withadjustmentstoavert                                                                                                                                           | N=45; 26 received MMF. Age:1 month to 16 years (mean: 58 months; median: 31 Males:females=17: 9. months).                                                                                                               | Nosignificantdifferencewasobservedbetweenthetwo groups in serum creatinine level or incidence of leukopenia requiring medical therapy during the first year post-Tx. GastrointestinalsymptomsobservedinCNppaediatricLTx an overallincidence of approximately 30%.Management routinely achieved along with the administration of oral gastric proton pump inhibitors. Only 1 patient (4%) recipientsincluded nausea,vomiting,and diarrhoea,with ofclinicalsymptomsbysimpleMMFdosereductionwas converted toTAC-based immunotherapy secondary to gastrointestinal intolerance of CNp. |
| Renzetal.1999                                                                                                                                                                                    | RationaleforClassificationofEvidence: Thisis aretrospective,small size(<50) single-centre study to describe the application of an immunosuppressive protocol using MMF,CsA,and prednisone as primary immunosuppression.                                                                                                                                                        | RationaleforClassificationofEvidence: Thisis aretrospective,small size(<50) single-centre study to describe the application of an immunosuppressive protocol using MMF,CsA,and prednisone as primary immunosuppression.                                                                                   | RationaleforClassificationofEvidence: Thisis aretrospective,small size(<50) single-centre study to describe the application of an immunosuppressive protocol using MMF,CsA,and prednisone as primary immunosuppression. | RationaleforClassificationofEvidence: Thisis aretrospective,small size(<50) single-centre study to describe the application of an immunosuppressive protocol using MMF,CsA,and prednisone as primary immunosuppression.                                                                                                                                                                                                                                                                                                                                                            |
| Seoet al.2020                                                                                                                                                                                    | Retrospective study to evaluatepaediatricLTx recipients for EBV load in relation to diagnosis PTLD at least 6monthsof follow- up). Comparator arm: No                                                                                                                                                                                                                          | Immunosupressive therapy with TAC, steroids and MMF was given. Dosage, formulation and duration of treatment not reported.                                                                                                                                                                                | N=142; number of paediatric patients on MMF unknown. Median age: 1.5 years (range: 0.8-6.1). Males:females=68: 74.                                                                                                      | Of the total 142 patients (unknown how many on MMF) 100developedEBVDNAemia;ofwhom14/100developed PTLD. Two patients (2/14, 14.3%) died at 38 months and 16months afterdiagnosiswithPTLD;thecausesofdeath werehepaticfailure and acuterespiratorydistress syndrome associated with Pneumocystis jiroveci pneumonia, respectively.                                                                                                                                                                                                                                                   |
| Seoet al.2020                                                                                                                                                                                    | RationaleforClassificationofEvidence: Thisis aretrospective,single-centrestudytomonitorEpstein-Barrviral loadfordiagnosingposttransplant lymphoproliferativedisorderinpediatric liver transplant recipients.                                                                                                                                                                   | RationaleforClassificationofEvidence: Thisis aretrospective,single-centrestudytomonitorEpstein-Barrviral loadfordiagnosingposttransplant lymphoproliferativedisorderinpediatric liver transplant recipients.                                                                                              | RationaleforClassificationofEvidence: Thisis aretrospective,single-centrestudytomonitorEpstein-Barrviral loadfordiagnosingposttransplant lymphoproliferativedisorderinpediatric liver transplant recipients.            | RationaleforClassificationofEvidence: Thisis aretrospective,single-centrestudytomonitorEpstein-Barrviral loadfordiagnosingposttransplant lymphoproliferativedisorderinpediatric liver transplant recipients.                                                                                                                                                                                                                                                                                                                                                                       |
| Study/Reference                                                                                                                                                                                  | StudyDesign                                                                                                                                                                                                                                                                                                                                                                    | Dosing,Formulation,                                                                                                                                                                                                                                                                                       | Demographics                                                                                                                                                                                                            | Key Findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Tannuriet al.2007                                                                                                                                                                                | Retrospective Study to evaluate renal function in patients who underwent orthotopic LTx between 1988 and 2003(15 years). Comparator Arm: No                                                                                                                                                                                                                                    | Duration(Where Available) Renal function was evaluated bybiochemicalparametersin five phases: immediately prior to MMF administration; 3, 6, 12 and 24 months after the introductionofMMF. MMF 10 mg/kg (b.i.d.) and increasedgraduallyto40 mg/kg/day within a two-week interval;formulationnot reported. | N=191; allreceived MMF. Age<18 years. Gender not specified.                                                                                                                                                             | 82% showed improvement of renal function parameters in comparisonwiththepretreatmentvaluespriortoMMF                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Tannuriet al.2007                                                                                                                                                                                | Rationale for Classification of Evidence: renal function.                                                                                                                                                                                                                                                                                                                      | Rationale for Classification of Evidence: renal function.                                                                                                                                                                                                                                                 | Rationale for Classification of Evidence: renal function.                                                                                                                                                               | Rationale for Classification of Evidence: renal function.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Vazinetal.2022                                                                                                                                                                                   | Retrospectivecohort study to examine the incidence, clinico-microbiological characteristics,risk factors, andtreatmentoutcomesof bacterial infections in liver transplant pediatric patients under 18years of following livertransplantation                                                                                                                                   | Dosing and formulation not available.Themeantime of infection after LTx was 7.87 ± 3.32 days.                                                                                                                                                                                                             | N=80; 69 on MMF Age 6.0 ± 4.0 years (median 5.0 years) Male:female=52:28                                                                                                                                                | Of the69patientsonMMF24patientsexperienced bacterial infection.Multivariateregression analysisshowed thattheonlyriskfactorforbacterialinfectionsafter LTx was thelength of ICU stay.The mean time of infection afterLT was7.87±3.32days.Intra-abdominal surgical site infection (24.24%), co-infection (19.69%), urinary tract infection(19.69%),and bloodstreaminfection(19.69%) werethemostcommonrecordedinfections.Unknown whichadverseeventswerereportedonMMF.                                                                                                                 |
| Vazinetal.2022                                                                                                                                                                                   | RationaleforClassificationofEvidence:                                                                                                                                                                                                                                                                                                                                          | RationaleforClassificationofEvidence:                                                                                                                                                                                                                                                                     | RationaleforClassificationofEvidence:                                                                                                                                                                                   | RationaleforClassificationofEvidence:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| This is a retrospective, medium sample (50-100) single-centre study to evaluate bacterial infections in liver transplant paediatric patients. Conference abstract (limited information provided) | This is a retrospective, medium sample (50-100) single-centre study to evaluate bacterial infections in liver transplant paediatric patients. Conference abstract (limited information provided)                                                                                                                                                                               | This is a retrospective, medium sample (50-100) single-centre study to evaluate bacterial infections in liver transplant paediatric patients. Conference abstract (limited information provided)                                                                                                          | This is a retrospective, medium sample (50-100) single-centre study to evaluate bacterial infections in liver transplant paediatric patients. Conference abstract (limited information provided)                        | This is a retrospective, medium sample (50-100) single-centre study to evaluate bacterial infections in liver transplant paediatric patients. Conference abstract (limited information provided)                                                                                                                                                                                                                                                                                                                                                                                   |
| Balci Sezeret al. 2020                                                                                                                                                                           | Retrospective study to evaluateinfectionasthe majorcause of morbidity and mortality after paediatric LTx who have received immunosuppressant. MMF as an Duration of study was not specified. Comparator arm: No                                                                                                                                                                | 34patientsreceivedstandard immunosuppressiveregimen after LTx consisting of TAC, MMFandsteroids. Dose,formulation and duration not reported.                                                                                                                                                              | N=34; all received MMF. Age:4-12 months (median: 8). specified. Gender not                                                                                                                                              | 27outof 34patientsreportedpresenceof at leastone pathogenic organism withinfirst sixmonths of Tx. Klebsiellapneumoniawasthemostcommonisolated bacteriafrombloodstreamandabdominalcathetersand cultures. Only one recipient had CMV infection during this urinecultures.Staphylococcusepidermidiswasthemost commonisolatedbacteriafromsubclaviancatheter period. No information is provided regarding the frequency andseverityoftheseevents.                                                                                                                                       |
| Balci Sezeret al. 2020                                                                                                                                                                           | RationaleforClassificationofEvidence: Thisis a retrospective,small sample (<50) study with a primary focus onpost-liver transplant infections.                                                                                                                                                                                                                                 | RationaleforClassificationofEvidence: Thisis a retrospective,small sample (<50) study with a primary focus onpost-liver transplant infections.                                                                                                                                                            | RationaleforClassificationofEvidence: Thisis a retrospective,small sample (<50) study with a primary focus onpost-liver transplant infections.                                                                          | RationaleforClassificationofEvidence: Thisis a retrospective,small sample (<50) study with a primary focus onpost-liver transplant infections.                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| Study/Reference          | Study Design                                                                                                                                                                                                                                                                                                                                                                                                                              | Dosing,Formulation, Duration(Where Available)                                                                                                                                                                                                 | Demographics                                                                                                            | Key Findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|--------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Hudertetal.2019          | Retrospective analysis to assess the clinical course of 10paediatricpatientsafter LTx who switched from a TAC based immunosuppression protocol to MMF monotherapy. Cumulative period of480 patient treatment-months (median: 37.5 months, range: 11-103).                                                                                                                                                                                 | AllpatientsreceivedMMF (dose and formulation not reported).                                                                                                                                                                                   | N=10;all received MMF. Mean age: 14.5 years(range: 3-19). Gender not specified.                                         | AfterswitchingtoMMF,fivebiopsiesinfourpatientswere performed due to abnormal liver function tests,but no acuteorchronictransplantrejectionwasnoted.Diarrhoea associatedwithMMFoccurredinonepatientbutceased upon dose reduction.There were no persistent haematologic pathologies attributable to MMF.                                                                                                                                                                                                                                                                                                                                       |
|                          | Rationalefor Classification of Evidence:                                                                                                                                                                                                                                                                                                                                                                                                  | Rationalefor Classification of Evidence:                                                                                                                                                                                                      | Rationalefor Classification of Evidence:                                                                                | Rationalefor Classification of Evidence:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Lightdale et al. 1997    | Prospective,non- randomised studyto analyse safety and effectiveness of MMF, CsA and steroid vs. AZA,CsA and steroid from December1993toOctober 1996 (2 years, 10 months). Comparatorarm:Yes.                                                                                                                                                                                                                                             | Group 1: MMF+CsA+steroid: n=20. MMF: 20-25 mg/kg b.i.d; formulation not reported. Group2:AZA+CsA+steroid: n=20.                                                                                                                               | N=40; 20 received MMF. Median age: 17 months. Gender not specified.                                                     | 9 patients (45%) in Group 1 (including MMF) and 13 patients(65%) in Group 2(control group)experienced bonemarrowsuppression.Therewasno difference betweenGroup1and Group2inchange inserum survival rate vs.95% in Group 2. creatinine at 6 months.At Year 1, Group 1had a 100%                                                                                                                                                                                                                                                                                                                                                               |
|                          | RationaleforClassificationofEvidence:                                                                                                                                                                                                                                                                                                                                                                                                     | RationaleforClassificationofEvidence:                                                                                                                                                                                                         | RationaleforClassificationofEvidence:                                                                                   | RationaleforClassificationofEvidence:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Rauschenfels et al. 2009 | In this prospective study, children after orthotopic LTx under therapy with MMF and CsA were compared with those under immunosuppression therapy with CNI. The median time was 4.7 (range: 1.1-15.6) years after orthotopic LTx, under a combined immunosuppressive therapy of MMF and CsA when compared with development of renal function in a historic control group with median time 5.1 (range: 1.0-10.7) years after orthotopic LTx | Group 1: MMF+CsA; n=25 Group 2: CNIs; n=51 (36 CsA,15 TAC) Dosage and formulation of MMF not reported.                                                                                                                                        | N=76; 25 received MMF. Age: 2-16.5 years. Group 1: male:female=14:11. Group 2: male:female=28:23. Gender not specified. | TheGFRincreasedfrom60mL/minto77mL/minat24 monthsinGroup 1,and the GFRshowed a decrease of Group 2.MMF dosage had tobereduced due to 11%from67±23mL/min to59±22mL/min at 24monthsin gastrointestinal side effects in 2 patients. In 1 patient in Group1acuterejectionoccurredafterrefusalof medication, whereas in Group 2 norejection was reported. Liver function tests and full blood cell counts in both groups showed no significant changes Introduction of MMFcombined withreduced CsA dosage leadstobetterimprovementofrenalfunctionofliver- transplanted recipients than group 2. Side effects under a close MMFmonitoring wererare. |
| Study/ Reference         | Study Design                                                                                                                                                                                                                                                                                                                                                                                                                              | Dosing,Formulation, Duration(WhereAvailable)                                                                                                                                                                                                  | Demographics                                                                                                            | Key Findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|                          | under immunosuppression therapy with CNI. Comparator arm: Yes                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                               |                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|                          | Rationalefor Classification of Evidence: Thisisaprospective,small sample(<50)studytocomparetwotreatmentregimens                                                                                                                                                                                                                                                                                                                           | Rationalefor Classification of Evidence: Thisisaprospective,small sample(<50)studytocomparetwotreatmentregimens                                                                                                                               | Rationalefor Classification of Evidence: Thisisaprospective,small sample(<50)studytocomparetwotreatmentregimens         | Rationalefor Classification of Evidence: Thisisaprospective,small sample(<50)studytocomparetwotreatmentregimens                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Sadiq et al.2013         | Evaluate incidence of MMF- induced diarrhoea in paediatric LTx patients & formulate uniform policy about timing of introduction of MMF& suitable dose.In this two-phase study, the first phase,records of children whohad LTxinlast 1 year were reviewed.All patients who had LTx in next 6 months were included in secondphase. Compactor arm: Yes (Two phase study)                                                                     | Phase 1:retrospective analysis with conventional dose of MMF.(n=36)(dose and formulation not reported) Phase 2:Prospective study where,based on group1 results, MMF dose was reduced(n=17).However exactdose afterreduction was not reported. | N=53, all 53 received MMF. Age and gender not specified.                                                                | Phase 1: 25 (70 %) patients developed diarrhoea.Out of these 22patients,(85.7%)had moderate to severe diarrhoea. Phase2:12(75%)patientsdeveloped diarrhoeabutonly 5(41.6%)patientshadmoderatetoseverediarrhoea. Noinformationwasavailableregardingwhetherthedose of MMFwasreduced inresponse todiarrhoea.                                                                                                                                                                                                                                                                                                                                    |
|                          | RationaleforClassificationofEvidence:                                                                                                                                                                                                                                                                                                                                                                                                     | RationaleforClassificationofEvidence:                                                                                                                                                                                                         | RationaleforClassificationofEvidence:                                                                                   | RationaleforClassificationofEvidence:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Teisseyre et al. 2006    | Thisstudy compared the efficacy and safety of steroid freeimmunosuppression based on TAC and MMF with TAC and steroids. Duration of study was not specified. Comparator arm:Yes                                                                                                                                                                                                                                                           | Group 1:TAC+MMF (dose and formulation not reported); n=19. Group 2: TAC+steroids; n=20.                                                                                                                                                       | N=39; 19 received MMF. Age<18 years. Gender not specified.                                                              | Two-phase(a small sample size (<50) prospective and a small sample size(<50)retrospective study)with a focus of MMF-induced diarrhoea. Group1showed fewer eventsof EBVDNAcopies,CMV infection and acute hepatitis than group 2.                                                                                                                                                                                                                                                                                                                                                                                                              |
|                          | Rationalefor Classification of Evidence: on TAC and MMF withTAC and steroids                                                                                                                                                                                                                                                                                                                                                              | Rationalefor Classification of Evidence: on TAC and MMF withTAC and steroids                                                                                                                                                                  | Rationalefor Classification of Evidence: on TAC and MMF withTAC and steroids                                            | Rationalefor Classification of Evidence: on TAC and MMF withTAC and steroids                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

| Study/Reference       | StudyDesign                                                                                                                                                                                                                                                                                                                                                                                                                  | Dosing,Formulation, Duration(WhereAvailable)                                                                                                                                                                           | Demographics                                                                                                                                                                                                | Key Findings                                                                                                                                                                                                                                                                                                                       |
|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Teisseyre et al. 2011 | Prospective,comparator study to analyse two methods of TAC-based immunosuppression with or study was not specified. without MMF.Duration of Comparator Arm:Yes                                                                                                                                                                                                                                                               | GroupA:TAC+MMF(dose and formulation not reported): n=22. Group B:TAC+steroids:n=22. MMF was administered from 0-90thday,andthenreduced anddiscontinuedfinally4 months after LTx.                                       | N=44; 22 received MMF. Age range: 5.8 weeks-18.1years. specified. Gender not                                                                                                                                | Group A(including MMF) showed reduced need for anti- hypertensive treatment in the early post-Tx period and 1- and 2-year post-Tx. Lower incidencesof EBVinfection was observed ingroup Morepatientsfrom groupAshowed normal liver histology Aat 1,2 and 3years afterLTx. 1 year post-LTx, and the difference was not significant. |
| Teisseyre et al. 2011 | Rationalefor Classificationof Evidence: This is a small sample size (<50) single-centre retrospective analysis evaluating the potential for MMF to enable CNl reduction and recovery of renal function.                                                                                                                                                                                                                      | Rationalefor Classificationof Evidence: This is a small sample size (<50) single-centre retrospective analysis evaluating the potential for MMF to enable CNl reduction and recovery of renal function.                | Rationalefor Classificationof Evidence: This is a small sample size (<50) single-centre retrospective analysis evaluating the potential for MMF to enable CNl reduction and recovery of renal function.     | Rationalefor Classificationof Evidence: This is a small sample size (<50) single-centre retrospective analysis evaluating the potential for MMF to enable CNl reduction and recovery of renal function.                                                                                                                            |
| Weineret al.2012      | Retrospectivechartreview of paediatric LTx recipients for primary infection with EBVand PTLD.Duration of study was not specified. Comparator arm: No                                                                                                                                                                                                                                                                         | Inductionwithdaclizumab (anti- IL-2 receptor antibody), steroids and MMF (15 mg/kg, b.i.d)with delayed initiation of TAC and maintenance steroids(mostly 6months) followed byTACmonotherapy. MMFformulationnotreported | N=187;allreceived MMF. Age: 1 month-20 years (the study includes young adults between 18 and 20 years). Gender not specified.                                                                               | EBVoccurredin46patients(25%)andPTLDoccurredin 16 (8.7%) patients. Therewasnoincreasedriskofgraftrejectionforgender, age at or indication for LTx, graft type, pre- LTx EBV and antiviral treatment.                                                                                                                                |
| Weineret al.2012      | RationaleforClassificationofEvidence: This is a large sample size (>100) retrospective chart review with a focus on primary infection with EBV and PTLD                                                                                                                                                                                                                                                                      | RationaleforClassificationofEvidence: This is a large sample size (>100) retrospective chart review with a focus on primary infection with EBV and PTLD                                                                | RationaleforClassificationofEvidence: This is a large sample size (>100) retrospective chart review with a focus on primary infection with EBV and PTLD                                                     | RationaleforClassificationofEvidence: This is a large sample size (>100) retrospective chart review with a focus on primary infection with EBV and PTLD                                                                                                                                                                            |
| Study/Reference       | Study Design                                                                                                                                                                                                                                                                                                                                                                                                                 | Dosing,Formulation, Duration(WhereAvailable)                                                                                                                                                                           | Demographics                                                                                                                                                                                                | Key Findings                                                                                                                                                                                                                                                                                                                       |
| Wierderkehret al.2012 | Prospective study to observe the frequency of the diarrhoea inMMF-treated LTx paediatric recipients andtocomparethiswith adults LTx recipients. LTx recipients with persistent afebrilediarrhoea were prospectively investigated for infections and intestinal morphology integrity of the gastrointestinal tract and the results werecompared with adults LTxrecipients. Durationofstudywasnot specified. Comparatorarm:Yes | All patients received MMF (dose and formulation not reported).Dosing and concomitant medications not specified.                                                                                                        | N=89; all received MMF. Mean age: 45 months. Males:females=34: 55.                                                                                                                                          | 4of89developedpermanentdiarrhoeaassociatedwith lossofweight and doseof MMFwasreduced (unspecified). Symptoms appeared 6 months after LTx in 2%4patients.All fourchildrenhaderosivecolitisandonehad aninfectionassociated.SubstitutionofMMFhadgood resultswithout increasedriskforrejection                                         |
| Wierderkehret al.2012 | RationaleforClassificationofEvidence: A medium samplesize(50-100)prospective study toobserve the frequency of the diarrhoea inMMF-treated LTxpaediatricrecipients and to comparetheresultswithadultpatients                                                                                                                                                                                                                  | RationaleforClassificationofEvidence: A medium samplesize(50-100)prospective study toobserve the frequency of the diarrhoea inMMF-treated LTxpaediatricrecipients and to comparetheresultswithadultpatients            | RationaleforClassificationofEvidence: A medium samplesize(50-100)prospective study toobserve the frequency of the diarrhoea inMMF-treated LTxpaediatricrecipients and to comparetheresultswithadultpatients | RationaleforClassificationofEvidence: A medium samplesize(50-100)prospective study toobserve the frequency of the diarrhoea inMMF-treated LTxpaediatricrecipients and to comparetheresultswithadultpatients                                                                                                                        |

## Heart Transplant Recipients

One infant-focused study (Singh et al. 2022) was identified in specific populations (e.g., newborns, toddlers, teenagers, etc), in which also female sex was reported as a gender-specific risk factor associated with higher 5-year mortality, conditional upon surviving the first post-transplant year.

The AEs commonly reported in the literature from HTx paediatric patients treated with MMF are infections, gastrointestinal disorders, and blood dyscrasias.

PTLD (post-transplant lymphoproliferative disorder) was reported as SAE in 4 of the 17 publications concerning HTx paediatric patients. In general, the incidence of PTLD in paediatric patients is higher than that in adults due to the higher incidence of pre-transplant negative EBV-serostatus among children who receive an EBV-seropositive organ (Nijland et al. 2016). This is reflected in the Special Warnings and Precautions for Use part of the currently approved CellCept SmPC Section 4.4, which states 'Patients receiving immunosuppressive regimens involving combinations of medicinal products, including mycophenolate mofetil CellCept, are at increased risk of developing lymphomas and other malignancies, particularly of the skin (see section 4.8). The risk appears to be related to the intensity and duration of immunosuppression rather than to the use of any specific agent.'

CAV (cardiac allograft vasculopathy) is another common serious complication occurring after HTx and is a major cause of graft loss and death. The frequency of occurrence increases, from approximately 30% of patients at 5 years after HTx, to 50% of patients at 10 years after HTx.

<div style=\"page-break-after: always\"></div>

## Liver Transplant Recipients

One study that aimed to determine the prevalence of PTLD (Imanieh et al. 2022) reported that the cumulative survival proportion was higher in males as well as in the patients aged under six years compared to females and the patients over six years old.

Based on the available literature, the AEs commonly reported in paediatric LTx patients treated with MMF were infections, gastrointestinal disorders and blood dyscrasias such as leukopenia and anaemia. These are all identified risks associated with MMF.

As for HTx, post-operative complications are a leading cause of mortality in paediatric LTx patients. Colombani et al (2000) reviewed the complications of transplant surgery, immunosuppression, rejection, and overall survival-rate in 30 paediatric patients aged 3 months to 7 years receiving orthotopic LTx between 1992 and 1998. All patients received MMF at a dose of 600 mg/m2 b.i.d. The authors reported 4 early deaths (13%), 1 from primary non-function, 2 from sepsis, and 1 from renal failure, arrhythmia and cardiac arrest.

Five of the 26 publications concerning paediatric LTx patients reported PTLD.

## Analysis of Individual Case Safety Reports in the Roche Global Safety Database

An analysis of cumulative data from the international birth date of MMF (i.e., 3 May 1995) up to 31 December 2022 was conducted for AE reports concerning adult and paediatric patients with renal, liver or heart transplant. Limited aggregate data are available with respect to the extent of MMF exposure, including data on doses received, dose intensity, etc.

The resulting aggregate data were analysed in terms of proportion of AEs. The analysis aimed to compare the proportions of AEs reported in paediatric HTx or LTx patients with the proportions of AEs reported in adult HTx or LTx patients, respectively. For paediatric patients, the proportions of AEs reported in patients with HTx or LTx (i.e., off-label use) were also compared with the proportion of AEs reported in patients with RTx (i.e., on-label use).

The estimated cumulative patient exposure to MMF in Company-sponsored interventional clinical trials where MMF was used as an investigational drug in any investigated indication is 16,226 patients, of which 451 patients were &lt; 18 years old. Of these, a certain number of patients have received MMF for already approved indications (e.g., RTx), or were exposed to MMF within an immunosuppressive protocol or as background therapy, so were not within the scope of this submission. The only study providing specific safety data relevant for inclusion in this submission was Study PA16497 (discussed above).

As of 2 May 2022, since the international birth date (3 May 1995), the estimated cumulative postmarketing patient exposure to MMF in any indication (i.e., both on-label and off-label) was 8.86 million patient-years. No specific data are available for post-marketing exposure to MMF in paediatric patients.

<div style=\"page-break-after: always\"></div>

Table 35 Distribution of Individual Case Safety reports and Adverse Events Reported in Paediatric versus Non-Paediatric Age Group

| Reports          | Paediatric Age Group   | Non-Paediatric Age Group   |
|------------------|------------------------|----------------------------|
| Renal Transplant | Renal Transplant       | Renal Transplant           |
| ICSRS            | 464                    | 10.359                     |
| AEs              | 1.477                  | 21.596                     |
| Heart Transplant | Heart Transplant       | Heart Transplant           |
| ICSRS            | 74                     | 961                        |
| AEs              | 245                    | 2.556                      |
| Liver Transplant | Liver Transplant       | Liver Transplant           |
| ICSRs            | 114                    | 2.267                      |
| AEs              | 287                    | 4.825                      |

AE = adverse event; ICSR = Individual Case Safety Report.

## Paediatric versus Non-Paediatric HTx Patients

Figure 5 Proportion of All AEs by SOC in Paediatric versus Non-Paediatric Patients with Heart Transplant

<!-- image -->

An evaluation of the SAEs reported in paediatric versus non-paediatric HTx patients confirmed the imbalances for the SOCs Neoplasms Benign, Malignant and Unspecified (15.2% vs. 5.9%), Gastrointestinal Disorders (12.9% vs. 8.3%), and Blood and Lymphatic System Disorders (11.7% vs. 7.2%). Whereas the predominant SAEs were driven by well-described adverse drug reactions (ADRs) of MMF (e.g., PTLD and gastric ulcer), and the limitations of post-marketing reports preclude an accurate assessment of frequency, it is possible that even minor gastrointestinal events such as vomiting or diarrhoea may lead to greater seriousness and/or severity in infants and children, for example due to dehydration or other complications.

<div style=\"page-break-after: always\"></div>

## Paediatric versus Non-Paediatric LTx Patients

Figure 6 Proportion of All AEs by SOC in Paediatric versus Non-Paediatric Patients with Liver Transplant

<!-- image -->

A markedly higher proportion (i.e., ≥ 3%) of AEs in paediatric patients was observed for the SOCs Gastrointestinal disorders (16.0% vs. 10.2%) and Investigations (11.5% vs. 6.7%). The imbalance under GI SOC was driven by adverse drug reactions such as diarrhoea, vomiting, and abdominal pain.

A markedly higher proportion (i.e., ≥ 3%) of SAEs in paediatric patients was mainly observed for the SOCs Gastrointestinal disorders (16.8% vs. 9.5%), and Surgical and medical procedures (3.5% vs. 0.5%). The vast majority of the SAEs reported in the SOCs Gastrointestinal disorders (e.g., diarrhoea, vomiting, duodenal ulcer, GI haemorrhages, pancreatitis) are adverse drug reactions associated with MMF and are described in the SmPC, which warns prescribers about these risks. Nevertheless, it is possible that even minor gastrointestinal events such as vomiting or diarrhoea may lead to greater seriousness and/or severity in infants and children, for example due to dehydration or other complications.

## Paediatric HTx and LTx versus Paediatric RTx

<div style=\"page-break-after: always\"></div>

Figure 7 Proportion of All AEs by SOC in Paediatric HTx and LTx Patients vs Paediatric RTx

<!-- image -->

AE=adverse event;HTx=heart transplant;LTx=liver transplant;SoC=system organ class;

RTx=renal transplant.

x-axis indicatesname ofSoCs y-axisindicatesproportionofAEs(%)

For HTx, a higher proportion of AEs was reported for the SOCs Neoplasm Benign, Malignant and Unspecified (10.6% vs. 1.6% in paediatric RTx), Blood and Lymphatic System Disorders (8.6% vs. 4.5% in paediatric RTx), and Skin and Subcutaneous Tissue Disorders (5.3% vs. 2.2% in paediatric RTx). The imbalance observed between the AEs reported under these SOCs across paediatric patients receiving HTx versus RTx might be explained by the very small number of reports from HTx (n=74) and RTx (n=464) recipients. In the SOC Neoplasms Benign, Malignant and Unspecified an additional explanation might be related to the higher level of immunosuppression usually achieved in HTx patients. This is supported by Mynarek et al. (2013), who reported an incidence of PTLD between 1%-10% in RTx; 4%-15% in LTx, and 6%-20% in lung, heart, and heart-lung transplants. The nature and frequency of the reported SAEs from SOCs Neoplasm benign, malignant and unspecified, Blood and Lymphatic System Disorders and Skin and Subcutaneous Tissue Disorders did not raise new safety concerns.

In paediatric patients with LTx a higher proportion of AEs when compared to paediatric patients with RTx was mainly seen for the SOCs Hepatobiliary Disorders (4.5% vs. 0.4%) and Injury, Poisoning and Procedural Complications (8.7% vs. 6.0%). A review of the AEs reported under the SOC Hepatobiliary Disorders showed events expected in LTx patients, which constituted either post-operative complications of LTx with unlikely association to MMF or were the result of LTx rejection. Most of the reports received under SOC Injury, Poisoning and Procedural Complications represent medication errors which could be related to the lack of guidance provided to the prescriber for paediatric LTx, as this indication is off-label worldwide (with the recent exception of the US and Pakistan). The nature and frequency of the reported SAEs from SOC Hepatobiliary Disorders and SOC Injury, Poisoning and Procedural complications in LTx patients did not raise new safety concerns.

<div style=\"page-break-after: always\"></div>

## Studies performed in Renal Transplant Paediatric Patients

Study MYC2190 was an open-label, dose ranging, pharmacokinetic, safety and tolerance study of oral mycophenolate mofetil in the prevention of rejection in paediatric renal allograf recipients. 33 paediatric renal transplant patients were recruited, aged 3 years to 18 years, who were given 23 mg/kg of mycophenolate mofetil orally, twice daily. Overall, the safety profile in these 33 children and adolescents was similar to that observed in adult recipients of solid organ allografts.

Study MYCS2675 was an open-label, safety, tolerance, and pharmacokinetic study of oral mycophenolate mofetil suspension in the prophylaxis of rejection in paediatric renal allograft recipients. 100 paediatric renal transplant patients aged 1 to 18 years were recruited. The type and frequency of adverse reactions in patients who were given 600 mg/m2, up to 1 g/m2 of mycophenolate mofetil orally, twice daily, were comparable to those observed in adult patients given 1 g mycophenolate mofetil twice daily. A summary of the more frequently occurring adverse reactions is shown in Table 36 below:

Table 36 Summary of adverse reactions observed more frequently in a trial investigating mycophenolate mofetil in 100 paediatric renal transplant patients (age/surface area-based dosing [600 mg/m 2 , up to 1 g/m 2  BID.])

| Adverse reaction (MedDRA)            | <6 years (n=33)     | 6-11 years (n=34)   | 12-18 years (n=33)   |
|--------------------------------------|---------------------|---------------------|----------------------|
| System Organ Class                   |                     |                     |                      |
| Infections and infestations          | Very common (48.5%) | Very common (44.1%) | Very common (51.5%)  |
| Blood and lymphatic system disorders |                     |                     |                      |
| Leukopenia                           | Very common (30.3%) | Very common (29.4%) | Very common (12.1%)  |
| Anaemia                              | Very common (51.5%) | Very common (32.4%) | Very common (27.3%)  |
| Gastrointestinal disorders           |                     |                     |                      |
| Diarrhoea                            | Very common (87.9%) | Very common (67.6%) | Very common (30.3%)  |
| Vomitting                            | Very common (69.7%) | Very common (44.1%) | Very common (36.4%)  |

Based on limited sub-set data (i.e. 33 of the 100 patients) there was a higher frequency of severe diarrhoea (common, 9.1%), and candida mucocutaneous (very common, 21.2%) in children under 6 years of age, compared to the older paediatric cohort in which no cases of severe diarrhoea were reported (0.0%) and candida mucocutaneous was common (7.5%).

## Renal Transplant Patients Less Than Two Years of Age

The CellCept dosage recommendations in the EU for the prophylaxis of acute transplant rejection in patients receiving allogeneic RTx currently exclude patients below 2 years of age. Of the 464 cases reporting 1,477 AEs for the paediatric age group receiving MMF for RTx, 12 cases containing 56 events concerned patients below 2 years who underwent kidney transplantation (cases of in utero exposure to MMF due to a maternal kidney transplantation were excluded). All patients were infants, of whom 11 patients were older than 3 months and in one case solely the age group infant was reported.

<div style=\"page-break-after: always\"></div>

Nine of the patients were male, two of the patients were female and for one patient sex was unknown. Bearing in mind the limitations of the relatively small infant patient sample in the Roche Global Safety Database, this imbalance is in line with the higher proportion of male infants receiving RTx observed by Hogan et al. (2016). Using data from renal registries in 35 European countries, these authors reported 442 male versus 232 female transplant recipients of age less than one year and 207 male versus 128 female recipients of age from one to two years between 1 January 2000 and 31 December 2012.

For paediatric RTx, the highest proportion of AEs was reported for the SOC Investigations (16.5%), followed by Infections and infestations (15.5%), and Gastrointestinal Disorders (14.6%). The proportions of AEs for all remaining SOCs were below 10%.

The proportions of all AEs by SOC in infant, child and adolescent RTx patients is presented in Figure 8 and Table 37 . A disproportion of ≥ 3% of reported AEs in infants compared to children and adolescents was noted in the SOCs Respiratory, Thoracic and Mediastinal Disorders (16.1% vs. 3.9% and 4.1%, respectively) and Infections and Infestations (21.4% vs. 14.6% and 16.8%, respectively).

An analysis of the AEs from SOC Respiratory, Thoracic and Mediastinal Disorders showed that the majority (5 AEs) were non-serious in nature. All 9 events under this SOC were reported in two patients which can explain the disbalance between the AE proportions in infant patients vs. patients from other age groups. Infections are in line with the safety profile of MMF and are due to its immunosuppressive properties.

The proportion of AEs in the SOC General Disorders and Administration Site Conditions was comparable for infants and children RTx recipients (10.7% vs. 8.9%) and were slightly higher in infants compared to adolescents (10.7% vs. 7.0%). The most reported AE from SOC General Disorders and Administrative Site Conditions both in the infant and child age group of RTx recipients was pyrexia (5.4% and 2.5%), while the proportion of pyrexia to all reported AEs in adolescent patients was 1.8%. In two of the three infant RTx patients for whom pyrexia was reported, an infectious condition was also present, insufficient information was provided for the third patient.

According to Jalanko et al. (2016), MMF use in this age group of patients was 60% and important longterm issues include infections, rejections, graft function, growth, bone health, metabolic problems, neurocognitive development, adherence to medication, pubertal maturation, and quality of life. Of those, only a relatively higher reporting rate for infections was observed in the Roche Global Safety Database in infants compared to other patient age groups.

<div style=\"page-break-after: always\"></div>

Figure 8 Proportion of all AEs by SOC in Infants (3 Months to 2 years) vs Children (2-10 Years) and Adolescents (12-18 Years) with RTx

<!-- image -->

x-axisindicatesnameofSoCs y-axisindicatesproportionofAEs(%)

<div style=\"page-break-after: always\"></div>

Table 37 Proportion of all AEs by SOC in Infants (3 Months to 2 years) vs Children (2-10 Years) and Adolescents (12-18 Years) with RTx

| System Organ Class                                                  | Infant Renal Transplant (3 months to 2 years)   | Infant Renal Transplant (3 months to 2 years)   | Child Renal Transplant (2-12   | Child Renal Transplant (2-12   | Adolescent Renal Transplant (12-18 years)   | Adolescent Renal Transplant (12-18 years)   |
|---------------------------------------------------------------------|-------------------------------------------------|-------------------------------------------------|--------------------------------|--------------------------------|---------------------------------------------|---------------------------------------------|
| System Organ Class                                                  | Event Count                                     | Proportion %                                    | Event Count                    | Proportion %                   | Event Count                                 | Proportion %                                |
| Infections and Infestations                                         | 12                                              | 21.43%                                          | 117                            | 14.59%                         | 86                                          | 16.76%                                      |
| Neoplasms Benign, Malignant and Unspecified (Incl Cysts and Polyps) | 0                                               | 0.00%                                           | 14                             | 1.75%                          | 4                                           | 0.78%                                       |
| Blood and Lymphatic System Disorders                                | 0                                               | 0.00%                                           | 35                             | 4.36%                          | 23                                          | 4.48%                                       |
| Immune System Disorders                                             | 0                                               | 0.00%                                           | 28                             | 3.49%                          | 42                                          | 8.19%                                       |
| Endocrine Disorders                                                 | 0                                               | 0.00%                                           | 3                              | 0.37%                          | 2                                           | 0.39%                                       |
| Metabolism and Nutrition Disorders                                  | 3                                               | 5.36                                            | 33                             | 4.11%                          | 19                                          | 3.70%                                       |
| Psychiatric Disorders                                               | 0                                               | %000                                            | 9                              | 1.12%                          | 10                                          | 1.95%                                       |
| Nervous System Disorders                                            | 1                                               | 1.79%                                           | 34                             | 4.24%                          | 21                                          | 4.09%                                       |
| Eye Disorders                                                       | 2                                               | 3.57%                                           | 9                              | 1.12%                          | 3                                           | 0.58%                                       |
| Ear and Labyrinth Disorders                                         | 0                                               | 0.00%                                           | 3                              | 0.37%                          | 1                                           | 0.19%                                       |
| Cardiac Disorders                                                   | 1                                               | 1.79%                                           | 5                              | 0.62%                          | 2                                           | 0.39%                                       |
| Vascular Disorders                                                  | 2                                               | 3.57%                                           | 15                             | 1.87%                          | 8                                           | 1.56%                                       |
| Respiratory, Thoracic and Mediastinal Disorders                     | 9                                               | 16.07%                                          | 31                             | 3.87%                          | 21                                          | 4.09%                                       |
| Gastrointestinal Disorders                                          | 7                                               | 12.50%                                          | 120                            | 14.96%                         | 67                                          | 13.06%                                      |
| Hepatobiliary Disorders                                             | 0                                               | %000                                            | 4                              | 0.50%                          | 1                                           | 0.19%                                       |
| Skin and Subcutaneous Tissue Disorders                              | 2                                               | 3.57%                                           | 14                             | 1.75%                          | 15                                          | 2.92%                                       |
| Musculoskeletal and Connective Tissue Disorders                     | 1                                               | 1.79%                                           | 23                             | 2.87%                          | 10                                          | 1.95%                                       |
| Renal and Urinary Disorders                                         | 1                                               | 1.79%                                           | 42                             | 5.24%                          | 22                                          | 4.29%                                       |
| Pregnancy, Puerperium and Perinatal Conditions                      | 0                                               | 0.00%                                           | 0                              | 0.00%                          | 0                                           | 0.00%                                       |
| Reproductive System and Breast Disorders                            | 0                                               | 0.00%                                           | 1                              | 0.12%                          | 1                                           | 0.19%                                       |
| Congenital, Familial and Genetic Disorders                          | 0                                               | 0.00%                                           | 0                              | 0.00%                          | 0                                           | 0.00%                                       |
| General Disorders and AdministrationSite Conditions                 | 6                                               | 10.71%                                          | 71                             | 8.85%                          | 36                                          | 7.02%                                       |
| Investigations                                                      | 5                                               | 8.93%                                           | 137                            | 17.08%                         | 95                                          | 18.52%                                      |
| Injury, Poisoning and  Procedural Complications                     | 4                                               | 7.14%                                           | 51                             | 6.36%                          | 24                                          | 4.68%                                       |
| Surgical and Medical Procedures                                     | 0                                               | 0.00%                                           | 1                              | 0.12%                          | 0                                           | 0.00%                                       |
| Social Circumstances                                                | 0                                               | 0.00%                                           | 0                              | 0.00%                          | 0                                           | 0.00%                                       |
| Product Issues                                                      | 0                                               | 0.00%                                           | 2                              | 0.25%                          | 0                                           | 0.00%                                       |
| Total                                                               | 56                                              | 100.00%                                         | 802                            | 100.00%                        | 513                                         | 100.00%                                     |

<div style=\"page-break-after: always\"></div>

Bearing in mind the relatively small number of infant patients in the Roche Global Safety Database (n=12), for some of whom multiple events were reported, all PTs reported in infant RTx patients are presented in Table 38 . The PTs reported for more than one infant patient were diarrhoea, pyrexia (3 each; 5.4% of all reported AEs) cough and nasal congestion (2 each; 3.6%). Of the 23 SAEs reported under this SOC in infant kidney transplant patients, 4 events resolved, 4 were resolving at the time of reporting, one was not resolved, and one had a fatal outcome. The outcome was unknown for the remaining 13 SAEs. For the eight events reporting resolution, MMF dose was unchanged in two instances, MMF dose was reduced or discontinued in response to two events, and the status of MMF therapy was unknown in relation to four events.

Table 38 Overview of AEs Reported in Infant RTx Patients

| SOC                                             | PT                                       |   Nonserlous | Serious   | Total   |
|-------------------------------------------------|------------------------------------------|--------------|-----------|---------|
| Infectlons and Infestaions                      | Bacleraemla                              |            0 | 1         | 1       |
| Infectlons and Infestaions                      | Bronchiolitis                            |            0 | 1         |         |
| Infectlons and Infestaions                      | Clostridium difficile colitis            |            0 | 1         | 1       |
| Infectlons and Infestaions                      | Cytomegalovirus viraemia                 |            0 | 1         |         |
| Infectlons and Infestaions                      | Epstein-Barr viraemia                    |            1 | 0         | 1       |
| Infectlons and Infestaions                      | Infecion                                 |            0 | 2         | 2       |
| Infectlons and Infestaions                      | Peritonitis                              |            0 | 1         | 1       |
| Infectlons and Infestaions                      | Polyomavirus-associated nephropathy      |            0 |           |         |
| Infectlons and Infestaions                      | Sepsis                                   |            0 | 1         | 1       |
| Infectlons and Infestaions                      | Viraemla                                 |            0 | 1         | 1       |
| Infectlons and Infestaions                      | Viral Infectlon                          |            1 | 0         |         |
| Infections and Infestatlons Total               | Infections and Infestatlons Total        |            2 | 10        | 12      |
| Metabolism and Nutrition Dlsorders              | Dehydralion                              |            1 | 0         | 1       |
| Metabolism and Nutrition Dlsorders              | Food intolerance                         |            1 | 0         |         |
| Metabolism and Nutrition Dlsorders              | Hypomagnesaemia                          |            1 | 0         | 1       |
| Metabolism and Nutrition Disorders Total        | Metabolism and Nutrition Disorders Total |            3 | 0         | 3       |
| Nervous System Disorders                        | Cerebrovascular accident                 |            0 | 1         | 1       |
| Nervous System Disorders Total                  | Nervous System Disorders Total           |            0 | 1         |         |
| Eye Disorders                                   | Eye discharge                            |            1 | 0         |         |
| Eye Disorders                                   | Lacrimation increased                    |            1 | 0         | 1       |
| Eye Disorders Total                             | Eye Disorders Total                      |            2 | 0         | 2       |
| Cardiac Disorders                               | Acute myocardial infarction              |            0 | 1         | 1       |
| Cardiac Dlsorders Total                         | Cardiac Dlsorders Total                  |            0 | 1         |         |
| Vascular Dlsorders                              | Arterlosclerosls                         |            1 | 0         |         |
| Vascular Dlsorders                              | Hypotenslon                              |            1 | 0         |         |
| Vascular Dlsorders Total                        | Vascular Dlsorders Total                 |            2 | 0         | 2       |
| Resplratory. Thoraclc and Mediastlnal Disorders | Bronchlal hyperreactivity                |            0 | 1         | 1       |
|                                                 | Cough                                    |            1 | 1         |         |
|                                                 | Dyspnoea                                 |            1 | 0         | 1       |
|                                                 | Nasal congestion                         |            2 | 0         |         |
|                                                 | Resplratory disorder                     |            0 | 1         | 1       |
|                                                 | Rhinorrhoea                              |            1 | 0         |         |
|                                                 | Tonsillar hypertrophy                    |            1 | 0         | 1       |

<div style=\"page-break-after: always\"></div>

| Respiratory,ThoracicandMediastinalDisordersTotal                            | Respiratory,ThoracicandMediastinalDisordersTotal      |   6 |   3 |   6 |
|-----------------------------------------------------------------------------|-------------------------------------------------------|-----|-----|-----|
| Gastrointestinal Disorders                                                  | Abdominal pain                                        |   1 |   0 |   1 |
| Gastrointestinal Disorders                                                  | Diarrhoea                                             |   3 |   0 |   3 |
| Gastrointestinal Disorders                                                  | Obstruction gastric                                   |   0 |   1 |   1 |
| Gastrointestinal Disorders                                                  | Retching                                              |   1 |   0 |   1 |
| Gastrointestinal Disorders                                                  | Vomiting                                              |   1 |   0 |   1 |
| Gastrointestinal Disorders Total                                            | Gastrointestinal Disorders Total                      |   6 |   1 |   7 |
| Skin and Subcutaneous Tissue Disorders                                      | Dermatitis diaper                                     |   1 |   0 |   1 |
| Skin and Subcutaneous Tissue Disorders                                      | Keloid scar                                           |   1 |   0 |   1 |
| Skin and SubcutaneousTissueDisordersTotal                                   | Skin and SubcutaneousTissueDisordersTotal             |   2 |   0 |   2 |
| Musculoskeletal and Connective Tissue Disorders                             | Myalgia                                               |   1 |   0 |   1 |
| Musculoskeletaland ConnectiveTissueDisordersTotal                           | Musculoskeletaland ConnectiveTissueDisordersTotal     |   1 |   0 |   1 |
| Renal and Urinary Disorders                                                 | Haematuria                                            |   1 |   0 |   1 |
| Renal and Urinary Disorders Total                                           | Renal and Urinary Disorders Total                     |   1 |   0 |   1 |
| General Disorders and Administration Site Conditions                        | Feeling abnormall                                     |   1 |   0 |   1 |
| General Disorders and Administration Site Conditions                        | Influenza like illness                                |   1 |   0 |   1 |
| General Disorders and Administration Site Conditions                        | Malaise                                               |   0 |   1 |   1 |
| General Disorders and Administration Site Conditions                        | Pyrexia                                               |   1 |   2 |   3 |
| GeneralDisordersandAdministrationSiteConditions Total                       | GeneralDisordersandAdministrationSiteConditions Total |   3 |   3 |   6 |
| Investigations                                                              | Biopsy kidney abnormal                                |   1 |   0 |   1 |
| Investigations                                                              | Blood creatinine increased                            |   1 |   0 |   1 |
| Investigations                                                              | Blood immunoglobulin G decreased                      |   1 |   0 |   1 |
| Investigations                                                              | Blood potassium increased                             |   1 |   0 |   1 |
| Investigations                                                              | Blood urea increased                                  |   1 |   0 |   1 |
| InvestigationsTotal                                                         | InvestigationsTotal                                   |   5 |   0 |   5 |
| Injury, Poisoning and Procedural Expired product administered Complications | Incorrect route of product                            |   0 |   1 |   1 |
|                                                                             | administration                                        |   0 |   1 |   1 |
|                                                                             | Medication error                                      |   0 |   1 |   1 |
|                                                                             | Off label use                                         |   0 |   1 |   1 |
| Injury,Poisoning andProcedural Complications                                | Injury,Poisoning andProcedural Complications          |   0 |   4 |   4 |
| Total                                                                       | Total                                                 |  33 |  23 |  56 |

The overall outcome of infant RTx has dramatically improved, with long-term patient and graft survivals of over 90 and 80 %, respectively. According to Jalanko et al. (2016), MMF use in infant RTx patients was 60% and important long-term issues include infections, rejections, graft function, growth, bone health, metabolic problems, neurocognitive development, adherence to medication, pubertal maturation, and quality of life.

## Comparison of the reported adverse events by SOC and PT by transplant type compared to adult data.

The paediatric AEs included in the table below are only those reported in conjunction with the proposed dosing regimen of 600 mg/m 2  of MMF orally b.i.d. up to 900 mg/m 2  b.i.d. AEs reported in paediatric patients, in the absence of dosing information, or where the dosing regimen differs, have been excluded. Due to the variety of dosing regimens and study design in the literature articles, the frequencies of AEs for paediatric transplant patients are presented as reported in the original article with denominators ranging between 20 and 55 (for specific denominators refer to the Table 39 footer).

<div style=\"page-break-after: always\"></div>

Table 39 Adverse Events Reported in Literature Articles - MMF Dose of 600 mg/m 2  up to 900 mg/m 2  b.i.d.

| Preferred term (MedDRA) System Organ Class                          | Paediatric heart transplant                                         | Adult heart transplant 6                                            | Paediatric hepatic transplant                                       | Adult hepatic transplant 6                                          |
|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|
| Infections and infestations                                         | Infections and infestations                                         | Infections and infestations                                         | Infections and infestations                                         | Infections and infestations                                         |
| Bacterial infections                                                | No data                                                             | Very common                                                         | Common 4                                                            | Very common                                                         |
| Viral infections                                                    | Very common 1,2                                                     | Very common                                                         | Common 4                                                            | Very common                                                         |
| Fungal infections                                                   | Common 1                                                            | Very common                                                         | No data                                                             | Very common                                                         |
| Gastrointestinal disorders                                          | Gastrointestinal disorders                                          | Gastrointestinal disorders                                          | Gastrointestinal disorders                                          | Gastrointestinal disorders                                          |
| Abdominal discomfort                                                | Very common 1                                                       | No data                                                             | No data                                                             | No data                                                             |
| Abdominal pain                                                      | No data                                                             | Very common                                                         | Common 3                                                            | Very common                                                         |
| Diarrhoea                                                           | Very common 1                                                       | Very common                                                         | Very common 3                                                       | Very common                                                         |
| Protein-losing gastroenteropathy                                    | No data                                                             | No data                                                             | Common 3                                                            | No data                                                             |
| Vomiting                                                            | No data                                                             | Very common                                                         | Common 3                                                            | Very common                                                         |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
| Lymphoproliferative disorder                                        | No data                                                             | Uncommon                                                            | Very common 3,4                                                     | Uncommon                                                            |
| Blood and lymphatic system disorders                                | Blood and lymphatic system disorders                                | Blood and lymphatic system disorders                                | Blood and lymphatic system disorders                                | Blood and lymphatic system disorders                                |
| Leukopenia                                                          | Very common 1                                                       | Very common                                                         | Very common 3                                                       | Very common                                                         |
| Myelosuppression                                                    | No data                                                             | No data                                                             | Very common 5                                                       | No data                                                             |
| Neutropenia                                                         | No data                                                             | No data                                                             | Common 3                                                            | No data                                                             |
| Immune system disorders                                             | Immune system disorders                                             | Immune system disorders                                             | Immune system disorders                                             | Immune system disorders                                             |
| Food allergies                                                      | No data                                                             | No data                                                             | Very common 4                                                       | No data                                                             |
| Nervous system disorders                                            | Nervous system disorders                                            | Nervous system disorders                                            | Nervous system disorders                                            | Nervous system disorders                                            |
| Neurotoxicity                                                       | No data                                                             | No data                                                             | Common 4                                                            | No data                                                             |
| Vascular disorders                                                  | Vascular disorders                                                  | Vascular disorders                                                  | Vascular disorders                                                  | Vascular disorders                                                  |
| Hypertension                                                        | No data                                                             | Very common                                                         | Very common 4                                                       | Very common                                                         |
| Metabolism disorders                                                | Metabolism disorders                                                | Metabolism disorders                                                | Metabolism disorders                                                | Metabolism disorders                                                |
| Hyperglycaemia                                                      | No data                                                             | Very common                                                         | Common 4                                                            | Very common                                                         |
| Type 1 diabetes mellitus                                            | Common 2                                                            | No data                                                             | No data                                                             | No data                                                             |
| Glucose tolerance impaired                                          | Common 2                                                            | No data                                                             | No data                                                             | No data                                                             |
| Renal and tubular disorders                                         | Renal and tubular disorders                                         | Renal and tubular disorders                                         | Renal and tubular disorders                                         | Renal and tubular disorders                                         |
| Nephropathy toxic                                                   | No data                                                             | No data                                                             | Common 4                                                            | No data                                                             |
| Renal failure                                                       | No data                                                             | No data                                                             | Common 4                                                            | No data                                                             |
| Renal tubular acidosis                                              | No data                                                             | No data                                                             | Very common 4                                                       | No data                                                             |
| General disorders and administrative site conditions                | General disorders and administrative site conditions                | General disorders and administrative site conditions                | General disorders and administrative site conditions                | General disorders and administrative site conditions                |
| Death                                                               | Common 2                                                            | No data                                                             | No data                                                             | No data                                                             |
| Multiple organ dysfunction syndrome                                 | Common 2                                                            | No data                                                             | No data                                                             | No data                                                             |
| Injury, poisoning and procedural complications                      | Injury, poisoning and procedural complications                      | Injury, poisoning and procedural complications                      | Injury, poisoning and procedural complications                      | Injury, poisoning and procedural complications                      |
| Transplant dysfunction                                              | No data                                                             | No data                                                             | Common 3, 4                                                         | No data                                                             |
| Investigations                                                      |                                                                     |                                                                     |                                                                     |                                                                     |

<div style=\"page-break-after: always\"></div>

| Preferred term (MedDRA)              | Paediatric heart transplant   | Adult heart transplant 6   | Paediatric hepatic transplant   | Adult hepatic transplant 6   |
|--------------------------------------|-------------------------------|----------------------------|---------------------------------|------------------------------|
| System Organ Class                   |                               |                            |                                 |                              |
| Cytomegalovirus test positive        | Very common 2                 | No data                    | No data                         | No data                      |
| Epstein-Barr virus antibody positive | No data                       | No data                    | Very common 3                   | No data                      |

b.i.d. = twice daily; MMF = mycophenolate mofetil; MedDRA = Medical Dictionary for Regulatory Activities.

Note: 'No data' pertains to the recommended dosage based on the available publications.

1 Dipchand et al. 2001 (21 patients, MMF dose 40±14 mg/kg)

2 Singh et al. 2010 (55 patients, MMF dose 1200 mg/m 2 )

3 Aw et al. 2008 (26 patients, MMF dose 40 mg/kg)

4 Colombani et al. 2000 (30 patients, MMF dose 600mg/m 2 /every 12 hours)

5 Lightdale et al. 1997 (20 patients on MMF, MMF dose 20-25 mg/kg b.i.d.)

6 CellCept SmPC

Seriousness and severity were typically not provided except for fatal events. In paediatric HTx patients, Singh et al. (2010) reported 6 deaths (9.6%), 5 of which were early hospital deaths in the posttransplantation period due to multiple-organ failure.

In paediatric LTx patients, Aw et al. (2008) reported two deaths: one (3.8%) due to graft dysfunction after the third transplantation, and second (3.8%) due to post-transplant lymphoproliferative disorder (B cell lymphoma). Colombani et al (2000) reported that post-operative surgical complications resulted in 4 early deaths (13%): one (3.3%) from primary nonfunction, two (6.7%) from sepsis, and one (3.3%) from renal failure-arrhythmia and cardiac arrest. Additionally, there was one (3.3%) late death from recurrent disease from hepatitis.

## Additional Safety Considerations

Although no pregnancy report concerning HTx or LTx patient was identified in the literature and cumulative safety reports, teratogenicity remains an important identified risk of MMF (Sifontis et al. 2006; Hoeltzenbein et al. 2012), and thus the relevant Warnings and Precautions in CellCept SmPC apply also to adolescents of child-bearing age.

Two reports of overdose in paediatric patients with HTx or LTx were identified in the cumulative safety dataset: the first occurred in a 13-year-old male patient with LTx, who on an unspecified date experienced overdose with no associated AEs (AER 611496). The second concerned a 9-month-old male patient with HTx who was accidentally administered a dose 10 times higher than prescribed, and developed abdominal distension, general physical health deterioration, intestinal ischaemia, metabolic acidosis, lactic acidosis, acute gastritis with haemorrhage, intestinal necrosis, and hyperglycaemia. Therapy with MMF was withdrawn and five days later the patient died due to these events. It is unknown whether an autopsy was performed (AER 2351337).

No literature is available on long-term follow up in paediatric HTx and LTx patients with MMF.

## 2.5.1. Discussion on clinical safety

No company-sponsored pivotal clinical trials were conducted to support the safety of MMF in the prophylaxis of organ rejection in paediatric recipients of allogeneic heart or liver transplants.

The presented clinical safety evidence to support the use of MMF in paediatric patients with HTx or LTx comes from:

- A literature review of published studies

<div style=\"page-break-after: always\"></div>

- Post-marketing reports from the Roche Global Safety Database
- A discontinued clinical trial in paediatric patients with LTx

9 paediatric patients (between the ages of 9 months and 5 years) were enrolled and followed for 14 days in a dose finding Phase IV study (Study PA16497) evaluating the safety, tolerability and pharmacokinetics of oral MMF in paediatric liver transplant (LTx) recipients on concomitant treatment with ciclosporin A (CsA) and corticosteroids. The patients were treated with MMF doses per center practice (MMF doses of 200 - 424 mg/m2). The study was discontinued due to recruitment issues. One AE, pyrexia, was reported, which was mild in intensity and assessed by the investigator as unrelated to trial treatment. No other AEs were reported during the study. This study was considered only supportive. Due to limited safety evaluation in the study no safety conclusion could be reached.

Initially, the MAH did not provide an integrated summary of available clinical evidence which allows evaluation of efficacy and related safety of the specific dosing scheme of MMF proposed for use in paediatric HTx and LTx patients. Given the unknown safety profile at recommended doses (starting dose of 600 mg/m2 of mycophenolate mofetil orally twice daily and maintenance dose of 900 mg/m2 twice daily), a literature summary was considered supportive of the extrapolation from adults and other indications (RTx).

The MAH has, upon CHMP request, presented tabulated reported adverse events by SOC and PT by % and by transplant type (LTx and HTx) along with a comparison to the adult data for the recommended doses (starting dose of 600 mg/m2 of mycophenolate mofetil orally twice daily and increased dose of 900 mg/m2 twice daily).

The MAH also provided a comparison of safety database analysis for paediatric patients receiving MMF for unlabelled indication of HTx and LTx vs. for labelled indication of RTx. This analysis did not consider exposure dose or duration, regardless, the comparisons from the safety database are considered supportive of the extrapolation from adults and other indications (RTx).

Based on the review of the available published studies and post-marketing reports the type and frequency of the reported adverse reactions in hepatic and cardiac transplant patients were consistent with those observed in paediatric and adult patients following renal transplant.

However, neoplasms Benign, Malignant and Unspecified, Gastrointestinal Disorders, and Blood and Lymphatic System Disorders were observed more frequently in paediatric HTx and LTx patients in comparison to adult groups. Differences in adverse events were also observed between paediatric HTx and LTx patients in comparison to paediatric RTx group. Reasons for paediatric population being more prone to these events and differences between RTx-HTx-LTx indications, or possible longer term exposure in paediatric population have been discussed but causal relationship with cellcept cannot be excluded. Therefore, differences (i.e. in nature, frequency, seriousness or reversibility of adverse reactions) have been described in section 4.8 of the SmPC and specific monitoring has been included in section 4.4 of the SmPC. In addition, new information on these risks will be presented in future PSURs, stratified by age.

The MAH also took the opportunity to update the information on the paediatric population in Section 4.8 of the SmPC; the summary of the safety profile in 2 studies (Study MYC2190 and Study MYCS2675) conducted in paediatric renal transplant patients was updated. These studies were previously submitted and assessed in variation EMEA/H/C/00082/II/0027. This was endorsed by the CHMP. In addition, upon CHMP request, the adverse reactions occurring more frequently in the paediatric renal transplant patients study were summarised in a table in section 4.8 of the SmPC.

The MAH also presented data from the safety database on off-label use of MMF in paediatric RTx patients below 2 years of age. From the limited analysis presented, it seems that the infections and respiratory events are up to 4 times more frequent in RTx patients below 2 years of age in comparison to older age

<div style=\"page-break-after: always\"></div>

groups. Due to small numbers, this should be interpreted with caution. Nethertheless, the increased occurrence of infections and respiratory events in the new paediatric population has been described in the SmPC.

As fatal cases of overdoses occurred in paediatric patients, the MAH updated section 4.9 to inform the prescribers of this risk.

At the time of approval of Cellcept in 1996, no RMP was required for registration. At the PRAC request, the MAH submitted an RMP to follow the known and new associated risks with Cellcept use. The known important identified risk Adverse pregnancy outcomes including Teratogenicity and Mutagenicity has been included in the RMP. And a new missing information was added: Long term safety (growth retardation, pubertal maturation and fertility, bone health, metabolic problems and neurocognitive development). The MAH will submit annual report to follow more closely the paediatric patients.

## 2.5.2. Conclusions on clinical safety

The safety profile in paediatric RTx patients 2 years and above forms the basis of safety profile expected in paediatric LTx and HTx patients and in paediatric population with RTx below 2 years (at starting dose of 600 mg/m2 of mycophenolate mofetil orally twice daily and maintenance dose of 900 mg/m2 twice).

Extrapolation of the safety profile (at starting dose of 600 mg/m2 of mycophenolate mofetil orally twice daily and maintenance dose of 900 mg/m2 twice daily) from RTx indication to other paediatric indications and younger subsets is supported by literature references and RWD.

Differences between age and transplant groups have been described in the SmPC to inform the prescriber as well as experience with medication errors have been reflected in the SmPC.

Uncertainties regarding long term safety are handled in the RMP and annual report will be submitted to closely follow this.

Overall mycophenolate mofetil has shown a well known and acceptable safety profile.

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.6. Risk management plan

The MAH was requested to submit an RMP with this application.

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 1.2 is acceptable.

The CHMP endorsed this advice without changes.

The CHMP endorsed the Risk Management Plan version 1.2 with the following content:

## Safety concerns

| Summary of safety concerns   |
|------------------------------|

<div style=\"page-break-after: always\"></div>

| Important identified risks   | Adverse pregnancy outcomes including Teratogenicity and Mutagenicity                                                                     |
|------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|
| Important potential risks    | None                                                                                                                                     |
| Missing information          | Long term safety (growth retardation, pubertal maturation and fertility, bone health, metabolic problems and neurocognitive development) |

## Pharmacovigilance plan

There are no additional pharmacovigilance activities.

## Risk minimisation measures

| Safety concern                                                                                                                           | Risk minimization measures                                                                                                                                                                                                                                                                                                                                   | Pharmacovigilance activities                                                                                                                                                                               |
|------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Pregnancy Adverse Effects including Teratogenicity and Mutagenicity                                                                      | Routine risk communication: • Section 4.3 of the EU SmPC Contraindications • Section 4.4 of the EU SmPC Special warnings and precautions for use • Section 4.6 Pregnancy & Lactation • Section 4.8 of the EU SmPC: Undesirable effects Legal status: CellCept is a prescription only medicine Additional risk minimization measures: HCP Guide Patient Guide | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Pregnancy Guided Questionnaires and enhanced follow up process Additional pharmacovigilance activities: None |
| Long term safety (growth retardation, pubertal maturation and fertility, bone health, metabolic problems and neurocognitive development) | Routine risk communication: Section 4.4 of the EU SmPC: Special warnings and precautions for use Section 4.8 of the EU SmPC: Undesirable effects Legal status: CellCept is a prescription only medicine                                                                                                                                                      | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Annual safety reports Frequency: Yearly Additional pharmacovigilance activities: None                        |

EU SmPC = European Union Summary of Product Characteristics; HCP = Healthcare Professional.

## 2.7. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.2, 4.4, 4.8, 4.9, 5.2, 5.3 and 6.6 of the SmPC have been updated. The Package Leaflet has been updated accordingly.

Changes were also made to the PI to bring it in line with the current Agency/QRD template, SmPC guideline and Excipients guideline which were reviewed and accepted by the CHMP.

<div style=\"page-break-after: always\"></div>

## 2.7.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable. The updates in the SmPC sections with this variation does not lead to substantial changes in the PL and therefore it is accepted that a user test is not performed.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

The purpose of solid organ transplantation is to restore organ function, thereby prolonging the life of the adult or child. Solid organ transplantation is considered a life-saving and definitive therapy for adults and children who are suffering from end-stage organ failure due to a variety of causes. The model of alloimmune response, involving both naïve and memory lymphocytes, in the rejection of transplanted organs has been described in detail in the literature (Halloran et al. 2004). Rejection episodes are not an to suggest that the mechanism of rejection is different in adults compared with children.

organ-specific complication and can occur for any transplanted organ. Additionally, there is little evidence Immunosuppression therapy is used to prevent rejection of the donor organ thereby enabling organ and patient survival.

## 3.1.2. Available therapies and unmet medical need

Immunosuppression is commonly separated into induction therapy (given at time of transplant), maintenance therapy (chronic medications), and acute rejection therapy (for the treatment of acute complications).

International Guidelines on Heart Transplant Guidelines for immunosuppression regimens specific to children are very limited. The ISHLT 2010 includes some recommendations specific to paediatric patients. Throughout these guidelines, most recommendations only receive an evidence level of C, based on consensus, due to the absence of randomised controlled clinical trials (Costanzo et al. 2010).

The International Guidelines on Liver Transplant (ILTS) 2019 Guidelines (adults and children) highlight the absence of robust studies for children but highlight the need for consensus-based guidelines to address the unique considerations in treating children, related to variations in growth and development, disease states, adherence, and risks of long-term exposure to IS. Paediatric-specific guidelines were developed by American Association for the Study of Liver Diseases and American Society of Transplantation in 2013. They make the case that for children there is no standard of care regimen, however, the current practice includes CNI based regimens (mainly TAC) as it avoids gingival hyperplasia and hirsutism associated with CsA. The use of MMF or mTOR inhibitors may enable reductions in steroid use and high dose CNI (Kelly et al. 2013).

CellCept is used off-label in the paediatric population with liver and heart transplants and most maintenance immunosuppressive protocols in children are similar to the protocols used in adults and employ a three-drug regimen consisting of a calcineurin inhibitor (CNI) (such as Cyclosporin A (CsA) or tacrolimus (TAC)), an antimetabolite agent (mycophenolate mofetil (MMF) or less commonly azathioprine

<div style=\"page-break-after: always\"></div>

(AZA)), and tapering doses of glucocorticoids over the first year post transplantation (Kobashigawa et al. 2006; Costanzo et al. 2010).

There is therefore a need for approved medicine for paediatric transplantation.

## 3.1.3. Main clinical studies

Knowledge about the use of MMF in the adult reference populations of RTx, HTx, and LTx transplant patients and in paediatric RTx patients has been used to extrapolate to the target paediatric HTx and LTx populations.

Only one clinical study including nine paediatric patients undergoing liver transplantation was submitted to support the extension of indication. The remaining evidence is coming from published literature and previously submitted studies in RTx patients.

The clinical efficacy data to support the use of MMF in paediatric HTx and LTx come from available publications of studies conducted in the paediatric population, including 14 studies relevant to paediatric HTx and 15 studies relevant to paediatric LTx patients.

## 3.2. Favourable effects

Mycophenolic acid (MPA) acts as a selective, uncompetitive and reversible inhibition of inosine monophosphate dehydrogenase (IMPDH) and through the de novo pathway of guanosine nucleotide synthesis without incorporation into DNA. This is independent of transplant type and can be transferred from HTx and LTx and RTx to one another.

In addition, data generated in Roche-sponsored studies and available in the literature show that there is no difference in the mean PK characteristics of MMF/MPA in paediatric transplant patients across the age group of 1-18 years. At the recommended dosage, the same therapeutic target exposure is reached independent of patient age.

The clinical efficacy data to support the use of MMF in paediatric HTx and LTx from the above-mentioned publications of studies conducted in the paediatric population may confirm the efficacy observed in adults. The studies consistently suggest a benefit for MMF over AZA. Available evidence suggests that like adults, regimens containing MMF are effective and, compared to regimens containing AZA, they result in improved renal function, allowing CNI and steroid dose reductions and therefore reduction in the incidence of acute rejection in paediatric patients.

## 3.3. Uncertainties and limitations about favourable effects

The paediatric extrapolation approach utilized is based on PK-comparison with the adult reference population, under the assumption that a similar exposure produces a similar efficacy. The approach is supported by one paediatric clinical study in liver transplant patients, study PA16497, previously submitted paediatric clinical studies in renal transplant patients and by published studies from the literature.

The published supporting studies are largely observational over a period of time, too small in sample size, and not designed to demonstrate the efficacy of MMF. They typically include MMF together with other therapeutic agents as a part of the immunosuppressive regimen, and it is therefore not possible to directly link or attribute any of the observed outcomes to MMF.

<div style=\"page-break-after: always\"></div>

Furthermore, very few of the publications retrieved are prospective studies; most studies are retrospective comparisons of transplant outcomes in the years before the introduction of MMF versus outcomes in the years after the inclusion of MMF in standard of care immunosuppressive regimens.

Therefore, although the studies consistently suggest a benefit for MMF, the impact of improved surgical and medical management is also likely to have influenced these findings.

However, all these additional data are only supportive. Since extrapolation from adults to children has been demonstrated, clinical efficacy is considered demonstrated.

Initially the MAH applied for an extension of indication in paediatric patients down to 3 months, however only limited data were available for infants (3 months to 1 year) and there was not enough data to support the justification for the PK comparability of MMF/MPA in infants and the proposed dosing regimen in this population. Therefore, the MAH proposed to include patients from 1 year instead of 3 months. This was considered acceptable by the CHMP. Indeed, PK comparability of MMF/MPA in children from 1 to 18 years has been demonstrated for RTx, LTX and HTx and the recommended paediatric dosing regimen in children from 1 to 18 years has been justified.

## 3.4. Unfavourable effects

Based on the review of the available published studies and post-marketing reports, the type and frequency of the reported adverse reactions in hepatic and cardiac transplant patients and renal patients below 2 years of age were consistent with those observed in paediatric and adult patients following renal transplant. No new safety signals have been identified. A few imbalances have been observed and described in the SmPC. Long-term safety has been identified as a missing information in the RMP and will be followed-up in the post-marketing setting.

## 3.5. Uncertainties and limitations about unfavourable effects

No new studies were performed in paediatric patients, therefore the safety profile in this new population is extrapolated from the known safety profile in paediatric RTx patients aged 2 years and older, and from other doses and indications as many of the supportive literature references lack the specific exposure or age groups.

From the limited analysis presented, it seems that the infections and respiratory events are up to 4 times more frequent in RTx patients below 2 years of age in comparison to older age groups. Due to small numbers this should be interpreted with caution. However, the increased occurrence of infections and respiratory events in this new paediatric population has been adequately described in the Section 4.8 of the SmPC.

Neoplasms Benign, Malignant and Unspecified, Gastrointestinal Disorders, and Blood and Lymphatic System Disorders were more frequent in paediatric HTx and LTx patients in comparison to adult groups. Similarly, differences in adverse events were observed between paediatric HTx and LTx patients in comparison to paediatric RTx group. These differences have been described and reflected in section 4.4 and 4.8 of the SmPC.

<div style=\"page-break-after: always\"></div>

## 3.6. Benefit-risk assessment and discussion

## 3.6.1. Importance of favourable and unfavourable effects

Knowledge about the use of CellCept/MMF in the adult reference populations of RTx, HTx, and LTx transplant patients and in paediatric RTx patients has been used to extrapolate to the target paediatric HTx and LTx populations.

PK comparability of MMF/MPA in children from 1 to 18 years has been demonstrated for RTx, LTX and HTx. The recommended paediatric dosing regimen in children from 1 to 18 years has been justified, so in conclusion, the pharmacokinetic data provided supports the approval of the application for use of MMF in children from 1 year to 18 year for all 3 types of transplantation.

The safety profile of MMF for the suggested dosing scheme and HTx-LTx indications in paediatric population is extrapolated from paediatric RTx patients who are 2 years and above to paediatric LTx and HTx patients. The safety profile (at starting dose of 600 mg/m2 of mycophenolate mofetil orally twice daily and maintenance dose of 900 mg/m2 twice daily) is similar to the known safety profile of the substance and no new safety signals were identified.

## 3.6.2. Balance of benefits and risks

The PK data support an extrapolation down to one year of age. The MAH initially proposed an extrapolation down to 3 months of age. However, there was not enough data to support the extrapolation to the infant population (3 months to 1 year). Therefore, the MAH decided to revise the indication to include children from the age of 1 year, this is agreed by the CHMP. The dosing regimen for this new population will be the same as for paediatric RTx patients above 2 years of age, with the possibility to increase the dose to 2g for paediatric RTx and 3g for paediatric LTx and HTx, in line with the adult indication.

Whilst some differences were seen in the paediatric population compared to the adult population, the overall safety profile appears generally consistent between paediatrics and adults. Adequate warnings regarding blood and lymphatic disorders and gastrointestinal disorders have been implemented in section 4.4 of the SmPC. No new safety signals were identified.

## 3.7. Conclusions

The overall B/R of Cellcept is positive in the following indication:

CellCept is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in adult and paediatric (1 to 18 years of age) patients receiving allogeneic renal, cardiac or hepatic transplants.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following group of variations acceptable and therefore recommends the variations to the terms of the Marketing Authorisation, concerning the following changes:

<div style=\"page-break-after: always\"></div>

| Variations accepted   | Variations accepted                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I, II and IIIB     |
| C.I.z                 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                 | Type IB | I, II and IIIB     |

C.I.6.a: Extension of indication to include paediatric patients (1 year to 18 years of age) for hepatic and cardiac transplants and to extend the indication for renal transplants for paediatric patients starting from 1 year, based on pharmacokinetic data, published literature and the Roche Global Safety Database. As a consequence, sections 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.2, 5.3 and 6.6 of the SmPC are updated. The Package Leaflet is updated accordingly. Version 1.2 of the RMP has also been approved.

Type IB (C.I.z): Update of the precautions to be taken before handling or administering the medicinal product in section 4.2 of the SmPC for the CellCept 500 mg tablets formulation in order to be in line with the other CellCept formulations. The Package Leaflet is updated to cross reference section 2 in section 6 for sodium content, in line with the QRD guidance.

In addition, the MAH took the opportunity to introduce minor editorial changes to the PI and bring the PI in line with the latest QRD template version 10.3.

The group of variations leads to amendments to the Summary of Product Characteristics, Annex II and Package Leaflet.

## Amendments to the marketing authorisation

In view of the data submitted with the group of variations, amendments to Annexes I, II and IIIB are recommended.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## Risk management plan (RMP)

The Marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.

In addition, an updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

## Additional risk minimisation measures

The Marketing Authorisation Holder (MAH) must agree about the content and format of the educational programme, including communication media, distribution modalities, and any other aspects of the

<div style=\"page-break-after: always\"></div>

programme, with the National Competent Authority.

The educational programme is aimed at ensuring that the health professionals and patients are aware of the teratogenicity and mutagenicity, the need for pregnancy tests before starting therapy with CellCept, the contraceptive requirements for both male and female patients and what to do in case of pregnancy during treatment with CellCept.

The MAH shall ensure that in each MS where CellCept is marketed, all healthcare professionals and patients who are expected to prescribe, dispense or use CellCept are provided with the following educational package:

-        Physician educational material
-         Patient information pack

The health professional educational material should contain:

-         The Summary of Product Characteristics
-         Guide for healthcare professionals

The patient information pack should contain:

-         The Package Leaflet
-         Guide for patients

The educational materials shall contain the following key elements:

Separate guides for healthcare professionals and patients should be provided. For patients, the text should be appropriately separated for men and women. The following areas should be covered in these guides:

- An introduction in each guide will inform the reader that the purpose of the guide is to tell them that a foetal exposure must be avoided and how to minimise the risk of birth defects and miscarriage associated with mycophenolate mofetil. It will explain that although this guide is very important it does not provide full information on mycophenolate mofetil and that the SmPC (healthcare professionals) and package leaflet (patients) supplied with the medicine must also be read carefully.
- Background information on mycophenolate mofetil teratogenicity and mutagenicity in humans. This section will provide important background information concerning the teratogenicity and mutagenicity of mycophenolate mofetil. It will provide details about the nature and magnitude of the risk, in line with the information provided in the SmPC. The information provided in this section will facilitate a correct understanding of the risk and explain the rationale for the following pregnancy prevention measures. Guides should also mention that patients should not give this drug to any other person.
- Counselling of patients: This section will emphasise the importance of a thorough, informative and ongoing dialogue between patient and healthcare professional about the pregnancy risks associated with mycophenolate mofetil and the relevant minimisation strategies including alternative treatment choices, if applicable. The need to plan a pregnancy will be highlighted.
- The need to avoid foetal exposure: Contraceptive requirements for patients of reproductive potential prior to, during and after treatment with mycophenolate mofetil. Contraceptive requirements for sexually active male patients (including vasectomised men) and female patients of childbearing potential will be explained. The need for contraception prior to, during and after treatment with mycophenolate mofetil, including details of the duration of time for which contraception must be continued after cessation of therapy, will be clearly stated.

<div style=\"page-break-after: always\"></div>

In addition, the text relating to women should explain the pregnancy test requirements prior to and during therapy with mycophenolate mofetil; including the advice for two negative pregnancy tests prior to starting therapy and the importance of the timing of these tests. The need for subsequent pregnancy tests during treatment will also be explained.

- Advice that patients should not donate blood during therapy or for at least 6 weeks following discontinuation of mycophenolate mofetil. Furthermore, men should not donate semen during therapy or for 90 days following discontinuation of mycophenolate mofetil.
- Advice on action if a pregnancy occurs or is suspected during or shortly after being treated with mycophenolate mofetil. Patients will be informed that they should not stop taking mycophenolate mofetil but must contact their doctor immediately. It will be explained that the correct course of action, based on an assessment of the individual benefit-risk, will be determined on a case-by-case basis through a discussion between the treating physician and the patient.

<div style=\"page-break-after: always\"></div>

## 5. References

Anderson GD. Developmental pharmacokinetics. Semin Pediatr Neurol.2010;17(4):208-13.

Arns W, Stephan Breuer S, Choudhury S, et al. Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. Clin Transplant 2005;19(2):199-206.

Attard TM, Dhawan A, Tredger JM, et al. Mycophenolic acid metabolite levels in pediatric liver transplantation: Correlation with a limited sampling strategy. J Appl Res. 2008; 8(2):135-42.

Aw MM, Samaroo B, Baker AJ, et al. Calcineurin-inhibitor related nephrotoxicity - reversibility in paediatric liver transplant recipients. Transplantation. 2001;72(4):746-9. [Aw-2001-01]

Aw MM, Verma A, Rela M, et al. Long-term outcome of mycophenolate mofetil rescue therapy for resistant acute allograft rejection in pediatric liver transplant recipients. Liver Transpl. 2008;14(9):13038. [Aw-2008-01]

Balci Sezer O, Baris Z, Ecevit Z, et al. Prevalence of infections in infants within the first 6 months of liver transplant. Exp Clin Transplant. 2020;18(Suppl 1): 93-95. [Balci-2020-01]

Barau C, Barrail-Tran A, Hemerziu B et al. Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients. Liver Transpl 2011;17(10): 1152-8. [Barau-2011-01]

Barau C, Furlan V, Debray D, et al. Population pharmacokinetics of mycophenolic acid and dose optimization with limited sampling strategy in liver transplant children. Br J Clin Pharmacol. 2012; 74(3): 515-24. [Barau-2012-01]

Bernard O, Guillemette C. The main role of UGT1A9 in hepatic metabolism of mycophenolic acid and the effect of naturally occurring variants. Drug Metab Dispos. 2004; 32(8): 775-8. [Bernard-2004-01]

Boyer O, Le Bidois J, Dechaux M, et al. Improvement of renal function in pediatric heart transplant recipients treated with low-dose calcineurin inhibitor and mycophenolate mofetil. Transplantation. 2005;79(10):1405-10.

Brown NW, Aw MM, Mieli-Vergani G, et al. Mycophenolic acid and mycophenolic acid glucuronide pharmacokinetics in pediatric liver transplant recipients: Effect of cyclosporine and tacrolimus comedication. Ther Drug Monit. 2002;24(5):598-606. [Brown-2002-01]

Bullingham R, Monroe S, Nicholls A, et al. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration J Clin Pharmacol 1996;36:31524. [Bullingham-1996-01]

Bullingham RES, Nicholls AJ, Kamm BR: Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet. 1998;34(6):429-55. [Bullingham-1998-01]

Bullingham RF, Nicholls A and Hale M: Pharmacokinetics of mycophenolate mofetil (RS61443): A short review. Transplant Proc. 1996b;28(2):925-9.[Bullingham-1996-02]

Castleberry C, Ziniel S, Almond C, et al. Clinical practice patterns are relatively uniform between pediatric heart transplant centers: A survey-based assessment. Pediatr Transplant. 2017;21(5),e13013:1-6. [Castleberry-2017-01]

Chardot C, Nicoluzzi JE, Janssen M, et al. Use of mycophenolate mofetil as rescue therapy after pediatric liver transplantation. Transplantation 2001;71(2):224-9. [Chardot-2001-01]

Colombani PM, Lau H, Prabhakaran K, et al. Cumulative experience with pediatric living related liver transplantation. J Pediatr Surg. 2000;35(1):9-12. [Colombani-2000-01]

Colvin M, Smith JM, Ahn Y, et al. OPTN/SRTR 2019 Annual data report: Heart. Am J Transplant. 2021;21 Suppl 2:356-440. [Colvin-2021-01]

<div style=\"page-break-after: always\"></div>

Costanzo MR, Dipchand A, Starling R. International Society of Heart and Lung Transplantation Guidelines. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2010;29(8):914 - 56. [Costanzo-2010-01]

Dehghani SM, Honar N, Inaloo S, et al. Neuromuscular complication after liver transplant in children: a single-center experience. Exp Clin Transplant. 2010;8(1):9-13. [Dehghani-2010-01]

Demetris AJ, Jaffe R, Tzakis A, et al. Antibody-mediated rejection of human orthotopic liver allografts. A study of liver transplantation across ABO blood group barriers. Am J Pathol. 1988;132(3):489-502. [Demetris-1988-01]

De Winter BCM, Neumann I, van Hest RM, et al. Limited sampling strategies for therapeutic drug monitoring of mycophenolate mofetil therapy in patients with autoimmune disease. Ther Drug Monit 31(3), 2009; 382-390. [Winter-2009-01]

Dhawan A. Immunosuppression in pediatric liver transplantation: Are little people different? Liver Transpl 2011;17(Suppl 3):S13-9. [Dhawan-2011-01]

Dhungel A, Mohan N, Goyal D, et al. Answering the donor graft shortagesuccessful outcome of abo incompatible pediatric living related liver transplants. J Clin Exp Hepatol. 2019;9(3):421-2. [Dhungel2019-01]

Dipchand A, Benson L, McCrindle B et al. Mycophenolate mofetil in pediatric heart transplant recipients: a single-center experience. Pediatr Transplant. 2001b;5(2):112-8. [Dipchand-2001-02]

Dipchand AI, Pietra B, McCrindle BW, et al. Mycophenolic acid levels in pediatric heart transplant recipients receiving mycophenolate mofetil. J Heart Lung Transplant. 2001a;20(10):1035-43. [Dipchand2001-01]

Dipchand AI, Kirk R, Edwards LB, et al. The Registry of the International Society for Heart and Lung Transplantation: Sixteenth Official Pediatric Heart Transplantation Report-2013; focus theme: age. J Heart Lung Transplant 2013;32:979-88. [Dipchand-2013-01]

Dipchand AI, Seifert-Hansen, M Early experience with varicella vaccination in pediatric heart transplant recipients. J Heart Lung Transplant. 2022;41(8):1023-26. [Dipchand-2022-01]

Ettenger R, Bartosh S, Choi L, et al. Pharmacokinetics of enteric-coated mycophenolate sodium in stable pediatric renal transplant recipients. Pediatric Transplant, 2005;9(6), 780-787. [Ettenger-2005-01]

Evans H, McKiernan P, Kelly D, et al. Mycophenolate mofetil for renal dysfunction after pediatric liver transplantation. Transplantation. 2005;79:1575-80. [Evans-2005-01]

Ferraris J, Duca P, Prigoshin N, et al. Mycophenolate mofetil and reduced doses of cyclosporine in pediatric liver transplantation with chronic renal dysfunction:changes in the immune responses. Pediatr Transplant. 2004;8(5):454-9.[Ferraris-2004-01]

Filler G, Bendrick-Peart J, Christians U. Pharmacokinetics of mycophenolate mofetil and sirolimus in children. Ther Drug Monit. 2008;30(2):138-42. [Filler-2008-01]

Filler G, Lepage N. To what extent does the understanding of pharmacokinetics of mycophenolate mofetil influence its prescription. Pediatr Nephrol. 2004b;19,962-5. [Filler-2004-02]

Filler G, Zimmering M, Mai I. Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression. Pediatr Nephrol. 2000;14(2):100-4. [Filler-2000-01]

Fine NM, Greenway SC, Mulvagh SL, et al. Feasibility of Real-Time Myocardial Contrast Echocardiography to Detect Cardiac Allograft Vasculopathy in Pediatric Heart Transplant Recipients. J Am Soc Echocardiogr, 2021;34(5): 503-10. [Fine-2021-01]

Fukuda T, Goebel J, Thøgersen H, et al. Inosine monophosphate dehydrogenase (IMPDH) activity as a pharmacodynamic biomarker of mycophenolic acid effects in pediatric kidney transplant recipients. J Clin Pharmacol. 2011;51(3):309-20. [Fukuda-2011-01]

<div style=\"page-break-after: always\"></div>

Gajarski RJ, Crowley DC, Zamberlan MC, et al. Lack of correlation between MMF dose and MPA level in pediatric and young adult cardiac transplant patients: Does the MPA level matter? Am J Transplant. 2004;4(9)1495-1500. [Gajarski-2004-01]

Gavaldà J, Cabral E, Alonso E, et al. Influenza A H1N1/2009 infection in pediatric solid organ transplant recipients. Transpl Infect Dis. 2012;14(6):584-8.[Gavalda-2012-01]

Giuliano K, Canner JK, Scully BB, et al. Epstein-Barr Virus Predicts Malignancy After Pediatric Heart Transplant, Induction Therapy and Tacrolimus Don't. The Annals of Thoracic Surgery. 2022;14(5):17941802. [Giuliano-2022-01]

Groetzner J, Reichart B, Roemer U, et al. Cardiac transplantation in pediatric patients: fifteen-year experience of a single center. Ann Thorac Surg. 2005;79(1):53-60. [Groetzner-2005-01]

Guentert TW: CellCept - Cyclosporine Interaction, Clinical Pharmacology Position Paper, 12 November 2014. [Guentert-2014-01]

Haflidadottir S, Østensen AB, Matthews IL, et al. Mycophenolate Mofetil Use Is Associated With Reduced Incidence of Food Allergy in Liver Transplanted Children. J Ped Gastroenterol Nutr 2022:75(2): 138-44. [Haflidadottir-2022-01]

Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med. 2004;351(26):2715-29. Erratum in: N Engl J Med. 2005;352(10):1056. [Halloran-2004-01]

Haregu A, McCulloch M, White S, et al. Efficacy and Safety of desensitization therapy in pediatric heart transplant candidates. J Heart Lung Transplant. 2021;40(4):S228-S229. [Haregu-2021-01]

Hingler S, Peters B, Yigitbasi M, et al. Impact of immunosuppressive therapy on anti-ebv specific CD8+ Tcells in pediatric heart transplant recipients. J Heart Lung Transplant. 2013;32(4):S191-2. [Hingler-201301]

Hoecker B, van Gelder T, Martin-Govantes J, et al. Comparison of MMF efficacy and safety in paediatric vs adult renal transplantation: subgroup analysis of the randomised, multicentre FDCC trial. Nephrol Dial Transplant. 2011;26(3):1073-79. [Hocker-2011-01]

Hoeltzenbein M, Elefant E, Vial T, et al. Teratogenicity of mycophenolate confirmed in a prospective study of the European Network of Teratology Information Services. Am J Med Genet A. 2012 Mar;158A(3):58896. [Hoeltzenbein-2012-01]

Hogan J, Couchoud C, Bonthuis M, et al. Gender Disparities in Access to Pediatric Renal Transplantation in Europe: Data From the ESPN/ERA-EDTA Registry. American J Transplantation 2016;16: 2097-2105. [Hogan-2016-01]

Honda M, Sugawara Y, Kadohisa M, et al. Long-term outcomes of ABOincompatible pediatric living donor liver transplantation. Transplantation.2018;102(10):1702. [Honda-2018-01]

Hudert C, Mueller S, Luck W. Mycophenolate motefil monotherapy in paediatric primary liver transplant patients. ESPGHAN 52nd Annual Meeting Abstracts 2019. J Pediatr Gastroenterol. 2019;68:1-1243. [Hudert-2019-01]

Imanieh MH, Jalali Z, Azarpira N, et al. Post-transplant Lymphoproliferative Disorder in Pediatric Liver Transplantation: A Population-based Study from Shiraz, Iran. Shiraz E-Med J. 2022;23(3):e110017. [Imanieh-2022-01]

Jacobsen MC, Manunta MD, Pincott ES, et al. Specific immunity to cytomegalovirus in pediatric cardiac transplantation. Transplantation. 2018;102(9):1569-75. [Jacobsen-2018-02]

Jalanko H, Mattila I, Holmberg C. Renal transplantation in infants. Pediatr. Nephrol. 2016;31:725-735. [Jalanko-2016-01].

Kis E, Vilmanyi CS, Szabo A. Complications after pediatric heart transplantation - 9 years single centre experience. 50th Annual Meeting of the Association for European Paediatric and Congenital Cardiology, Rome, Italy, June 1-4, 2016. Cardiol Young. 2016;26(S1), S1-S181. [Kis-2016-01]

<div style=\"page-break-after: always\"></div>

Kobashigawa JA, Miller LW, Russell SD, et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 2006; 6:1377. [Kobashigawa-2006-01]

Kwong AJ, Kim WR, Lake JR, et al. OPTN/SRTR 2019 Annual Data Report: Liver. Am J Transplant. 2021;Suppl 2:208-315. [Kwong-2021-01]

Lammers AE, Roberts P, Brown KL, et al. Acute rejection after pediatric heart transplantation: far less common and less severe. Transpl Int. 2010;23(1):38-46. [Lammers-2010-01]

Lamour JM, Mason KL, Hsu DT, et al. Early outcomes for low-risk pediatric heart transplant recipients and steroid avoidance: A multicenter cohort study (Clinical Trials in Organ Transplantation in Children CTOTC-04). J Heart Lung Transplant. 2019;38(9):972-81. [Lamour-2019-01]

Langman IJ, LeGatt DF, Halloran PF, Yatscoff RW: Pharmacodynamic assessment of mycophenolic acidinduced immunosuppression in renal transplant recipients. Transplantation 1996;62(5):666 72. [Langman-1996-01]

Lehmkuhl H, Schubert S, Schweiger M, et al. Immunosuppression with everolimus in pediatric de-novo heart transplantation. Thorac Cardiovasc Surg. 2011;59(S 01):V10. [Lehmkuhl-2011-01]

Leiskau C, Rajanayagam J, Pfister E, et al. Side effects and efficacy of renal sparing immunosuppression in pediatric liver transplantation - A single center matched cohort study. Pediatr Transplant. 2018;22(5):e13207. [Leiskau-2018-01]

Li F, Cai J, Sun YF et al. Pediatric Heart Transplantation: Report from a single center in China. Chin Med J (Engl). 2015;128(17):2290-4. [Li-2015-01]

Lightdale J, Renz JF, Ascher NL, et al. Mycophenolate mofetil with cyclosporine and prednisone as effective primary immunosuppression in children following liver transplantation. In Gastroenterology 1997 Apr 1;112(4): A1320-A1320. 1600 John F Kennedy Boulevard, Ste 1800, Philadelphia, PA 19103-2899. [Lightdale-1997-01]

Lobritto SJ, Rosenthal P, Bouw R, et al. Pharmacokinetics of mycophenolate mofetil in stable pediatric liver transplant recipients receiving mycophenolate mofetil and cyclosporine. Liver Transpl. 2007;13(11):1570-5. [Lobritto-2007-01]

Marshall CD, Richmond ME, Singh RK, et al. A comparison of traditional versus contemporary immunosuppressive regimens in pediatric heart recipients. J Pediatr. 2013;163(1):132-6. [Marshall-201301]

Martin S, Alvarez F, Anand R, et al. Outcomes in children who underwent transplantation for autoimmune hepatitis. Liver Transpl. 2011;17(4):393-401. [Martin-2011-01]

Meiser BM, Jagiello-Kraatz M, Pfeiffer M, et al. The efficacy of mycophenolate mofetil treatment after heart transplantation is highly dependent on mycophenolate trough levels. Circulation 1997;96(8S)Suppl,64-I. [Meiser-1997-01]

Meiser BM, Pfeiffer M, Schmidt D, et al. Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: Importance of mycophenolic acid therapeutic drug monitoring. J Heart Lung Transplant. 1999; 18(2):143-9. [Meiser-1999-01]

Michelon H, Köni J, Durrbach A, et al. SLCO1B1 genetic polymorphism influences mycophenolic acid tolerance in renal transplant recipients. Pharmacogenomics 2010;1(12):1703-13. [Michelon-2010-01]

Miura M, Satoh S, Inoue K, et al. Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic ploymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol 2007;63:1161-69. [Miura-2007-01]

Miura M, Kagaya H, Satoh S, et al. Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients. Ther Drug Monit 2008;30(5):559-564. [Miura-2008-01]

<div style=\"page-break-after: always\"></div>

Miyagi SJ, Collier AC: Pediatric development of glucuronidation: The ontogeny of hepatic UGT1A4. Drug Metab Dispos. 2007;35(9):1587-92. [Miyagi-2007-01]

Moffett BS, Hong BJ, Denfield SW, et al. The effect of medication regimens on cardiac allograft vasculopathy in pediatric heart transplant recipients. J Heart Lung Transplant. 2014;33(4):p.Abs610. [Moffett-2014-01]

Musuamba FT, Rousseau A, Bosmans JL, et al. Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus. Clin Pharmacokinet 2009;48:745-758. [Musuamba-2009-01]

Mysore K, Himes R, Rana A, et al. ABO-incompatible deceased donor pediatric liver transplantation: Novel titer-based management protocol and outcomes. Pediatr Transplant. 2018;22(7):e13263. [Mysore-201801]

Nayagam JS, Heneghan MA, Samyn M, et al. Epstein-Barr virus status and immunosuppression use in paediatric autoimmune liver disease. Aliment Pharmacol Ther. 2022;55:455-63. [Nayagam-2022-01]

Nijland ML, Kersten MJ, Pals ST, et al. Epstein-Barr virus-positive posttransplant lymphoproliferative disease after solid organ transplantation: pathogenesis, clinical manifestations, diagnosis, and management. Transplantat Direct. 2016;2(1). [Nijland-2016-01]

Niranjan V, Donner B, Petri H, et al. Mycophonolate mofetil and red cell aplasia. Drug safety report 1031262. 2008. [Niranjan-2008-01]

Nobili V, Comparcola D, Sartorelli M, et al. Mycophenolate mofetil in pediatric liver transplant patients with renal dysfunction: preliminary data. Pediatr Transplant. 2003;7(6):454-7. [Nobili-2003-01]

Nunoda S, Homma S, Shitakura K, et al. Post-transplant care during the late post-transplant period in pediatric heart transplant patients: a single-center experience. Pediatr Transplant. 2013;17(3):316. [Nunoda-2013-01]

Oellerich M, Shipkova M, Schütz E, et al. Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: Implications for therapeutic drug monitoring. Ther Drug Monit. 2000;22(1):20-6. [Oellerich-2000-01]

Öztürk H, Ekşi NB, Sarı S, et al. Predictable and unusual adverse effects of immunosuppression in pediatric liver transplant patients. Exp Clin Transplant. 2019;17(Suppl 1):230-3. [Oztuk-2019-01]

Parant F, Rivet C, Boulieu R, et al. Age-related variability of mycophenolate mofetil exposure in stable pediatric liver transplant recipients and influences of donor characteristics. Ther Drug Monit. 2009;31(6):727-33. [Parant-2009-01]

Picard N, Ratanasavanh D, Prémaud A, Le Meur Y, Marquet P. Identification of the UDPglucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos. 2005;33(1):139-46. [Picard-2005-01]

Rauschenfels, Grothues, Marquardt, et al. Mycophenolate mofetil-associated reversal of glomerular filtration rate loss in liver-transplanted children. Journal of Pediatric Gastroenterology and Nutrition. 2009;48(Suppl 3):E114-5. [Rauschenfels-2009-01]

Reichel S, Roemer U, Rinker,.Mycophenolate mofetil and azathioprine in children after heart and heartlung transplantation: comparison of infections and rejection episodes. (Ger.).2000. [Reichel-2000-01]

Renz JF, Lightdale J, Mudge C, et al. Mycophenolate mofetil, microemulsion cyclosporine, and prednisone as primary immunosuppression for pediatric liver transplant recipients. Liver Transpl Surg. 1999;5(2):136-43. [Renz-1999-01]

Rosenthal LM, et al. Long-term follow-up of calcineurin inhibitor-free immune suppression in pediatric heart transplantation recipients. Thoracic and Cardiovascular Surgeon 2021;69 (Suppl 2). [Rosenthal2021-01]

Rossano JW, Dipchand AI, Edwards LB, et al The registry of the international society for heart and lung transplantation: nineteenth pediatric heart transplantation report-2016; focus theme: primary diagnostic indications for transplant. The J Heart Lung Transplant. 2016;35(10):1185-95. [Rossano-2016-01]

<div style=\"page-break-after: always\"></div>

Rother A, Glander P, Vitt E, et al. Inosine monophosphate dehydrogenase activity in paediatrics: agerelated regulation and response to mycophenolic acid. Eur J Clin Pharmacol. 2012;68(6):913-922. [Rother-2012-01]

Ruth ND, Kelly D, Sharif K, et al. Rejection is less common in children undergoing liver transplantation for hepatoblastoma. Pediatr Transplant. 2014;18(1):52-7. [Ruth-2014-01]

Sadiq J, Mckiernan P, Ong E, et al. Mycophenolate-induced diarrhea in paediatric liver transplant patients. Abstract #160. Pediatr Transplant. 2013;17:80. [Sadiq-2013-01]

Satoh S, Tada H, Murakami M, et al. Circadian pharmacokinetics of mycophenolic acid and implication of genetic polymorphisms for early clinical events in renal transplant recipients. Transplantation 2006; 82(4), 486-493. [Satoh-2006-01]

Schubert S, Renner C, Hammer M. Relationship of immunosuppression to Epstein-Barr Viral load and lymphoproliferative disease in pediatric heart transplant patients. J Heart Lung Transplant. 2008;27(1):S100-5. [Schubert-2008-01]

Schuetz E, Shipkova M, Armstrong VW, et al. Identification of a pharmacologically active metabolite of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Clin Chem. 1999;45(3):419-22. [Schuetz-1999-01]

Schukfeh N, Lenz V, Metzelder M, et al. First case studies of successful ABOincompatible living-related liver transplantation in infants in Germany. Eur J Pediatr Surg. 2015;25(1):77-81. [Schukfeh-2015-01]

Seo E, Kim J, OH SH. et al. Epstein-Barr viral load monitoring for diagnosing post-transplant lymphoproliferative disorder in pediatric liver transplant recipients. Pediatr Transplant. 2020;24(4):110:e13666. [Seo-2020-01]

Shaw LM, Korecka M, Venkataramanan R, et al. Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transplant. 2003;3(5):534-42. [Shaw-2003-01]

Shen Z, Wang Z, Zhu Z, et al. Pediatric liver transplantation in 31 consecutive children. Chin Med J (Engl). 2008;121(20):2001-3. [Shen-2008-01]

Shipkova M, Armstrong VW, Oellerich M, et al. Mycophenolate mofetil in organ transplantation: focus on metabolism, safety and tolerability. Expert Opin. Drug Metab Toxicol. 2005;1(3):505-26. [Shipkova2005-01]

Siber GR, Echeverria P, Smith AL, et al. Pharmacokinetics of gentamicin in children and adults. J Infect Dis. 1975;132:637-51. [Siber-1975-01]

Siddiqi N, Lamour JM, Hsu DT. The effect of MMF dose and trough levels on adverse effects in pediatric heart transplant recipients. Pediatr Transplant. 2015;19(6):618-22. [Siddiqi-2015-01]

Sifontis NM, Coscia LA, Constantinescu S, et al. Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus. Transplantation. 2006. [Sifontis-2006-01]

Singh RK, Humlicek T, Jeewa A, et al. Pediatric cardiac intensive care society 2014 consensus statement: Pharmacotherapies in Cardiac Critical Care Immune Therapy. Pediatr Crit Care Med. 2016;17(Suppl 1):S69-76. [Singh-2016-01]

Singh TP, Cherikh WS, Hsich E. The International thoracic organ transplant registry of the international society for heart and lung transplantation: Twentyfifth pediatric heart transplantation report-2022; focus on infant heart transplantation. J Heart Lung Transplant. 2022;41(10):1357-65. [Singh-2022-01]

Singh TP, Faber C, Blume ED, et al. Safety and early outcomes using a corticosteroid-avoidance immunosuppression protocol in pediatric heart transplant recipients. J Heart Lung Transplant. 2010;29(5):517-22. [Singh-2010-01]

<div style=\"page-break-after: always\"></div>

Staatz CE, Tett SE: Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet. 2007;46(1):13-58. [Staatz-2007-01]

Starzl TE, Iwatsuki S, Van Thiel DH, et al. Evolution of Liver Transplantation.Hepatology. 1982;2(5):61436. [Starzl-1982-01]

Tang JT, deWinter BC, Hesselink DA, et al. The pharmacokinetics and pharmacodynamics of mycophenolate mofetil in younger and elderly renal transplant recipients. Br J Clin Pharmacol. 2017;83(4),812-22. [Tang-2017-01]

Tannuri U, Gibelli NE, Maksoud-Filho JG, et al. Mycophenolate mofetil promotes prolonged improvement of renal dysfunction after pediatric liver transplantation: experience of a single center. Pediatr Transplant. 2007;11(1):82-6. [Tannuri-2007-01]

Teisseyre J, Kalicinski P, Markiewicz-Kijewska M, et al. A comparison of two methods of tacrolimus based immunosuppression with or without MMF for early steroid withdrawal in children after liver transplantation-preliminary results: 282. Liver Transpl. 2006;12(5):C-71. [Teisseyre-2006-01]

Teisseyre J, Kalicinski P, Markiewicz-Kijewska M, et al. Three years follow up of two methods of tacrolimus-based immunosuppression with or without MMF for early steroid withdrawal in children after liver transplantation. Abstract# 370. Pediatr Transplant. 2011;15:131. [Teisseyre-2011-01]

Tönshoff B, Devid-Neto E, Ettenger R, et al. Pediatric aspects of therapeutic drug monitoring of mycophenolic acid in renal transplantation. Transplant Rev. 2011; 25(2):78-89. [Tonshoff-2011-01]

Tuite GC, Quintessenza JA, Asante-Korang A, et al. Heart transplantation for pediatric and congenital cardiac disease: A comparison of two eras over 23 years and 188 transplants at a single institution. World J Pediatr Congenit Heart Surg. 2021;12(1):17-26. [Tuite-2021-01]

Ueno T, Kodama T, Noguchi Y, et al. Serum trough concentration and effects of mycophenolate mofetil based on pathologic findings in infants after liver transplantation. Transplant Proc. 2020;52(6):1855-57. [Ueno-2020-01]

Urschel S, Larsen IM, Kirk R, et al. ABO-incompatible heart transplantation in early childhood: an international multicenter study of clinical experiences and limits. J Heart Lung Transplant. 2013;32(3):285-92. [Urschel-2013-01]

Uwai Y, Motohashi H, Tsuji Y, et al. Interaction and transport characteristics of mycophenolic acid and its glucuronide via human organic anion transporters hOAT1 and hOAT3. Biochem Pharmacol 2007;74:161168. [Uwai-2007-01]

Vazin A, Shahriarirad R, Azadeh N, et al. Incidence, Clinicomicrobiological Characteristics, Risk Factors, and Treatment Outcomes of Bacterial Infections Following Liver Transplantation in Pediatrics: A Retrospective Cohort Study. Arch Pediatr Infect Dis. 2022;10(4):e118809. [Vazin-2022-01]

Vogl M, Weigel G, Seebacher G, et al. Evaluation of the EMIT Mycophenolic Acid Assay From Dade Behring. Ther Drug Monit. 1999;21 (6) p638

Wang J; Figurski M; Shaw LM, et al. The impact of P-glycoprotein and Mrp2 on mycophenolic acid levels in mice. Transplant Immunol 2008;19 (3-4): 192-196. [Wang-2008-01]

Weber L, Shipkova M, Lamersdorf T, et al. Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. J Am Soc Nephrol. 1998;9(8):1511-20. [Weber-1998-01]

Weber LT, Lamersdorf T, Shipkova M, et al. Area under the plasma concentration-time curve for total, but not for free, mycophenolic acid increases in the stable phase after renal transplantation: A longitudinal study in pediatric patients. Ther Drug Monit. 1999;21(5):498-506. [Weber-1999-01]

Weber LT, Shipkova M, Armstrong VW, et al. The pharmacokineticpharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: A report of the german study group on mycophenolate mofetil therapy. J Am Soc Nephrol. 2002;13(3):759-68. [Weber-2002-01]

<div style=\"page-break-after: always\"></div>

Weiner C, Weintraub L, Wistinghausen B, et al. Graft rejection in pediatric liver transplant patients with Epstein-Barr Viremia and post-transplant lymphoproliferative disorder. Pediatr Transplant. 2012;16(5):458-64. [Weiner-2012-01]

Wieland E, Shipkova M, Schellhaas U, et al. Induction of cytokine release by the acyl glucuronide of mycophenolic acid: a link to side effects? Clin Biochem 33, 2000;107-113. [Wieland-2000-01]

Wierderkehr JC, Coelho IM, Silva EM, et al. Persistent diarrhea in patients submitted to liver transplant in use of mycophenolate mofetil. Abstract #P-185. Liver Transpl. 2012;18:S200. [Wierderkehr-2012-01]

Wolff NA, Burckhardt BC, Burckhardt G, et al. Mycophenolic acid (MPA) and its glucuronide metabolites interact with transport systems responsible for excretion of organic anions in the basolateral membrane of the human kidney. Nephrol Dial Transplant 22, 2007; 2497-2503. [Wolff-2007-02]

Xinias I, Mavroudi A, Vrani O, et al. Liver transplantation in Greek children: 15 years' experience. Pediatr Rep. 2010;2(2):e14. [Xinias-2010-01]

Yoo EC, Alvarez-Elías AC, Todorova EK, Filler G: Development changes of MPA exposure in children. Pediatr Nephrol. 2016;31(6):975-82. [Yoo-2016-01]